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Identifying early defects in protein homeostasis (“proteostasis”) in neurodegeneration 
could shed light into disease-promoting events and provide promising therapeutic 
targets for disease modification. A key player in the regulation of proteostasis is the 
dual function chaperone and E3 ligase C-terminus of Hsc-70 interacting protein 
(CHIP). Its role in neurodegenerative diseases, including dementia with Lewy bodies, 
and the severe progeria and proteotoxic phenotype seen in CHIP KO mice support its 
neuroprotective effects, but the underpinning molecular mechanisms remain largely 
unknown and understudied. This project aimed to identify the protein targets of CHIP 
in a neuronal cell model of disease.   
 
I knocked out CHIP expression using CRISPR/Cas9 technology from induced-
pluripotent stem cells (iPSC) derived from a synucleinopathy patient with dementia 
and differentiated them into cortical neurons. A label-free quantitative mass 
spectrometry to analyse CHIP-dependent changes was conducted and the proteome 
defined. This comparative proteomic analysis revealed that of all the proteins 
identified and significantly changed between CHIP KO and WT lines, only 35 proteins 
could be (directly or indirectly) regulated by CHIP. This supports the emerging 
hypothesis that CHIP can be chaperone-independent docking-dependent E3 ligase, 
having tight specificity for substrates, in this model of synucleinopathy with mild 
proteotoxic stress. 
 
Annexin and other calcium-binding proteins, in particular Annexin A2 and its 
interacting protein S100-A11, were the most over-represented proteins in the CHIP 
KO cortical neurons. From this comprehensive target discovery investigation, I have 
validated Annexin A2 increases in CHIP KO cells and have detected an endogenous 
Annexin A2:CHIP interaction, both in vitro and in situ, in different CHIP cell models. 
Moreover, CHIP-dependent ubiquitination of Annexin A2 was also identified, both in 
vitro and in situ. Single-chain antibodies against CHIP have been engineered to 
modulate its activity. By collapsing the higher molecular weight structures of CHIP, 
CHIP-dependent ubiquitination of Annexin A2, but not other substrates, is enhanced.     
 
Annexins are a conserved family of calcium-regulated phospholipid-binding proteins 
that are required for membrane repair and maintenance of membrane homeostasis. 
Given these functions, several types of membrane damage assays were conducted 
and suggested that CHIP KO cells are more sensitive to damage, despite retaining 
the ability to repair. This impairment in membrane resilience was also seen in CHIP 
KO cells expressing a E3 ligase-dead CHIP mutant, but the phenotype was partly 
rescued in the cell lines expressing a chaperone-dead CHIP mutant or wild-type 
CHIP. Compromised Annexin A2:S100A11 interactions (important for the repair 
complex) and a different lipidomic profile between CHIP WT and KO cells could 
contribute to this phenotype.  
 
Although there are reports of annexins being overexpressed in some 
neurodegenerative diseases, there have been no follow-up studies deciphering the 
molecular mechanisms of annexins within neurons. I have identified Annexin A2 as a 
substrate for CHIP and revealed other novel calcium-regulated membrane-binding 
CHIP targets. Thus, CHIP is likely to play a role in regulating membrane protein 
homeostasis and maintaining membrane integrity, which may help to explain the 
neuroprotective actions of CHIP. This is of relevance within the emerging field of 




Neurodegeneration is a progressive phenomenon where brain cells (neurons) 
become gradually worse in health and eventually die. Identifying early changes to 
their repertoire of proteins may shed light into disease-promoting events and provide 
promising therapeutic targets for disease modification. A key player in the regulation 
of proteins is an enzyme called CHIP, which is both capable of acting as a chaperone 
for misfolded proteins and signalling them for degradation. Its role in 
neurodegenerative diseases and the rapid ageing and cellular toxicity seen in mice 
lacking CHIP support its neuroprotective effects. How this happens mechanistically is 
largely unknown and understudied. This project aimed to identify the protein targets 
of CHIP in a brain cell model of disease.   
 
To address this aim, I deleted the CHIP protein from stem cells derived from a 
Parkinson’s patient with dementia (a type of neurodegenerative disease) and 
engineered them to become neurons similar to the ones found in the area of the brain 
affected in patients of dementia, the cortex. I did a deep analysis of the repertoire of 
proteins in these neurons (with and without CHIP), to identify CHIP-dependent 
changes. Of all the proteins identified, only 35 proteins seem to be changed between 
the neurons with and without CHIP. This supports the emerging school of thought that 
CHIP can regulate a tight subset of proteins in our model of disease, rather than 
affecting multiple proteins. 
 
The protein levels of Annexin A2 are higher in neurons lacking CHIP. In different CHIP 
cell models, CHIP was shown to interact with Annexin A2. Furthermore, a CHIP-
dependent addition to Annexin A2 protein was identified, and I have engineered 
antibodies targeting CHIP that stimulate this addition to Annexin A2, but not to other 
protein clients of CHIP.  
 
Annexins are required for repairing and maintaining the integrity of a shielding 
structure that envelopes each cell (plasma membrane), as well as internal structures 
within the cell (intracellular membranes), to protect them from the environment. Given 
these functions, several experiments to induce membrane damage were conducted 
and suggested that CHIP KO cells are more sensitive to damage, despite retaining 
the ability to repair. This impairment in membrane resilience was also seen in cells 
lacking normal CHIP but expressing a form of CHIP that is not capable of targeting 
proteins for degradation. However, this observation was reversed when cells have a 
form of CHIP that is not capable of being a chaperone to client proteins or when cells 
were re-introduced fully functional CHIP. Compromised interactions of proteins 
important for the membrane repair mechanism (Annexin A2 and S100-A11 proteins) 
and a different composition of lipids (present in membranes) between cells with and 
without CHIP could contribute to this phenomenon.  
 
Although annexins have been reported to be dysregulated in some 
neurodegenerative diseases, there have been no follow-up studies deciphering the 
underlying mechanisms in neurons. We have identified Annexin A2 as a CHIP-
regulated protein and have revealed other novel target proteins of the enzyme. Thus, 
CHIP is likely to play a role in regulating membrane-related proteins and maintaining 
membrane integrity, which might help to explain the neuroprotective actions of CHIP. 
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Chapter 1: Introduction  1 
Chapter 1: Introduction 
The majority of neurodegenerative diseases are broadly classified as proteinopathies, 
being defective in protein homeostasis. This thesis focuses on α-synucleinopathy, as 
an example of such diseases, and a key protein in the regulation of the cellular 
proteome, the C terminus of Hsc70-interacting protein (CHIP).   
 
 
1.1 Protein homeostasis 
1.1.1 Regulation of protein homeostasis 
Protein homeostasis (“proteostasis”) refers to the preservation of proper 
concentration, distribution and functions of proteins. Its regulation is key for normal 
cellular physiology and is achieved through the safeguarding of protein synthesis and 
protein quality control (PQC) mechanisms mediating protein maturation, folding and 
degradation. The main proteolytic routes are ubiquitin-proteasome system (UPS) and 
the lysosome-autophagy pathway. The proteostasis network includes >1000 
accessory factors and regulatory components1, having more than 300 different 
members of chaperones, co-chaperones and adaptors2. One can easily appreciate 
the importance of PQC when considering the number of proteins involved and the 
functional redundancy between different PQC mechanisms, all with the same 
function: maintain proteostasis3.   
 
 
1.1.2 Proteostasis regulation in neurons 
The UPS plays a critical role in the spatial and temporal control of protein turnover in 
the nervous system - important for the maintenance and modulation of neuronal and 
synaptic structures and signalling complexes. The regulation of proteostasis 
influences neuronal activity4, plasticity5, development and differentiation6. For 
example, at the post-synaptic terminal, ubiquitination ensures sustained density of 
neurotransmitter receptors upon neurotransmitter release, thus readily influencing 
synaptic activity6. However, the precise mechanism for how local degradation of 
proteins is achieved in non-dividing neurons remains unclear. 
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Molecular chaperones and ubiquitination enzymes are also important for regulation of 
proteostasis via the autophagy-lysosome pathway. Its main role is to mediate the 
turnover of defected and aggregated proteins, multimeric complexes and whole 
organelles, which cannot be handled by the proteasome. Autophagy can be non-
selective (chaperone-mediated autophagy (CMA)) or selective (chaperone-assisted 
selective autophagy (CASA)) in the degradation of cargo7. The latter is ubiquitin (Ub)-
dependent8. Under normal conditions, CASA is the preferred route for lysosomal 
degradation, whilst CMA is induced by proteotoxic stress. Both CMA and CASA have 
been implicated in the regulation of proteostasis during ageing3,7.  
 
 
1.1.2 Dysregulation of proteostasis 
It is clear that neuronal health is maintained by tightly controlled and coordinated 
ubiquitin-proteasomal and autophagy-lysosomal degradative events. Not surprisingly, 
there is growing evidence to support the involvement of the UPS in the pathogenesis 
of neurodegeneration. Firstly, inclusion bodies (commonly seen across 
neurodegenerative diseases) contain Ub, ubiquitinated proteins and other 
components of the UPS and, the closely connected, molecular chaperone system. 
Secondly, post-mortem brains of patients with Parkinson’s disease (PD) and 
Alzheimer’s disease (AD) revealed an impairment in proteasomal activity. Thirdly, 
mutations in UPS proteins cause neurodegenerative diseases, e.g. the E3 ligase 
Parkin and the deubiquitinating enzyme (DUB) UCHL1 in PD, the DUB ATX3 in 
spinocerebellar ataxia (SCA)9, and a mutation in Ub that is associated with AD 
(causing proteasomal inhibition10 and impairment in axonal transport11). Accordingly, 
model organisms with compromised UPS have increased neurodegeneration, e.g. 
SCA1 mice with loss-of-function of the E3 ligase Ube3a have more severe 
neurodegeneration12. Likewise, loss-of-function mutations of CHIP cause a 
multisystemic syndrome with severe neurodegeneration13 (see Section 1.4 CHIP and 
neurodegeneration), and CHIP knock-out (KO) mice have increased 
neurodegeneration14,15. 
 
A common pathogenic hallmark across neurodegenerative diseases is the 
progressive accumulation of misfolded/unfolded proteins – reflective of a proteostasis 
profile that reflects a state of stress. Here, PQC mechanisms to maintain cellular 
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health are compromised, failing to cope with the accumulated proteins and falling into 
a viscous cycle of increasing protein aggregation, which causes other proteins to 
become sequestered, dysregulated and dysfunctional (Figure 1.1)8. This can promote 
the switch from proteasomal to autophagy pathways for protein degradation (this 
phenomenon is seen during ageing)16. In fact, with increasing severity of 
neurodegenerative diseases, autophagy becomes more important as the UPS 
capacity becomes compromised, but eventually the autophagy-lysosome pathways 















The prevailing hypothesis is that aged organisms also have increased pressure on 
PQC mechanisms1. In fact, the quality of housekeeping processes dictates, at least 
partly, the “fitness” of cells, resulting in selective neurodegeneration and influencing 
the longevity of organisms. Hence, ageing is the greatest risk factor for 
neurodegenerative diseases. 
 
Figure 1.1: Loss of proteostasis 
Proteins become kinetically trapped in conformations, having to overcome free-energy 
barriers to enter an energetically favourable folding path (with decreased free energy). These 
events are facilitated by chaperones. The aggregation process is biphasic: initially governed 
by intramolecular contacts and later by intermolecular interactions between folded proteins. 
Although PQC mechanisms counteract the aggregation process, eventually aggregates, toxic 
oligomers and amyloid fibrils form.  
(Amm et al.8) 
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For example, worms with increased proteasomal activity have decreased levels of 
polyubiquitinated proteins, a more rapid protein turnover and extended lifespan17. The 
opposite was observed in transgenic mice with decreased proteasomal activity18 and 
in worm models of accelerated ageing (Figure 1.2)19. Thus, functionally, a decline in 
proteasomal activity may promote ageing18, and has been detected in brains of AD 
patients10. Not only are proteostasis and ageing inextricably linked, they are 
associated to stress tolerance1. Worms with enhanced resistance to proteotoxic 
stress resistance have a longer lifespan17. Therefore, in the context of 
neurodegeneration, where cellular stress levels are high and PQC mechanisms are 
“aged”, regulation of proteostasis is likely to be critical in the progression of disease 
and onset of progeria. This highlights the intimate relationship between stress, 
















To counteract cytotoxicity caused by misfolded proteins, multiple strategies come into 
play, including refolding or buffering of toxic misfolded proteins by molecular 
chaperones, different proteasomal and lysosomal degradative branches, and 
processing of aggresomes20. Independent of the PQC mechanisms employed to 
counteract proteotoxic stress during ageing and the course of neurodegenerative 
diseases, the end-effect is the same: despite the extensive proteome remodelling in 
attempt to maintain proteostasis, ultimately, a state of marketed proteome imbalance 
is reached.  
A B 
Figure 1.2: Decline in PQC mechanisms in lifespan mutant worms 
The longevity of worms was manipulated by interfering with the insulin and insulin-like 
signalling pathway. Long-lived (the daf-2 mutant) and short-lived (the daf-16 and hsf-1 
mutants) worms were studied. The longevity of daf-2 worms requires daf-16 activation and 
hsf-1 (a transcription factor of multiple chaperones and co-chaperones).    
A) Abundance of small HSPs (6-11 different proteins) across worm models.  
B) Abundance of proteasomal subunits (19-27 different proteins) across worm models, 
reflective of 26S proteasomal activity.  
(Walther et al.19) 
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Before reaching such state of chaos, early and more subtle changes in proteostasis 
are likely to be of significance in disease onset and progression – particularly when 
considering the need for tight regulation of proteostasis in neurons. There has been 
extensive investigation into the effect of UPS defects in the homeostasis of disease 
proteins, however how the proteostasis of other proteins is being affected, and in turn 





1.2.1 Synucleinopathy pathology 
Synucleinopathies are a group of neurodegenerative diseases in which the pathology 
is driven by the abnormal accumulation of α-Synuclein (α-Syn). This includes PD, 
Dementia with Lewy bodies (DLB) and multiple systems atrophy (MSA)21,22. α-Syn 
favours the formation of insoluble, fibrillary aggregates in neurons and/or glial cells. 
These are referred to as Lewy bodies (LBs) and contain various nitrated, 
phosphorylated and ubiquitinated proteins at their granular core, which is surrounded 
by a filamentous halo primarily composed of neurofilament and α-Syn (Figure 1.3)23,24. 
The α-Syn aggregation process promotes the formation of β-sheet-rich structures, 
making LBs immunoreactive to thioflavin-S. Phosphorylation of α-Syn at serine 129 
is also regarded as a pathogenic post-translational modification23. Interestingly, LBs 
also contain proteins involved in PQC mechanisms, including heat-shock proteins 











Figure 1.3: Lewy bodies (LBs) 
A) Confocal image of a Substantia Nigra LB stained for Ub (red) and α-Syn (yellow). B) LB 
and Lewy nitrate in grafted dopaminergic neurons stained for α-Syn.  
(Olanow and Brundin23) 
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It is believed that, in healthy conditions, native α-Syn exists in equilibrium with different 
conformational and/or oligomeric states. However, in the absence of a higher molar 
ratio of monomers to the other species, or if partially folded α-Syn self-assembles, 
stable oligomers are formed, which undergo slow conversion into fibrils and eventually 
form LBs and Lewy neurites26–28. In disease, abnormal α-Syn homeostasis can be 
driven by an overproduction of α-Syn due to point mutations or multiplications 
(duplications or triplications) of the SNCA gene, for example, which disrupts the 
equilibrium and drives aggregation27. At a cellular level, this accumulation challenges 
housekeeping processes of the proteasome, lysosome, endoplasmic reticulum (ER), 
mitochondrion and the plasma membrane. These eventually fail due to the cumulative 
defects caused by α-Syn23,27,29–31. The net effect of increased α-Syn synthesis and 
inadequate clearance, promotes more aggregation and neuronal dysfunction. This is 
a viscous cycle leading to increasing toxicity and neurodegeneration.  
 
The pathology is more severe in patients with SNCA triplications compared to 
duplications, supporting the hypothesis that synucleinopathies are α-Syn-dose-
dependent23. Mixed diseases, such as cases of AD with α-Syn accumulation, are also 
more severe28, causing a greater decline in cognitive function32. Mechanistically it has 
been proposed that this is ruled by the innate ability of the α-Syn species to self-
aggregate and seed the formation of aggregates22,33, following a “prion-like” 
behaviour22. Furthermore, α-Syn may have synergistic effects in causing dementia 
with other pathogenic proteins of AD, tau and amyloid-β (Aβ), by promoting 




α-Syn is upregulated during development, in injury or other conditions that require 
neuronal plasticity, which explains the age-related accumulation of the protein. It is 
abundantly expressed by the SNCA gene and its name derives from its nuclear and 
cytoplasmic subcellular localisation. The cytosolic form of α-Syn (making up 1% of 
total cytosolic protein) is present mainly at presynaptic terminals, rather than in the 
soma29. A fraction (10-15%) is also membrane-bound32.   
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α-Syn is a highly dynamic but intrinsically disordered protein. The ability of α-Syn to 
adopt diverse conformational states confer multifunctionality in health (although its 
main physiological role is still unknown) and help to explain why α-Syn species cause 
broad neuronal defects in disease. The N-terminus, non-amyloid β/A4 component 
(NAC) region and C-terminus of this 14 kDa protein27 result in different structural 
properties (Figure 1.4)34, which are also influenced by the abundance of α-Syn, 
interactions with proteins and lipids and the overall cellular homeostasis27,35. 
Interestingly, α-Syn was first identified by analysing the SDS-insoluble fraction from 
post-mortem AD brains, as it has the propensity to form β-sheet structures, thus 
promoting protein oligomerisation and fibrillogenesis28. On the other hand, the C-
terminus of α-Syn is highly negatively charged and prone to remain unstructured29, 
while the N-terminus acts as a hydrophobic core with lipid-binding motifs (several 
imperfect repeats of the lipid-binding, lysine-rich motif, KTKEGV) that drives towards 






















Figure 1.4: Structure of α-synuclein 
A) The N-terminal, NAC and C-terminal domains of α-Syn, with some point mutations 
associated with familial PD indicated. The disease-associated phosphorylation occurs Serine 
at position 129. B) Schematic representation of micelle-bound α-Syn. Upon binding to the 
negatively-charged phospholipids (e.g. vesicles) α-Syn undergoes a large-scale disorder-to-
helix transition forming two non-contacting antiparallel helices in the N-terminal (in blue).   
(Gallegos et al.34) 
 
Chapter 1: Introduction  8 
Rather simplistically, it is generally accepted that the α-helical form of α-Syn is 
associated with its physiological roles in synaptic plasticity and learning, 
neurotransmitter release and maintenance of synaptic pools, whilst its β-sheet 
conformation drives pathology. In support of this physiological functions, a model for 
α-Syn-dependent vesicle budding has been proposed, allowing α-Syn to mediate and 
sense both vesicle budding and docking and to regulate membrane remodelling 
processes (such as membrane curvature) (Figure 1.5)26. For such, α-Syn undergoes 
a large-scale disorder-to-helix transition upon binding to phospholipids, forming two 
non-contacting antiparallel helices in the N-terminus and, to a lesser extent, the more 
flexible C-terminal domain, which remains available for regulation via post-
translational modifications and protein-protein interactions with vesicle proteins 
(Figure 1.4B)26,34,36. However, there is also a potential role for helical/lipid-induced 
intermediates during the aggregation process. Firstly, vesicles confine α-Syn into a 
small area, which increases the local concentration and drives aggregation through 
mass action. Secondly, lipid-induced α-helical conformation favour intermolecular 













































Over the years β-sheet-rich structures have been regarded as the pathogenic species 
in synucleinopathies, however the focus has shifted from the large and insoluble fibrils 
within LBs to the smaller and soluble oligomeric species. The idea that the process of 
fibril formation per se, rather than the fibrils themselves, lead to cellular toxicity has 
been growing in popularity27. If this theory is correct, formation of LBs could be an 
active method to isolate and facilitate clearance of the toxic intermediate oligomeric 
species and to convert them into the more stable fibrils that exhibit reduced 
toxicity23,27,28. Alternatively, LB formation could be an epiphenomenon, which 
develops as proteins get trapped in the hydrophobic core. During the course of 
disease, LBs could become toxic by blocking neuronal trafficking and capturing critical 
neuronal components28. Anything from α-Syn monomers, oligomers or fibrils, either 
Figure 1.5: Model of α-synuclein-dependent synaptic vesicle budding/docking 
In this schematic, poorly structured protein regions are represented as solid lines, while helical 
regions are filled bars or cylinders. The unbound, intrinsically disordered state of α-Syn is in 
dynamic equilibrium with the vesicle-bound extended-helix state. Upon vesicle binding, the 
later can convert to the broken-helix state. Physiological transitions between these states are 
depicted as black arrows. The pathogenic aggregation cascade can also be driven by 
intermolecular association of these intermediate states: the membrane-associated N-terminal 
helices may bring the disordered regions into close proximity, facilitating intermolecular β-
sheet formation. This results in amyloid oligomer and fibril generation. This pathogenic 
behaviour of α-Syn is represented by the orange arrows.   
(Dikiy & Eliezer26) 
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soluble or insoluble, α-helical or β-sheet-rich in structure, has been given some 




1.3 C-terminus of Hsc70-interacting protein (CHIP) 
With loss of proteostasis at the core of neurodegeneration, there is great interest in 
understanding the role of regulators of proteostasis in this disease context. Namely, 
the dual chaperone and E3 ligase enzyme, CHIP, has been studied across some 
neurodegenerative diseases, including α-synucleinopathies. Functional studies 
investigating CHIP have consistently described it as neuroprotective13,14,25,37.   
 
CHIP is encoded by the STIP1 homology and U-box containing protein 1 (STUB1) 
gene. It is ubiquitously expressed and is especially important in tissues that are active 
with regards to metabolism and protein turnover, such as the brain, heart and skeletal 




To better understand its functions, efforts have been put into investigating the dynamic 
structure of CHIP. It contains a C-terminal U-box domain, a N-terminal 
tetratricopeptide repeat (TPR) domain and a linker domain (Figure 1.6A)25,39,40. The 
U-box domain is the most conserved41. It resembles the Really interesting new gene 
(RING)-finger domain, although it is stabilized by intramolecular hydrogen bonds and 
salt bridges rather than Zn2+ ions. Functionally, it targets Ub-conjugates to protein 
substrates, consistent with the RING-finger type of E3 ligases42. These have been 
previously regarded as having a “passive” role in scaffolding E2 and Ub and bringing 
them into close proximity42 (through its U-box hydrophobic groove39). However, 
crystallography data revealed the possibility of a more active role in determining E2 
and Ub conformations, due to the folded-back position that Ub adopts as the E2 
interacts with a protomer of the E3, which locks the C-terminal tail of Ub at the E2 
active site43,44. This is expected to influence the type of ubiquitination pattern and the 
specificity of the enzymes involved in the ubiquitination process. 
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CHIP has three TPR domain units, generating three pairs of anti-parallel helices. This 
facilitates protein-protein interactions between TPR- and non-TPR-containing 
proteins41. TPR-containing proteins are involved in a diverse spectrum of cellular 
functions with the majority  of them regulating proteostasis, including protein transport 
and protein folding45. The hydrophobic pocket of the CHIP’s TPR domain allows 
binding to the C-terminus of  Hsc70/Hsp7046 and Hsp9039. The crystal structure of 
CHIP bound to either HSP proteins illustrates how CHIP adopts an unusual 
asymmetric homodimer in which each protomer has pronounced structural 
differences (Figure 1.6B)39. Furthermore, hydrogen/deuterium exchange-mass 
spectrometry (HX-MS) revealed that the TPR domain is very flexible and when bound 
to Hsp70/90 it becomes more stable and organised. This “locked” conformation can 
be modelled by mutating the lysine 30 to a structure favouring amino acid. The 
flexibility of the TPR domain also correlates with that of the U-box domain, indicating 
intramolecular allosteric regulation of the domains. The E3 ligase activity decreases 
significantly upon Hsp70/90 binding, possibly to ensure that one of its dual functions 

















































Finally, the charged domain, also called coiled-coil/helix-turn-helix (HH) region, of 
CHIP is flanked by both enzymatic domains. This region is important for CHIP 
dimerization39. CHIP homodimers form asymmetrically, having an elongated protomer 
and a compact/bent one. Asymmetry in homo-oligomers is rare: 75% of the 
homodimers have global asymmetry scores of ≤ 0.4 (indicator of a highly symmetry 




TPR domain Charged domain U-box domain 




Figure 1.6: Structure of CHIP 
A) Schematic of the functional domains of CHIP (numbers represent amino acid (aa) 
numbers). The TPR region includes TPR 1 (26-59 aa), TPR 2 (60-93 aa) TPR 3 (95-127 aa) 
domains.    
B) Crystal structure of murine CHIP (PDB 2C2L) as monomers (i and ii) and an asymmetrical 
dimer (iii). In the latter conformation, one protomer (ii) has a hairpin structure formed by two 
straight helices, while this interaction is broken in the other protomer, having its helices 
separate (i).  
(A: Information according to Nikolay et al.40 and Zhang et al.39; B: Adapted from Zhang et al.39) 
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a greater degree of asymmetry)48. Such rarity in structure is likely to be intimately 
linked to its complex functions and intricate auto-regulation.   
 
 
1.3.2 Regulation of CHIP 
The spatiotemporal control of CHIP functions in different conditions (unstressed and 
stressed) still need further attention. This includes understanding how its substrate 
specificities change depending on the cellular context1 and how the activity of CHIP 
is regulated. Not only can interactions with chaperones49 and other proteins and 
lipids50 influence the activity of CHIP, intrinsic mechanisms of regulation have been 
proposed. Different oligomeric states (dimeric, tetrameric or even higher) of CHIP 
have been described, thus regulation could occur at a conformational level. In vivo it 
is believed that CHIP is largely dimeric, although this state could be in equilibrium with 
tetrameric CHIP, which is detected at higher concentrations40. Furthermore, our group 
has previously reported an allosteric regulation between the TPR and U-box domains 
via intra-molecular interactions47.  
 
A few studies have reported regulation of CHIP through post-translational 
modifications, including phosphorylation and ubiquitination. CHIP is phosphorylated 
by Cyclin-dependent kinase 5 (Cdk5) at serine 20, which negatively affects its 
neuroprotective functions. Cdk5 is a member of the cyclin-dependent kinases 
important in the regulation of post-mitotic processes in the nervous system and 
becomes dysregulated across neurodegenerative diseases. This post-translational 
modification inhibits CHIP’s interaction with its substrate, truncated apoptosis-
inducing factor (tAIF). As a result, tAIF does not get ubiquitinated and triggered for 
proteasomal degradation, causing tAIF-mediated neuronal cell death (via oxidative 
stress). Additionally, the negative regulation of CHIP by Cdk5 was also shown to 
inhibit CHIP-mediated ubiquitination and degradation of α-Syn and p5351.    
 
CHIP is differentially ubiquitinated by E2 enzymes (the ubiquitination mechanism is 
explained in Section 1.3.3c). The UbcH5A E2 enzyme attaches Ub chains with non-
specific linkages to CHIP1. While Ube2W directed-monoubiquitination was seen on a 
non-lysine N-terminal residue of CHIP52 (abolishing its E3 ligase activity) and on lysine 
K2 (believed to enhance CHIP function)53. Furthermore, Ube2w-directed 
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monoubiquitination of CHIP may stimulate CHIP-Ataxin-3 complex formation, allowing 
this DUB to regulate the extent and duration of substrate ubiquitination by CHIP. It 
does so by limiting the length of Ub chains required on CHIP substrates to target them 
for degradation and by deubiquitinating ubiquitinated CHIP upon completion of 
substrate ubiquitination. Therefore, through their opposing activities, Ube2w and 
Ataxin-3 (and potentially other E2 and DUB enzymes) participate in initiating, 
regulating and terminating the CHIP ubiquitination cycle53.  
 
Another important mechanism for the regulation of Ub ligases, including CHIP, is 
through auto-ubiquitination. Analysis of in vitro ubiquitination assays by mass 
spectrometry (MS) identified two ubiquitination sites on Ub (K63 and K48) and one on 
CHIP (K22). This finding suggests that the auto-ubiquitination pattern of CHIP either 
consists of two types of polyubiquitination chains (with K63- and K48-linkages) 
coexisting or is formed by heteropolymers, including both modifications sites in the 
same chain54. While K63 polyubiquitin chains are associated with proteasome-
independent pathways, both K48 and K48/63 polyubiquitin chains preferentially 
associate with the proteasome for degradation. Therefore, this may be a mechanism 
for CHIP regulation (auto-ubiquitination is discussed further in Section 6.3.2c)55.    
 
   
1.3.3 Canonical functions of CHIP 
Arguing in favour of CHIP having important roles in cell biology is its strong 
conservation (having orthologues in plants, worms, flies, fish and mammals)1. Evident 
from its structural domains, CHIP functions as both co-chaperone and chaperone-
dependent E3 ligase. These canonical functions will be reviewed in this order and, for 
a comprehensive understanding, an overview of both the chaperone and 
ubiquitination cascades will be included.  
 
 
a. Overview of the chaperone system 
Despite being determined by the amino acid sequence and favoured by 
thermodynamics, protein folding is an energetically costly processes, relying on the 
adenosine triphosphate (ATP)-dependent action of chaperones to assist folding8. In 
fact, it is estimated that more than 30% of newly synthesised proteins are degraded 
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due to the inability to fold properly. Chaperones bind to hydrophobic regions exposed 
in unfolded/partially folded proteins or aggregation-protein proteins. The function of 
chaperones becomes especially important when stressors (including mutations, heat, 
oxygen radicals, heavy metal ions, etc) disturb proteostasis, compromising protein 
structure and function. It is not surprising that in response to stress cells upregulate 
HSPs, including the cytosolic chaperones Hsp70 and Hsp90, and small HSPs, Hsp40 
and Hsp2756.   
 
Molecular chaperones refold damaged proteins and can accompany terminally 
misfolded proteins to their disposal machinery, a decision that is mediated by the 
protein triage network8. Both Hsp9056 and Hsp70-Hsp408 are capable of targeting 
terminally misfolded proteins for proteasomal degradation. When in a complex with 
Hsp40 or Hsp104, the refolding capacity of Hsp70 is enhanced and it is capable to 
actively dissociate small and large aggregates, respectively8,56,57. Also, Hsp90 and 
Hsp70 can crosstalk regarding activity and target specificity. Hsp90 is able to bind 
denatured proteins who’s folding is then finalised by Hsp708. 
 
b. CHIP as a co-chaperone 
CHIP was discovered by the Patterson group as a binding protein for Hsc7041 (as its 
name suggests) and, later, Hsp9058 as well. These are highly conserved HSPs that 
function as molecular chaperones, binding to and orchestrating the folding of other 
proteins in association with co-chaperones that dictate their substrate affinity. This 
first study revealed CHIP:Hsc70 interaction but failed to detect chaperone activity. In 
fact, HSP-dependent substrate binding and refolding of luciferase was abolished in 
the presence of CHIP. Thus, CHIP was characterised as a co-chaperone that 
















































Figure 1.7: CHIP as a negative regulator of the chaperone functions of HSPs and protein 
folding 
A) First mechanistic schematic of CHIP supporting that it inhibits the forward reaction of the 
Hsc70-Hsp70 substrate binding cycle. In the forward reaction, ATP is hydrolysed to release 
the substrate, which is promoted by Hsp40. Hsp40 stabilises the ADP-bound state, high-
affinity conformation of Hsc70, enhancing its chaperone activity. 
B) ATPase activities of Hs70/Hsp70 in the presence and absence of CHIP and/or other co-
chaperones. CHIP compromises the ATPase activity of HSPs (by preventing ATP binding or 
inhibition ATP hydrolysis) and/or blocks the interactions of Hsc70/Hsp70-Hsp40 complex with 
the denatured substrate. Different between Hsc70/Hsp70 with/without Hsp40: * and † P < 0.05; 
difference between Hsc70/Hsp70 with Hsp40 in the presence and absence of CHIP: ** (or ††) 
P < 0.05. Six replicates for each condition. 
(Adapted from Ballinger et al.41) 
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Subsequently, the paper reporting the Hsp90:CHIP interaction, shed light into the 
dynamic and key function of CHIP: modulation of the cellular protein triage decisions 
that regulate the balance between protein folding and degradation. This capacity of 
the cell to determine the fate of a protein is achieved through the cooperation of 
chaperones with the degradation machinery. Upon Hsp90 binding to the TPR domain 
of CHIP, Hop and p23 dissociate from the Hsp90 heterocomplex. This CHIP-
dependent remodelling of the Hsp90 heterocomplex disfavours substrate refolding 
and promotes its ubiquitination instead. For example, the glucocorticoid receptor (a 
Hsp90 substrate) has decreased steroid-binding activity in the presence of CHIP, due 
to misfolding, and becomes polyubiquitinated. This modification directs it for 
proteasomal degradation, explaining the decreased receptor steady-state levels in 
cells overexpressing CHIP58. Therefore, CHIP was able to shift the activity of Hsp90 
from protein folding to degradation58–61.  
 
This hypothesis was then challenged by a study supporting the intricate nature of the 
protein triage and suggesting that this change from folding to degradation machinery 
induced by CHIP was not generally true for all Hsp70 substrates57. Unexpectedly, 
overexpression of CHIP enhanced protein refolding in stressed mammalian cells 
(after heat shock) (Figure 1.8A)57, despite previously described as an inhibitor of 
Hsp70 ATPase and chaperone activity in vitro. Therefore, although features of the 
mechanism are shared (ATP- and Hsp70-dependent, but Hsp90-independent and 
mediated by the TPR domain of CHIP), the consequences differ, making it unclear 
what determines the fate of Hsp70-bound substrates. Clearly, the cellular state (e.g. 
stress) influences how proteostasis is regulated. More recently, there has been 
growing appreciation for the conformation of the substrates, which can be heavily 
influenced by stress, dictating their fate (i.e. refolding versus degradation)47,62.  
 
During the recovery from heat shock, luciferase refolding was increased in the 
presence of both Hsp70 and CHIP compared to Hsp70 alone, and this was dependent 
on the TPR domain of CHIP (Figure 1.8B)57. The increased luciferase refolding and 
Hsp70-luciferase interactions detected in cells overexpressing CHIP could have 
different explanations. Firstly, CHIP may increase Hsp70 folding activity by 
counteracting the inhibitory effect that excess Hsp40 levels has on Hsp70 activity 
(Hsp40 reduces Hsp70 recycling by stabilising the ADP-bound state of Hsp70 for 
longer, preventing other substrates from interacting). Secondly, CHIP may promote 
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ATP-bound Hsp70 by preventing ATP hydrolysis, having a higher substrate on-off 
rate (i.e. lower substrate affinity), which could lead to a better loading of denatured 
substrates to Hsp7057. Thus, the binding of Hsp70 to the TPR domain of CHIP could 
stabilise Hsp70-polypeptide complexes. The importance of ATP-bound conformation 
of chaperones for the refolding cycle is particularly important in conditions of cell 
stress41 and underlies why CHIP-mediated increases in chaperone activity have been 
reported under conditions of stress57. However, stabilisation of the Hsp70 complex 
could also drive the assembly of the CHIP E3 ligase complex, favouring the 

















Figure 1.8: CHIP as a positive regulator of HSP chaperone activity and protein folding 
Luciferase refolding in cells overexpressing CHIP, Hsp70 or Hsp70 and CHIP (A) and cells 
overexpressing different forms of CHIP: full-length and CHIP lacking the U-box or the TPR 
domains (B) during recovery from heat shock.   
(Kampinga et al.57) 
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c. Overview of ubiquitination 
Beyond the molecular chaperone network, the UPS also plays a crucial role in 
regulation of the proteome. The UPS is the primary means by which proteins are 
degraded, removing misfolded or damaged proteins and to regulating signalling 
pathways. It is a highly conserved system that plays a central role in cell proliferation, 
transcription, apoptosis, immunity, development and other cellular processes. 
Through a coordinated process relying on ATP and a cascade of enzymes, ubiquitin 
(Ub), a 76-amino acid protein, is added to substrates to create a ubiquitination 
signature that triggers different cellular fates. Each cycle involves, a Ub-activating 
enzyme (E1), a Ub-conjugating enzyme (E2) and a Ub ligase (E3). Initially, E1 forms 
a thio-ester bond with Ub, which allows Ub to then bind to E2. Finally, the formation 
of an isopeptide bond between the C-terminus of Ub and the ε-amino group of lysine 
residue of the substrate protein is catalysed by the E3 (Figure 1.9). Specificity of 
ubiquitination is largely controlled at the level of the E3 ligases. Over E3s of different 
domains, properties and activities have been identified and each is responsible for 
the ubiquitination a subset of proteins9,64,65. Furthermore, post-translational 
modifications on substrates that affect their interaction with ubiquitination enzymes39. 
Another degree of regulation is achieved through the action of DUBs, which reverse 
the isopeptide bonds connecting Ub molecules to the client protein. They replenish 
the pool of Ub by allowing Ub recycling, reverse the Ub status of proteins66, and 
remove free Ub chains that would otherwise overwhelm the proteasome3.  
 
Ub itself has 7 lysine residues that allow for Ub chains to be formed with specific 
linkages when a certain lysine within Ub is linked to the C-terminal glycine of another 
Ub (K6, K11, K27, K29, K33, K48 and K63). The most common are K48-chains and, 
together with K63-chains, account for 80% of total mammalian linkages. Substrates 
can be mono-, multi-mono and poly-ubiquitinated, leading to specific cellular 
effects9,67,68 (Figure 1.9). Although ubiquitination occurs predominantly on lysine 
residues on a substrate, other residues (cysteine, serine and threonine) have also 
been identified and these are believed to serve as proteasomal degradation signals8.  
 
Ubiquitinated proteins are targeted to the 26S proteasome, a highly abundant 
proteolytic complex. It consists of a 20S catalytic core particle capped at either end 
with the 19S regulatory particle. The latter contains Ub receptors and DUBs that 
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function in the recruitment and processing of ubiquitinated proteins, and ATPase 
subunits to unfold the substrate. The unfolded substrate is then exposed the 
chymotrypsin-like, trypsin-like and caspase-like activities of the core particle for 






























Protein endocytosis, lysosomal degradation, localization, 
trafficking, complex assembly and nuclear exportation, DNA 
repair, Histone regulation, Transcription 
Proteasomal 
degradation 
Endocytosis, DNA repair, Proteasomal 
degradation (sometimes), Regulate protein 
function, subcellular localization and 
protein:protein interactions 
Figure 1.9: Ubiquitination 
Illustration of the ubiquitination cascade. Depending on the ubiquitination profile, ubiquitinated 
proteins have different cellular fates62,64,65.  
(Adapted from Cell Signalling Technology9) 
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d. CHIP as a chaperone-dependent E3 ligase 
After being studied as a co-chaperone involved in the refolding of proteins, the focus 
then shifted into investigating its role as a chaperone-dependent E3 ligase61,65. The 
turnover of unfolded Cystic fibrosis transmembrane conductance regulator69 and the 
glucocorticoid receptor58 are examples of such activity.  
 
Interestingly, despite extensive functional redundancy in PQC components, these 
CHIP-mediated ubiquitination events were HSP- and substrate-specific57. Both HSP 
and CHIP substrate specificity is influenced by the conformation of the substrate20. 
CHIP preferentially degrades denatured luciferase compared to native, in a HSP-
dependent manner (showing a  10-fold difference in an ex vivo Ub conjugation 
assay)56. This supported the school of thought that CHIP is primarily involved in 
ubiquitination and degradation of HSP-bound substrates, which tend to be 
misfolded/unfolded proteins20,39.  
 
The U-box of CHIP confers its ubiquitination activity for both its E3 and E4-like 
activities65,70,71. Through the cooperation of specific E2 enzymes, CHIP can 
ubiquitinate client proteins in different ways, leading to different cellular fates39,65. For 
example, Ubc13-Uev1a directs K63 polyubiquitin chains and UbcH5 can lead to K48 
polyubiquitin chains added to the substrate and/or CHIP (auto-ubiquitination)65. CHIP 
catalyses the elongation of Ub chains attached to substrates that were previously 
initiated by another Ub ligase, targeting substrates for proteasomal degradation. For 
example, the Parkin-associated endothelin receptor-like receptor (Pael-R) is 
ubiquitinated by Parkin initially, but CHIP’s association with Hsp70 dissociates the 
latter from Parkin, causing Parkin and Pael-R to become free. As a result, CHIP 
increasing the rate of Pael-R ubiquitination and clearance65,71.  
 
Since most of the chaperone-client interactions are driven by PQC pathways, there is 
strong evidence to suggest that CHIP plays an important role in maintenance of 
proteostasis, both in physiology (under resting conditions) and in pathology (under 
stress). However, in the latter, PQC pathways become challenged and response 
mechanisms come into play. This extends the repertoire of chaperone-mediated 
targets and, in turn, reflects CHIP as a promiscuous co-chaperone and E3 ligase. 
Nonetheless, it is unclear if this stress-responsive behaviour represents the main 
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function of CHIP, or if it emerges secondary, as a stress-induced function that diverts 
CHIP from its intrinsic cellular functions at basal conditions.  
 
e. Role of CHIP in the protein triage 
Given its dual E3 ligase and chaperone functions, CHIP mediates PQC and plays an 
integral role in proteostasis. CHIP can influence decisions of the protein triage, where 
the fate of specific denatured protein is decided, promoting its refolding by the 
molecular chaperone network or degradation via the UPS or lysosome (). It remains 
unclear how these different PQC branches communicate with each other and favour 
a specific pathway. The functional relationship between molecular chaperones and 
the UPS is key for the protein triage and has been proposed to work either in a 






















































Figure 1.10: CHIP at the protein triage 
At the point of triage, the fate of unfolded/misfolded proteins (or aggregated proteins – not 
shown in the schematic) is decided: promoting protein folding/refolding or degradation. CHIP 
interacts with the client protein in a chaperone-dependent or -independent manner. Likewise, 
CHIP-mediated folding of the client protein can be chaperone-dependent (where CHIP acts 
as a co-chaperone), or chaperone-independent (relying on CHIP’s intrinsic chaperone activity 
– discussed in Section 1.3.4). Alternatively, CHIP can direct ubiquitination of the client protein 
to promote its degradation. Again, this mechanism can be chaperone-independent (as part of 
the non-canonical functions of CHIP discussed in Section 1.3.4) or not.       
 
Chapter 1: Introduction  24 
From a competitive perspective, the fate of the denatured protein may be dictated by 
the relative activities of the chaperone system versus the UPS. For example, addition 
of exogenous Hsp70 inhibited degradation of denatured luciferase and promoted 
refolding, whilst the opposite was observed when CHIP was added instead56. 
Alternatively, such competitive nature may arise from the affinity of a substrate for a 
chaperone or protease. A kinetic model for maintaining PQC has been proposed, in 
which the “decision” to degrade a substrate is determined by unproductive on and off 
cycling of substrate-chaperone interactions58.  
 
However, there is also evidence for a highly collaborative network of interactions 
between the molecular chaperone network and the UPS. First, both systems 
developed to be intrinsically able to recognise non-native proteins (including partially 
unfolded, misfolded and incorrectly modified proteins, as well as unassembled 
subunits of complexes), or proteins in the wrong cellular compartments, thus having 
substrates in common. Secondly, systems have common ATP-dependent methods of 
unfolding proteins and share certain components56,58. For example, Hsp90 and 
Hsp70, which apart from functioning independently as chaperones, are required for 
ubiquitination of a subset of proteins (mainly those highly hydrophobic)61. Finally, they 
work jointly and in a dynamic manner to maintain proteostasis and prevent protein 
aggregation. Under basal conditions both systems communicate with each other to 
ensure adequate regulation of protein homeostasis. For example, specific BAG-
Hsp70 interactions favour CHIP-dependent substrate degradation by the proteasome 
or lysosome, or inhibit its ubiquitination activity8. Similarly, when the UPS is 
inhibited/compromised (seen in neurodegeneration, for example), cells respond by 
upregulating HSPs56,58.  
 
CHIP may work in this dynamic communication between the refolding and 
degradation branches. CHIP can convert clients of HSPs to the UPS for degradation. 
Artificial systems have provided some mechanistic insight into this regulation. For 
example, the refolding of denatured luciferase by HSPs (Hsp90 and Hsp70/Hsp40) is 
abolished when CHIP is introduced and, instead, the client protein becomes 
ubiquitinated56. Mechanistically, it was suggested that CHIP stimulates the release of 
the Hsp90 ATPase activity modulating cofactor p23, suppressing the affinity and 
folding activity of Hsp90, hence favouring ubiquitination3. Hsp90 and Hsp70 have 
been broadly described as having opposing effects: promoting refolding or 
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degradation of the target protein, respectively72. Another example is the competitive 
binding of CHIP and Hsp40 to Hsp70, where displacement of Hsp40 prevents the 
folding capacity of the chaperone complex56,57.  
 
At a cellular level it is likely that there is an attempt at chaperone-mediated refolding, 
as a first stage of triage. If successful, this allows the client protein to be removed 
from the triage system. However, if this fails, the co-chaperone CHIP comes into play 
to initiate chaperone-dependent ubiquitination35,56, supporting a sequential mode of 
action for these PQC mechanism. The chaperone-directed recruitment of CHIP 
triggers an allosteric interaction between the TPR and U-box domains3,47. Both TPR 
and U-box domains are required for degradation of denature luciferase to be favoured 
over refolding, showing that both E3 ligase activity and chaperone-interaction 
capability is required56. Mechanistically, the TPR domain mediates interacts with the 
HSP-substrate complex, enabling CHIP-dependent ubiquitination of the hydrophobic 
substrate. Hypothetically, all clients of Hsp70 and Hsp90 are potential targets of CHIP, 
although not all CHIP substrates are recruited by chaperones3 (evident from the non-
canonical functions of CHIP – refer to Section 1.3.4 Non-canonical functions of CHIP). 
Studies using Hsp90 inhibitors supported such overlap in repertoire of client proteins. 
For example, the interferon regulatory factor 1 (IRF-1), which is positively regulated 
by Hsp90, becomes degraded upon Hsp90 inhibition possibly by CHIP (in the 
presence or absence of Hsp70)73. Likewise, CHIP was reported to be responsible for 
the degradation of aberrantly phosphorylated tau (a substrate of Hsp90) upon Hsp90 
inhibition, in a Hsp70-dependent manner35. The canonical view is that CHIP is 
targeted to Hsp90-bound substrates by Hsp70 for ubiquitination58,61. However, it has 
been reported that loss of CHIP does not affect Hsp90 substrates, arguing that Hsp90-
bound CHIP may not be exclusively involved in the ubiquitination of Hsp90 client 
proteins, as was previously concluded from experiments overexpressing CHIP74. This 
paved way to the hypothesis that CHIP may have other functions than those relying 
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1.3.4 Non-canonical functions of CHIP 
Historically, studies investigating the role of CHIP have focused on its functions as a 
co-chaperone and chaperone-dependent E3 ligase. However, this does not 
necessarily mean that these are the primary functions of CHIP, just that the data on 
CHIP is skewed towards these canonical functions. Looking at more recent literature, 
the non-canonical functions of CHIP are emerging, reporting intrinsic chaperone and 
E3 ligase properties41,45,75,76.  
 
There has been increasing evidence to support that CHIP has substrate specificity69 
and may be capable of substrate recognition and direct binding – a function that was 
previously reported to be undertaken by the HSPs. Therefore, under some conditions, 
CHIP might be able to bypass the requirement for a chaperone partner77. Although it 
is arguably a poor substrate of CHIP, identification of Hsp70 as a substrate was critical 
to pioneer investigation into the chaperone-independent E3 ligase activity of CHIP. 
Apart from being functionally regulated by CHIP as a co-chaperone and upregulated 
by CHIP-mediated transcriptional induction of HSF1 to protect against proteotoxic 
stress3,78 (another non-canonical activity of CHIP), Hsp70 is also a direct 
ubiquitination substrate of CHIP. CHIP-mediated Hsp70 ubiquitination triggers its 
degradation and takes place in the aftermath of stress, to bring Hsp70 levels back to 
basal3,79.  
 
An elegant example of CHIP as a docking-dependent chaperone-independent E3 
ligase is its interaction with IRF-1. CHIP binds directly to free IRF-1 by docking to the 
intrinsically disordered domain within the central region of IRF-177 and this causes 
site-specific ubiquitination80. Interestingly, this interaction is dependent on the cellular 
environment - under conditions of mild heat stress IRF-1 readily is ubiquitinated by 
CHIP, resulting in its degradation. However, in unstressed cells, CHIP acts as a 
chaperone of IRF-1, increasing its steady-state levels (Figure 1.11). CHIP:IRF-1 


























Likewise, CHIP-mediated regulation of p53 has been reported to capitalise on both 
the intrinsic chaperone and E3 ligase properties of CHIP. Potentially via its chaperone 
activity, CHIP prevented wild-type (WT) p53 from thermal inactivation in vitro and 
restored the native-like conformation of p53 (capable of DNA-binding) in heat shocked 
cells. Furthermore, it was proposed that CHIP might be a direct chaperone of WT p53 
for its translocation to the nucleus under heat shock conditions. As an E3 ligase, CHIP 
was reported to mediate the degradation of WT and mutant p53. These processes 
were chaperone-independent81.   
 
Rosser and colleagues63 looked more closely into the intrinsic chaperone activity of 
CHIP. CHIP was able to refold denatured luciferase in vitro and in cells in a manner 
that was independent of Hsp70. The chaperone function was temperature-sensitive, 
increasing when exposed to heat shock. Interestingly, the group suggested that 
through its chaperone activity, CHIP was able to maintain heat-denatured luciferase 
in a foldable and ubiquitination-competent conformation. Indeed, following heat 
shock, CHIP was also capable of ubiquitinating the substrate, in the absence of 
A 
B 
Figure 1.11: Dual role of CHIP as chaperone and E3 ligase of IRF-1 
A) A375 cells transfected with a titration of Myc-CHIP were heat-shocked and harvested 
immediately (Heat stress) or allowed to recover for 1h (Recovery). SDS-PAGE/immunoblot 
using anti-IRF1, anti-Myc and anti-GAPDH mAbs.   
B) In vitro ubiquitination assay with GST-IRF1 and a titration of His-CHIP (until 1mg). SDS-
PAGE/immunoblot using anti-CHIP and anti-IRF1 mAbs.  
(Narayan et al.77) 
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chaperones. Ultimately, the levels of luciferase ubiquitination increased and protein 
aggregation decreased63. 
 
The intrinsic E3 ligase activity of CHIP was supported by the CHIP-dependent 
ubiquitination of biologically relevant proteins in the absence of chaperones, including 
Smad1/582, the insulin receptor (INSR)62 and Daxx83. Smad1/5 binds to the TPR 
domain of CHIP and competes with the binding of HSPs, which suppresses CHIP-
mediated ubiquitination82. Likewise, CHIP-dependent ubiquitination of the INSR 
occurs in a chaperone-free in vitro reaction and the TPR domain is required for direct 
recognition of the substrate. Interestingly, the CHIP-dependent ubiquitination of Daxx 
is stress-induced and Ub chain formation utilises non-canonical lysine linkages that 
are associated with resistance to proteasomal degradation. Daxx binds to the charged 
domain of CHIP83. Although CHIP:substrate interaction could occur directly, as with 
IRF-177, this has not been addressed  specifically (instead, only the structural domains 
necessary for the interaction were deduced from mutational analysis).          
 
CHIP is not unique in possessing both intrinsic chaperone and E3 ligase activities. 
The mouse double minute 2 (MDM2) protein utilises these functions to regulate the 
proteostasis of p53 in cells. As observed with other chaperones, p53 undergoes 
MDM2-mediated folding-unfolding cycles to promote its folding to a conformation that 
has high affinity towards its promoter sequence. At the same time, MDM2 can trigger 
the degradation of p53 by ubiquitination. Such apparent contradictory mode of action 
(capable of both refolding and degrading protein targets)84 is also seen for CHIP77 
and, similarly, is likely to be regulated by interactions with molecular chaperones 
(including Hsp90)84.  
 
The properties of CHIP allow it to regulate protein stability, turnover (including 
transcription and degradation), trafficking (e.g. ubiquitination renders proteins in 
insoluble cellular compartments85) and activity (e.g. ubiquitinated proteins may act as 
scaffolding proteins for signalling hubs39,86). CHIP has been associated with a wide 
and diverse array of substrates (including signalling molecules, receptors, kinases, 
etc) resident in different subcellular compartments (including the cytoplasm, plasma 
membrane, nucleus, ER and Golgi complex)65,87. Concomitantly, CHIP plays direct or 
indirectly roles in numerous cellular processes important in health and disease65, such 
as quality control of the ER, response to stress (including heat stress and oxidative 
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stress), protection from stress-induced apoptosis, ageing and senescence, 
metabolism, proliferation, immunity (both potentiating and dampening inflammatory 
responses) and proteasomal and autophagy-lysosomal degradation20. CHIP has 
functions in disorders including PD, AD, Huntington’s disease, Atherosclerosis, SCA1, 
hypogonadism and cancer20,87.  
 
Chaperones are highly promiscuous with regards to their client proteins. Therefore, 
when chaperones interact with CHIP, it is likely that the interactome of CHIP expands 
and the proteostasis of more proteins becomes influenced by CHIP. This can widen 
the scope of CHIP’s functions, potentially activating more secondary functions 
(beyond its intrinsic functions). Given the intimate relationship of CHIP and molecular 
chaperones in the protein triage system, the main roles and mechanisms of action of 
CHIP may be confounded by the influence of the chaperones. Therefore, identification 
of direct substrates of CHIP (chaperone-independent) is likely to shed light into its 




1.4 CHIP and neurodegeneration 
1.4.1 CHIP-related diseases 
Across the literature, the neuroprotective properties of CHIP prevail and have been 
reported to be driven by both the canonical and non-canonical functions of CHIP. 
Perhaps the most compelling evidence to support the importance of CHIP in health 
comes from studies into CHIP-related diseases.    
 
CHIP mutations are autosomal recessive and lead to a syndrome (referred to as 
Gordon Holmes syndrome13)  with broad symptoms, including cerebellar ataxia. The 
syndrome can be grouped into five major classes88: 
• Mitochondrial energy deficiencies (eg. Friedreich’s ataxia), 
• Ataxias with DNA repair defects (eg. Ataxia telangiectasia), 
• Metabolic ataxias, 
• Congenital ataxias,  
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• Degenerative ataxias (such as Autosomal recessive cerebellar ataxia, ARCA, 
including Spinocerebellar ataxia autosomal recessive type 16, SCAR16).  
The effects of CHIP dysfunction are described as being gradual, eventually causing 
a multisystemic disease with severe dementia (Figure 1.12). This illustrates the 

















Multiple STUB1 mutations have been linked to the pathogenesis of SCAR16. 
Although their molecular and cellular consequences are still unclear, they support a 
loss-of-function disease mechanism. SCAR16 is an adolescent-onset, fate and rare 
form of neurogenerative disease characterized by ataxia, gait instability, loss of 
balance and discoordination, due to cerebellar degeneration, in addition to cognitive 
impairment. Apart from mutations that abort translation of full-length CHIP, 13 point 
mutations have been reported, spanning from the TPR domain (E28K, N65S, A79D/T 
and L123V), to the linker region (N130I, K145Q, W147C, L165F and M211I) and the 
U-box (S236T, M240T and T246M)38,49. These are biallelic STUB1 mutations 
identified by screening ataxia patients with whole exome sequencing. The majority of 
these mutations are inherited in a compound heterozygotic manner and they affect its 
protein structure and folding. Some mutations impair CHIP’s catalytic activities, while 
others destabilise the protein, or both. The end-effect is compromised CHIP activity 
as a chaperone and, possibly more severely, as an E3 ligase13,38,49.   
Figure 1.12: Clinical spectrum of CHIP (STUB1) mutations 
Although single individuals may be missing some of these symptoms (eg. patients with Gordon 
Holmes syndrome), these are part of a continuum of CHIP-associated disease features, rather 
than in isolation. 
(Hayer et al.13) 
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CHIP mutant were showed a severely compromised E3 ligase activity (namely N65S 
and L123V38,49, and U-box mutants S236T, M240T and T246M (Figure 1.13))49. A 
possible explanation is the mutated residues are important for CHIP-substrate 
binding, thus directly diminishing CHIP’s docking-dependent intrinsic E3 ligase 
activity. This is the case of the N65S CHIP mutant, which only poorly ubiquitinated 
Hsc70 whilst having an auto-ubiquitination pattern similar to WT CHIP38. However, an 
impaired CHIP-substrate binding may be caused indirectly: by a compromised 
interaction between CHIP and the previously formed chaperone-substrate complex 
(which facilitates ubiquitination of misfolded proteins). Indeed, some TPR mutant 
CHIP isoforms (N65S and L123V) showed a weakened affinity for chaperones by 
fluorescence polarization assay, which is likely to impair CHIP-chaperone interaction, 
being a possible pathogenic mechanism49. However, it is not the common biological 
consequence of all TPR mutant CHIP isoforms, since E28K showed similar 














A second hypothesis of the mechanism of action of CHIP mutants is that these fail to 
ubiquitinate substrates due to defects in E2 recruitment (preventing Ub chain 
formation) or structural defects preventing the anchoring of ubiquitination chains on 
the substrate38,49. Time-resolved fluorescence energy transfer (TR-FRET) revealed 
that mutations in the U-box and the TPR mutant N65S prevented E2 recruitment49. 
Hence, it is not surprising that the T246M mutant failed to ubiquitinate Hsc70 and to 
Figure 1.13: E3 ligase activity of CHIP mutations 
In vitro ubiquitination assay of Hsp70 by WT and SCAR16 CHIP mutants performed for 1h at 
37ºC.  
(Kanack et al.49) 
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auto-ubiquitinate38. The other mutations only formed free Ub chains due structural 
defects (causing a poor alignment between the E2 and the substrate)49.  
 
A third mechanism that is not mutually exclusive regarding mutations that impair the 
catalytic domains are mutation-driven changes in overall protein folding and 
oligomeric state that would also lead to loss-of-function. T246M CHIP, and other 
mutants, had a loss of secondary structure38,49. This structural instability explains its 
tendency to aggregate (from dimeric to mainly monomeric and higher-order 
oligomers38) both in vitro and in cells. In the latter system, a decrease in the steady-
state levels of CHIP was also observed, which could have similar consequences to 
CHIP loss-of-function38,49. However, this mechanism does not apply to all mutations 
in enzymatic domains, since the TPR mutant E28K showed a 28% and 67% decrease 
in dimeric and monomeric conformations, respectively, while the N65S mutation 
increases the formation of highly stable dimers, having a similar biophysical profile as 
WT CHIP38. This mechanism of action seems to be particularly relevant for CHIP 
mutants with point mutations in the linker domain (e.g. M211I)38. Alternatively, rather 
than resulting in bulk structural changes in CHIP, mutations in the U-box directly or 
the TPR domain can alter the flexibility and molecular motions of the U-box domain, 
compromising the E3 ligase activity. Mutations and interactions to the TPR domain 
has been shown to allosterically regulate the U-box, including chaperone-binding47. 
Therefore, using Hsp70 as a read-out of the E3 ligase activity of the SCAR16 CHIP 
mutants is not ideal, since chaperone-binding itself allosterically inhibits the U-box.  
 
 
1.4.2 Neuroprotective activity of CHIP 
The association of CHIP loss-of-function mutations to neurodegeneration is strong 
proof-of-concept of its involvement in the maintenance of neuronal health. However, 
we lack mechanistic insight into its neuroprotective actions.  
 
Age is the strongest risk factor for neurodegenerative diseases, thus indirect and 
direct effects of CHIP in the ageing processes could help to explain its actions. 
Furthermore, given the proteinopathic nature of most neurodegenerative diseases, 
CHIP could also help to prevent widespread protein accumulation or counteract the 
dysregulation of specific disease-associated proteins (such as α-Syn in 
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synucleinopathies). These potential neuroprotective mechanisms will be reviewed. It 
is interesting to consider that advanced neurodegeneration mimics, to some extent, 
loss-of-function of CHIP, as WT CHIP can become trapped in the aggregates formed 




a. Indirect role of CHIP in regulating longevity 
The course of neurodegeneration is long and complex, having a cascade of events 
that unravel before aggregate formation, detection of disease biomarkers and 
manifestation of clinical symptoms. There extensive evidence to suggest that CHIP 
counteracts protein dyshomeostasis, preventing proteotoxicity, which is a known 
driver of ageing. This is largely due to its pivotal roles in PQC and stress responses. 
Furthermore, small changes in its expression and/or activity are likely to have 
pronounced effects in cell health, due to its dual actions and vast substrates.  
 
CHIP KO mice and Drosophila have increased proteotoxic stress compared to age-
matched WT - evident from the rapid age-dependent accumulation of oligomers 
(Figure 1.14)14,62. In parallel, CHIP KO mice have compromised 26S proteasomal 
activity14 and extensive oxidative stress (both at protein and lipid levels) in the brain15. 
CHIP KO flies are also more sensitive to drug-induced oxidative stress62. Whether 
impairments in PQC mechanisms and redox homeostasis are a cause or 
consequence of the proteotoxic stress, they feed a viscous cycle that is commonly 
seen in ageing and, more severely, across neurodegenerative diseases. There is 
strong evidence to suggest that oxidative stress contributes to ageing89. However, the 
accelerated ageing phenotype observed in CHIP KO mice was more severe than in 
animals lacking enzymes directly involved in redox homeostasis (e.g. superoxide 
dismutase, SOD), supporting the role of CHIP in the regulation of different 


































Another mechanism by which CHIP has been implicated in the prevention of 
proteotoxic stress, is in the maturation of aggresomes. Cells lacking CHIP have 
increased protein aggregates that fail to form mature aggresomes, a process that is 
dependent on its E3 ligase activity90. These have been described as neuroprotective, 
as age-dependent aggregate load is believed to improve proteostasis and mitigate 
the effects of proteome imbalance. Aggregates in aged long-lived worms consist 
mainly of highly abundant and stable proteins (with lower intrinsic aggregation 
propensity), whilst aggregates in aged short-lived worms include more aggregation-




Figure 1.14: Proteotoxic stress in CHIP KO mice and Drosophila 
A) Dot blot using an anti-oligomer antibody against cortical tissue lysate of CHIP KO and WT 
mice of 3 and 12 months old (left). R120G (α-R-crystallin) was used as a positive control 
(right). The antibody recognises soluble aberrantly folded oligomers.  
B) Oligomer levels were 3-fold higher in both 3- and 12-month old CHIP KO mice compared 
to age-matched controls (right). 
C) Loss-of-function allele chn-1 (by155) lack the single CHIP worm ortholog have increased 
age-dependent aggregation of a mutant polyglutamine protein and have decreased survival 
rates when treated with paraquat (drug-induced oxidative stress). 
(A-B: Min et al.14; C: Tawo et al.62) 
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The composition of the latter resembles inclusions detected across 
neurodegenerative diseases19. This supports the hypothesis that controlled 
sequestration of disease proteins may be a beneficial and active defence mechanism. 
Like small HSPs (Figure 1.15 B&C), CHIP may contribute to this active, proteome-
wide mechanism in promoting protective aggregation19,90. CHIP-mediated aggresome 
maturation requires ubiquitination of inducible nitric oxide synthase (iNOS) by CHIP 
in a chaperone-dependent manner. Ubiquitinated iNOS becomes sequestered in 
aggregates and interacts with HDAC6, which is necessary for maturation of the 
aggresome. This mechanism is promoted in conditions of proteasomal overload. 























Signs of a progeria phenotype in CHIP KO models were observed at both cellular and 
organ levels. For example, tissues derived from CHIP KO cells had markers of 
senescence (including senescence-associated β-galactosidase and lower 
A B C 
Figure 1.15: Aggresome formation 
A) In young adult WT worms, proteostasis is maintained and soluble aggregates (red) are 
efficiently cleared. 
B) In aged WT worms, accumulated aggregation-prone species associate with small HSPs. 
These may act to seed and concentrate aggregation material. However, mechanisms of 
protective aggregation are only partly active when proteostasis is strongly reduced. 
C) In daf-2 mutant worms with increased longevity, mechanisms of protective aggregation 
formation are fully active, thus proteostasis collapse is delayed.    
(Adapted from Walther et al.19) 
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proliferation rate compared to WT), compromised energy biogenesis and 
mitochondria homeostasis14,15,78. Therefore, if CHIP-mediated neuroprotective 
mechanisms are chronically or become gradually impaired during the course of 
disease, homeostatic defects build up and premature ageing is the end-result.  
 
 
b. Direct role of CHIP in regulating longevity 
One way in which CHIP can influence the development of neurodegenerative 
diseases is by directly modulating proteins involved in the regulation of longevity, 
since ageing is intimately related with neurodegeneration. P53 is a key modulator of 
cell arrest, repair and death when stressed or damaged, by transcriptionally regulating 
genes involved in cell cycle control, DNA repair, apoptosis and cellular senescence 
(irreversible growth arrest). To remain responsive, p53 levels must be kept at low 
levels and accumulate upon stress, having its levels regulated by various post-
translational modifications and Ub-dependent proteasomal degradation. The latter is 
chiefly mediated by the E3 ligase MDM2, but chaperone-dependent ubiquitination of 
p53 by CHIP has been reported91, although the supporting data is weak and derived 
from overexpression systems.  
 
However, it has been reported that p53 levels are increased in presenescent cells and 
then decreased in terminally senescent cells, which negatively correlates with CHIP 
levels and activity. This paved way to the hypothesis that CHIP-mediated degradation 
of p53 is important for a timely transition to arrest, whilst MDM2 regulates p53 at basal 
conditions91. As mentioned, CHIP KO mice have increased markers of senescence14 
and CHIP silencing in young fibroblasts results in premature senesecence91. 
Furthermore, in a senescence-accelerated mouse model, CHIP expression was 
abnormally decreased in the cerebral cortex and hippocampus92. Taken together, 
CHIP could regulate longevity via regulation of p53 and senescence.  
 
More recently, CHIP has been reported to ubiquitinate the INSR and affect the 
lifespan of organisms. Not only does the insulin and insulin-like growth factor 1 
signalling (IIS) influence longevity, it regulates innate immunity, stress response and 
proteotoxic stress resistance. CHIP loss-of-function worms have a reduced lifespan 
that is mimicked by RNAi-mediated downregulating daf-16 (a transcription factor 
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downstream of daf-2, the worm orthologue of INSR), and in turn the IIS. This 
phenotype was not further reduced by deleting the CHIP orthologue, chn-1 (Figure 
1.16A), implying that CHIP might affect longevity through the IIS. Mechanistically, 
CHIP-mediated chaperone-independent mono-ubiquitination of INSR triggers 
endocytic-lysosomal turnover, under basal conditions. However, with increasing 
proteotoxic stress (i.e. during ageing), the capacity of CHIP to degrade the INSR is 
diminished (Figure 1.16B), leaving to its accumulation which is associated with the 
activation of pro-ageing genes62. Therefore, through PQC mechanisms, CHIP can 



























Figure 1.16: CHIP modulates longevity pathways directly 
A) C. elegans chn-1 mutant (by155) exhibits a reduced lifespan compared to WT and in a 
similar manner as worms with depleted daf-16 (by RNAi). Daf-16 depletion in the chn-1 mutant 
worm did not reduce longevity further. 
B) WT worms that were temperature-shifted (from 15ºC to 25ºC at day 1 of adulthood) show 
an age-related increase in daf-2 that was not significantly detected in controls worms.  
(Tawo et al.62) 
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c. CHIP interactions with disease-specific proteins 
The presence of CHIP within LB of patients with α-Synucleinopathies25 and its ability 
to ubiquitinate α-Syn25,93 supported its involvement in the pathology of PD and DLB25. 
Through its chaperone and E3 ligase activity, CHIP could counteract the accumulation 
of toxic misfolded, disease-associated proteins. Multiple studies have supported this 
hypothesis as a possible mechanism of action underlying CHIP’s neuroprotective 
effects.  
 
Although there are increasing studies reporting interactions between CHIP and α-
Syn, the biochemical details and biological significance of such remain largely 
unknown, because assays tend to rely on overexpression systems and the use of 
tagged or modified proteins. Not only are these non-physiological systems, but the 
overexpression of CHIP is intrinsically fraudulent due to its expected pronounced 
effects on proteostasis. Nonetheless, the prevailing hypothesis regarding the role of 
CHIP in the context of synucleinopathy is that its neuroprotective effects are driven 
by CHIP-dependent regulation of α-Syn homeostasis.  
 
In vitro37 and in vivo94 studies aimed at observing α-Syn aggregation in difference 
CHIP backgrounds, suggested that CHIP may play a role in suppressing α-Syn 
aggregation and inclusion formation. Overexpression of CHIP decreased the number 
and size of α-Syn aggregates (Figure 1.17) and significantly prevented neuronal loss, 
mitigating α-Syn-induced toxicity94. In vitro mutational strategies (using CHIP∆U and 
CHIP∆TPR) showed that this CHIP-mediated reduction in α-Syn oligomer formation 
occurs in an chaperone-dependent manner, involving Hsp7037 or Hsp9035. This was 
contradicted by Shin et al.25, who reported that either of CHIP’s enzymatic domains 
independently were sufficient to achieve reduction of α-Syn-rich inclusions and 
change their morphology from large inclusions to diffuse micro-aggregates (Figure 
1.18). Therefore, different pathways (non-degradative and/or degradative via the 
proteasome or lysosome) may be employed25. The biological significance of these 











































Figure 1.17: Effect of CHIP on in vivo α-synuclein aggregation 
A) For the in vivo bimolecular fluorescence complementation (biFC) assay rats were co-
injected AAV-venus1-synuclein and AAV-synuclein-venus2 ± AAV-myc-CHIP. Interaction of 
both tagged synuclein fragments results in venusYFP fluorescence (by reconstituting the 
fluorophore), hence regarded as a read-out of α-Syn aggregation. CHIP presence decreased 
fluorescence intensity by 50% (B) and venusYFP-positive cells by 35% (C). 
(Dimant et al.94) 
Figure 1.18: Effect of CHIP on in vitro α-synuclein aggregation 
H4 cells cotransfected with Syn-T, synphilin-1, and either CHIP, CHIP∆U, or CHIP∆TPR were 
immunostained for α-Syn.  
A) Quantification of the number of inclusions per cell.  
B) Single cells immunopositive for inclusions in the different co-transfection conditions, 
together with the quantification of large inclusions present (below). CHIP (b) and CHIP∆U (c) 
transfection resulted in a reduction of the number of large inclusions compared to control cells 
(a), while CHIP∆TPR (d) cells had large inclusions with a similar morphology to those seen in 
cells without CHIP overexpression (a). Therefore, CHIP’s effect on inclusions seems to be 
largely dependent on its chaperone functions.   
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There is limited in vitro (Figure 1.19A) and in situ (Figure 1.19B) evidence to support 
that CHIP mono-, multi-mono- and/or poly-ubiquitinates α-Syn68. However, α-Syn 
ubiquitination tends to be studied under optimal conditions and in genetically 
manipulated models, thus direct evidence of CHIP-dependent ubiquitination of 
endogenous α-Syn in both healthy and synucleinopathy background is still lacking. 
This could be of biological significance, given the suggested negative correlation 
between α-Syn ubiquitination and aggregation. Overexpression of mutant α-Syn 
fragments that could not be ubiquitinated resulted in a 16% increase in oligomerisation 
compared to WT fragments. Oligomerisation was quantify using the bimolecular 
fluorescence complementation assay68. This approach is not only limited by the 
problems associated with overexpression, but also by the effects of introducing a 
























Figure 1.19: CHIP-mediated ubiquitination of α-synuclein in vitro (A) and in cells (B) 
A) In vitro ubiquitination assay was performed by incubating purified recombinant human 
untagged WT α-Syn, Ub, Ube1, UbcH5b, CHIP, and Mg-ATP as indicated. Reactions were 
analysed by SDS-PAGE/immunoblot using anti-α-Syn and anti-Ub Abs.  Mono- and 
polyubiquitinated α-Syn species were detected. The asterisk (*) indicates a non-specific band.  
B) H4 cells were transfected with syn-luc1, myc-CHIP, HA-Ub and FLAG-BAG5, as shown. 
Immunoprecipitations with anti-luc were performed and analysed by SDS-PAGE/immunoblot 
using anti-α-Syn and anti-HA Abs. The asterisk (*) indicates cross-reactivity of the secondary 
antibody with the immunoglobulin light chain.   
(Kalia et al.68) 
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Both chaperone and E3 ligase functions may cumulatively contribute to the regulation 
of α-Syn homeostasis, since reduction of CHIP levels caused a 35% increase in 
oligomerisation of WT α-Syn fragments68. Despite the limitations of the studies 
discussed, all of them support the direct relationship between of α-Syn homeostasis 
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1.5 Objectives of this thesis 
Although defects in protein homeostasis are regarded as early drivers of 
neurodegeneration, these tend to be studied in the context of aggregation (i.e. 
proteotoxic stress). However, aggregates are the consequence of years of disease 
and are rather late biomarkers of cellular stress. Early and more subtle changes in 
the proteome could shed light into disease-promoting events. These are also likely to 
be the most promising therapeutic targets to stop or slow down disease progression. 
 
This project aims to investigate the protein targets of CHIP in a synucleinopathy 
background prior to pronounced proteome imbalances and neurodegeneration. 
Identification of protein targets of CHIP could help explain its early neuroprotective 
effects, which remain largely unknown. In contrast, several mechanisms have been 
proposed regarding its chaperone and E3-ligase functions in models with late 
biomarkers or symptoms of disease, where comprehensive and robust stress 
responses have been activated. This masks the intrinsic functions of CHIP, which 
could have the most biological significance in promoting neuroprotection.   
 
For a comprehensive understanding of how CHIP regulates protein homeostasis in 
neuronal cells, this project focuses on the manipulation of endogenous CHIP. This 
will be accomplished using a combination of novel precision biologic tools and gene-
edited authentic neuronal cell models. Chapter 3 describes the engineering of CHIP 
KO patient-derived induced pluripotent stem cells (iPSC) and subsequent 
differentiation into cortical neurons. The effect of the deletion on the proteome will be 
evaluated using an unbiased approach (Chapter 4).  
 
Candidate protein targets identified will be further investigated in different CHIP cell 
models in attempt to obtain mechanistic insight into the underlying CHIP-mediated 
regulation and its possible cellular significance (Chapter 5). Finally, tools to modulate 
CHIP’s activity in vitro and in situ will be produced and their effect evaluated in 
Chapter 6. The aim is to enrich our understanding of the biochemical properties and 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Chemicals  
All chemicals and solvents were obtained from commercial sources (Sigma, if not 
otherwise stated) and are Analar or molecular biology grade. Buffers were made up 
with deionized water.  
 
2.1.2 Cell lines  
Table 2.1: Cell lines and culturing conditions 
Cell line Gene edit Culturing conditions Origin 
SH-SY5Y CRISPR control (CHIP WT) DMEM (41965-039, 
Gibco), 10% fetal bovine 
serum (10270-106, 








CHIP KO expressing 
H260Q mutant CHIP (stable 
transfection) 
CHIP KO expressing K30A 
mutant CHIP (stable 
transfection) 
CHIP KO expressing WT 
CHIP (stable transfection) 
AST23 Unedited iPS-Brew XF (130-104-
368, StemMACS, 
Miltenyi Biotech Inc.), 
37ºC, 5% CO2 in a 
humidified atmosphere. 
iPSC derived from 
the fibroblasts of a 
synucleinopathy 
patient (carrying a 
SNCA triplication) 
Clone name: C1 
CRISPR control (CHIP WT) 
Clone name: D3 
CHIP heterozygous null 
Clone name: C6 
CHIP KO (homozygous) 
The parental (unedited) cell lines were a kind gift from Dr Tilo Kunath.  
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2.1.3 Antibodies 
Table 2.2: Primary antibodies 
Target Class Name/Reference Source 
CHIP Mouse mAb 3.1 Gift by B. Vojtesek 
α-Synuclein Mouse mAb 610787 BD Biosciences 
ANXA2 Mouse mAb Ab54771 Abcam 
ANXA2 Rabbit pAb Ab41803 Abcam 
S100-A11 Rabbit pAb 10237-1-ap Proteintech 
p53 Mouse mAb DO-1 Gift by B. Vojtesek 
LC3B Rabbit pAb Ab48394 Abcam 
p62 Rabbit pAb BML-PW9860 Enzo Life Sciences 
K48-specific 
chain linkage 
Rabbit mAb 4289S Cell Signalling Technology 
K63-specific 
chain linkage 
Rabbit mAb 5621S Cell Signalling Technology 
Ubiquitin Mouse mAb P4D1, sc-8017 Santa Cruz Biotechology 
Ubiquitin Mouse mAb F-11, sc-271289 Santa Cruz Biotechology 
Ubiquitin Mouse mAb FK2, PW8810 BioMol 
V5 Mouse mAb (IgG2a) Ab27671 Abcam 
V5 Goat pAb Ab9137 Abcam 
β(III)-tubulin Mouse mAb IgG2b Tuj, T8660 Sigma 
Pax6 Mouse mAb IgG1 AB_528427 DSHB 
Tbr1 Rabbit pAb ab31940 Abcam 
Ctip2 Rat mAb ab18465 Abcam 
Cux1 Rabbit pAb sc-13024 Santa Cruz Biotechnology 
HLA-B Rabbit pAb PA5-35345 Invitrogen 
HLA-A Rabbit pAb PA5-29911 Invitrogen 
HLA-C Rabbit mAb Ab126722 Abcam 
β-actin Mouse mAb A5441 Sigma 
GAPDH Mouse mAb 1650326 Abcam 
VGF Mouse mAb B-8 Santa Cruz 
VGF Rabbit pAb Ab69989 Abcam 
IFITM1/3 Mouse mAb MHK Gift by B. Vojtesek 
INSR Mouse mAb Ab69508 Abcam 
Hsp90 Mouse mAb SPA-830 Stressgene Bioreagents 
Corp. 
PARP Mouse mAb MAB3290 Millipore 
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Table 2.3: Secondary antibodies 
Target Class Conjugate Reference Source 
Mouse Rabbit pAb HRP-conjugate PO260 Dako 
Rabbit Swine pAb HRP-conjugate PO217 Dako 
Mouse (IgG1) Goat pAb A488 A21121 Invitrogen 
Mouse (IgG1) Goat pAb A555 A21127 Invitrogen 
Mouse (IgG2b) Goat pAb A647 A21242 Invitrogen 
Mouse (IgG2b) Goat pAb A488 A21141 Invitrogen 
Rat Goat pAb A630 A11007 Invitrogen 
Mouse (IgG1) Donkey pAb A488 A21202 Invitrogen 
Mouse (IgG1) Donkey pAb A594 A21203 Invitrogen 
Rabbit Donkey pAb A488 A21206 Invitrogen 
Rabbit Donkey pAb A555 A31572 Invitrogen 
Mouse Donkey pAb PLA, minus probe DUO92001 Sigma 
Rabbit Donkey pAb PLA, plus probe DUO92005 Sigma 
 
2.1.4 Plasmids 
Table 2.4: Plasmids 
Plasmid Description Expression Source 
pSF-CMV (OG2) Contains the pUC high-copy 
origin of replication. Ampicillin 
resistance. 
Mammalian Oxford  
LentiV2 CRISPR 
plasmid  
Contains two expression 
cassettes: hSpCas9 and the 
guide RNA: 
GGCCGTGTATTACACCAACC 
Mammalian Erisa Nita 
pmaxGFP Encodes GFP. Mammanlian Lonza 
16AAVZBP_scFv_11F 
_V5_pMA-T 
Holder plasmid containing the 
V5-tagged scFv-encoding 




Holder plasmid containing the 
V5-tagged scFv-encoding 
insert. Ampicillin resistance. 
Bacterial Invitrogen 
pET3a Encodes His-tagged wild-type 
CHIP 
Bacterial Gift from Dr 
Vikram 
Narayan 
pet15b -UbcH5α Encodes the E2 conjugating 
enzyme, UbcH5α. Ampicillin 
resistance. 
 Gift from Dr 
Fiona Lickiss 
 
The glycerol stocks of BL21-DE3 bacteria expressing either 11F or 7A scFv antibodies 
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2.1.5 Primers 




Tm = 68ºC 
 
 
b. For quantitative reverse transcription PCR (qRT-PCR) 
Primers for qRT-PCR (outlined in Table 2.5) were obtained from Sigma and designed 
using the Universal ProbeLibrary Assay Design Center (Roche). 
 






Primer (5’ – 3’) Efficiency 
Forward sequence Reverse sequence 
hCDK6 85 gaactaggcaaagacctacttctga ggtgggaatccaggttttct 2.161 
hNanog 87 tctccaacatcctgaacctca ttgctattcttcggccagtt 2.004 
hOct4 78 tgccgtgaaactggagaag gcttggcaaattgttcgagt 2.015 
hVimentin 11 agatggcccttgacattgag cagggaggaaaagtttggaa 1.844 
hNestin 65 acctgtgccagcctttctta gccaaggtaggggtacgg 2.154 
hOtx2 86 aacctcccatgaggctgtaa ggtggacaggttcagagtcc 2.007 
hEmx1 25 ctctccgagacgcaggtg ttcttctgctcggactcagg 2.015 
hPax6 20 tcaccatggcaaataacctg cagcatgcaggagtatgagg 1.980 
hFoxG1 58 tactaccgcgagaacaagca tcacgaagcacttgttgagg 2.075 
hTbr2 69 gagtcggcaggtgggtag tcttccgaggggaaggtaa 1.953 
hTbr1 31 ttcaaataacaatgggcagatg gtctcagggaaagtgaacgtct 2.156 
hCtip2 82 ccgccagagatagggttttt ctggtcatgcacaacctcag 2.032 
hCux1 20 agaggccactgccctattct ctggagatgatggaaagcagt 2.019 
hBrn2 80 ctttgcaggcgagtaaccag ttctagctatcacacactctcctca 1.967 
hSNCA 68 gagggagtggtgcatggt tgctgtcacacccgtcac * 
hStub1 70 gttcgtgggccgaaagta ggcccggttggtgtaata 1.874 
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2.2 Microbiological techniques 
All microbiological techniques were performed using aseptic conditions.   
 
2.2.1 Growth of bacterial cultures 
Bacterial cultures were grown in Luria-Bertani (LB) broth in an incubator-shaker at 
37ºC and 220 rpm. To ensure adequate aeration, the sterile vessels used were at 
least 4-times the volume of the culture being grown. According to the resistance of 
the plasmid, selective antibodies were added to the culture (for ampicillin, a 




1% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
Sterilised by autoclaving (121ºC, 20 min). 
 
LB-agar plates were prepared by heating agar until liquid, cooling it to about 40ºC, 
adding the selective antibiotic (using the same final concentration as above) and 
pouring into 90 mm petri dishes. The plates are further cooled until the agar has 
solidified and were then allowed to dry at 37ºC for 1 h prior to use.  
 
LB agar 
1% (w/v) Tryptone  
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
1.5% (w/v) Agar 
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2.2.2 Glycerol stocks 
For long time storage of bacterial cultures, glycerol stocks were prepared. For such, 
800 µl of overnight culture was aliquoted into a sterile cryotube and 200 µl of 70 % 
(v/v) sterile glycerol was added and mixed gentle. Glycerol stocks were snap-frozen 
in liquid nitrogen and stored at -80ºC. 
 
  
2.2.3 Preparation of competent cells 
Bacteria (DH5a and BL21(DE3)) from glycerol stocks (Invitrogen) were inoculated into 
3 ml of sterile, antibiotic-free LB broth and incubated overnight in a shaking incubator 
at 37ºC and 220 rpm. The overnight culture was diluted 1:200 in fresh LB media (e.g. 
250 µl of the overnight culture into 50 ml of LB media) and grown until OD600 nm 
(measured using Lambda Bio, Perkin Elmer) has reached 0.4 - 0.6. The culture was 
then cooled down on ice and then centrifuged at 4000 rpm for 15 min at 4ºC.  
 
The pellet was resuspended in ice cold buffer I (16 ml when using the volumes 
mentioned above) and incubated for 10 min on ice. Cells were centrifuged again as 
above. The pellet was resuspended in ice cold buffer II (2 ml) and incubated for 10 
min on ice. This was then aliquoted into pre-chilled sterile microcentrifuge tubes. The 
aliquots (containing 50 µl of competent cells) were snap-frozen in liquid nitrogen and 
stored at -80ºC.  
 
Buffer I 
60 mM CH3COOK 
10 mM RbCl 
10 mM CaCl2 
40 mM MgCl 
15 % (v/v) Glycerol 
pH 5.8 with CH3COOH 
Sterilised by filtration (using a 0.22 µm filter). 
 
Buffer II 
10 mM MOPS 
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10 mM RbCl 
75 mM CaCl2 
15 % (v/v) Glycerol 
pH 6.5 with NaOH 
Sterilised by filtration (using a 0.22 µm filter). 
 
 
2.2.4 Transformation of competent cells by heat shock 
DNA (100-200 ng of plasmid DNA or 10 µl of the ligation reaction) was added to a 50 
µl aliquot of DH5α E. coli previously thawed on ice. The mixture was incubated for 30 
min on ice and then heat shocked: incubated for 40 sec at 42ºC and then quickly 
cooled on ice for 2 min. LB broth (450 µl) was then added and the bacterial cells were 
placed in a shaking incubator for 1 h at 37 ºC and 220 rpm. Cells (100-150 µl) were 
plated onto 10-cm LB agar plates with the appropriate antibiotic and incubated upside 
down overnight at 37ºC.  
 
 
2.3 Molecular biology techniques 
2.3.1 Plasmid DNA amplification, extraction and quantification 
As described, 5 ml or 250 ml overnight bacterial cultures were used for small (QIAprep 
Spin Miniprep Kit, Qiagen) or large (HiSpeed Plasmid Maxi Kit, Qiagen, or GeneJET 
Plasmid Maxiprep Kit, Invitrogen) scale plasmid DNA purification, respectively. DNA 
extraction was performed according to manufacturer’s instructions. Plasmid DNA was 
eluted in nuclease-free water, quantified using a Nanodrop ND-1000 
spectrophotometer and stored at -20ºC.  
 
 
2.3.2 Agarose gel electrophoresis of DNA 
Agarose gels were prepared by dissolving electrophoresis-grade agarose (Invitrogen) 
(1% w/v) in 1X TAE buffer. Once completely dissolved, the agarose was cooled down 
and SYBR®Safe DNA Gel Stain (1:10000; Invitrogen) was added prior to pouring the 
gel into the chamber. DNA samples were diluted in 6x loading dye (at a ratio of 5:1, 
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sample:dye) prior to loading onto the agarose gel. Alongside the samples, DNA 
ladders were loaded (either Quick-Load 100 bp DNA ladder or 1 kb DNA ladder, from 
New England Bioscience). The gel was run in 1x TAE buffer at 80-100 V for 45-60 
min and visualised using an UV lamp imaging system a built-in camera.  
 
1x TAE buffer 
40 mM Tris 
1 mM EDTA 
pH 8 with glacial acetic acid. 
 
DNA loading dye (6x) 
0.25% (w/v) Bromophenol blue 
0.25% (w/v) Xylene cyanol 
15% (v/v) Glycerol  
 
 
2.3.3 Polymerase chain reaction (PCR) 
Gene amplification was performed using the high fidelity Pfu DNA polymerase, which 
possesses 3’ to 5’ exonuclease proof-reading activity, preventing errors, and has 
higher thermostability. Reactions were prepared as follows. When preparing multiple 
samples, master mixtures were made.  
 
Table 2.6: Components for PCR 
Component Volume/amount Final concentration 
2x Pfu Master Mix (R551, Rovalab) 25 µl 1x 
100 µM Forward primer (Sigma) 0.2 µl 0.4 µM 
100 µM Reverse primer (Sigma) 0.2 µl 0.4 µM 
DNA template 100-200 ng 
DNAse-free water Total volume of 50 µl  
When using the PCR products for TOPO cloning, Taq DNA polymerase (M1661, 
Promega) was used instead.  
 
For amplification of STUB1 (CHIP), the following PCR cycling programme was used: 
1. Initial denaturation (98ºC for 30 sec) 
2. Denaturation (98ºC for 5 sec) 
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3. Annealing cycles x35 (68ºC for 10 sec) 
4. Extension (72ºC for 2 min) 
5. Final extension (72ºC for 2min) 
6. Hold (4ºC forever).  
PCR was performed using the Agilent SureCycler 8800 machine.  
 
 
2.3.4 DNA sequencing 
DNA Sanger sequencing was performed by Source Bioscience (LifeSciences) using 
their stock primers or either forward or reverse primers that were used for cloning. 
 
 
2.3.5 RNA extraction 
RNA extraction was performed using the Epicentre MasterPureTM Complete DNA and 
RNA Purification Kit (Epicentre, MC85200), according to the manufacturer’s 
instructions. RNA was resuspended in RNAse-free water and riboguard RNAse 
inhibitor (Invitrogen, 10777019). To ensure contaminating DNA is removed, DNAse I 
(New England Biolabs) was added according to manufacturer’s instructions. RNA 
concentration and purity were assessed using a Nanodrop spectrophotometer.  
 
 
2.3.6 cDNA synthesis 
Total RNA (1 µg) was used for cDNA synthesis. When such concentration of RNA 
yielded less than 12 µl, RNAse-free water was added to make up this volume. Next, 
samples were incubated with 1 µl of 10 mM dNTP mix (10297018, Invitrogen) and 1 
µl of random primers (50 ng/µl) (PCR-545-020T, Invitrogen) at 65ºC for 5 min and 
then cooled on ice. After a brief centrifugation, 4 µl 5x First strand buffer (28025013, 
Invitrogen), 2 µl of 0.1M DTT (28025013, Invitrogen) and 1 µl riboguard RNAse 
inhibitor (10777019, Invitrogen) were added and incubated at 37ºC for 2 min. Note 
that when preparing multiple samples, master mixtures were made.  
 
Then 1 µl M-MLV reverse transcriptase (200 units/µl) (28025013, Invitrogen) or 1 µl 
RNase-free water (for the control sample) was added per sample and mixed. Samples 
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were incubated for 10 min at room temperature, and then 60 min at 37ºC. For 
inactivation of the reserve transcriptase, samples were incubated for 10 min at 90ºC. 




2.3.7 Quantitative Reverse Transcription PCR (qRT-PCR) 
Each reaction contained 2 µl of 2 µM primer mix (containing both forward and reverse) 
(Sigma), 0.1 µl of 10 µm UPL Probe (UPL61THRU70, Roche), 5 µl of 2x UPL Probe 
Master Mix (04707494001, Roche) were performed in 386-well plates, as described 
by the manufacturer’s instructions. This was made up as a stock mix for all samples 
and replicates. In each well, 7 µl of this mix and 3 µl of cDNA was added. For each 
primer used, three technical replicates were included. Moreover, for each plate, 
expression of the housekeeping gene (TATA-binding protein, TBP) was quantified. 
The plate was sealed and centrifuged for 2 min at 1000 rpm. It was then analysed 
using the Roche LightCycler® 480 System with the Universal Probe Library (UPL) 
(Roche).  
 
Primers were designed using the Roche UPL Assay design centre and, when 
possible, intron-spanning primers were designed. Prior to their use for the 
quantification of gene expression, primers were tested. For such, a dilution series of 
a positive control sample was made and a negative control (without reverse 
transcriptase) was included. Primers with efficiency close to 2 were selected.  
 
Raw data includes the crossing point (Cp) value (the cycle at which fluorescence 
achieved the threshold) for each reaction. The average Cp of TBP expression per 
biological replicate was calculated. To determine the level of relative expression, the 
difference between this Cp value and that obtained for each sample (i.e. each 
replicate from all primer sets used) was analysed (∆Cp TBP – Cp Sample). Assuming 
a doubling of the target DNA during each cycle, 2^∆Cp TBP – Cp Sample was calculated, 
followed by the average and standard deviations of the technical replicates per gene 
analysed.   
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2.3.8 Cloning using restriction sites 
a. Designing V5- and 3xFLAG-tagged 11F scFv plasmids 
Inserts were designed encoding either V5- or 3xFLAG-tagged 11F scFv antibody and 
subsequently sub-cloned into a high-copy number mammalian plasmid (pSF-CMV 
(OG2)). Inserts were optimised for Homo Sapiens and included the coding region for 
11F. At the C-terminus, one plasmid encoded for the V5-tag and the other the 3xFLAG 
tag. A SGSG linker between the protein and tag was added to enhance flexibility and 
aid detection of the tag. An extra alanine was added as well to prevent methylation. 
Two restriction enzyme (RE) sequences were added at either end of the DNA (5’ 
BamHI and 3’ XbaI) although the REs that will be used are NcoI (C/CATGG) and XbaI, 
because the sequence for the former RE is created by the sequence for BamHI 
(GGATCC) together with the start of the coding region of 11F (ATGGCC) (underlined), 
thus preventing frameshift mutations. The 3’ end RE site is just after the stop codon. 
The use of two different REs creates two different complementary ends in both the 
insert and vector, ensuring incorporation of the insert into the plasmid with the correct 
orientation (i.e. directional cloning). Inserts were extracted from host plasmids and 
added to the mammalian expression cassette, which includes the kozak consensus 
sequence to promote expression.         
 
 
b. Restriction digestion 
Double digestion of the destination vector and holding plasmids (containing inserts 
encoding the V5- and 3xFLAG-tagged 11F scFv antibody) was performed using REs 
(New England Biolabs), NcoI_HF (C/CATGG) and XbaI (T/CTAGA) (enzyme activity: 
10000 U/ml), and a compatible buffer, CutSmart Buffer (B7204S, New England 
Biolabs), according to manufacturer’s instructions. Each reaction contains, 1 µg of the 
insert/vector DNA, restriction enzyme buffer (1x), 10 units of each restriction enzyme, 
making up a 20 µl solution. Digestion was performed for 2-3 hours at 37ºC in water 
bath. Control experiment with no/either restriction enzymes are included. 
 
The digested products are analysed on a 1% agarose gel. Next, single bands 
corresponding to the double-digested vector and insert are excised from the gel under 
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UV light. The DNA is extracted using the QIAquick Gel Extraction Kit (Qiagen), 




Ligation of double-digested gel-extracted insert and vector was performed using T4 
DNA ligase (M0202, New England Biolabs), following manufacturer’s instructions. Per 
reaction (with a total volume of 20 µl), 10 units of the T4 DNA ligase was used, in 
addition to its buffer, 50-100 ng of vector and the appropriate amount of insert. The 
amount of insert used was calculated as follows: 
 
Amount of insert (ng) = 
Amount of vector (ng) × Size of vector (kb)





Different vector:insert ratios were tested (1:4 and 1:5) to increase the chance of a 
successful ligation reaction. Ligation reactions were prepared on ice and incubated 
overnight at room temperature.  
 
As previously described, 5 µl of the ligation product was used to transform competent 
DH5α cells (as previously described). Single colonies were picked and used for 
making glycerol stocks. To verity the presence of the insert in the selected clones, 
they were double digested again with the same REs used for cloning – a band 
corresponding to the insert should be visible. Positive clones were further analysed 
by DNA sequencing to confirm that the insert is present, free of indels and in-frame 
with the open reading frame and tag.  
 
 
2.3.9 Cloning using TOPO cloning kit 
PCR products obtained using Taq DNA polymerase were suitable for sub-cloning into 
a vector (pCR 2.1-TOPO TA) optimised for high efficiency transformation, using the 
TOPO-TA Cloning Kit for Subcloning (450641, Invitrogen) according to the 
manufacturer’s instructions. DH5α competent cells were transformed, as previously 
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described, and the DNA of single colonies was extracted using the QIAprep Spin 




2.4 Biochemical techniques 
2.4.1 Protein quantification 
a. BCA assay 
When the sample concentration is low, the Micro BCA Assay Kit (23235, Thermo 
Scientific) is used according to the manufacturer’s instructions of the “microplate 
procedure”. This method has a detection range of 2-40 µg/ml and the concentration 
of samples is compared to a dilution series of known concentrations of bovine serum 
albumin (BSA) (A9647, Sigma), ranging the detection limit and sample concentration. 
Samples and standards were loaded on a 96-well plate and analysed in triplicates. 
The plate is incubated shaking for 2 hours at 37ºC prior to being cooled down and 
analysed by a spectrophotometer (Spark Multiplate Reader, Tecan) in absorbance 
mode at 562 nm. The long incubation ensures that the reactions reach completion, 
achieving more accurate results and an increased linear working range at lower 
protein concentrations. However, the kit is incompatible with some sample buffers, 
thus compatibility is check prior to use. 
 
 
b. Bradford assay 
More routinely, Bradford assays were used to quantify protein concentrations, 
especially of cell lysates. Again, the concentration of samples is compared to a dilution 
series of known concentrations of BSA (A9647 Sigma), ranging the sample 
concentration (commonly from 0-2.5 mg/ml). The 5x Bradford reagent (5000006, Bio-
Rad) was diluted with water to 1x prior to use, and 200 µl is added per well in a 96-
well plate. The BSA standards and the protein-containing samples (e.g. 1 µl of cell 
lysate) are added to each well and mixed thoroughly. Each sample is quantified in 
duplicate/triplicate. Two negative control (lacking BSA) are added, one included the 
diluent of the BSA standards (water) and the other the buffer of the samples. The 
plate was promptly analysed using a spectrophotometer (Spark Multiplate Reader, 
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Tecan) in absorbance mode at 595 nm, seeing that this assay is time-dependent. The 
absorbance readings of known concentrations of BSA were plotted, yielding a linear 
standard curve that was used to deduce the concentrations of the unknown samples, 
based on their absorbance values.   
 
 
c. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) compared with known BSA concentrations 
The concentration of recombinant proteins is checked using SDS-PAGE and 
Coomassie blue. A dilution series of the sample, as well as the BSA (A9647, Sigma), 
is loaded onto a single gel. Once stained with Coomassie blue, the intensity of the 
bands can be quantified using Image Studio Lite (LI-COR Biosciences) and the 
concentration of the recombinant protein can be deduced from the linear standard 




Again, the concentration of recombinant proteins can be readily analysed using a 
Nanodrop ND-1000 spectrophotometer. Again, concentration is calculated from the 
absorbance at 280 nm. To improve accuracy, the extinction coefficient of the protein, 
ε, (obtained from the ProtParam online tool: https://web.expasy.org/protparam/) 
should be included into the Beer’s Law equation: A = ε × L × c, where A is absorbance 




a. In-house polyacrylamide gels 
Polyacrylamide gels were prepared in-house using the gel cast Mini-Protean 3 Cell 
apparatus (Bio-Rad) and either 1.0 mm or 1.5 mm gap glass plates (depending on 
the volume required to be loaded). Additionally, depending on the assay and number 
of samples, either 10- or 15-well combs were used. Stacking and resolving solutions 
were prepared as in Table 2.7, and higher percentage resolving gels were selected 
for analysis of proteins with small molecular weights. The appropriate resolving gel is 
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prepared and poured first onto the gel cast. It is then overlaid with isopropanol to 
ensure the gel solidifies in a straight manner and to prevent air bubbles. Once 
polymerised, the isopropanol is removed, and the stacking gel is prepared and poured 
into the cast.  
 
Table 2.7: Resolving and stacking gels for SDS-PAGE 
Reagents Resolving gel Stacking gel 
Acrylamide, 30% (w/v) and bis-
acrylamide, 0.8% (w/v) 
(Protogel, National diagnostics) 
10% 12% 15% 5% 
Tris pH 8.8 
(Sigma) 
375 mM 375 mM 375 mM - 
Tris pH 6.8 
(Sigma) 
- - - 125 mM 
SDS (w/v) 
(Sigma) 
0.1% 0.1% 0.1% 0.1% 
APS (w/v) 
(Sigma) 
0.1% 0.1% 0.1% 0.1% 
TEMED (w/v) 
(Sigma) 
0.004% 0.004% 0.004% 0.1% 
 
Generally, about 30 µg of cell lysate was loaded. The protein samples are diluted in 
sample buffer (2x) in a 1:1 ratio (v/v). The mix was heated for 3-4 min at 95ºC (unless 
otherwise stated) and subsequently loaded onto the gel. Pre-stained protein ladders 
were loaded in parallel as size markers. Gels were run in 1x Tris-Glycine-SDS running 
buffer and at 120 V for about 1h, until the dye front has reached the bottom of the gel, 
or a marker of a specific size has migrated until a position of interest.  
 
Sample buffer (2x) 
300 mM Tris (pH 6.8) 
5% (w/v) SDS 
25% (v/v) Glycerol 
Bromophenol blue to desired colour 
200mM DTT (unless otherwise stated), added freshly 
 
Tris-Glycine-SDS running buffer (1x) 
192 mM Glycine 
25 mM Tris base 
0.1% SDS (w/v) 
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b. Precast gel protocol 
Precast gradient gels (4-12% Bis-Tris Gels, Invitrogen) were run using MOPS buffer 
(1x) (Invitrogen) at 180 V for about 1 h.  
 
 
2.4.3 Coomassie staining of SDS-PAGE gels 
Once proteins were separated by SDS-PAGE, the gels are submerged in Coomassie 
blue stain solution for 30 min. Next, the gel is rinsed and then incubated overnight 
with destain solution shaking. Destained gels are scanned using a plate imager 
(Odyssey® SA Infrared Imaging System, Li-Cor Biosciences).  
 
 
Coomassie blue stain solution 
50% (v/v) Methanol 
10% (v/v) Glacial acetic acid 
0.2% (w/v) Coomassie brilliant blue R-250 
 
Destain solution 
7.5% (v/v) Methanol 
10% (v/v) Glacial acetic acid 
 
 
2.4.4 Western blotting (WB) 
After SDS-PAGE, proteins were transferred onto 0.2 µM pore nitrocellulose blotting 
membrane (Advantec) using the Mini Trans-Blot® wet electroblotting systems (Bio-
Rad). Transfer was carried out in tanks containing 1x transfer buffer for 1h30m at 100 
V, or overnight at 30 mA. To prevent overheating, an ice pack was added in the tank 
(and replaced half way) or conducted at 4ºC (when overnight). 
 
When indicated, membranes were overlaid with 0.4% or 4% paraformaldehyde (PFA) 
(Sigma), as indicated, and incubated for 30 min at room temperature. Subsequently, 
the membrane was thoroughly washed with PBS, three times for 5 min each, while 
shaking. Optionally, following transfer membranes were rinsed with phosphate 
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buffered saline (PBS) and stained with India ink (Pelican black) to confirm that 
proteins were transferred properly.  
 
All membranes were washed briefly with PBS containing 0.1% (v/v) Tween-20 (PBS-
Tween) and then blocked with PBS-Tween with 5% BSA (Sigma, A9647) for 1 h at 
room temperature or overnight at 4ºC. Next, primary antibodies (Table 2.2) were 
diluted in the blocking buffer and incubated for 1 h at room temperature or overnight 
at 4ºC in a humidified chamber, depending on the nature of the antibody. Blots were 
then washed with PBS-Tween, as previously. The appropriate horse peroxidase 
(HRP)-conjugated secondary antibodies (Table 2.3) were also diluted 1:2000 in 
blocking solution and added to membranes for 1 h at room temperature. This is 
followed by the same washing conditions. Finally, for antibody signal detection, 
enhanced chemiluminescence (ECL) reagents I and II were prepared in a 1:1 ratio 
(v/v) and overlaid on the membranes for 1 min. Excess solution was removed and 
blots were exposed to Hyperfilm ECL (Amersham) or X-Ray film (SLS) for the required 
period of time. The former is used when the expected signal is weak. Films were 
developed using a film processor (SRX-101A, Konica Medical).  
 
Transfer buffer (1x) 
24 mM Tris 
191 mM Glycine  








0.1% (v/v) Tween-20 
5% (w/v) Dried skimmed milk (Marvel) 
 
ECL I 
2.5 mM Luminol 
0.4 mM p-Coumaric acid 
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0.1 M Tris pH 8.8 
 
ECL II 
0.02% (v/v) Hydrogen peroxide 
0.1 M Tris pH 8.8 
 
 
2.4.5 Two-dimension electrophoresis (2DE) 
Two-dimension electrophoresis were performed in collaboration with Jitka Zakova†. 
On the first dimension, samples were analysed on immobilized pH gradient (IPG) 
strips (pH 3-10 NL). On the second dimension, samples were analysed on 12% 
polyacrylamide gels by SDS-PAGE. When gels were visualised by Coomassie blue 
staining, 200 µg of protein lysate was loaded, while when used for WB, 100 µg was 
loaded. For WB, PVDF membrane was used.    
 
2.4.6 Protein purification 
a. Purification of His-CHIP 
BL21(DE3) competent cells were transformed with pET15b-CHIP (His6-tagged WT 
CHIP), as previously described. A colony was picked and used to inoculate a starter 
culture of 50 ml of LB broth supplemented with ampicillin, which was incubated 
overnight at 37ºC and 220 rpm. Next, 10 ml of this was used to inoculate 1 L of the 
same LB medium. Cells were incubated in the same conditions until OD600 was 0.4-
0.6 (mid-Log phase). Once reached, protein expression was induced with 1 mM 
isopropyl β-D-1-thigalactopyranoside (IPTG).  
 
Protein expression was induced for 4 h at 30ºC and 220 rpm. An aliquot of cells (1 ml) 
before and after IPTG addition was taken to assess the induction of protein expression 
(the OD600 was recorded for both). Cells were harvested by centrifugation (4000 g for 
40 min at 4ºC) and the supernatant was discarded. The cell pellet was resuspended 
 
† Department of Molecular Pathology and Biology, University Hospital Ostrava, Hradec Kralove, Czech 
Republic 
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with 5 ml of Lysis Buffer (without the components marked with an asterisks) and was 
then snap frozen in liquid nitrogen and stored at -80ºC.  
 
To test the expression levels, all aliquots taken were centrifuged at 13000 rpm for 15 
min at 4ºC and pellets were re-suspended in cold PBS or lysis buffer in an appropriate 
volume relative to the OD600 readings. A fraction (20 µl) of each was isolated and the 
rest was sonicated 3 times for 5 seconds at amplitude 10 microns (MSE Soniprep 150 
Plus ultrasonic disintegrator) with 5 second intervals resting on ice, or until samples 
become clear. Sonicated samples were centrifuged at 13000 rpm for 5 min at 4 ºC 
and the pellet formed was discarded. An aliquot (10 µl) of both sonicated samples 
(soluble protein) and both non-sonicated samples (total protein) was taken and 
analysed by SDS-PAGE stained with Coomassie blue.  
 
If adequate protein expression is confirmed, the pellet was thawed on ice and 20 ml 
of cold Lysis Buffer was added (with all the components, resulting in the indicated final 
conentrations). Cells were resuspended by pipetting and incubated for 1 h on ice. 
Next, cells were sonicated three times for 15 sec each at an amplitude of 10 microns 
and with 30 second intervals, on ice.  
 
The lysate was then centrifuged for 15 min at 16000 g and 4ºC and the supernatant 
was collected. It was filtered through a 0.22 µM filter to exclude cell particles and 
insoluble components and then mixed with Ni2+-NTA agarose beads (1 ml, 50% slurry) 
(Qiagen) that have been previously washed with Wash Buffer I. For batch-binding, 
the mix was incubated for 1 h, at 4ºC on a rotating wheel. It was then transferred to a 
10 ml disposable column (MoBiTec) and allowed to empty by gravity. The flow through 
was collected. The beads were then washed twice with 5 ml Wash Buffer I, twice with 
5 ml Wash Buffer I + ATP and three times with 5 ml Wash Buffer II. Aliquots of each 
wash were collected. Finally, 2 ml of Elution Buffer was added to the beads and 
incubated for 30 min at 4 ºC while rotating. The eluate was collected and applied onto 
a buffer exchange column (Zeba Spin Desalting Column, Thermo Scientific) that has 
been pre-washed three times using 2.5 ml Protein Buffer. Buffer exchange was 
performed according to the manufacturer’s instructions (the centrifugation step was 
performed for 2 min at 1000 g and 4ºC). The sample was aliquoted, snap frozen in 
liquid nitrogen and stored at -80ºC. The purity and concentration of the eluate was 
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20 mM Tris pH 8 
300 mM NaCl 
0.3% NP-40* 
1 mg/ml lysozyme* 
1 x Protease inhibitor mix* 
 
Protease inhibitor mix (10x) 
200 µg/ml Leupeptin 
10 µg/ml Aprotinin 
20 µg/ml Pepstatin 
100 µg/ml Soybean trypsin inhibitor 
10 mM Benzamidine 
20 mM Pefabloc 
10 mM EDTA 
 
Wash Buffer I 
20 mM Tris pH 8 
300 mM NaCl 
0.3% NP-40 
2 mM Benzamidine 
20 mM Imidazole  
 
Wash Buffer I + ATP 
Wash Buffer I 
10 mM MgCl2 
5 mM ATP  
 
Wash Buffer II 
20 mM Tris pH 8 
300 mM NaCl 
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0.3% NP-40 
2 mM Benzamidine 
40 mM Imidazole 
 
Elution Buffer 
20 mM Tris pH 8 
150 mM NaCl 
300 mM Imidazole 
 
Protein Buffer 
20 mM Tris pH 8 
150 mM NaCl 
 
 
b. Purification of scFv antibodies 
Glycerol stocks of BL21(DE3) competent cells transformed with either 11F or 7A scFv 
plasmids were used to inoculate 5 ml of LB supplemented with ampicillin and 0.1% 
glucose, which was incubated overnight 37 ºC and 220 rpm. Each starter culture was 
then used to inoculate 250 ml of LB with the same supplements and incubated at the 
same conditions until it reached OD600 0.4-0.6. Protein expression was induced with 
1 mM IPTG and incubated overnight at 30 ºC and 220 rpm. Aliquots before and after 
induction of protein expression were taken, as previously described (in section a).  
 
Bacterial cells were harvested by centrifugation at 4000 g for 40 min at 4 ºC and the 
supernatants was discarded. Cell pellets were re-suspended in 10 ml of cold, sterile 
PBS before being snap frozen in liquid nitrogen and stored at -80ºC.   
 
If the expression was adequate, the bacterial cell pellets were thawed on ice and 100 
µl triton-X100 was added. After a 30 min incubation on the rotating wheel at 4 ºC, 
pellets were sonicated four times for 15 s each at amplitude 10 microns, with 30 s 
intervals in between. Pellets were on ice the whole time during the sonication step 
and then were centrifuged at 13000 rpm for 10 min at 4 ºC. The supernatants were 
collected and filtered using a 0.22 µm membrane. In the meantime, for the purification 
of each scFv, 30 mg of Protein A Sepharose resin (CL-4B GE Healthcare) were 
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weighed and washed 3 times with 400 µl ddH2O. Beads were allowed to settle 
sediment by gravity or with low speed centrifugation.  
 
The beads were re-suspended in 400 µl ddH2O and mixed with the lysate. For batch-
binding, the mixture was incubated for 1 h at 4ºC on a rotating wheel. It was then 
transferred into a 10 ml disposable column with a filter and the flow through was 
collected. Five washes with 1 ml PBS-1% triton X-100 were made and aliquots were 
collected as the solution left the column. Elutes were collected by added 500 µl of 0.2 
M glycine pH 2 four times in total and these were collected into microcentrifuge tubes 
with 75 µl of 1 M Tris pH 9 previously added. For the last elute, another 500 µl of 0.2 
M glycine pH 2 was added and the column was incubated rotating for 15 min at 4 ºC. 
The elute was collected in the same manner. The purification was performed either 
on ice or at 4 ºC. Samples were stored at 4 ºC.  
 
A fraction of the total purified scFv (200 µl of each elute) was buffer exchanged. 
Exchange columns (Zeba Spin Desalting Column, Thermo Scientific) were prepared 
according to the manufacturer’s instructions and washed with 2.5 ml of 1 M Hepes 
buffer with 150 mM NaCl. The concentration and purity of the Tris-Glycine elution 
fractions and the buffer exchanged sample was assessed by Nanodrop and by SDS-




2.5 In vitro assays 
2.5.1 T7 endonuclease I assay 
As part of the screening process to identify positive clones derived from Clustered 
regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene-editing 
technology, the T7 endonuclease I assay (M0302, New England Biolabs) was used 
as an early detection method. It was used according to the manufacturer’s instructions 
and required PCR products that were derived as previously described. The T7 
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2.5.2 In vitro ubiquitination assays 
In vitro ubiquitination assays were performed with the following components unless 
otherwise stated: 3 µg His-CHIP (purified in-house), 1 µM UbcH5α, 100 nM Ube1 (E-
305, Boston Biochem), 2 µg Ub (U-100H, Boston Biochem), 30 mM ATP (A7699, 
Sigma) and the reaction buffer (25 mM HEPES, 10 mM MgCl2 and 0.5 mM DTT). 
Specifically, the UbcH5α was wither made in-house (purified in-house by Dr Fiona 
Lickiss) or, for the mapping of ubiquitination sites directly from the reaction, was 
commercially obtained (E2-616, Boston Biochem), due to the presence of the MS-
incompatible glycerol in the former. When indicated, either 0.1 µg α-synuclein 
(purified in-house by Dr Vikram Narayan), 25 or 50 nM untagged or His-tagged 
Annexin A2 (ANXA2) (ab93005 and ab188455, respectively, Abcam) or 25 ng p53 
(purified in-house from insect cells by Prof Kathryn Ball) were used as substrates. 
Each reaction volume was 24 µl and, when preparing multiple sample, a master mix 
was made. CHIP was added last. When indicated, 7A or 11F scFv antibodies were 
added at the concentrations specified. The reaction(s) was prepared on ice and then 
incubated at 30 ºC in a water bath for 45 min, unless otherwise stated. Samples were 
then snap frozen in liquid nitrogen or analysed by WB (the reaction was stopped by 
denaturing with heat and the loading dye).  
 
 
2.5.3 Hydrogen-deuterium exchange (HDX) 
The dynamics of the interaction between CHIP and 11F scFv antibody were monitored 
in vitro by hydrogen-deuterium exchange (HDX), in collaboration with Dr Lenka 
Hernychova and Dr Bořivoj Vojtesek‡.  
 
Human recombinant untagged CHIP (purified in-house by Dr Jia Ning) in 2 μM (final 
concentration) was diluted with 48 µl HEPES buffer (50mM HEPES, pH 7.5, 150mM 
NaCl, 1mM DTT) in H2O that was used for the preparation of the undeuterated control 
samples and for the peptide mapping. Deuterated samples containing CHIP either 
free or in complex with 11F scFv antibody in molar ratio 1:1 (protein:antibody) were 
 
‡ Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech 
Republic 
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preincubated for 60 min on ice. Then deuterium exchange was started by dilution with 
HEPES buffer in D2O (pD 7.1) carried out at room temperature. Deuteration was 
quenched at 30 s, 5 min, and 15 min by the addition 3.5 µl quench buffer (1 M glycine, 





2.6 Cell culture 
2.6.1 Culturing of cell lines 
All tissue culture disposables were from Greiner-Cellstar, unless otherwise stated. 
Cells were monitored daily using a bright-field inverted phase-contrast microscope 
and were confirmed to be mycoplasma-negative by periodic testing using the 
Luciferase-based MycoAlertTM detection kit (Lonza), following the manufacturer’s 




SH-SY5Y cells were maintained in the appropriate medium, which was changed every 
2-3 days. When 70-80% confluence, cells were washed briefly with PBS and 
passaged using trypsin (0.05% trypsin + 0.02% EDTA, Gibco, 15090), for a 10 cm2 
plate, 2 ml of trypsin was added. Cells were incubated for 3-4 min until detached. 
Trypsin was deactivated by dilution with the culturing medium (in 5:1, medium:typsin, 
ratio). Cell were plated at 1:10 or 1:5 (v/v) for routine culturing or counted and plated 




To promote attachment, high survival and long-term maintenance self-renewal 
capacity, iPSC were plated on plastic previously coated with Laminin-521 (100 µg/ml, 
Biolamina). For such, Laminin-521 was diluted in dPBS with calcium and magnesium 
(14040083, Gibco) to a final concentration of 5 µg/ml. Enough to cover wells properly 
was added (e.g. 1000-1200 µl for a 6-well). Plates were sealed with parafilm and 
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incubated overnight at 4ºC or for 2 h at 37ºC. When using glass coverslips, coating 
with poly-L-ornithine is required prior to the addition of Laminin-521.  
 
iPSC were maintained in the appropriate medium, which was changed daily or every 
2 days. When 70-80% confluence, or when cells presented early signs of 
differentiation morphology, iPSC were passaged using 0.5 mM EDTA (UltraPure 0.5 
M EDTA, pH 8, 15575020, Gibco), diluted in dPBS without calcium and magnesium 
(D8537, Sigma). Initially, cells were washed with 0.5 mM EDTA and then incubated 
with fresh solution for 15-20 min at 37ºC (i.e. until cells are partly detached but 
completely). This has been optimised for the iPSC AST23 parental line and CRISPR-
derived clones. After the incubation, EDTA is discarded and cells are lifted by flushing 
with culturing medium (iPS-Brew XF medium). Cells were triturated by pipetting a 
maximum for four times, before being passaged onto a new plate. Ideally, cells are 




For long-term preservation of cell stocks, cells were cryopreserved in the appropriate 
solution and stored temporarily (for 24 hours) at -80ºC in a Mr. FrostyTM Freezing 
Container (Thermo Scientific) and then transferred to liquid nitrogen. For short-term 




Cryopreservation solution was prepared containing 50% FBS (10270-106, Gibco), 
10% DMSO (276855, Sigma) and 40% DMEM. SH-SY5Y were frozen at 70-80% 
confluency in a 10 cm plate, or equivalent. Cells were lifted with trypsin, as previously 
described. After centrifugation, the supernatant was discarded, and cells were 
resuspended with 3 ml of cryopreservation solution. Three aliquots were made and 
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b. iPSC 
Culturing medium (iPS-Brew XF medium) was supplemented with the ROCK inhibitor, 
Y27632 dichloride (1254, R and D, Tocris) for a final concentration to 10 µM, to 
promote cell survival. Previously, 10 mM stocks of Y27632 dichloride were made by 
diluting with PBS (D8537, Sigma).  
 
iPSC were frozen when 70-80% confluent in a 6-well. Cells were lifted with EDTA, as 
previously described, and transferred to medium supplemented with Y27632 
dichloride. After centrifugation (3 min at 800 rpm), the supernatant was discarded and 
the cell pellet was resuspended with 1.5 ml of Stem Cell banker (Stem-Cell Banker 




2.6.3 Cell recovery 
a. SH-SY5Y 
Cryovials with frozen cells were quickly thawed at 37ºC (in the water bath) until 
partially thawed. Culturing medium (DMEM supplemented with FBS) was added and 
cells were transferred into a 15 ml centrifugation tube. A total of 9 ml of medium should 
be added to ensure removal of residual DMSO. Cells were centrifuged for 5 min at 
1000 rpm and the supernatant was discarded. The cell pellet was resuspended with 




Cryovials with frozen iPSC were also quickly thawed at 37ºC (in the water bath) until 
partially thawed (~1 min). The supplemented medium (iPS-Brew XF medium with 10 
µM Y27632 dichloride) was added (8 ml) and cells were centrifuged for 3 min at 800 
rpm. The supernatant was discarded and cells were gently resuspended with fresh 
supplemented medium and plated on 6-well plates (with a total volume of 2 ml) or 
smaller. The medium was changed to fresh medium without Y27632 dichloride after 
1 day, unless otherwise stated. This drives a morphological change from extended 
cells to round.  
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2.6.4 Transient transfection of DNA (SH-SY5Y cells) 
a. Electroporation 
Cells were transfected with plasmids using a NucleofectorTM 2b Device and Amaxa 
Cell Line Nucleofector Kit V (VCA-1003, Lonza) according to manufacturer’s 
instructions (2 µg of plasmid was used per transfection). Cells were platted onto 6-




Transient transfections were more frequently done using Attractene transfection 
reagent (301005, Qiagen) according to the manufacturer’s instructions. Cells were 
transfected at about 70% confluency and were harvested about 24 h post transfection. 
 
   
2.6.5 Drug treatments 
SH-SY5Y cells were treated with different inhibitors Ub-dependent pathways (Table 
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Table 2.8: Principle effects and working concentrations of drugs used 
Drug Pathway 
inhibitor 
Details Reference Treatment 
Bafilomycin 
A1 (BafA1) 


















Autophagy Inhibits lysosomal 
acidification, inactivating 
lysosomal enzymes and 









3 mM for 
16h 
V34-2 Endosomal Inhibits dynamin I and II, 




10 µM for 
16h 
MG-132 Proteasomal Inhibitor of proteases and 
peptidase activity of the 




50 µM for 
4h  








2.6.6 Cell counting 
For consistency across experiments and to allow comparison between different 
conditions (eg. between CHIP KO cells and WT cells), cell plates were seeded with 
similar cell numbers. For such, once adherent cells were detached, an aliquot was 
taken, further triturated by pipetting to obtain single cells and cells were counted using 
a haemocytometer or an automated cell counter. When using the latter, a 15 µl aliquot 
containing single cells was diluted 1:1 with 0.4% Trypan Blue stain (T13001, Labtech) 
and added to a cell counting slide (L12001, Labtech). This was analysed in an 
automated cell counter (Luna BF cell counter, L10001, Labtech). The average of 
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2.6.7 Coverslip preparation 
a. Sterilization 
For immunofluorescence-based assays, cells were plated on glass coverslips. Round 
glass coverslips of 13 mm (631-0149, VWR International) or 25 mm (631-0171, VWR 
International) were washed with 70% ethanol and autoclaved at 180ºC for at 30 min.  
 
 
b. Differentiated SH-SY5Y 
Although undifferentiated SH-SY5Y cells do not need prior coating of coverslips, 
differentiated SH-SY5Y do. Poly-L-Ornithine (100 ug/ml, P4957, Sigma) was diluted 
with dPBS without calcium and magnesium (D8537, Sigma) to achieve a final 
concentration of 15 ug/ml, which was added on top of the coverslip placed in the 4 or 
24-well plate or 12-well plate. The plate was sealed and incubated overnight at room 




Coverslips seeded with iPSC were coated primarily with poly-L-ornithine and then with 
Laminin-521, as previously indicated.  
 
 
d. Cortical differentiation 
Coverslips seed with neural stem and progenitor cells and cortical neurons were 
coated primarily with poly-L-ornithine, as previously indicated, and then with Laminin-
111 (100 ug/ml, Biolamina). Laminin-111 was diluted in dPBS with calcium and 
magnesium (14040083, Gibco) to a final concentration of 5 µg/ml. Enough to cover 
the coverslips properly was added (e.g. 1000-1200 µl for a 6-well). Plates were sealed 
with parafilm and incubated overnight at 4ºC. 
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2.6.8 Lipidomics analysis 
a. Preparation and harvesting of cells 
SH-SY5Y WT and KO cells were grown in 10 cm plates in culturing medium containing 
DMEM and FBS. Prior to cell harvest (24 h before) the medium was changed to fresh, 
serum-free media (just DMEM). Cells were scraped in the medium and on ice and 
transferred to microcentrifuge tubes. They were centrifuged for 10 min at 2000 rpm 
and 4ºC. The condition medium (supernatant) was collected in a new microcentrifuge 
tube and snap frozen with liquid nitrogen prior to storage at -80ºC. The cell pellet was 
washed with PBS and centrifuged again at the same conditions. The buffer was 
discarded, and the cell pellet was snap frozen in liquid nitrogen and stored at -80ºC. 
 
 
b. Cell lysis and lipidomics  
Cell lysis and lipidomics was conducted in collaboration with Dr Irena Dapic and Dr 
Laura Bindila‖. Lipid extraction and liquid chromatography-mass spectrometric 
multiple reaction monitoring (LC-MRM) assays were performed as described in Lerner 
et al.98.  
 
 
2.6.9 Harvesting cells 
Cells were washed three time with PBS at room temperature. Next, enough cold PBS 
was added to overlay the plate/well (e.g. 1 ml for a 10 cm plate) and cells were 
scrapped on ice with a cell scrapper. Detached cells were transferred to a 
microcentrifuge, which was then centrifuged for 5 min at 4000-5000 rpm and 4ºC. The 
cell pellet was either lysed or snap frozen in liquid nitrogen and stored at -80ºC. 
Alternatively, cells were lysed on the plate using a urea-based buffer.   
 
 
2.6.10 Mammalian cell lysis  
Cells were either lysed with a triton-based or urea-based lysis buffer. When cells were 
scrapped, a volume of about three-times that of the size of the cell pellet was added. 
 
‖ Institute for Physiological Chemistry, University Medical Center Mainz, Germany 
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However, when cells were lysed on the cell culture plate, the minimum volume of 
buffer (just enough to overlay the well) was used (e.g. 80-100 µl for a 24-well plate). 
To aid lysis, the plate was placed on a shaking platform. When cells were lysed for 
MS, urea-based lysis buffer was added to the cell culture plate (i.e. cells were not 
scrapped) and MS-compatible detergent was used instead of triton.  
 
After a 30 min incubation with the cell lysis at 4ºC (for the triton-based buffer) or room 
temperature (when using the urea-based buffer), cells we centrifuged for 20 min at 
13000 rpm and 4ºC or 12ºC, depending on the buffer. The supernatant transferred 
into a new microcentrifuge tube and the protein concentration was assessed as 
previously described.  
 
Triton-based lysis buffer 
50 mM HEPES pH 7.5 
0.2% (v/v) Triton X-100 
150 mM NaCl 
10 mM NaF 
2 mM DTT 
0.1 mM EDTA 
1x Protease inhibitor mix 
 
Urea-based lysis buffer 
8 M Urea 
50 mM HEPES pH 8 
100 mM KCl 
1 mM DTT 
0.5% (w/v) n-Dodecyl-β-D-maltoside (for MS-compatible buffer) or 0.2% Triton X-100 
(for non-MS-compatible buffer) 
 
 
2.6.11 Differentiation of SH-SY5Y  
SH-SY5Y were differentiated using retinoic acid. Cells were detached using trypsin 
and counted, as previously described, in order to be seeded at 11.8 x 103 cells/cm2. 
Cells plated on coverslips require poly-L-ornithine coating. Cells were maintained in 
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DMEM + FBS medium for 2 days and then switched to the differentiation media. Half 
of the media was replaced every 2-3 days with retinoic acid added freshly every time. 
Working stocks of the retinoic acid have been previously prepared by dilution with 
DMSO to a final concentration of 10 mM. These were stored at -80ºC (long-term) or -
20ºC (short-term) and protected from light. The differentiation was maintained for 7-
14 days, depending on desired end-point.  
 
SH-SY5Y Differentiation media 
1x DMEM/F12 (21331-020, Gibco) 
1x Neurobasal (21103-049, Gibco) 
1 mM L-glutamine (200 mM, 25030-024, Gibco) 
0.5x N2 supplement (100x, 17502001, Gibco) 
10 µM Retinoic acid (R2625, Sigma) 
 
 
2.6.12 Differentiation of iPSC into cortical neurons  





2.7 Cell-based assays 
2.7.1 Clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas9 gene editing technology 
a. Nucleofection  
iPSC were subjected to CRISPR/Cas9 technology. Both Geltrix matrix (A1413201, 
Gibco) and Laminin-521-coated plates were prepared (according to the 
manufacturer’s instructions or as previously described) for the seeding of 
electroporated cells. Geltrex matrix was diluted in DMEM/F12 (21331-020, Gibco).  
 
To promote single cell detachment, cells were washed with PBS and then incubated 
with Accutase (A6964, Sigma) for about 10 min (until detached). Lifted cells were 
transferred to a 15 ml centrifuge tube, counted and centrifuged for 3 min at 800 rpm. 
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The supernantant was discarded and cells were resuspended in culturing medium 
(iPS Stem-Brew XF) supplemented with 10 µM Y27632 dichloride.   
 
For nucleofection, the Human Stem Cell Nucleofector (VPH-5012, Lonza) was used 
according to the manufacturer’s instructions. Different conditions were tested: 
transfection with 3 µg of the LentiV2 CRISPR plasmid (encoding both Cas9 and the 
gRNA directed to the coding region of CHIP – kindly gifted by Erisa Nita95) and co-
transfection with 2 µg of this plasmid and 1 µg of a GFP-encoding plasmid (pmaxGFP 
vector) (a 2:1 molar ratio). Electroporation was performed with the B-016 program in 
a NucleofectorTM 2b Device (AAB-1001, Lonza). Cells were plated at low density onto 
four 10 cm plates either coated with Laminin-521 or Geltrix-coated plates. Cell 
transfected with both plasmids were treated with different doses of puromycin, since 
the GFP-encoding plasmid contains a puromycin resistance gene. All electroporated 
cells were maintained in medium supplemented with Y27632 dichloride for 2 days to 
promote cell survival.  
 
 
b. Colony selection 
Once single cells grew into small colonies they passaged onto individual wells within 
a 96-well plate. Prior to this, cells were treated for 2 h with culturing medium 
supplemented (iPS-Brew XF) with 10 µM Y27632 dichloride, to increase survival. 
Cells were then washed with HBSS containing calcium and magnesium (14025, 
Gibco) and then incubated with 250 U/ml of Collagenase Type IV (17104019, Gibco), 
diluted in the same HBSS, for 30 min to facilitate subsequent detachment from the 
matrix and improve survival. The solution was discarded, and the culturing medium 
was supplement with 0.5 U/ml Penicillin + 500 ng/ml Sreptomycin (15140122, Gibco) 
and 10 µM Y27632 dichloride.  
 
For manual colony picking, an inverted phase contrast microscope with a camera and 
auxiliary screen was used. Small, isolated colonies within the 10 cm plates were 
selected by mechanical detachment (a combination of scrapping and aspirating, using 
a pipette with clipped tips). As they were transferred onto individual wells within a 96-
well plate, they were gently triturated by pipetting to partially dissociate the colony. 
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They were grown in this supplemented medium for 2 days before fresh iPS-Brew XF 
was added.   
 
c. Validation of clones 
Once clones grew from the 96-well plate, they were passaged into incrementally 
increasing plates. Two duplicate 96-well plates were used to screen positive clones 
by immunofluorescence (IF) using anti-CHIP mAb and to extract DNA for PCR. The 
latter was then used for direct sequencing from the PCR product and for TOPO 
cloning and subsequent sequencing (as previously described). Once clones occupied 
two duplicate 24-well plates, one was used for screening via WB and the other for 
mycoplasma testing and cryopreservation.  
 
 
2.7.2 Subcellular fractionation 
Cytoplasmic, membrane and nuclear fractions of from CHIP WT and KO SH-SY5Y 
cells were achieved using the Subcellular Protein Fractionation kit (78840, Thermo 
Scientific), according to the manufacturer’s instructions. The fractions were analysed 
by WB. The expression of CHIP, ANXA2, Hsp90 and PARP were analysed. The latter 




2.7.3 Immunoprecipitation (IP) 
a. Annexin A2 and CHIP co-IP 
Two 10 cm of CHIP WT cells (80% confluent) were harvested by scrapping and 
incubated in lysis buffer. The lysate concentration was assessed by Bradford assay 
and 500 µg of lysate was used per IP/control condition, except for the condition lacking 
lysate. The following conditions were tested: 
• Beads + lysis buffer + Ab 
• Beads + WT lysate 
• Beads + WT lysate + Ab 
Of these aliquots, two were added 1 µg of anti-ANXA2 Rb pAb. All samples were 
incubated overnight at 4ºC and on a rotating wheel. 
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For the IP, columns (Mobicols with 2 different screw caps without filters, MoBiTec 
#M1002) with filters (35 µm pore size, MoBiTec #M513515) were used. Sepharose 
protein G beads (17-0618-01, GE Healthcare) were aliquoted (20 µl per IP/control 
condition) and were washed three times with PBS buffer containing 0.1% Tween-20 
(PBS-Tween). Between washes, beads were allowed to pellet by gravity. Post-
incubation, the lysate/control samples were added to the beads. The mixture was 
incubated for 1 h at 4ºC on a rotating wheel. Again, beads were pelleted by gravity. 
Three washes with PBS-Tween were the performed, allowing the beads to pellet 
between each wash. For the elution, 50 µl of SDS-PAGE sample buffer was added, 
and the samples were heated for 5 min at 95ºC.  
 
The IP was analysed by WB, as previously described. Each sample (40 µl) was loaded 
on an SDS-PAGE 12% gels, in parallel to 30 µg of WT lysate. The immunoblot was 
first probed with HRP-conjugate anti-Mouse pAb (for 1 h at room temperature), to 
identify background bands derived from the beads and antibody itself. Next, the 
immunoblot was probed with anti-CHIP mAb (for 1 h at room temperature), to 
determine the expression of CHIP across the different samples. Finally, the 
immunoblot was probed with anti-ANXA2 pAb (overnight at 4ºC).     
 
Of note, these were the optimised conditions for this ANXA2 and CHIP co-IP. Different 
conditions were tested, including IP with different anti-ANXA2 and anti-CHIP 
antibodies, buffers containing calcium (since part of the ANXA2 interactome is 




50 mM Tris pH 8 
150 mM NaCl 
5 mM EDTA 
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b. Recombinant scFv and endogenous CHIP IP 
SH-SY5Y CHIP KO and WT cells grown in 10 cm plates were harvested and lysed, 
and the protein concentration was measured by Bradford assay, as previously 
described. Protein A Sepharose beads (17-0780-01, CL-4B GE Healthcare) were 
weighed into microcentrifuge tubes (10 mg each). They were washed three times with 
600-700 µl of ddH2O and in between washes beads settled by gravity. Beads were 
then re-suspended with 50 µl of ddH2O (manufacturer’s instructions suggest 1 g in an 
end volume of 4/5 ml), thus having a binding capacity of 1000 µg (according to the 20 
mg/ml binding capacity).  
 
Buffer exchanged 11F scFv or its buffer (25 mM HEPES + 150 mM NaCl) were added 
to the beads (30 µl), except for the control conditions. Subsequently, the mixture was 
incubated for 1 h at 4ºC on a rotating wheel. The 500 µg of lysate from WT cells or 
CHIP KO cells, or the equivalent volume of lysis buffer, were added to either 11F scFv 
or buffer-containing beads. Next, samples were incubated for 1 h at room temperature 
on a rotating wheel (previous data showed no different between these incubation 
conditions and overnight at 4ºC – data not shown).    
 
After each incubation time, beads were transferred to a small column (Mobicols with 
2 different screw caps without filters, MoBiTec #M1002) with filter (35 µm pore size, 
MoBiTec #M513515) and were washed 5 times with 200 µl of wash buffer. Beads 
were then re-suspended in 100 µl of wash buffer and all samples were transferred 
into new microcentrifuge tubes. Beads were let to settle and the supernatant was 
discarded.  
 
SDS-PAGE sample buffer was added in a volume that was approximate to that of the 
beads, 40 µl. Samples were heated at 95 ºC for 3-4 min and loaded in a 12% gel for 
SDS-PAGE/WB. Cell lysates (20 µg) were also ran alongside to the IP samples. 
Membranes were probed with HRP-conjugate anti-Mouse pAb to assess non-specific 
binding. After this, membranes were incubated with anti-CHIP mAb and then the same 
secondary antibody.  
 
Protocol optimisation was performed by introducing two different changes. Firstly, a 
blocking step was added, where beads were incubated for 1 h at 4 ºC on the rotating 
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wheel with 3% BSA in wash buffer, after batch-binding (incubation with 11F scFv) and 
before incubation with the lysate. Secondly, lysates were pre-cleaned by incubating 
with beads (2010 µg lysate: 50 µg beads, i.e. about 40:1) for 1 h, at 4 ºC on the rotating 
wheel. As before, 500 µg of lysate was added to 10 mg (50 µl) of beads with or without 
11F.   
 
 
2.7.4 Fixing cells 
Independent of the fixation reagent(s) used, cells were rinsed with PBS prior to 
fixation. Enough fixative was added to submerge the coverslip thoroughly.  
 
 
a. 4% Paraformaldehyde (PFA) 
The PFA solution was made in-house and stored for a maximum of 6 months at -
20ºC. The desired amount of PFA to make a 4% solution was dissolved in 60ºC 
ddH2O. 2N NaOH was added until the solution became clear. Then PBS tablets 
(Sigma) were dissolved to make a 1x solution. The pH was adjusted to 7.2 with HCl 
and the solution was filtered (Stericup Durapore 0.22µm PVDF, 5643, Millipore). 
Aliquots were stored at -20ºC.  
 
Coverslips were incubated with 4% PFA for 15-min at room temperature and 
protected from light. Next, they were washed three times with PBS for 5 min each, 
while gently shaking.   
 
 
b. 4% PFA and methanol 
Cells were fixed with 4% PFA, as previously described. After the 4% PFA was 
removed and cells were rinsed with PBS, cool methanol (M/400/17, Fisher Chemical) 
was added for 5-10 min (the plate should be on a flat surface at -20ºC). Next, cells 
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c. 10% Formalin  
Cells were incubated with commercial 10% formalin for 15 min at room temperature 
and protected from light. Subsequently, three washes with PBS for 5 min each, while 
gently shaking, were performed.  
 
d. Methanol and acetone  
Pre-chilled methanol (M/400/17, Fisher Chemical) and acetone (A/0600/15, Fisher 
Chemical), mixed at a 1:1 ratio, were added to cells. This was incubated on a flat 




2.7.5 Immunofluorescence (IF) 
For immunofluorescence (IF) assay, cells were plated on sterile coverslips at low 
density and incubated for at least 24h before analysis. Once about 50% confluent, 
cells were fixed in 4% PFA or another fixative, as indicated. Coverslip preparation and 
fixation methods have been previously described.  
 
Once fixed and washed with PBS, cells were incubated with blocking solution for 1 h 
at room temperature, gently shaking. This prevents non-specific binding of the 
fluorophore-conjugated secondary antibody. The blocking solution is either 2% (v/v) 
donkey or goat serum (the same species as the origin of the secondary antibodies 
used), diluted in PBS with 0.1% Tween-20 (PBS-Tween). Cells were incubated 
overnight at 4ºC with the primary antibody(s) desired. Next, cells were washed three 
times for 5 min at room temperature, while gently shaking. In the meantime, 
fluorophore-conjugated secondary antibodies were diluted in the same blocking 
solution and added to cells for 1 h at room temperature, protected from light. Post-
incubation, cells were washed three times with PBS-Tween and then incubated with 
DAPI (62248, Invitrogen) diluted in PBS (1:5000) for 5 min. Finally, they were washed 
and mounted.  
 
For mounting, excess solution was removed from the coverslips and these were 
added to ~10 ml of mounting media (VECTASHIELD® Antifade Mounting Medium, H-
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1000, Vector Laboratories) on the microscope slide (cells should become covered in 
mounting media). The coverslips were blotted to removed excess mounting media 
before being sealed with varnish. After 24h at 4ºC, the slides were imaged.    
 
 
2.7.6 Proximity ligation assay (PLA) 
The proximity ligation assay (PLA) was performed using the Duolink In Situ Detection 
Reagents Green kits (DUO92014, Sigma). Firstly, cells were plated on coverslips and 
fixed as previously described for IF. They were washed three times with PBS for 5 
min, while gently shaking, and blocked with 2% donkey serum in PBS with 0.1% triton 
X-100 (PBS-Triton) for 1 h at room temperature. Two primary antibodies of a 
combination of mouse and rabbit species were diluted in the blocking solution and 
incubated overnight at 4ºC. Next, cells were washed again three times with PBS-
Triton for 5 min each, on a slow shaking platform.  
 
Per coverslip, 4 µl of anti-rabbit PLUS (DUO92005, Sigma) and 4 µl anti-mouse 
MINUS (DUO92001, Sigma) probes were diluted in 32 µl of Ab diluent. For this and 
all subsequent mixtures of PLA reagents, a master mix was prepared and then added 
to all coverslips simultaneously. The mixture was incubated for 20 min at room 
temperature. In the meantime, cells were washed three times for 5 min with PBS 
(about 80 µl each time). All washes were performed on a slow shaking platform. Once 
the probes were added to the coverslips, this was incubated at 37ºC for 1 h in a 
humidified chamber. Next, coverslips were washed three times for 5 min with Buffer 
A. The ligation mix was prepared by adding 8 µl of 5x ligation stock, 31 µl of ddH2O 
and 1 µl of ligase (per coverslip), which was then added to the coverslips and allows 
to incubate for 30 min at 37ºC in a humidified chamber.  
 
Post-incubation, the coverslips were washed three times for 5 min with Buffer A. In 
the meantime, the amplification mix was made as follows: 8 µl of 5x amplification 
stock, 31.5 µl of ddH2O and 0.5 µl of polymerase (per coverslip). This was added to 
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Coverslips were then subjected to a series of washes (each for 5 min with gentle 
shaking), as follows:  
- Twice with Buffer A 
- Three times with Buffer B 
- Twice with 0.01x Buffer B 
Then DAPI (62248, Invitrogen) was diluted in 0.01x Buffer B (1:2500) and added to 
each coverslip for 5 min, while protected from light. Coverslips were then washed 




150 mM NaCl 
10 mM Tris pH 7.4 (adjusted with HCl) 
0.05% Tween-20 µm 
 
Buffer B 
100 mM NaCl 
250 mM Tris pH 7.5 (adjusted with HCl) 
Filtered with 0.22 µm 
 
 
2.7.7 Membrane assays 
a. Permeability assay 
Cortical neurons were washed with HEPES-based buffer (10 mM HEPES diluted in 
HBSS containing 1-26 mM calcium and magnesium (24020117, Gibco)). Next, 
neurons were incubated with green cell-impermeable dye (lysine fixable 10-kD FITC 
dextran, D1820, Invitrogen) diluted 1:100 in the HEPES-based buffer, for 5 min at 
37ºC. Neurons were rinsed with HEPES-based buffer and fixed with 4% PFA. In 
addition to assessing the degree of permeability (by the intensity of the intracellular 
dye), the expression of ANXA2 was also analysed in parallel by IF (performed as 
previously described), using anti-ANXA2 pAb and a secondary antibody with a 
different emission wavelength. The co-localisation of the green dye and ANXA2 was 
assessed using ImageJ.    
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b. Membrane injury induced by glass beads 
Most membrane-injury assays were done in collaboration with Dr Jesper Nylandsted§ 
(except for the bead-rolling).  
 
 
i. Bead rolling-induced injury 
Cells were incubated with HEPES-based buffer (10 mM HEPES diluted in HBSS 
containing 1-26 mM calcium and magnesium (24020117, Gibco)). Coverslips were 
transferred to O-rings (Z503959 Sigma) on a 6-well plate. The green cell-impermeable 
dye (lysine fixable 10-kD FITC dextran, D1820, Invitrogen) was diluted 1:100 in the 
HEPES-based buffer and 30 µl was added per coverslip. Previously weighed glass 
beads (26 mg) (glass beads, acid-washed 425-600 µm, G8772, Sigma) were added 
per coverslip, except for the control coverslips, which were not subjected to injury. 
The plate containing the coverslips was manually inverted by 30º back and forward 8 
times. Cells were allowed to recover for 5 min at 37ºC. The beads were removed by 
submerging the coverslips in a HEPES-based buffer and the cells were immediately 
fixed with 4% PFA, as previously indicated. Cells were then incubated with DAPI 
(62248, Invitrogen) diluted in PBS (1:5000) for 5 min. Next, they were washed and 
mounted, as previously described.  
 
When indicated, instead of being fixed immediately after recovery, cells were 
incubated with red cell-impermeable dye (lysine fixable 10-kD FITC dextran, D1863, 
Invitrogen) was diluted 1:1000 in the HEPES-based buffer (30 µl) for 5 min at 37ºC. 
Next, cells were rinsed with HEPES-based buffer and fixed with 4% PFA, stained with 
DAPI and mounted.   
 
The intracellular intensity of the dye(s) was asses by epifluorescence microscopy, 
both quantitatively and qualitatively. This is a read-out of increase permeability, since 
poor membrane integrity (e.g. glass bead-induced holes) favours intracellular 
incorporation of the dye.  
 
 
§ Danish Cancer Society Research Centre, Copenhagen, Denmark  
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ii. Injury induced by mixing glass bead by vortex 
SH-SY5Y were detached using trypsin and counted, as previously described. Cells 
were centrifuged for 5 min at 1000 rpm, the media was removed, and the pellet was 
resuspended in culturing media to obtain a solution with 200,000 cells/ml. A fraction 
(400 µl) was then added to microcentrifuge tubes containing 250 mg of glass beads 
each. These were mixed by vortex for 30 s, 60 s, 90 s, 120 s, 150 s and 180 s. Three 
controls were added: microcentrifuge tubes with cells and without beads were either 
not vortexed or vortexed for 180s, while another contained both cells and beads was 
not mixed by vortex.  
 
After the injury, cells were plated in triplicates in 96-well plates (50 µl added to each 
well). Wells were incubated with 2.5 µg/ml Hoechst-33342 (H3570, Invitrogen) and 2 
µg/ml propidium iodide (P4864, Sigma) diluted in HBSS (24020117, Gibco) for 2 min 
at 37ºC. Cells were imaged with a plate cytometer (Celigo cytometer, Brooks Life 
Science Systems) and analysed using Celigo Software Version 2.1.  
 
 
c. Membrane injury induced by digitonin  
Digitonin is a membrane pore-forming detergent that wound cholesterol-rich 
membranes (Figure 2.1). For this membrane-wounding assay, SH-SY5Y and iPSC 
cells were plated into 96-well plates at 1 x 104 and 1 x 105 cells/well, respectively. 
Once wells are 90% confluent, they were treated with different concentrations of 
digitonin (0, 3, 5, 7, 10, 13, 15, 17, 20, 25 and 30 µg/ml), in triplicates. Digitonin stocks 
of 5 mg/ml were previously prepare and heated up to 97ºC for <5 min and vortexed 
briefly prior to use. Digitonin was diluted in either culturing media (DMEM with FBS or 
iPS-Brew media, depending on the cell line) or HBSS without calcium and 
magnesium. When repair is allowed (in the presence of calcium), digitonin was 
incubated for 10 or 20 min, as indicated. However, when repair is impaired (in the 
presence of HBSS without calcium), the incubation is reduced to 2 min. Incubations 




















Post-incubation, wells were incubated with 2.5 µg/ml Hoechst-33342 (H3570, 
Invitrogen) and 2 µg/ml propidium iodide (P4864, Sigma) diluted in the same media 
as digitonin for 2 min at 37ºC. Cells were imaged with a plate cytometer (Celigo 
cytometer, Brooks Life Science Systems) and analysed using Celigo Software 
Version 2.1. 
 
When indicated, digitonin treatment was also performed prior to PLA experiments. 
For such, cells were treated with 15 µg/ml digitonin for 15 min, before being washed 
with PBS and fixed.   
 
 
d. Membrane injury induced by UV laser 
SH-SY5Y cells were plated in glass bottom wells. When 50-60% confluent, cells were 
incubated with HEPES-based buffer (10 mM HEPES diluted in HBSS containing 1-26 
mM calcium and magnesium (24020117, Gibco)) and 1mg/ml of FM1-43 dye (T3163, 
Invitrogen). Injury was performed by irradiating a small region (1-2 µm2) for <10-100 
ms with a pulsed UV laser (Rapp OptoElectronic) close to cellular projections.  
 
 
Figure 2.1: Schematic of digitonin-induced membrane damage 
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2.7.8 Microscopy 
a. Live-imaging  
Cells were imaged every 4-10 s starting before the injury and continuing for 3 min 
following injury, while maintained at 37ºC. The injury response was imaged with a 63x 
objective using the Nikon confocal microscope equipped with a PerkinElmer spinning 
disk. Microscope hardware was controlled by Volocity (PerkinElmer) and live-imaging 
data was analysed using the same software. 
 
 
b. Epifluorescence microscopy 
IF-based assays were visualised using the Axio Imager (Zeiss) with 63x, 40x and 20x 
objectives. Microscope hardware was controlled by Micromanager Software 




2.8 Mass spectrometry (MS)-based assays 
2.8.1 Sample preparation 
Cells were lysed in a urea-based MS-compatible buffer and protein concentration was 
assessed using Micro BCA assay or Bradford assay, as previously described. For 
cortical neurons, specifically, biological replicates were imaged by phase-contrast, 
lysed on-plate and protein concentration was assessed using the Micro BSA assay. 
Two biological replicates per cell line that had similar morphology and confluency 
were pooled together to yield 80 µg samples. This was repeated twice, yielding three 
samples per cell line (each pooled from biological duplicates). The next steps of 
sample preparation and the MS analysis was performed in collaboration with Dr Jakub 




‡ Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech 
Republic 
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a. Filter-aided sample preparation (FASP) 
FASP is a proteomic technique used for the preparation of samples for bottom-up MS 
analysis. Here, samples are subjected to on-column proteolysis to yield peptides. 
Firstly, each filter (Sartorius Stedim Biotech, #VN01H02 with a 10 kD cutoff) was 
incubated with 100 µl of a urea-based buffer (8M Urea + 0.1 M Tris, pH 8.5), to which 
80-100 µg of the protein was then added. The mixture was centrifuged for 15 min at 
14,000 g and 20ºC. Next, another 100 µl of the urea-based buffer was added, as well 
as 20 µl of 100 mM Tris 2-carboxyethyl phosphine hydrochloride, TCEP (a reducing 
agent) (C4706, Sigma). The reaction was incubated for 30 min on a shaking thermo-
block at 37ºC and 600 rpm. This was followed by centrifugation for 15 min at 4,000 g 
and 20ºC. The sample was then alkylated by the addition of 20 µl of 300 mM 
iodoacetamide (IAA) (I6125, Sigma), together with 100 µl of the urea-based buffer. 
This was mixed on the thermo-block for 1 min at 600 rpm and 25ºC and then incubated 
for 20 min at room temperature (protected from light). After being centrifuged for 15 
min at 14,000 rpm and 20ºC, the flow-through was discarded and 100 µl of 100 mM 
ammonium bicarbonate was added. Again, the sample was centrifuged for 20 min at 
14,000 rpm, which was followed by another addition of 100 µl 100 mM ammonium 
bicarbonate and a centrifugation step. Next, 100 µl of 50 mM ammonium bicarbonate 
was added and, finally, trypsin (Promega) was added in a mass ratio 1:50 (w/w) 
(trypsin:protein). The sample was collected in a low-binding collecting tube (Axygen). 
The sample was mixed at 600 rpm for 1 h and then incubated overnight in a humidified 
chamber at 37ºC. The peptides were eluted by centrifugation at 14,000 rom for 15 




b. Peptide quantification 
Peptide concentration was measured using the Quantitative Colorimetric Peptide 
Assay, following the manufacturer’s instructions (23275, Thermo Scientific). The 
absorbance of the reaction was measured using a TECAM spectrophotometer at 480 
nm. A calibration curve was created and used to deduce the peptide concentration of 
samples. Based on this, 25 µg of peptides per sample were transferred into a new 
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low-binding microcentrifuge tube and dried in a SpeedVac at 35ºC for 1 h or until no 
residual liquid is present. Samples were stored at -80ºC. 
 
 
2.8.2 Mapping of ubiquitination sites 
a. From reactions 
Samples were processed by FASP and measured in data-dependent positive mode. 
The MS precursor mass range was set from m/z 400 Da up to m/z 1250 Da and from 
m/z 200 Da up to m/z 1600 Da in MS/MS. Cycle time was 2.3 seconds and in each 
cycle 20 most intensive precursor ions were fragmented. Subsequently, their 
corresponding MS/MS spectra were measured. Precursor exclusion time was set to 
12 sec. Precursor ions with intensity below 50 cps were suspended from the IDA 
experiment. The extraction of mass spectra from chromatograms, their annotation 
and deconvolution were performed using Protein Pilot 4.5 (SCIEX, Toronto, Canada). 
MS and MS/MS data were searched using the Uniprot+Swissprot database restricted 
to Homo sapiens taxonomy. Fixed modification – alkylation on cysteine using 
iodoacetamide and digestion using trypsin was set for all searches. An emphasis on 
identification of GlyGly modification (ubiquitination) was selected in the software. FDR 
analysis was performed by searching the shotgun data against the decoy search 
database. 
 
MS/MS spectra were inspected for evidence of product ions bearing the GlyGly 
modification. Ubiquitinated peptides identified by a set of product ions without GlyGly 
modification (less than 3 GlyGly modified product ions) were excluded from analysis 
and considered as false positive. 
 
This was conducted in collaboration with Dr Jakub Faktor and Dr Bořivoj Vojtesek‡. 
 
 
‡ Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech 
Republic 
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b. From polyacrylamide gels partly resolved by SDS-PAGE 
In vitro ubiquitination assays with CHIP in the presence and absence of untagged 
ANXA2 were conducted as previously described. Upon completion, the reactions 
were diluted with loading dye and loaded an SDS-PAGE gel. Electrophoresis was 
performed until the dye front reach the interface between the stacking and resolving 
gels. Individual bands were the excised from the gel and stored at -20ºC.  
 
Gel pieces were washed with 100 mM ammonium bicarbonate and acetonitrile and 
then incubated with 50 mM iodoacetamide for 30 minutes at room temperature in the 
dark. Gel pieces were washed again three times as before and then incubated 
overnight with 1:100 trypsin:protein at 37ºC in 100 µl 100 mM ammonium 
bicarbonate, 10% acetonitrile.  
  
Excess liquid was removed and peptides were extracted from the gel with 2x 10 
µl acetonitrile. Extracted peptides were then added to a fresh tube, before being 
diluted to 2% acetonitrile in 0.1% trifluoroacetic acid, and finally underwent solid-
phase extraction on C18 stage-tips.  
  
The acidified peptide solution was loaded onto an activated (15 µl methanol), 
equilibrated (50 µl 0.1% TFA) C18 StAGE tip, and washed with 50 µl 0.1% TFA. The 
bound peptides were eluted with 40 µl 80% ACN 0.1% TFA and concentrated to less 
than 8 µl in a vacuum concentrator. The final volume was adjusted to 15 µl with 0.1% 
TFA.  
 
Online UPLC was performed using a Thermo Ultimate 3000 Nano. Following the C18 
clean-up, 5 µl peptide solution were injected onto a C18 packed emitter and eluted 
over a gradient of 2%-28% acetonitrile in 40 min, followed by 76% acetonitrile for 6 
min, with 0.5% acetic acid throughout. Eluting peptides were ionised at +1.7kV before 
data-dependent analysis on a Thermo Fusion Lumos. MS1 was acquired 
with mz range 350-1400 and resolution 60,000, and 2-second cycle for fragmentation 
with normalised collision energy of 28, and an exclusion window of 12 seconds. MS2 
were collected with resolution 30,000 and AGC targets for MS1 and MS2 were 7e5 
and 5e4 respectively. 
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Finally, the data were analysed using MaxQuant (v 1.6.3.3) in conjunction 
with Uniprot fasta database 2018_09, with match between runs (MS/MS not 
required), LFQ with 1 peptide required and normalization skipped. “GlyGly (K)” was 
added to the variable modifications. Modifications with a localization probability of 
>0.8 were considered.  
 




HDX analysis by MS (HDX-MS) was conducted in collaboration with Dr Lenka 
Hernychova and Dr Bořivoj Vojtesek‡. HDX experiments were performed as 
previously described.  
  
Mass spectrometric analysis was carried out using an Orbitrap Elite mass 
spectrometer (Thermo Fisher Scientific, Massachusetts, USA) with ESI ionization 
online connected with a robotic system based on the HTS-XT platform (CTC 
Analytics, Zwingen, Switzerland).  The instrument was operated in a data-dependent 
mode for peptide mapping (high performance liquid chromatography (HPLC)-
MS/MS). Each MS scan was followed by MS/MS scans of the top three most intensive 
ions from both collision-induced dissociation (CID) and higher-energy collisional 
dissociation (HCD) fragmentation spectra.  
 
Tandem mass spectra were searched using SequestHT against the cRap protein 
database (ftp://ftp.thegpm.org/fasta/cRAP) containing the sequence of the CHIP 
protein with the following search settings: mass tolerance for precursor ions of 10 
ppm, mass tolerance for fragment ions of 0.6 Da, no enzyme specificity, two maximum 
missed cleavage sites and no-fixed or variable modifications were applied. The false 
discovery rate at peptide identification level was set to 1%. Sequence coverage was 
analysed with Proteome Discoverer software version 1.4 (Thermo Fisher Scientific, 
 
¶ Institute for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK 
‡ Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech 
Republic 
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Massachusetts, USA) and graphically visualized with MS Tools application99. Totally 
94.72% of CHIP protein sequence was covered by 294 identified unique peptides.  
 
Analysis of deuterated samples was done in HPLC-MS mode with ion detection in the 
orbital ion trap. The MS raw files together with the list of peptides (peptide pool) 
identified with high confidence characterized by requested parameters (retention time, 
XCorr, and ion charge) were processed using HDExaminer version 2.2 (Sierra 
Analytics, Modesto, CA).  The software analysed protein and peptides behaviour and 
created the uptake plots that showed peptide deuteration over time with calculated 
confidence level (high, medium confidence are accepted, low confidence is rejected). 
The results from peptide pool were displayed as graph showing the evolution of 
deuteration at individual parts of the protein at the same time and different protein 





2.9 Software and statistics 
2.9.1 Analysis of DNA sequences 
To identify indels in the STUB1 gene in the clones derived from CRISPR/Cas9-based 
gene editing, the SnapGene software was used. Here, sequences obtained from PCR 
products and the DNA extracted from competent cells transformed using the TOPO 
cloning kit were aligned with the human WT STUB1 gene.  
 
 
2.9.2 Imaging analysis 
Fluorescent images were analysed by ImageJ in multiple ways. Firstly, different 
channels were isolated and overlaid using this software to represent co-localisation 
signal. For some experiments, such co-localisation was quantified using the “Coloc 2” 
plugin, according to the software’s instructions, which resulted in a colocalization 
index (the Pearson’s colocalization number) that was compared across conditions/cell 
lines. Secondly, ImageJ was used to create maximal projections from z-stacks of 
images.  
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Additionally, the signal intensity of single images or maximal projections was 
quantified using this software. For such, colour channels were isolated and the 
brightness and contrast of the per channel was adjusted in a consistent manner 
across replicates within an experiment, to improve signal:background. When the 
signal of interest is localised to the cytoplasm or membrane, rather than restricted to 
the nucleus, the mean intensity of the channel of interest is recorded and normalised 
by that of DAPI (for normalisation purposes).  
 
In the glass bead-rolling assay, the fluorescence of the intracellular dye was quantified 
per area of the nucleus (represented by the DAPI staining). For such, after splitting 
the different channels per image, the intensity of the green channel was adjusted to 
1000-7500. Next, the DAPI channel was selected and a binary image was created 
using the default threshold. The different nuclei were highlighted using the “Analyse 
particles” plugin (using an arbitrary size that would identify nuclei, e.g. 20 to infinity), 
which was then manipulated manually to adequately detect the nuclei present in the 
image. The highlighted areas were added to the regions of interest (ROI) manager 
and overlaid on the adjusted fluorescence channel of interest (green). The mean 
intensity was measured and, if >2000 the cells was classified as injured (the arbitrary 
value was achieved by qualitative analysis of the images). The percentage of cells 
injured compared to the total cells analysed was calculated and compared across cell 
lines.  
 
Finally, ImageJ was also used for the quantification of PLA signal. For the majority of 
the PLA experiments, the number of PLA puncta per field of view was counted 
manually and then this was divided by the number of nuclei (represented by DAPI 
staining) present. However, the quantification of the PLA analysing the interactome of 
ANXA2 and S100-A11, which resulted in abundant signal, was performed in a semi-
automated manner. For such, the PLA channel was isolated, and the total integrated 
density was measured (i.e. ROI were not selected). This was then divided by 10000 
and then normalised by the number of nuclei within each image (that was counted 
manually). The effect of slightly varying background intensities was proven to not 
change the results obtained significantly (data not shown). All quantifications were 
conducted using TIFF images.  
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2.9.3 Live-imaging analysis 
The Volocity software (PerkinElmer) was used for live-imaging analysis. The kinetics 
of repair was measured by monitoring the uptake of FM1-43 dye as a change in 
fluorescence at regions of interest over the course of imaging. The software was also 
used to measure the distance migrated by cells upon laser-induced injury was 
quantified by measuring the length from the end of a single projection to the cell body 
both before and after injury, in projections that are close to the site of injury.  
 
 
2.9.4 Quantification of immunoblots and polyacrylamide gels 
analysed by SDS-PAGE 
Immunoblots and gels stained with Coomassie blue were scanned and specific bands 
were quantified using Image Studio Lite (using TIFF images). The background 
intensity was used to normalise the quantification of each band. Quantification takes 
into account the intensity and area occupied by the signal. Quantification of proteins 
of interest was normalised by that of the loading control.  
 
 
2.9.5 Statistical analysis 
Normality tests and statistical analysis were performed using Prism GraphPad. When 
datasets pass the D’Agostino-Pearson normality test (alpha=0.05), they were 
analysed using the student’s t-test or One-way/Two-way Analysis of Variance 
(ANOVA) statistical tests with Holm-Sidak’s multiple comparison post-hoc test, as 
indicated. When the data failed the normality test applied, a non-parametric statistical 
test was performed, Kruskal-Wallis test, with the Dunn’s multiple comparisons post-
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Chapter 3: Engineering iPSCs to generate 
isogenic neuronal cell models 
 
3.1 Introduction 
3.1.1 Existing physiological models for studying CHIP function 
Largely due to the lack of authentic models to study CHIP, cell biologists have relied 
on overexpression systems25,57. These are particularly inadequate when studying 
tightly-regulated enzymatic housekeeping pathways, such as ubiquitination and other 
PQC mechanisms, in which CHIP functions. Furthermore, overexpression of CHIP is 
likely to interfere with the interactome of other TPR-containing proteins.   
 
Recently, iPSC lines have been engineered to model CHIP-related diseases101,102, 
thus moving towards a more biologically relevant system. Regarding animal models, 
the first CHIP KO mouse model was reported in 200378. Since then other groups have 
characterised it from different angles14,15,103,104, but no new mouse models have been 
engineered. Drosophila and C. elegans CHIP models have also been derived, but 
their phenotype was not characterised in detail, except for their reduced longevity62. 
All these models support a robust neuroprotective role for CHIP, however, the 
underlying mechanisms are largely unknown.   
 
 
a. Homozygous CHIP KO mice 
CHIP KO mice were first established by the Patterson group78. The first three exons 
of the CHIP gene were replaced with a selection cassette (PGK-Neo for expression 
of neomycin resistance) by homologous recombination. CHIP homozygous KO mice 
have significant mortality in prenatal (5% has been reported78) and early postnatal 
periods (studies reported 20%78 and 95%103). These mice had thymic atrophy, a 
characteristic non-specific response to abnormal stress tolerance78. Although the first 
report of CHIP KO mice did not observe obvious morphologic abnormalities in the 
surviving mice78, two subsequent sutides14,103 reported compromised bodyweights 
(Figure 3.1A). Additionally, the latter group observed severe neurological and 
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peripheral phenotypes in CHIP KO mice, which have profound gait impairment 
(dysbasia)103.  
 
Overall, the literature agrees with the severe progeria phenotype exhibited: CHIP KO 
mice have a 60% decrease in longevity compared to WT (Figure 3.1B) and a 31% 
gender-specific decrease in longevity, with male mice showing increased 
progeria14,15. Accordingly, CHIP KO mice had profound progressive reductions in 






















Interestingly, both the CHIP KO mice and its isolated fibroblasts have compromised 
responses to stress. For example, Hsp70 upregulation in response to heat shock was 
reduced by 50-60% in fibroblasts (similar to that observed in cells lacking the inducer 
of HSPs, HSF-1) and severely impaired in multiple tissues, including the brain. In 
parallel, caspase-3 protein levels and activity were enhanced in CHIP KO mice, 
indicative of cell death. Accordingly, all CHIP KO mice subjected to heat stress died 
A 
B 
Figure 3.1: CHIP KO mouse model 
A) CHIP KO mice have small body sizes and enhanced progressive kyphosis.  
B) CHIP KO mice have significantly reduced lifespans. Cohort including male and female CHIP 
KO (n = 82) and WT (n = 128) mice. 
(Min et al.14) 
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rapidly, either during or immediately thereafter, compared to WT mice that only 
recorded 25% death during recovery78.   
 
 
b. Heterozygote CHIP mutant mice 
The extreme phenotype of CHIP homozygous KO mice can confound investigation 
into protein targets of CHIP KO mice. Heterozygote mice were generated from the 
established CHIP KO mouse model78 and analysed by McLaughlin and colleagues104. 
Gross abnormalities, such as body and brain weights and muscle tone, which were 
seen in homozygous KO mice were normal in the heterozygous mice. However, 
cardiac dysfunction, brain dysfunction (detected by specific motor disturbances) and 
impaired response to environmental stress were maintained. Finally, the 
heterozygous CHIP mice are likely to be a better model to investigate human 
diseases, seeing that no total loss-of-function mutation in CHIP have been reported 
in humans104.   
 
 
c. CHIP mutant iPSC 
Recently, iPSCs were reprogrammed from fibroblasts of a 12-year-old patient with 
Gordon Holmes syndrome/SCAR16, having severe early-onset multi-systemic 
neurodegeneration. The cell line carries two heterozygous mutations in the STUB1 
gene, encoding for CHIP, leading to a premature stop codon at Arg119 and a point 
mutation (Ile294Phe) at the protein level. Cells express markers of pluripotency 
genes, including OCT4, and can differentiate into ectodermal cell lineages101.  
 
 
d. CHIP KO iPSC 
The same group established iPSCs from fibroblasts of a healthy 37-year old woman. 
These were then transfected with two tracrRNA ribonucleoprotein complexes 
targeting exon 2 and 3 of STUB1 for CRISPR/Cas9 gene-editing. Sequencing 
confirmed that the homozygous KO line carries a deletion resulting in a protein with a 
frameshift mutation (p.Val94Alafs*5) leading to nonsense-mediated decay and loss of 
CHIP protein. Again, the iPSCs express markers of pluripotency and have 
differentiation potential102.  
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3.1.2 CRISPR/Cas9-based gene-editing technology 
Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas is a defence 
mechanism of the microbial adaptive immune system that uses RNA-guided 
nucleases to cleave foreign genetic elements (e.g. virus or plasmid)105. In bacteria 
and archaea, the mechanism has three stages, adaptation/acquisition of CRISPRs to 
invaders, CRISPR RNA (crRNA) biogenesis and invader silencing106–108. This 
mechanism has been exploited to allow targeted nucleases to be used for genome 
alteration with high precision (Figure 3.2)105,109. There are three types of CRISPR/Cas 
systems identified, but type II from S. pyogenes is the most widely used system for 
genetic manipulation and utilizes the nuclease Cas9.  
 
It has been suggested that Cas9 protein intrinsically interacts with nuclei acids in a 
non-specific manner, thus the RNA components confer specificity105. The crRNA array 
not only encodes the guide RNA for directing the nuclease to the DNA target, but also 
encodes an essential auxiliary trans-activating crRNA (tracrRNA)105. TracrRNA is 
complementary to the repeat sequences in pre-crRNA and forms an RNA duplex107,109 
(Figure 3.2A). The two RNAs complex with Cas9. 
 
Both crRNA and tracrRNA are critical for Cas9-mediated targeted DNA cleavage108. 
Mechanistically, tracrRNA ensures target DNA recognition, possibly by directing the 
orientation of Cas9 on the complementary strand. The crRNA has a short high-affinity 
binding site (called the “seed” sequence) in its 3’ end, which is the protospacer-
encoded portion of the crRNA and governs the efficiency of target binding107. The 
region of the crRNA is complementary to the seed sequence (8-12 bp) in the target 
DNA, thus directs the Cas9 to this site for subsequent cleavage108,109.  
 
For the CRISPR/Cas9 methodology, the crRNA and tracrRNA have been fused to 
create a chimeric, single-guided RNA (gRNA)105 (Figure 3.2B109). It retained the 
hairpin structure and mimicked the dual-RNA structure required to guide Cas9108. This 
allows bypassing of the adaptation/acquisition and crRNA biogenesis steps and, by 
designing gRNAs, DNA sequences of interest can be targeted.    
 
While the architecture of the gRNA used influences the efficiency of Cas9 activity for 
any given locus109, the protospacer adjacent motif (PAM) dictates the cleavage 
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location105,108. The PAM conforms to an NGG consensus sequence within the target 
DNA, which occurs downstream of the crRNA binding sequence108 (Figure 3.2C). This 
is the PAM requirement for Cas9, although it varies across different Cas proteins105. 
The PAM plays a role in the recruitment of the ribonucleoprotein (Cas9-
tracrRNA:crRNA) complex to the correct target DNA site. Mutating a single G 
nucleotide compromised the interaction108. Therefore, specific recognition of the PAM 
sequence by Cas9 as a pre-requisite for target DNA binding108.  
 
For gene-editing, the expression of Cas9 and the requisite gRNA is induced in the 
model of interest. Commonly, the gRNA is engineered to specify the 20-nt targeting 
sequence (not including the PAM) (Figure 3.2C). Cas9 cleavage results in a double 
strand break, which can undergo repair by non-homologous end joining (NHEJ) or 
homology directed repair (HDR), resulting in genome editions (Figure 3.2D). NHEJ 
occurs in the absence of a repair template and is error-prone. Insertions/deletion 
(indel) mutations can result in gene KO, if they occur within a coding exon or within 
promoters/enhancers105,109. HDR, on the other hand, is a high-fidelity repair pathway 
that can generate precise and defined modifications at a target locus. Although it 
occurs less frequently than NHEJ, it can be driven by the presence of an exogenously 
introduced repair template. Templates contain homologous sequences flanking the 
insert sequence and are effective methods for making small edits (e.g. introduction of 
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Figure 3.2: Naturally occurring and engineered CRISPR/Cas9 
A) Naturally occur CRISPR/Cas system. TracrRNA hybridizes to the pre-crRNA repeat, 
forming a duplex RNA that is recognized and cleaved by the ribonuclease RNase III13,14. Such 
processing of crRNAs requires the presence of Cas913,14. The pair of RNAs (crRNA-tracrRNA) 
complex with Cas9 allowing Cas9 to recognise and cleave foreign DNAs bearing the 
protospacer sequences.  
B) Engineered CRISPR/Cas systems use a single gRNA to target Cas9 to the target DNA site. 
C) Cas9 is a large protein that includes both HNH and RuvC-like nuclease domains11,13. Each 
domain cleaves the complementary and noncomplementary strands of the target DNA, 
respectively14. The gRNA mediates the cleavage of DNA sites that are complementary to the 
5’ 20nt of the gRNA and lie adjacent to a PAM sequence.  
D) Once dsDNA is cleaved, repair can be mediated by non-homologous end joining (NHEJ) 
or homology directed repair (HDR). 
(A-C: Sander et al.109; D: Ran et al.105) 
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a. Advantages of the CRISPR/Cas9 system 
The extensive advantages of the CRISPR/Cas9 technology drove its rapid expansion 
from being a niche to mainstream method used by many researchers across different 
fields109. It allows the generation of modified cell lines, having enormous potential 
across basic science to medicine and biotechnology105. It aids in the investigating 
protein function, by deleting protein-encoding genes or altering functional domains, 
enabling more accurate disease modelling109. Compared to gene-editing technologies 
previous used (e.g. using zinc-finger nucleases and transcription activator-like 
effector nucleases), the system is easy to design, highly specific and 
customizable105,109. The use of single gRNAs also increased the editing efficiency 
rates, compared to double gRNA systems109. This contributed to the great potential of 
CRISPR/Cas technology for high-throughput and multiplex gene editing. By changing 




b. Limitations of the CRISPR/Cas9 system 
Despite advances compared to other methodologies, the main drawback of 
CRISPR/Cas9 is off-target mutagenesis. Potential off-targets include sites that differ 
by up to five positions within the protospacer region compared to the on-target site 
and/or have an alternative PAM sequence than ‘5-NGG (such as 5’-NAG)105,109. The 
occurrence of off-targets is influenced by enzyme concentration, the abundance of 
similar sequences in the target genome and, potentially, the accessibility of off-target 
sites (dictated by epigenetics)105. Beyond the problem of the presence of off-target 
mutagenesis, albeit at variable frequencies, is the challenge in predicting the off-
targets109. Thus, development of unbiased strategies to globally assess the off-target 
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3.1.3 Parkinson’s induced pluripotent stem cells (iPSC) 
A patient within the Iowa kindred with Familial Lewy Body Parkinsonism caused by a 
triplication of the SNCA locus (Figure 3.3A) had rapid and progressive motor and 
cognitive decline97,110. Fibroblasts from this patient were reprogrammed into iPSCs by 
transfecting the Yamanaka transcription factors (OCT4, SOX2, KLF4 and c-Myc) 
(Figure 3.3B). The underlying rational is its potential as a model of both familial and 
sporadic PD97. Familial PD has been reported from several duplication and triplication 
SNCA kindreds111 and multiple GWAS studies have identified polymorphisms around 
SNCA as the most significant genetic risk factor for sporadic PD112. The iPSC lines 
engineered were able to differentiate into neuronal lineages. Patient-derived iPSC 
have four copies of the SNCA gene, causing a twofold increase in α-Syn expression 
both in undifferentiated state and upon differentiation into dopaminergic neurons 
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3.1.4 Cortical neuron differentiation 
 
a. Neural induction 
Neural induction is the first step in neuronal differentiation from stem cells. Dual-
SMAD inhibition is necessary and sufficient for neural induction of human pluripotent 





Figure 3.3: Patient-derived iPSC  
A) The patient with Familial Lewy Body Parkinsonism due to a triplication locus spanning 
multiple genes, including SNCA.    
B) Phase contrast images of AST (patient-derived) and NAS (derived from a healthy relative) 
fibroblasts and de novo iPSC colonies at day 20 post-viral transduction. Scale bar, 100 μm. 
C) Quantitative RT-PCR analysis of SNCA expression normalised with a pan-neuronal marker 
(MAPT). Twofold or greater increase in SNCA expression in neurons derived from AST iPSC.  
D) Western blot analysis of SNCA expression showing a doubling in AST-derived neurons.  
(Devine et al.22) 
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pluripotent stem cells to become Pax6+ neural progenitors (an early marker of 
neuroectodermal differentiation). Dual-SMAD inhibition achieves complete neural 
conversion of >80% of stem cells (whilst the use of either inhibitor alone only yields 
<10%)113.  
 
However, for efficient cortical differentiation, inhibition of SMAD signalling in 
combination with retinoid-mediated pathways is critical114,115. The use of retinoic acid 
is reported to result in the conversion of >95% of stem cells into cortical stem and 
progenitor cells 15 days after neural induction115. In vivo, retinoids promote derivation 
of neural stem cells, regulate the transition from neural stem cell expansion into 
neurogenesis in the cerebral cortex and pattern cortical tissue to caudal and/or ventral 
identities in a concentration-dependent manner113–115.  
 
During neural induction, a process that lasts around 11 days, cells undergo multiple 
changes in morphological and expression profile. Between days 3 and 5 neural 
patterning takes place, with markers of pluripotency (e.g. OCT4) becoming silenced, 
achieving a population of Oct4-/Pax6+ intermediate cells. At day 5, epiblast markers 
(FGF5 and OTX2) are highly expressed. The protein expression of Pax6 gradually 
increases and becomes strong in the majority of the cells by day 7. The lineage of 
these early Pax6+ neuroectodermal cells is biphasic. Initially, large numbers of neural 
crest-like cells form. This is followed by rosette neural stem cells (expressing the 
neural stem cell marker, Nestin), which drive rosette formation113. Cortical rosettes 
have an obvious apico-basal polarity, with many mitoses located at the apical, luminal 
surface of each rosette115. Spontaneously, rosette neural stem cells acquire anterior 
CNS markers (OTX2 and FOXG1B)113.   
 
 
b. Cortical neurogenesis 
To achieve successful cortical neurogenesis and differentiation in situ, one approach 
has been to recapitulate in utero development, thus generating all classes of cortical 
projection neurons in a fixed temporal order115. A key feature is the generation of both 
primary and secondary cortical stem and progenitor cells following neural induction. 
They mimic the main population of cortical stem cells (the neuroepithelial ventricular 
zone), as well as the secondary populations found in the inner and outer 
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subventricular zones (the basal progenitor cells and the outer radial glial cells) of the 
developing human cortex115.  
 
The primary cortical progenitor cells generated from pluripotent stem cells make up 
the major population of rosettes, these are Pax6+/OTX2+/Ki67+ polarized cells with 
radial processes. These give rise to secondary progenitor cells, which are composed 
of two subpopulations: basal/intermediate progenitor cells and radial glial cells 114,115. 
The former are TBR2+/Ki67+/Pax6- and lack basal processes. About half of the Tbr2+ 
population are cycling stem and progenitor cells (co-expressing Ki67), whilst the rest 
are newly born, post-mitotic neurons. Expressing of secondary progenitors (FOXG1 
and TBR2) increases over time. These progenitor cells are present at the periphery 
of each rosette and make up 10-15% of its cells114,115. The other subpopulation of 
secondary progenitor cells are radial glial cells, marked by Pax6+/TBR2- expression 
and lengthy basal processes115. 
 
Following the establishment of cortical neural rosettes, fundamental principles of 
neural development govern the ability of these three critical classes of progenitors to 
generate complex populations of cortical projection neurons, in a cell-intrinsic manner. 
Around 2-3 weeks after initiation of neural indication, early-born deep-layer neurons 
(TBR1+ and/or CTIP2+) form and become the major population ~day 35114. From day 
28, synaptic markers are detected, including the glutamatergic postsynaptic protein 
PSD-95, the major synaptic vesicle protein, synaptophysin, and the presynaptic 
protein, Munc13-1. These are detected in close proximity, likely to represent physical 
synapses, although still functionally inactive114,115. However, by days 45-50, physical 
and functional synapses are detectable and become more abundant over the 
subsequent weeks114. After around 70 days of cortical differentiation, late-born upper-
layer neurons (Stab2+/Cux1+/Brn2+ neurons) are detected114,115. Once all populations 
have developed, complex patters of spontaneous activity are detected (at day 80 and 
above). It was reported that functional cortical neural networks only emerge in culture 
after 2-3 months114. Although this protocol promotes the formation of cortical neurons, 
glial cells emerge from at a later stage. Heterogeneous astrocytes (both GFAP+/S100+ 
and GFAP-/S100+ populations) appear around day 60 and become more abundant 
over the next 40 days, making up approximately 1-7% of cells in culture115.    
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By capturing the complexity of human cortical progenitor cell types found in vivo, the 
in situ system is able to achieve the diversity of projection neuron types in the human 
cortex115. Moreover, the time frame for cortical neurogenesis and emergence of 
functional cortical neural networks observed in situ is remarkably similar to that 
occurring during development114. Glutamatergic projection neurons destined for the 
six layers of the adult cortex are generated in a stereotyped temporal order, with deep-
layer neurons being produced first and upper-layer neurons last. In utero, once these 
are generated, the different classes form local microcircuits between them. This is 





Methods of neuronal differentiation from stem cells allow the generation of disease-
relevant cell types, establishing models to elucidate disease mechanisms and a 
platform to validate candidate drugs and therapies in target cell types. Cortical neuron 
differentiation, in specific, enabled functional studies of human cortex development, 
function in health and dysfunction in disease114,115. Furthermore, when combined with 
patient-derived iPSC technology, individual-specific cortical networks can be 
generated, carrying a genetic background of interest115.  
 
Beyond its potential applications, certain features make this protocol useful. Firstly, 
the use of dual-SMAD inhibition results in neural patterning response that can be 
achieved within a short period of time (~19d). Previously, neural induction was stromal 
feeder-mediated and would take 30-50 days113. Secondly, the purity and robustness 
of the protocol are great advantages, as they allow almost pure cultures of cortical 
stem and progenitor cells to be produced repeatedly. Finally, this system is likely to 
recapitulate cortex-specific mechanisms, as it generates cultures of both deep- and 
upper-layer excitatory neurons, which are electrically active and form functional 
circuits114,115. This contributes to the biological relevance its findings when used as a 
model. In fact, some argue that human iPSC-derived cortical neurons are a more 
adequate model than rodent-based ones due to intrinsic differences in cortical 
neurogenesis between the species. Cortical neurogenesis in rodents takes 
approximately 6 days and has reduced complexity and diversity in the stem cell 
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populations and neuron cell types derived (lacking primate-specific neuron types in 




However, it is unclear whether all classes of cortical stem and progenitor cells are 
present and, as discussed, progenitor cell populations are key to achieve the full 
spectrum of neurons114. Furthermore, this protocol generates glutamatergic projection 
neurons, while GABAergic interneurons were not detected. This could be a limitation 
when modelling the cerebral cortex, as it consists of two major classes of neurons: 
excitatory, glutamatergic projection neurons (making up about 80%) and GABAergic 
interneurons. During development, glutamatergic neurons are derived from cortical 
stem and progenitor cells, whilst the GABAergic neurons are generated outside of the 
cortex and migrate115.    
 
Another significant drawback of across differentiation methodologies is clonal 
variation, which can arise from different sources. When differentiating iPSC that have 
been reprogrammed from mature cells, genetic and epigenetic changes introduced 
during the course of reprogramming may influence the ability of cells to differentiation. 
For example, the differentiation of iPSC clones that are epigenetically prone to source 
cell memory, become bias towards the source cell lineage. Also, the inherent variable 
and dynamic nature of the differentiation process per se can also introduce genetic 
and epigenetic changes that may potentially cause phenotypic changes during or in 
the aftermath of differentiation97,116,117. This makes it more challenging to achieve an 
isogenic set of iPSC lines with comparable differentiation potentials116. However, both 
Chambers et al.113 and Shi et al.114,115 have reported reproducible results in neural 
induction and cortical neurogenesis across cell lines, arguing that the robustness of 
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3.2 Results 
3.2.1 CHIP KO iPSC using CRISPR/Cas9 
Within our group, a neuroblastoma cell line, SH-SY5Y, capable of differentiating into 
neurons was previously engineered using CRISPR/Cas9 to ablate the expression of 
the CHIP-encoding gene, STUB1 – work was conducted by Erisa Nita95. SH-SY5Y 
cells have been widely used in the field of neuroscience research due to its ease for 
genetic manipulation, low maintenance and cost, human origin and ability to 
differentiate into neuronal lineages118.  Within the scope of my PhD project, the 
engineering of a CHIP SH-SY5Y model is viewed as proof-of-concept for the ability to 
ablate CHIP expression in cells using this system and without affecting cell viability.   
 
Given its success, the same CRISPR/Cas9 system was used in a patient-derived 
iPSC line. The gRNA was designed to target downstream of ATG within the first 
coding exon (exon 1) of STUB1, increasing the likelihood of an indel mutation 
knocking out CHIP protein. The guide sequence used is 
GGCCGTGTATTACACCAACC GGG (PAM sequence underlined). According to the 
MIT software*, it has a quality score of 94% and predicted to have 30 off-target sites, 
of which 7 are located in genes. The gRNA was inserted into a LentiV2 backbone, 
containing the Cas9 gene, using the restriction enzyme BsmB1 (Figure 3.4A). SH-
SY5Y were successfully electroporated with the LentiV2 vector containing the gRNA, 
along with a GFP-encoding plasmid, using Amaxa nucleofection (Lonza), achieving 
high transfection efficiency  (94% GFP+ cells) and CHIP KO clones (Figure 3.4B-D)95. 
Interestingly, the PCR product derived from genomic DNA of what was then 
characterised as a CHIP KO clone (labelled “KO1” in the agarose gel) shows two 
amplicons of different sizes, whilst the other lane (labelled “WT”) shows an amplicon 
of a single size (Figure 3.4B). This reflects the presence of pronounced indels in one 
of the alleles of the KO clone, which was confirmed by sequencing (Figure 3.4C). The 
other allele has a single nucleotide deletion, thus its PCR product is of a similar size 





* http://crispr.mit.edu  
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Figure 3.4: CHIP KO SH-SY5Y cells  
A) Map of the LentiV2 plasmid and the restriction sites of the BsmB1 enzyme used. The gRNA 
was inserted into the vector. Digestion also yield a 2-kb product that contains another 
restriction site (BspD1) that was used for screening of successfully digested and ligated 
clones.  
B) PCR products flanking the region of the STUB1 gene where the gRNA sequence were 
made from genomic DNA of two different CRISPR clones and analysed using a 1% agarose 
gel.   
C) The sequences of both alleles of the CHIP KO clone are shown aligned with the human 
WT STUB1 gene. The STUB1 exons (brown), coding regions (blue), forward and reverse 
primers (magenta) and gRNA (green) are indicated. One allele has a single nucleotide 
deletion, whilst the other has multiple deletions and insertions.   
D) CHIP protein expression in the clones was analysed by SDS-PAGE/immunoblot. Both anti-
CHIP and anti-β-tubulin mAbs were used.   
(A, B and C: Adapted from Nita95; C: collaborative work with Erisa Nita) 
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Aiming to obtain a disease-relevant CHIP KO cell model, I genetically manipulated 
iPSC derived from a patient with triplication of α-Syn using CRISPR/Cas9. More 
specifically, the AST line was used for this project, not only because of its twofold 
increase in α-Syn mRNA and protein expression (Figure 3.3C&D), but also for its 
differentiation potential (previously, it was shown to successfully form dopaminergic 
neurons97). Once cells were electroporated, single colonies were picked manually, as 
single cell sorting tends to be too stressful for iPSCs. Cell survival was optimised by 
treating cells with the ROCK inhibitor Y-27632 and Collagenase Type IV, to partially 
detached cells from the underlying matrix prior to dissociation of the colony using 
mechanical force. Different matrices were also tested (Laminin-521, which we 
routinely use for iPSC culturing, and Matrigel) and colonies were obtained from both.  
 
Once colonies became confluent in 24-wells, clones were screened by IF with anti-
CHIP mAb and using the T7 endonuclease I assay. The former was unsuccessful 
(data not shown) given the difficulties in confidently classifying clones are 
immunopositive or negative, due to the characteristic high nucleus:cytoplasm ratio of 
iPSCs, in combination with the predominantly cytoplasmic expression of CHIP. Next, 
the DNA of each clone was extracted and the region flanking the gRNA target 
sequence in STUB1 was amplified by PCR. The PCR products were annealed and 
subjected to the T7 endonuclease I assay. This enzyme recognises and cleaves non-
homologous dsDNA, thus detecting indels. The reactions with and without the 
endonuclease were ran on an agarose gel (Figure 3.5). The following clones had extra 
bands from the incubation with the T7 endonuclease, hence were of interest: A1, F1, 
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Proliferating clones, including those of particular interest, were analysed by WB to 
assess the expression of the CHIP protein (Figure 3.6). While some clones had 
increased CHIP levels compared to WT iPSC and SH-SY5Y, clones D2 and D3 had 
about half the amount of CHIP, clone A7 had a negligible band and C6 had 
Figure 3.5: T7 Endonuclease I assay of iPSC CRISPR clones 
Agarose gels (1%) containing the T7 endonuclease reactions (top) and controls (bottom) of 
the different CRISPR clones. CHIP KO and WT SH-SY5Y were included as positive and 
negative controls, respectively. Clones selected from Laminin-521 and Matrigel coated plates 
were tested. 
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undetectable CHIP levels. Clones D2, D3 and A7 could be heterozygote mutants for 
CHIP or, given the very low expression levels, A7 could be a KO clone with some 
















To confirm the CHIP genotype of clones of interest, PCR products flanking the gRNA 
sequence were generated and sent for sequencing (Figure 3.7). Firstly, the parental 
line (AST) and the C1 CHIP-expressing CRISPR clone were identical to the published 
sequence for the human STUB1 gene (Figure 3.7B). Therefore, these cell lines 













Figure 3.6: Western blot analysis of iPSC CRISPR clones 
Cell lysate from CRIPSR clones were analysed by SDS-PAGE/immunoblot using anti-CHIP 
(1:10000) and anti-β-actin (1:5000) mAbs. Positive controls were included: the patient-derived 
iPSC parental line (AST23), its isogenic control line (AST 2KO6) and the WT SH-SY5Y cells. 
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Figure 3.7: CRISPR/Cas9-based editing of patient-derived iPSC 
Alignment of the sequences derived from the CRISPR clones with the human STUB1 gene (A 
& C), and the predicted CHIP amino acid sequence (B & D). The STUB1 exons (brown), 
coding regions (blue), forward and reverse primers (magenta) and gRNA (green) are indicated.  
A) Sequencing of the PCR products derived from CHIP WT-expressing lines: the parental line 
(AST23) (a) and the C1 CRISPR clone (b).  
B) Predicted CHIP protein sequence expressed from A is identical to WT CHIP.  
C) Sequencing of plasmid DNA derived from the TOPO cloning using PCR product obtained 
from genomic DNA of the C6 CRISPR clone (a) is shown together with the sequencing of the 
PCR product (b) 
D) Predicted CHIP protein sequence expressed from C has frameshift and nonsense 
mutations (p.N65TfsX7).  
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For the potential CHIP KO clone, C6, in addition to PCR product sequencing, PCR 
products were sub-cloned into the TOPO cloning vector and competent E. coli cells 
were transformed. The plasmid DNA from 25 E. coli colonies (from two independent 
experiments) was isolated and sequenced. All sequences from colonies harbouring 
an insert of the expected size and the PCR product were identical. CRISPR/Cas9 
resulted in a single GC base pair deletion close to the PAM sequence, GGG (Figure 
3.7C). This is predicted to cause a frameshift in the protein coding region, which 
eventually results in a premature stop codon (p.N65TfsX7). Therefore, the truncated 
mRNA is likely to be degraded by nonsense-mediated decay, yielding a homozygous 
CHIP KO line. Finally, sequencing identified D3 clone as a heterozygote for CHIP 
(data not shown).  
 
 
3.2.2 Differentiation of CHIP KO iPSC into cortical neurons 
Protocol development for efficient neural induction and cortical differentiation, and 
subsequent validation, was a significant part of my PhD. When successful, I was able 
to differentiate the parental line (AST) and CRISPR-edited clones (the CHIP-
expressing control, C1, and the CHIP KO, C6) of the patient-derived iPSC into cortical 
neurons simultaneously and in three independent experiments (in two different 
laboratories). 
 
The differentiation process is highly dynamic, passing through multiple gene 
expression and morphological changes – from a monolayer of cycling iPSCs to neural 
progenitors within rosettes, which then extend processes and generate functional, 
post-mitotic neurons. An overview of these changes is outlined in Figure S.1. 
Validation of the differentiation and assessment of cell identity was performed by 
qPCR and IF assays at multiple stages and by MS once mature (in Chapter 4: Effect 
of CHIP on the proteome).  
 
 
a. Neural induction 
The neural induction protocol developed was based on the initial methodology 
proposed by Chambers et al.113, as well as the optimisations conducted by Shi et 
al.114,115 for efficient cortical differentiation. I optimised it further for our CHIP patient-
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derived iPSC model. Development of an optimal neural induction protocol is critical, 
as it not only ensures efficient cortical induction and subsequent neuronal 
differentiation, but also promotes robust and reproducible differentiation114. 
 
Since both published protocols agreed that a high plating density is required 
(recommended 18,000 cells/cm2 for plating113 or enough to be confluent at day 1), I 
plated our iPSC lines at 80,000 cells/cm2. In agreement with both protocols, cells were 
initially cultured with ROCK inhibitor Y-27632 to promote survival. In detail, after 
seeding and each passage, cells were treated with 10 µM Y27632 dichloride (1254, 
R and D, Tocris) for 48 or 24 hours, respectively.  
 
In contrast to the original protocols, once iPSCs were seeded for differentiation they 
were maintain in differentiation media, rather than cultured in stem cell conditions until 
confluent (72h according to Chambers et al.113 or when 95% confluent115). 
Additionally, while Shi et al. use CELLstart-coated plates for neural induction and later 
switch to Laminin-coated plates, I decided to use Laminin-111 (Biolamina) coated 
plates throughout the differentiation process. Laminin-111 brings together the 
favourable aspects of both matrices: promotes stem cell survival and proliferation and 
drives differentiation. Glass coverslips were pre-treated with poly-L-ornithine (P4957, 
Sigma).  
 
The studies above mentioned113–115 both suggest the use of 500 ng/ml Noggin (or 1 
µm Dorsomorphin114,115), a BMP inhibitor, and 10µM SB431542, an inhibitor of 
Lefty/Activin/TGFβ pathways, for neural induction. However, they contrast in the 
temporal specificity of the treatments. Chambers et al.113 removed SB431542 after 5 
days of differentiation and used increasing amounts of N2 media (containing Noggin) 
until day 11113, while Shi et al.114,115 added both inhibitors during the first 8-11 days. 
Given the optimisation nature of the latter study, I developed a protocol that was 
primarily based on this. For 11 days, I treated iPSCs with 10 µM SB431542 (616461, 
Merck Chemicals, Calbiochem) and 100 nM LDN (130-103-925, Miltenyi Biotech) (a 
derivative of Drosomorphin that also inhibits BMP type I receptors, preventing 
activation of downstream SMADs).   
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These supplements were added to N2-containing differentiation media based on what 
Shi et al.114 developed for optimal neural induction, neurogenesis and neuronal 
differentiation. This study used a 1:1 mixture of N2-containing media (DMEM/F12, 1x 
N2, 5 μg/ml Insulin, 1mM L-Glutamine, 100 μm non-essential amino acids, 100 μM 2-
mercaptoethanol, 50 U/ml Penicillin and 50 mg/ml Streptomycin) and 1x B27-
containing media (Neurobasal, B27 with retinoic acid, 200 mM Glutamine, 50 U/ml 
Penicillin and 50 mg/ml Streptomycin)114,115. I used the following media: DMEM/F12 
(21331-020, Gibco):Neurobasal media (21103-049, Gibco) in 1:1 ratio, 0.5x B27 
supplement with retinoic acid (50x, 17504044, Gibco), 0.5x N2 supplement (100x, 
17502001, Gibco) and 2mM L-glutamine (200 mM, 25030-024, Gibco). From days 2-
11, the media was changed daily and freshly supplemented with the SMAD inhibitors.  
 
 
b. Cortical neurogenesis 
At day 11, I passaged neuroepithelial cells (that were a confluent monolayer at this 
point) to promote cortical neurogenesis and differentiation. According to Shi et al.114, 
cells should be plated as clumps (300-500 cell aggregates), thus the group uses 
Dispase to dissociated cells. However, I decided to use Collagenase Type IV instead 
because the use of Dispase is associated with increased risk of degradation of the 
culture if residual Dispase persists, as it is not inhibited by the media. Cells were 
incubated with 250 U/ml Collagenase Type IV (17104019, Gibco) diluted in HBSS 
containing calcium and magnesium (14025, Gibco), for 30 min at 37ºC. They were 
triturated by pipetting several times (with 1 ml pipette tips) and then washed twice in 
wash media (1:1 DMEM/F12 and neurobasal media supplemented with 10 µM 
Y27632 dichloride) with centrifugation steps (3 min at 300 g) in between, to ensure 
removal of the enzyme. Cells were plated at a 1:1.5 and kept for 24 hours in 
differentiation media containing 10 µM SB431542, 100 nM LDN and 10 µM Y27632 
dichloride. After this, the media was renewed daily or every 2 days. In line with Shi et 
al.114, upon appearance of rosettes (that form around days 12-17) cultures were 
passaged as clumps. This was done at day 17, using Collagenase Type IV (instead 
of Dispase), and this time cells were plated at a 1:2 ratio and only Y27632 dichloride 
was added.  
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A final passage was suggested by Shi et al.114, when neurons first begin to accumulate 
at the outside of rosettes, between days 25 and 30. At this stage the cells should be 
dissociated into single cells using Accutase and re-plated at 50,000 cells/cm2. I used 
the same methodology at day 25 of differentiation and the plating density was dictated 
by the use of each culture: wells used for IF were plated at a low density, 35,000 
cells/cm2, and those for WB and MS analysis were plated at a higher density, 80,000 
cells/cm2. Incubation with Accutase (A6964, Sigma) was optimised to 10-15 min at 
37ºC. To ensure single cells are obtained, after triturated several times in Accutase, 
cells were added to the wash buffer and filtered using a 40 µm cell strainer, prior to 
counting and plating. As previously, cells were cultured with 10 µM Y27632 dichloride 
for 24h after plating.  
 
Cells were then fed routinely until mature. To promote neuronal survival, I 
supplemented the medium with 20 ng/ml BDNF (450-02-100, Peprotech) and 20 
ng/ml GDNF (450-10-100, Peprotech) neurotrophic factors. These human 
recombinant proteins were reconstituted in 0.1% BSA (Bovine Albumin Fraction V, 
7.5% solution, 15260037, Gibco) in PBS (D8537, Sigma). After a full media change 
(to remove the Y27632 dichloride at day 26), half of the media was exchanged twice 
a week until day 80, or otherwise stated, with fresh differentiation media containing 
BDNF and GDNF.  
 
 
c. Validation of cortical differentiation 
As with cortical neurogenesis in utero, the differentiation process in situ can be 
monitored through markers arising with temporal specificity. A schematic of the 
differentiation and the different markers of cell types arising during the course of 
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C D E 
Figure 3.8: Overview of the cortical differentiation  
A) Overview of methodology. 
B) Schematic of the cortical differentiation from human pluripotent stem cells (PSCs). Different 
progenitor and neuronal markers arise throughout the differentiation. Cell identity was 
characterised using the markers outlined by the red boxes. Classes of cortical projection 
neurons (CPN: callosal projection neurons) in the layers of the adult cortex. 
C) Quantitative RT-PCR for markers of pluripotency and neuronal lineage. Pax6 is a 
neuroectodermal marker, while Otx2 and FGF5 are epiblast markers and Oct4 is a stem cell 
marker.  
D) Quantitative RT-PCR for the expression of cortical stem cell transcription factor FOXG1 
and the marker of secondary progenitor cells and newly-born neurons, TBR2.  
E) Neurons (Tuj1+) express TBR1, CTIP2 and Brn2 with temporal specificity.  
(B: Adapted from Shi et al.115; C: Chambers et al.113; D&E: Shi et al.115) 
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Quantitative RT-PCR was performed at day 0, 11, 25, 45 and 80, which are key time-
points during the differentiation that reflect changes in cell identities. Figure 3.9 shows 
a decline in pluripotency and stem-renewal markers (CDK6, NANOG and OCT4 
genes) from day 0 to day 11. On the contrary, markers of the primary cortical stem 
and progenitor cells (including the VIM, NES, OTX2, EMX1 and PAX6 genes) 
increase from day 0 to 11 (Figure 3.10). The second differentiation experiment 
(referred to as “differentiation 2”), which is aimed for MS analysis, has a more 
promising profile at day 11. Markers of the secondary progenitors (the FOXG1 and 
TBR2 genes) increase at day 25 (Figure 3.11). However, the expression of TBR2 was 
very low relative to TBP, making the levels detected not reliable. The transcription of 
the TBR1 and CTIP2 genes, markers of early-born, deep-layer neurons, was 
assessed at day 0, 25, 45 and 80 (Figure 3.12). Again, TBR1 expression is low but 
showed a slight increase from day 0 to day 25. CTIP2 expression, on the other hand, 
clearly peaks at day 45 across the time-point analysed. Next, the transcription profile 
of markers of late-born, upper-layer neurons (CUX1 and BRN2 genes) was analysed 
(Figure 3.13). Although CUX1 expression seemed to be relatively unchanged 
between days 25 and 45 (but higher than the qRT-PCR results of undifferentiated 
cells), BRN2 expression clearly peaks at day 25. Finally, SNCA shows a modest 
increasing trend throughout the course of differentiation, while STUB1 expression 
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Figure 3.9: Decline in pluripotency and stem-renewal markers upon neural induction 
RNA was extracted from neurons of the CHIP KO line (KO) and two CHIP-expressing lines 
(the parental line (P) and the CRISPR control (WT)) at the indicated days of differentiation and 
qRT-PCR was performed. The expression of CDK6, NANOG and OCT4 was assessed. The 
latter two are strong markers of pluripotency and they are virtually unexpressed at day 11 of 
differentiation. CDK6 is a cycling marker, which is expected to decrease but still be present in 
the cortical stem cells, as they proliferate to expand and generate progenitors. Results were 
normalised to TATA binding box protein (TBP) gene expression and bars represent averages. 
Two independent differentiation experiments were included in this assay. Error bars represent 
standard deviation of three technical replicates. The colour-coded hash (#) indicates that the 
particular cell line, at the specific time point and from a specific differentiation experiment was 
not assayed.  
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Figure 3.10: Increase in markers of cortical stem and progenitor cells 
RNA was extracted from neurons of the CHIP KO line (KO) and two CHIP-expressing lines 
(the parental line (P) and the CRISPR control (WT)) at the indicated days of differentiation and 
qRT-PCR was performed. The expression of VIM, NES, OTX2, EMX1 and, the commonly 
used marker of neuroectodermal differentiation, PAX6 was assessed. Results were 
normalised to TATA binding box protein (TBP) gene expression and bars represent averages. 
Two independent differentiation experiments were included in this assay. Error bars represent 
standard deviation of three technical replicates. The colour-coded hash (#) indicates that the 
particular cell line, at the specific time point and from a specific differentiation experiment was 
not assayed.  
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Figure 3.11: Markers of secondary cortical progenitor and stem cells 
RNA was extracted from neurons of the CHIP KO line (KO) and two CHIP-expressing lines 
(the parental line (P) and the CRISPR control (WT)) at the indicated days of differentiation and 
qRT-PCR was performed. The expression of FOXG1 and TBR2 was assessed. The levels of 
the latter were very low. Results were normalised to TATA binding box protein (TBP) gene 
expression and bars represent averages. Two independent differentiation experiments were 
included in this assay. Error bars represent standard deviation of three technical replicates. 
The colour-coded hash (#) indicates that the particular cell line, at the specific time point and 
from a specific differentiation experiment was not assayed. 
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Figure 3.12: Markers of early-born deep-layer neurons 
RNA was extracted from neurons of the CHIP KO line (KO) and two CHIP-expressing lines 
(the parental line (P) and the CRISPR control (WT)) at the indicated days of differentiation and 
qRT-PCR was performed. The expression of TBR1 and CTIP2 was assessed. These are 
markers of early-born and deep-layer neurons. Both markers increased with neural induction 
and cortical differentiation. Results were normalised to TATA binding box protein (TBP) gene 
expression and bars represent averages. Two independent differentiation experiments were 
included in this assay. Error bars represent standard deviation of three technical replicates. 
The colour-coded hash (#) indicates that the particular cell line, at the specific time point and 
from a specific differentiation experiment was not assayed. 
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Figure 3.13: Markers of late-born upper-layer neurons 
RNA was extracted from neurons of the CHIP KO line (KO) and two CHIP-expressing lines 
(the parental line (P) and the CRISPR control (WT)) at the indicated days of differentiation and 
qRT-PCR was performed. The expression of CUX1 and BRN2 was assessed. These are 
commonly used markers of upper-layer neurons. The expression of both BRN2 and, to a lesser 
extent, CUX1 peaked at day 25, but had a sustained expression later in the course of 
differentiation, compared to the lack of expression in undifferentiated cells. Results were 
normalised to TATA binding box protein (TBP) gene expression and bars represent averages. 
Two independent differentiation experiments were included in this assay. Error bars represent 
standard deviation of three technical replicates. The colour-coded hash (#) indicates that the 
particular cell line, at the specific time point and from a specific differentiation experiment was 
not assayed. 
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As described in the literature113–115, formation of a homogenous neuroepithelial 
monolayer of Pax6+ progenitor stem is critical for successful differentiation. At day 11, 
Pax6 expression was widespread and strong across cell lines and rosette structures 
begin to emerge (Figure 3.15). Although some β(III)-tubulin expression is observed, 
the structures are still small and do not show the characteristic branching of neuronal 
processes. However, by day 25 long and interconnecting processes are visible and 
the majority of cells retain Pax6 expression (Figure 3.16). Additionally, some TBR1 
Figure 3.14: Expression of SNCA and STUB1 
RNA was extracted from neurons of the CHIP KO line (KO) and two CHIP-expressing lines 
(the parental line (P) and the CRISPR control (WT)) at the indicated days of differentiation and 
qRT-PCR was performed. The expression of SNCA and STUB1 was assessed. The results 
were normalised to TATA binding box protein (TBP) gene expression and bars represent 
averages. Two independent differentiation experiments were included in this assay. Error bars 
represent standard deviation of three technical replicates. The colour-coded hash (#) indicates 
that the particular cell line, at the specific time point and from a specific differentiation 
experiment was not assayed. 
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staining was detected in both Pax6+ and Pax6- cells. In attempt to characterise 
neuronal identity, markers of deep-layer neurons (CTIP2 and TBR1) were analysed 
at a protein level at day 50 (Figure 3.17). At this timepoint Shi et al.115 describe around 
25% and 20% CTIP2 and TBR1-expressing neurons, respectively. Our cultures 
exceed these numbers both as single- and co-expressing markers. Furthermore, no 
significant difference was observed between CHIP KO and WT neurons. By day 80, 
when neurons are considered mature and harvested for proteomic analyses, these 
deep-layer neurons are still present (Figure 3.18), along with Cux1-expressing upper-
layer neurons (Figure 3.19). In these mature neurons, α-Syn is expressed across 
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Figure 3.15: Neural induction 
Neurons of the CHIP KO line and two WT CHIP-expressing neurons (the parental line and the 
CRISPR control) were fixed with 4% PFA at day 11 of differentiation. IF was performed using 
anti-Pax6 mAb (IgG1; 1:40), anti-β(III)-tubulin mAb (IgG2a; 1:1000) and DAPI. Phase contrast 
and fluorescent images were taken. Pax6 is an early ectodermal marker and β(III)-tubulin is a 
neuron-specific marker. These samples alabre from the second differentiation experiment. 
Scale bar, 200 µm. 
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Figure 3.16: Cortical neurogenesis and differentiation in CHIP WT and KO neuronal 
cultures 
CHIP WT (A) and KO (B) neurons were fixed with 4% PFA at day 25 of differentiation. IF was 
performed using anti-Pax6 mAb (IgG1; 1:40), anti-Tbr1 pAb (1:200) anti-β(III)-tubulin mAb 
(IgG2a; 1:1000) and DAPI. Phase contrast and fluorescent images were taken. The former 
two markers are expressed by cortical progenitor and stem cells and β(III)-tubulin is neuron-
specific. Pax6 staining is heterogenous, with some cells have strong expression, while have 
weaker expression. Tbr1 expression is less prominent, with a minority of the cells being Tbr1+. 
The projection of processes and the three-dimensional architecture acquired by neurons at 
this stage is evident. Moreover, cells are seen both in clumps and more diffuse. These samples 
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Figure 3.17: Quantification of early-born deep-layer neurons at day 50 
CHIP WT and KO neurons were fixed with 4% PFA at day 50 of differentiation. Corticothalamic 
projection neurons of layer 6 express both TBR1 and CTIP2, while corticospinal motorneurons 
of layer 5 only express CTIP2. Expression of these markers was analysed by IF and, for the 
second differentiation experiment (“Differentiation 2”) quantified (A). Cells were incubated with 
anti-CTIP2 mAb (1:500), anti-TBR1 pAb (1:400) and DAPI.  
A) Dashed lines represent the percentage of TBR1 and/or CTIP2 expressing cortical neurons 
that Shi et al.115 reported in their cultures at this timepoint. The percentage of neurons 
expressing TBR1 and/or CTIP2 was compared across CHIP genotypes using a paired t-test. 
Differences were not significant (ns).  
B) The TBR1 and CTIP2 expression was similar across differentiation experiments and cell 
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Figure 3.18: Early-born deep-layer neurons at day 80 
CHIP WT (A) and KO (B) neurons were fixed with 4% PFA at day 80 of differentiation. IF was 
performed by incubating neurons with anti-Ctip2 mAb (1:500), anti-Tbr1 pAb (1:400) and DAPI. 
Phase contrast and fluorescent images were taken. Across cultures, neurons expressing Tbr1 
only (red arrows), Ctip2 only (green arrows), or both (yellow arrows) were present. These 
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Figure 3.19: Late-born upper-layer neurons at day 80 
Neurons derived from two CHIP-expressing iPSC lines (the parental line (A) and the CRISPR 
control (B)) and a CHIP KO iPSC line (C) were fixed with 4% PFA at day 80 of differentiation. 
IF was performed by incubating neurons with anti-α-Syn mAb (IgG1, 1:500), anti-β(III)-tubulin 
mAb (IgG2a; 1:1000) anti-Cux1 pAb (1:200) and DAPI. Phase contrast and fluorescent images 
were taken. Low Cux1 expression, a marker of late-born, upper-layer neurons, is observed. In 
contrast, α-Syn and β(III)-tubulin staining is widespread and shows the interconnecting 
network between neurons. Scale bar, 100 µm. 
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Finally, although the majority of the cells differentiate from the neuroepithelium 
monolayer into more structured neural rosettes and neural networks, a journey that 
gains three-dimensional structure and complexity, some cells fail to differentiate 
properly. These can be detected within cultures by the distinctive flat morphology 
(Figure 3.20). Furthermore, they are slowly proliferating, thus competing in space with 
the post-mitotic neurons. “Flat cells” were observed in about 11% of the differentiating 
cultures and they tend to emerge late in the differentiation process (being observed 
around day 45). Possibly due to clonal variation or other reasons, the CHIP KO line 
seemed to have a higher propensity for having some “flat cells” within cultures. These 
were either discarded or used for assays, such as immunofluorescence, where “flat 














Figure 3.20: “Flat cells” in neuronal cultures 
A minority of the cells in our neuronal cultures are cycling and have a characteristic “flat” 
morphology. Two areas (top and bottom row) with “flat cell” populations (bearing different 
morphologies) were observed over time. “Flat cells” (red arrows) grow over time. These phase 
contrast images were obtained from cultures of the CHIP KO line. Scale bar, 200 µm.  
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3.3 Discussion 
3.3.1 Engineering patient-derived iPSC 
a. Advantages, limitations and use of iPSC technology 
Prior to iPSC technology, the field of neurodegeneration relied on transgenic models 
of synucleinopathy that do not fully replicate the phenotype of human disease. Primary 
neuronal cultures from rodent models were also popular, although these are difficult 
to maintain in vitro and do not self-renew. Also, rodent α-Syn has an amino acid 
change at position 53 that is pathogenic in humans. Different cell lines were also 
transformed to engineer models of synucleinopathy, but these are limited by their 
genetic background and manipulations can disrupt cell signalling pathways97. Also, 
overexpression of poorly controlled transgenes, such as SNCA, has its own problems, 
especially in the context of synucleinopathies, which are dose-dependent111.  
 
Undoubtedly, iPSC technology made the generation of patient-specific stem cells 
feasible and readily accessible117. The potential uses of iPSC are extensive. These 
cells can be used as a platform for drug screening and for cell-replacement therapies. 
Of particular interest, iPSC can be used to probe disease mechanisms97,117 and study 
early disease-promoting events in a mechanistic manner. These are likely to be 
pathogenic, rather than the changes that occur at later stages of the disease, which 
may be protective97. Furthermore, they are likely to have increased therapeutic 
potential. Although the use of iPSC may be limited when modelling diseases that arise 
from complex interplays between environment and multiple genes116, this is not the 
case for the SNCA triplication is monogenic and fully penetrate.  
 
Despite the compelling advantages of the use of iPSC models, its limitations should 
also be considered. The major drawback of the use of iPSC is clonal variability97,116,117. 
It can confound our ability to distinguish disease-associated features, limiting the use 
of iPSC for disease modelling116. During the production, selection and culturing of 
iPSC, variability can arise from three levels: 
1. The inconsistency in criteria that define iPSC lines as pluripotent; 
2. The inherent variability between the cell lines derived from different donors 
(inter-individual variability), i.e. due to different genetic backgrounds; 
 
Chapter 3: Engineering iPSCs to generate isogenic neuronal cell models
  134 
3. The variability in the cell lines derived from the same donor (inter-clonal 
variability), i.e. due to the stochastic nature of the reprogramming 
method116,117. 
 
Additionally, clonal variability in our CHIP iPSC can arise from the genetic engineering 
using CRISPR/Cas9. The inherent mutational nature of the system can result in off-
targets105,109, which could drive variability between sets of isogenic CHIP models that 
would otherwise be regarded as identical (except the STUB1 genotype). Such inter-
clonal variability can affect the self-renewal and differentiation capacity of edited 
clones, if off-targets occur at critical genes. In fact, while maintaining edited clones, 
some lost their pluripotency and self-renewal abilities, while others were highly 
unstable and differentiated spontaneously into unknown lineages.  
 
Therefore, following CRISPR/Cas9, cell lines may no longer fulfil all pluripotency 
criteria, introducing another level of variability116,117. However, both the parental line 
before CRISPR/Cas9 and the clones derived had the expected morphology of iPSC, 
self-renewal ability resembling embryonic stem cells, expressed pluripotency genes 
(including Oct4 and Nanog) and were able to differentiate – meeting the criteria that 
define iPSC116.  It has been proposed that when iPSC lines fulfil stringent pluripotency 
criteria, their clonal variability is low116. This supports the use of iPSC technology for 
investigating subtle-disease associated changes116.  
 
 
b. CHIP KO patient-derived iPSC 
Patient-derived iPSC were subjected to a CRISPR/Cas9 system aimed at introducing 
indels in the coding region of STUB1 to abolish CHIP expression in a homozygous 
manner. As seen from the WB (Figure 3.6), clone C6 does not expressed CHIP, and 
sequencing confirmed the presence of identical biallelic genetic mutations (Figure 
3.7). Interestingly, the T7 endonuclease I assay was negative for the C6 clone, 
supporting that its DNA is perfectly match at the amplified STUB1 locus (targeted by 
the CRISPR/Cas9 system).  
 
Theoretically, the DNA strand that is complementary to the target-binding sequence 
in the crRNA/gRNA (spanning 20 bp) is cleaved 3 bp upstream of the PAM105,108. 
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Although such editing signature was observed in the CHIP KO SH-SY5Y clone, 
having a single base-pair deletion at this position (work performed in collaboration 
with Erisa Nita), this indel occurred at 5 bp upstream of the PAM in our CHIP KO iPSC 
clone. The non-complementary strand, on the other hand, is reported to be commonly 
cleaved at one or more sites within 3-8 bp upstream of the PAM108. Indeed, multiple 
indels were observed in the non-complementary strand in CHIP KO SH-SY5Y cells, 
but not in the CHIP KO iPSC line. It is important to stress that both SH-SY5Y and 
iPSC cell lines were edited using the same CRISPR/Cas9 system (including the same 
gRNA).  
 
Differences in gene-editing signature could be due to differential properties between 
the cell lines or differences in cell cycle status. When compared to cancer cell lines, 
iPSC are notoriously more challenging to edit. This is mainly due to their lower DNA 
repair efficiency (0.1-1% HR efficiency) after Cas9-induced double strand breaks 
compared to cancer lines, which have abnormally high rates (5- to 20-fold higher)119–
121. Also, differences in chromatin structure due to intrinsic differences in cell cycle 
could also affect the activity of the Cas9121,122 and DNA repair mechanism 
employed123.     
 
Interestingly, in our CHIP KO iPSCs, the non-complementary strand was identical to 
the complementary strand, thus occurring within the 3-8 bp range. Recent studies 
have argued that CRISPR/Cas9-based gene-editing has highly-preferred indels and 
is not random. Recently, Chakrabarti and colleagues122 found that CRISPR/Cas9 
technology can achieve high precision in DNA editing, driven by intrinsic preference 
for specific indels at target sites. The class (insertion or deletion) and size of the indel 
can be predicted by the target site. Nucleotides at positions 4 and 5 before the PAM 
sequence are particularly influential in the editing signature. When position -4 is an 
adenine, which is the case of our gRNA, this correlated with a precision indel 
frequency of 0.42 and 77% likelihood of repair mediated by insertions versus 
deletions. Such precision index was increased to 0.53 when the nucleotide at position 
-5 was a cytosine, as found in our gRNA. Therefore, the design of our CRISPR/Cas9 
system would statically favour precise genome editing and such was observed. 
Furthermore, the group also found that precise targets displayed a strong bias 
towards single-nucleotide indels, which was seen in both alleles of the iPSC CHIP KO 
line and one allele of the SH-SY5Y. Nevertheless, although repair occurred in a 
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precise manner, it created deletions rather than insertions, which were reported to be 
less probable. Importantly, this contradicts the assumption that, based on the 
stochastic nature of NHEJ, CRISPR/Cas9-based gene editing is random. The indels 
detected in our CHIP KO iPSC argue for canonical NHEJ repair pathway, rather than 
microhomology-mediated end joining (MMEJ), seeing that small indels rather than 
larger deletions were observed122.   
 
The identical bilallelic single base-pair deletion is predicted to cause a frameshift 
mutation, eventually causing a premature stop codon. Ultimately these mutations 
result in nonsense-mediated decay, abolishing CHIP expression. Interestingly, the 
pattern of indels yielded by this CRISPR/Cas9 system was similar to one allele of the 
SH-SY5Y CHIP KO cell line (having a single nucleotide deletion as well) (refer to 
Figure 3.4C).  
 
  
3.3.2 Differentiation potential 
During cortical differentiation cells are subjected to multiple morphogenic factors and 
undergo substantial changes in their proteome and cell identity. It is not surprising 
that differentiation is associated with some degree of variability, as cell-intrinsic 
differences influence their response to the factors, in addition to the inherent variability 
associated with long culturing of cells. However, similarities in cell morphology and 
expression profile were observed across iPSC lines of different CHIP genotypes 
throughout the course of differentiation. This suggests that these iPSC lines have 
similar differentiation potentials and dynamics – key criteria to allow adequate 
comparative proteomics.  
 
The three iPSC lines (P, WT and KO) have similar stem cell signatures (including 
NANOG and OCT4 gene expression), thus deletion of CHIP expression does not 
affect pluripotent properties. These markers are rapidly lost by day 11, in parallel to a 
decrease in proliferating rate (evident from the decrease in CDK6 expression) (Figure 
3.9). Importantly, at day 11, the monolayer of neuroepithelial cells undergoing rosette 
formation express Pax6 and OTX2 proteins, as detected by IF (Figure 3.15) and/or 
qPCR (Figure 3.10). These cells are the primary cortical progenitor cells and become 
the main population of rosettes (Figure 3.8C)113–115. The secondary progenitor cells 
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are mainly characterised by TBR2114,115. However, despite observing an increase from 
day 0, the relative gene expression of TBR2 was low (Figure 3.11). Arguing in favour 
of the success of the differentiation is the high expression levels of FOXG1 mRNA of 
neural stem cell cultures (Figure 3.11), which has been described to precede TBR2 
expression (Figure 3.8D)115. Therefore, in agreement with previously characterised 
markers of cortical stem and progenitor cells115, our cultures expression key 
transcription factors of neural induction: FOXG1, Pax6, Vimentin, OTX1/2 and TBR2.  
 
At day 25, the expression of Pax6 has decreased when compared to day 11 (indicated 
by both qPCR and IF) but remains strong (Figure 3.10). This was expected since the 
subpopulation of secondary progenitor cells that are Pax6- (the basal/intermediate 
progenitor cells) only make up around 10-15% of the cells within each rosette114,115. 
These Pax6-expressing cells are likely to be radial glial cells (characterised by 
Pax6+/TBR2- expression and long processes115). It was reported that from around day 
35, early-born deep-layer neurons (TBR1+ and/or CTIP2+) are the main population of 
cells (Figure 3.8E)114. This was consistent with our observation at days 45-50 (Figure 
3.12 & Figure 3.18). Moreover, late-born upper-layer neurons would be expected by 
day 70114 and indeed were observed at day 80 (Cux1+/Brn2+) (Figure 3.13 & Figure 
3.19). The mRNA expression profile of Brn2 over time, however, was not expected, 
having a peak at day 25. Although the cortical differentiation protocols114,115 have not 
included the Brn2 transcription profile over the course of differentiation, the 
percentage of Brn2+ neurons increases from day 25 to 50 (Figure 3.8E) and is 
maintained at day 70 (analysed by IF). Therefore, the increase in Brn2 mRNA 
expression at day 25 may promote its protein expression from this timepoint onwards. 
 
The identity of different types of cortical projection neurons was defined by their 
combinatorial expression a core set of transcription factors: TBR1, CTIP2, Cux1 and 
Brn2114. At the end of the course of differentiation (day 80), co-cultures of mature 
deep-layer (Figure 3.18) and upper-layer neurons (Figure 3.19) were achieved. Since 
the majority of the changes observed were consistent with those reported by Shi et 
al.114,115 and Chambers et al.113, including in its temporal specificity, we are confident 
that our iPSC-derived neurons adequately model cerebral cortex neurons. By day 80, 
mature neurons are likely to function in cortical neural networks115. The increase in 
the synaptic protein α-Syn at the later stages of differentiation (Figure 3.14 & Figure 
3.19) may reflect this. Importantly the expression of STUB1 remained largely 
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unchanged throughout differentiation (Figure 3.14). Therefore, subsequent proteomic 
differences identified between CHIP genotypes at different differentiation states are 
not likely to be due to a change in CHIP expression. Furthermore, we can conclude 
that CHIP does not affect the differentiation potential of the iPSC lines.    
 
Although CHIP KO and WT patient-derived iPSC were able to differentiate with similar 
kinetics and yield comparable neuronal co-cultures, the CHIP KO line was more 
variable, have an increased propensity to form “flat cells” (Figure 3.20). These have 
been described as fibroblast-like cells – a mitotic cell population, with a characteristic 
wide-spread cytoplasm and flat morphology124.  They express Nestin, collagens, 
collagen fibre crosslinking proteins and synthesizing enzyme, the extracellular matrix 
protein fibronectin and platelet-derived growth factor receptors124,125. Although 
fibroblast-like cells are phenotypically similar to neural progenitor cells, these are 
distinct populations. “Flat cells” tend to emerge late in adult neural progenitor cells 
culture and, despite their high degree of plasticity and tendency towards a 
neuroectodermal lineage, are incapable to give rise to neurons or astrocytes. They 
do not express markers of the neuronal lineage (β(III)-tubulin and GFAP)124. 
Therefore, the occurrence of fibroblast-like cells within neuronal cultures suggests 
heterogeneity and diminished differentiation efficiency, as these cells have a greater 
proliferative capacity and can dominate long-term cultures124. Although it is unclear 
what drives the appearance of these cells, the increased propensity of the CHIP KO 
line to have “flat cells” would argue for a restricted differentiation potential compared 
to the other iPSC lines. However, given the detection of fibroblast-like cells across all 
iPSC-derived cultures and the low frequency of these cells (in <11% of CHIP KO 
differentiation cultures), this does not limit the potential use of this CHIP KO iPSC line.  
 
 
3.3.3 Neuronal CHIP models 
Given the variability between iPSC clones, the variable responses to the neural 
differentiation protocol, and the heterogeneity of neural differentiation97, it is 
challenging to obtain a set of cell lines (WT and KO) that are similar in cellular state 
for comparative proteomics. As these patient-derived iPSC lines display similar 
pluripotent and self-renewal capacities and comparable differentiation potentials, we 
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have engineered a cell model that is valid and robust for investigating the protein 
targets of CHIP in a disease-relevant background and cell-type.   
 
However, the cumulative potential variability from both the generation of iPSC and 
differentiation into neurons emphasizes the need to generate multiple iPSC lines and 
neuronal cultures97. This increases the likelihood of achieving iPSC lines of identical 
states, capable of complete differentiation and able to form matching isogenic sets 
with equivalent differentiation efficiency97,116. This is particularly applicable to the field 
of age-related diseases, as using older tissues for iPSC generation is associated with 
increased inherent clonal variability, when compared to using embryonic or juvenile 
tissue117. Also, enough clones are required in order to surpass biological variability 
and identify disease-related phenotypes116. Therefore, by having multiple CHIP KO 
lines, findings can be thoroughly investigated across lines. In the future, the A7 clone 
that had low CHIP expression could be further analysed and, if a mixed population of 
cells are present (both CHIP-expressing and not), the CHIP KO cells can be isolated.   
 
Although another CHIP KO iPSC line was not achieved, any findings from the 
comparative proteomics study will be also investigated in our SH-SY5Y CHIP KO 
model. If molecular and cellular phenotypes and underlying mechanisms are 
maintained across the different cell lines this increases the robustness and validity of 
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Chapter 4: Effect of CHIP on the proteome 
 
4.1 Introduction 
4.1.1 Studying the proteome 
Proteomics is a large-scale and comprehensive study of the proteins of a cell or 
organism (i.e. the proteome). It aims to analyse the homeostasis and function of 
proteins at a given time126. The biggest challenge of proteomics is the complexity of 
the proteome126,127. Due to alternative splicing and post-translational modifications, 
the approximate 22,000 human genes translate to ~400,000 proteins126. Its dynamic 
nature drives a vast array of qualitative and quantitative protein changes in response 
to differences in the extracellular and intracellular environment. Thus, by comparing 
the proteome of two or more different states of a cell or organism (e.g. diseased 
versus non-diseased), mechanistic insight underlying the change of state can be 
achieved126,127. Changes in protein expression levels and major post-translational 
modifications (PTMs) have been associated with disease mechanisms. PTMs 
regulate protein folding, stability, subcellular localization and function128.  
 
At present, proteomics often analyses the proteome as a static snapshot within its 
dynamic continuum. Ultimately, the aim is to resolve the proteome with temporal 
specificity and to decipher signalling cascades responsible for the changes observed. 
Despite multiple human proteins identified by proteomic methodologies, it is estimated 
that only 5-10% of pair-wise interactions of the human interactome have been 
characterised128.     
 
Fundamental advances within the mid-1990s promoted proteomic research. Firstly, 
2DE technology became a robust method to separate proteins. Secondly, MS-based 
methods were developed and allowed the identification of proteins with high degree 
of sensitivity and specificity. And thirdly, the growing large-scale genomic research 
constantly contributed to the number of sequences catalogued in databases. These 
became the basis for bioinformatic tools, allowing databases to be queried to aid in 
proteome identification127.  
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4.1.2 Two-dimensional electrophoresis (2DE) technology 
2DE technology was first introduced in the early 1970s. It exploited the structural and 
biophysical diversity of proteins within the proteome to achieve high-resolution 
separation127. In the first dimension of 2DE, proteins are separated on a gel based on 
their isoelectric point (pI), i.e. charge, a technique called isoelectric focusing126,127. The 
pI is the pH at which the protein carried no net charge, hence does not migrate within 
an electric field126. In the second dimension, proteins are separated by SDS-PAGE 
according to their molecular weight127. Following separation, proteins in the 2D gel are 
visualised by staining. Different staining methods have varying sensitivity, 
reproducibility, detection limits and may or not be compatible with subsequent MS 
analysis127,128. Finally, the stained gel can be digitalised for qualitative and quantitative 
analysis. Software programs can be used to quantify specific spot patterns 
(representative of proteins/isoforms) within a single or across multiple gels126,127. They 
have been designed for spot detection, matching, normalization and quantification, 
thus determining meaningful features128.  
 
 
a. Advantages of 2DE 
This is a useful separation technique that despite being established years ago is still 
routinely used. 2DE technology is also technically and financially more accessible 
than MS127. It allows a global view of a sample proteome by simultaneously resolving 
thousands of proteins on a single gel127,128. Importantly, comprehensive data can be 
derived from 2DE gels including biochemical properties of proteins (pI and MW), 
relative quantification (based on the density of the staining) and presence of isoforms 
(including PTMs)126,127. Proteins with PTMs can be readily detected by 2D gels due to 
their horizontal/vertical clustering pattern127. Furthermore, 2DE immunoblotting with 
specific antibodies can confirm the presence of isoforms and screen for possible 
PTMs (e.g. phosphorylation)128.   
 
 
b. Limitations of 2DE 
Beyond being labour-intensive and having relatively low throughput127, there are 
fundamental drawbacks that prevent its widespread application. Firstly, protein 
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separation is limited by spatial resolution when analysing complex proteomes. This 
can result in differential protein processing (when a single protein produces multiple 
spots), co-migrating spots (multiple proteins with similar properties represented by the 
same spot) and spots migrated outside of the detection limit. The end-effect is 
compromised protein detection, identification and quantification127,129. Resolution can 
be optimized by using a series of narrow overlapping immobilised pH gradient 
strips127,128 or by introducing a pre-fractionation step (e.g. sequential extraction of 
proteins based on solubility or subcellular localisation) prior to 2DE separation127.  
 
Secondly, its intrinsic bias towards proteins with specific characteristics means that 
only a subset of the proteome is analysed by 2DE-based proteomics. Highly abundant 
proteins tend to be more readily detected, while low-abundance proteins are not 
detected by staining limitations and are masked by the high-abundance proteins. 
These low-abundance proteins include regulatory proteins and receptors and 
isoforms with PTMs, which play key roles in cellular processes and might be of 
interest127–129. Increasing sample load promotes the detection of low abundance 
proteins129. Moreover, very small/large proteins and proteins with extremely 
basic/acidic pI values are unsuitable for the gel limits. Hydrophobic proteins, such as 
membrane proteins, are also disfavoured by 2DE, due to their poor solubility in 
extraction solutions127,128.  
 
Thirdly, the problems associated with the staining techniques for protein visualisation 
also compromise the quantification accuracy and sensitivity of the 2DE. These 
include: the narrow dynamic range of stains, the bias of the stain for certain protein 
characteristics, and the low staining reproducibility and sensitivity of some staining 
methods127.  
 
However, the biggest drawback in 2DE technology was the inability to identify 
unknown 2DE-separated proteins. This was largely answered by combining 2DE with 
MS, where separated bands representative of proteins of interest were excised from 
the gel and identified and quantify by MS127.  
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4.1.3 Mass spectrometry (MS) 
MS developed from the drive to discover unknown proteins of interest130. Over 10,000 
proteins have been detected from whole-cell lysate, contributing to the human 
proteome drafts130. There are efforts to characterise at least one protein product of all 
protein-coding genes (20,300 genes)131.  
 
MS has been described as the most powerful method in terms of throughput and 
proteome coverage130. However, its high technical complexity and cost of 
instrumentation and limited dept of proteomic databases have restricted its impact131. 
MS can be performed with labelling techniques or as a label-free method. Labelling is 
often done using stable isotopes and yields more precise and accurate quantitative 
proteomics data. However, labelling has its own disadvantages: its complex, 
expensive, bias towards proteins with higher turnover and limits the sample number 
and type analysed130,132. Label-free methods, on the other hand, are easy to use and 
have no sample limitations, but can have low quantification precision and accuracy130.  
 
MS-based proteomics can be broadly grouped into “bottom-up” and “top-down” 
strategies. The former is widely used and analyses small peptides for protein 
identification and quantification, whilst the latter approach investigates native proteins. 
“Bottom-up” experiments are initiated by cleaving proteins into peptides (commonly 
using trypsin that cleaves at lysine and arginine residues) and the first separation is 
achieved using liquid chromatography (LC). Once peptides are separated based on 
hydrophobicity, having different retention times (RTs), they become ionized and enter 
the mass spectrometer. The first MS measurement determines the masses of all 
peptides, referred to as peptide-mass fingerprinting and obtaining the first dimension 
of analysis (MS1)127.  
 
 
a. Tandem mass spectrometry (LC-MS/MS) 
MS1 is not sufficient for accurate protein identification because the same ionized 
peptides can be achieved from different proteins, given the redundancy in amino 
acids. Tandem MS (referred to as MS2 or MS/MS) solves this problem by enabling 
identification and characterisation of isomeric precursor ions by adding another 
dimension of data, their unique fragmentation profile (i.e. the set of product ions 
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derived). Furthermore, it improved the quantification capacity of the method and 
allowed for structural information to be deduced from selected ions.   
 
Specific peptides (parent/precursor ions) are isolated in the first quadrupole of the 
mass spectrometer. They are fragmented in the second quadrupole, where precursor 
ions are converted into product ions of different mass-to-charge (m/z) values. Usually 
this involves energetic collisional dissociation of the ion to cause fragmentation with 
gases, such as nitrogen. Mainly b and y product ions are produced from the cleavage 
of peptide bonds during fragmentation (Figure 4.1). Product ions are then detected in 

















b. Data-dependent acquisition mass spectrometry 
Data-dependent acquisition (DDA) MS (also targeted/shotgun proteomics) is bias 
towards proteins with higher relative abundance within the sample. It does so by 
selectively isolating and fragmenting peptides with higher intensities at a given 
chromatographic elution time130 (Figure 4.2). Alternatively, user-defined transitions 
(combination of precursor peptide and fragment ion) can be selected for individual 
analysis, which is referred to as selected acquisition monitoring. This can extend to 
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Figure 4.1: b and y ions from fragmentation of peptide bonds 
The dotted line represents the fragmentation of the precursor ion, yielding product ions (b and 
y ions). 
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Although shotgun proteomics have made remarkable progress in deconvoluting 
complex proteomes131, its application was limited by the relative low number of 
proteins (50-100) that could be identified and quantified in a single injection. This was 
improved by distributing sample complexity among several instrument injections using 
fractionation techniques (e.g. strong anion exchange or off-gel electrophoresis) prior 
to LC-MS/MS131. Additionally, this is also limited by the need to specify target proteins 
for each sample prior to data acquisition, thus requiring prior knowledge of the sample 
and potentially compromising the depth of proteomics131.         
 
 
c. Data-independent acquisition mass spectrometry 
Data-independent acquisition (DIA) MS (also untargeted proteomics) improved the 
reproducibility, sensitivity, accuracy and increased the dynamic range of MS-based 
proteomics130,133. When compared to DDA, it greatly increased the information 
acquired from a sample. DIA is a group of methods in which ions within a selected 
m/z range are fragmented and analysed in tandem MS/MS.  
 
Sequential window acquisition of all theoretical mass spectra (SWATH-MS) vastly 
extended the throughput of proteins that can be targeted in a sample, using a large-
scale multiple acquisition monitoring. It combines data-independent acquisition and 
Figure 4.2: Data-dependent acquisition mass spectrometry 
Peptides are ionized into ions (referred to as precursor ions), specific precursor ions are 
selected in the first quadrupole (Q1), fragmentated in the second quadrupole (Q2) into product 
ions and analysed in the last section of the mass spectrometer. For DDA, the criteria to select 
the precursor ion is based on abundance. 
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targeted data extraction and requires a high-resolution spectrometer and a peptide 
spectral library match130,131. SWATH-MS continuously fragments all the peptides 
(precursor ions) within consecutive m/z windows, termed swathes133. In the TOF 
accelerator, product ions are exposed to a known voltage and fly over a known length, 
thus the time of flight is recorded, and the mass can be deduced from this data (Figure 
4.3). Spectra for all peptides belonging to different mass intervals for each RT point 
is recorded, obtaining 3-dimensional data (Figure 4.4A). This can be represented as 
both precursor ion relative intensity against time (chromatograph) and product ion 



























Figure 4.3: Data-independent acquisition mass spectrometry 
Peptides are ionized into ions (referred to as precursor ions), specific precursor ions within a 
selected m/z range are selected in the first quadrupole (Q1) for fragmentation in the second 
quadrupole (Q2) into product ions. The Time-of-Flight (TOF) of the ions is then recorded, 
achieving mass spectra for all product ions of selected precursor ions.   
 
































Peptides, and in turn ion products, belonging to a single protein have similar RT, thus 
can be overlapped and normalised. The most abundant peptides and ion products are 
used for the identification of a protein, through sequence prediction. The theoretical 




Figure 4.4: SWATH-MS 
A) SWATH-MS analyses multiple proteins in samples in three dimensions (retention time, 
precursor and product ion intensities and mass/charge ratio).  
B) Ionized peptides (precursor ions) are identified throughout the chromatogram (relative 
abundance/intensity over time) for a specific swath (selection window). At a particular retention 
time, product ions and their intensities are analysed and represented as a mass spectrum. 
(A: Adapted from Hunter135; B: Adapted from Mohammed et al.134) 
 
Chapter 4: Effect of CHIP on the proteome  149 
spectra known peptides and retention time data, and therefore is used as a reference 
to identify unknown proteins. This is possible because peptides tend to have a 
reproducible RT and fragmentation pattern. The library has been generated from 
fractionated or enriched samples previously analysed in the DDA mode131. Nowadays, 
this database can be used to generate a theoretical identification library in silico.  
 
 
i. Advantages of SWATH-MS 
Arguably, SWATH-MS does not go deeper into the proteome compared to DDA-
based MS per se130. Its throughput potential, however, enables greater proteome 
coverage for a single experiment. Theoretically, no data is discarded during 
acquisition by SWATH-MS, achieving a deeper proteome coverage133. This is an 
advantage over selected acquisition monitoring, where target peptides need to be 
determined prior to data acquisition131. SWATH-MS datasets are recorded 
independently can be re-mined subsequently using targeted analysis strategy131.  
 
Another advantage of SWATH-MS is the high quantification accuracy and the 
precision it offers130,131. This label-free quantification strategy is capable of spectral 
counting, where the number of fragment spectra of the peptides derived from a given 
protein is counted132. Quantification is possible due to the linear relationship between 
signal intensities and sample loading amounts (i.e. the number of acquired spectra is 
an indicator of the amount of the protein)131,132. The spectral counting approach yields 
a relative quantification of protein abundance. Quantification accuracy is greater when 
protein abundance ratios are about 1:1 (i.e. when fold changes are moderate) and 
decreases substantially when protein abundances differ greatly (e.g. by more than 4-
fold)130,136, although it can detect large changes132. Fold changes tend to be an 
underestimation of the real value due to limitations in ionization and ion detection, 
which affect ion with high concentrations to a greater extent130. Nevertheless, for most 
biological studies, the exact fold change is not necessary to determine its biological 
significance130. This is particularly true for chaperones and E3 ligases, as they have 
a wide interactome and can influence the homeostasis of multiple proteins, thus a fold 
change of 2, for example, can have pronounce cellular effects. Although less 
common, SWATH-MS can also be used for absolute quantification using peptide 
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chromatographic peak intensity measurements130,132,133. Here, the chromatographic 
peak area of all transition ions belonging to a specific protein is measured130,132.  
 
 
ii. Limitations of SWATH-MS 
The main drawback of SWATH-MS used to be the requirement for a peptide spectral 
library. However, large-scale human proteomic studies have greatly contributed to an 
extensive library130,131. Nowadays, the main limitation of SWATH-MS is sample 
complexity133. Previously SWATH-MS was used to study less complex systems (e.g. 
enriched peptide mixtures)131, but increasingly it is used for proteome scale analysis 
of complex samples with PTMs130. For example, SUMO and Ub-derived isopeptides 
have been detected using SWATH-MS133. However, given the nature of “bottom-up” 
proteomics, PTMs may be cleaved from the peptide upon trypsinization (such as Ub 
chain linkages), limiting the use of MS for PTM identification133.  
 
Furthermore, obtaining in-depth coverage of the complex human proteome remains 
a challenge. The great range of abundance levels of proteins (with copy numbers from 
tens of millions to single digits) not only compromises quantification accuracy but can 
also mask the detection of low abundance peptides. Also, mass spectrometers have 
limited dynamic ranges of detection136. This can affect the analysis of a complex 
proteome containing proteins with high and low expression levels and both 
unmodified and modified PTMs. Fractionation steps (e.g. SDS-PAGE separation prior 
to MS) improve the limit of detection. This is particularly relevant when studying 
ubiquitination substrates in unstressed cells, where the levels of ubiquitinated species 
are kept low136. However, SWATH-MS can achieve a useful proteome coverage, 
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4.2 Results 
4.2.1 Preliminary proteomics of CHIP cell models using 2DE 
As a first approach to investigate whether STUB1 gene deletion (ablation of CHIP 
protein expression) resulted in bulk changes in the proteome, we focused on two 
models with isogenic STUB1 deletions: iPSC and undifferentiated SH-SY5Y. The 
former cells were generated as described in Chapter 3. However, the SH-SY5Y CHIP 
model was previously made by Erisa Nita95 in our group using CRISPR/Cas9 
technology (with the same Cas9 and gRNA-encoding plasmid as that I used to 
generated CHIP KO iPSC) (Figure 3.4). This cell line was chosen because of its 
neuroblast-like phenotype (with non-polarized cell bodies, few truncated processes 
and the expression of immature neuronal markers) (Figure S.2), low maintenance and 
cost, human origin and ability to differentiate118. It is a neuroblastoma line that was 
originally derived from a metastatic bone tumour biopsy.  
 
As a preliminary approach to assess the overall effect of loss of CHIP on the cellular 
proteome, 2D gels of cell lysates derived from isogenic CHIP KO and WT cells of two 
cell lines, SH-SY5Y and iPSC, were performed (Figure 4.5), in collaboration with Jitka 
Zakova†. Interesting, similar patterns were seen across CHIP genotypes, suggesting 
that CHIP deletion likely results in specific changes in the proteome with relatively 
minor differences in steady state levels rather than grossly changing the intensity and 
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4.2.2 Proteomics of the CHIP cortical neuron model using 
SWATH-MS 
a. Overview of the changes in the proteome 
Once mature cortical neurons were generated and validated (see section 3.3.3) they 
were harvested (at day 80 of the differentiation) for protein quantification using 
proteomics methodologies and analysed in collaboration with Dr Jakub Faktor and Dr 
Bořivoj Vojtesek‡. Label-free SWATH-MS was used to identify proteins and their 
relative abundance between sample pairs. Each sample was pooled from 2 wells of 
differentiated cells and triplicates were analysed. Different analyses were performed 
comparing neurons derived from the non-engineered parental line (referred to as P) 
and from CRISPR clones, both CHIP+/+ (WT) and CHIP-/- (KO). In an attempt to 
account for the inherent variability of the cortical differentiation, the KO cells were 
compared to both control cell lines (P and WT). SWATH-MS data was compared 
between and within conditions to assess inter- and intra-heterogeneity by principal 
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Figure 4.5: 2D gels of different CHIP cell models 
Undifferentiated iPSC and SH-SY5Y CHIP KO and WT cells were lysed with urea-based lysis 
buffer and analysed by 2D gels (pH 3-10NL strips). For each gel, 200 µg of lysate was loaded, 
and gels were stained with Coomassie blue.  
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component analysis (PCA) (Figure 4.6). The biological replicates of the WT samples 
grouped together on the positive scores of PC1, while the KO biological replicates 
were found in the negative range. This supports the existence of genotype-specific 
proteomic changes between KO and WT cells. Overall, the intra-heterogeneity 



























When the SWATH-MS data comparing CHIP KO neurons with CHIP-expressing 
neurons was analysed using the Ingenuity Pathway Analysis software, pathways 
associated with neurodegenerative diseases (PD and AD) where identified as being 
Figure 4.6: Principal component analysis of the proteomics analysis of cortical neurons 
of different CHIP genotypes  
CHIP KO cortical neurons (red clusters) segregate between scores 0 to -14,000 on PC1, while  
CHIP WT cortical neurons (green clusters) are found between scores 0 to 14,000 on PC1. 
Each colour-coded cluster represents a biological replicate (3 of each genotype). Three 
technical replicates for each biological replicate cluster together and are represented by the 
dots within each individual cluster.  
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related to the data set (Figure S.3). This suggests that the proteome of our patient-
derived neurons models, to some extent, disease-associated pathways.    
 
The comparative proteomics analysing CHIP KO neurons with CHIP-expressing 
neurons (P, Figure 4.7, and WT, Figure 4.8) are represented as volcano plots. These 
show that the vast majority of the proteins identified were not changed with regards 
to fold change (dots coloured in grey), while the outliers of the graph (dots in red) are 
potential proteins of interest. Over-represented proteins have increased fold change 
(in terms of ion products) in CHIP KO cells compared to WT cells, and the opposite 
trend is seen for under-represented cells. The most changed significant proteins 
identified in P vs KO and WT vs KO comparative proteomics are listed in Table S.1 & 
Table S.2 and Table S.3 & Table S.4, respectively. SWATH-MS data comparing P 




























































Figure 4.7: Comparative proteomics of mature cortical neurons derived from the 
parental and CHIP KO iPSC lines 
SWATH-MS analysis of the parental line compared to CHIP KO cortical neurons. Cut off 
criteria (≤0.5 and ≥2 or ≤0.67 and ≥1.5 fold change) are represented by the dotted lines and 
shaded areas. Proteins (dots) that do not meet this fold change criteria are colour-coded in 
grey and does that do are in red. Over-represented proteins in the CHIP KO sample compared 
to WT have negative log (fold change), while under-represented proteins have positive values. 
The top 10 most under- and over-represented proteins that were significantly changed (P < 
0.05) are numbered. The dot representing CHIP is indicated.    
 




































Figure 4.8: Comparative proteomics of mature cortical neurons derived from the CHIP 
WT and CHIP KO iPSC lines 
SWATH-MS analysis of the CHIPS WT (CRISPR control) compared to CHIP KO cortical 
neurons. Cut off criteria (≤0.5 and ≥2 or ≤0.67 and ≥1.5 fold change) are represented by the 
dotted lines and shaded areas. Proteins (dots) that do not meet this fold change criteria are 
colour-coded in grey and does that do are in red. Over-represented proteins in the CHIP KO 
sample compared to WT have negative log (fold change), while under-represented proteins 
have positive values. The top 10 most under- and over-represented proteins that were 
significantly changed (P < 0.05) are numbered. S100-A11 was also included in the over-
represented list of proteins (11th position) as it shares functional overlap with the most changed 
proteins. The dot representing CHIP is indicated.  
 




































Figure 4.9: Comparative proteomics of mature cortical neurons derived from the 
parental and CHIP WT iPSC lines 
SWATH-MS analysis of the parental line compared to CHIP WT (CRISPR control) cortical 
neurons. Cut off criteria (≤0.5 and ≥2 or ≤0.67 and ≥1.5 fold change) are represented by the 
dotted lines and shaded areas. Proteins (dots) that do not meet this fold change criteria are 
colour-coded in grey and does that do are in red. Over-represented proteins in the CHIP WT 
sample compared to P have negative log (fold change), while under-represented proteins have 
positive values. The top 10 most under- and over-represented proteins that were significantly 
changed (P < 0.05) are numbered. 
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b. Similarities across the comparative proteomics data of cortical 
neurons of different CHIP genotypes 
The majority of proteins identified in each comparative proteomics analysis (e.g. CHIP 
KO vs WT) were also present in the other analyses across the different cell lines (e.g. 
parental line vs CRISPR control), account for a 97.8% overlap (Figure 4.10A). When 
applying cut-off criteria (Figure 4.10B&C), the majority of the proteins shared in 
common are between the two analyses comparing different CHIP genotypes (113 and 
40 proteins, depending on the stringency of the cut-off criteria) and are excluded from 
the P vs WT analysis. When removing proteins that are unlikely to be affected by 
CHIP, such as proteins changing significantly between P and WT and keratin, 110 
and 35 proteins could be of interest (Figure 4.10D&E). These under- and over-
represented proteins may be changing in CHIP KO cortical neurons compared to 





























































Figure 4.10: Venn diagrams showing the overlap of proteins identified by SWATH-MS 
across CHIP cell models 
Comparisons between the parental line (P), the CHIP WT CRISPR control (WT) and CHIP KO 
cortical neurons are shown. 
A) Total proteins identified, independent on p-value and fold-change.  
B) Proteins identified with fold changes of ≤ 0.67 and ≥ 1.5.  
C) Proteins identified with fold changes of ≤ 0.5 and ≥ 2.  
 
















c. Proteins of interest 
When selecting candidate proteins that are likely to be affected by the expression of 
CHIP (i.e. proteins of interest), proteins that are significantly changed in both P vs KO 
and WT vs KO screens were favoured, as these are less likely to be changed due to 
CHIP-independent factors (e.g. differences in differentiation status). Under- or over-
represented proteins in the P vs KO and/or WT vs KO analyses that were excluded 
from or unchanged in P vs WT are of interest, as these could be affected by CHIP 
genotype (Table 4.1 & Table 4.2). These two SWATH-MS analyses are compared in 
Figure 4.11 and show a positive linear relationship (r = 0.7305 and r2 = 0.5337 with P 
value < 0.0001#), with proteins under- and over-represented in both experiments. 
Proteins of particular interest (with roles in neuronal health, membrane homeostasis 




# Pearson correlation:  
r quantifies the direction and magnitude of the correlation (ranges from -1 to 1). 
r2 is the coefficient determinant and is the proportion of the variance in the two sets of data 
that is shared (ranges from 0 to 1).  
P value: probability of the null hypothesis (that the population correlation coefficient for the pair 
of variables is zero).  
D E 
Figure 4.10 (continued)  
Comparisons between the parental line (P), the CHIP WT CRISPR control (WT) and CHIP KO 
cortical neurons are shown. 
D) As B but with keratin and proteins found in P vs WT removed.  
E) As C but with keratin and proteins found in P vs WT removed.  
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Table 4.1: Proteins identified by SWATH-MS that are over-represented in CHIP KO 
cortical neurons compared to the control lines 
Control lines are the CRISPR control, WT, and the parental line, P. Fold changes ≤ 0.05. 
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Table 4.2: Proteins identified by SWATH-MS that are under-represented in CHIP KO 
cortical neurons compared to the control lines 
Control lines are the CRISPR control, WT, and the parental line, P. Fold changes ≤ 0.05. 
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Figure 4.11: Comparing the proteomic differences between cortical neurons derived 
from two CHIP-expressing iPSC lines and the CHIP KO line.  
The two CHIP-expressing lines are the CRISPR control line, WT and the parental line, P. Log2 
fold changes of proteins identified in both SWATH-MS experiments are plotted. Proteins of 
particular interest are colour-coded. Pearson correlation: r = 0.7305, r2 = 0.5337 and P value 
(two-tailed) < 0.0001 (****).   
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4.2.3 Proteomics of the other CHIP KO models 
Aiming to better understand how CHIP affects the proteome of different non-neuronal 
and neuronal cell lines, the proteome of CHIP KO and WT iPSC and differentiated 
SH-SY5Y cells was also analysed by SWATH-MS. This data was compared to the 
SWATH-MS analyses from the patient-derived cortical neurons to obtain insights into 
the degree to which STUB1 deletion changes the proteome, and whether proteins 





As previously, the SWATH-MS data obtained from CHIP WT vs KO iPSC was 
represented as a volcano plot (Figure 4.12) and shows that the majority of proteins 
are unchanged. The most under- and over-represented proteins are listed in Table 
S.7 & Table S.8. Some of the proteins identified are likely to be responsible for its 































Figure 4.12: Comparative proteomics of CHIP WT and CHIP KO iPSC lines 
SWATH-MS analysis of the CHIPS WT (CRISPR control) compared to CHIP KO iPSC lines. 
Cut off criteria (≤0.5 and ≥2 or ≤0.67 and ≥1.5 fold change) are represented by the dotted lines 
and shaded areas. Proteins (dots) that do not meet this fold change criteria are colour-coded 
in grey and does that do are in red. Over-represented proteins in the CHIP KO sample 
compared to WT have negative log (fold change), while under-represented proteins have 
positive values. The top 10 most under- and over-represented proteins that were significantly 
changed (P < 0.05) are numbered.  
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b. Differentiated SH-SY5Y cell lines 
The proteome of undifferentiated SH-SY5Y was previously analysed by SWATH-MS95 
(work performed by Erisa Nita and Jakub Faktor), using the same methodology and 
instrumentation as for the analysis of cortical neurons. Although some SH-SY5Y lines 
express immature neuronal markers in its basal state, differentiation drives the 
expression of mature neuronal markers and a more complex neuron-like morphology. 
It has been reported that during the course of differentiation, cells become post-
mitotic, neuritic processes form and extend, there is increased excitability of the 
plasma membrane, formation functional synapses and induction of neuron-specific 
enzymes, neurotransmitters and receptors118.  
 
To investigate the effect of CHIP on the proteome of a different neuronal-like model, 
differentiated SH-SY5Y cells were used. Markers of neuronal identity were detected 
in the proteomic analysis, such as multiple transporters (e.g. sodium/potassium-
transporting ATPase and various amino acid transporters), synaptic markers (e.g. 
synaptogyrin, synpatophysin and synaptic vesicle proteins) and other neuronal 
markers (e.g. cell cycle exit and neuronal differentiation protein 1 and the neuron-
specific β(III)-tubulin, which was also validated by IF, Figure S.4). These features 
confirm the neuronal-like identity of the neurons and the fact that the majority had 
similar fold changes in CHIP KO and WT cells suggests that their differentiation state 
was comparable. Nevertheless, the type of the neurons obtained is unclear and likely 
to have some degree of variable due to the genomic instability of the SH-SY5Y cell 
line. Markers of adrenergic, cholinergic and dopaminergic neurons have been 
reported for differentiated SH-SY5Y lines using retinoic acid118. However, this line 
differentiates into tyrosine hydroxylase-negative neurons (supported by our SWATH-
MS data and previous results, not shown), thus it is unlikely that the neurons are 
dopaminergic nor adrenergic. Additionally, the absence of dopamine transporters and 
markers of dopaminergic progenitors from the SWATH-MS data supports this. The 
presence of multiple acetyltransferase enzymes and components would suggest the 
samples have some cholinergic identity. The comparative proteomic analysis of 
differentiated SH-SY5Y WT versus CHIP KO cells is represented in Figure 4.13 and 
mostly changed proteins are listed in Table S.9 & Table S.10. Again, the vast majority 
of proteins identified have similar fold changes.  
 
 




































Figure 4.13: Comparative proteomics of CHIP WT and CHIP KO differentiated SH-SY5Y 
cells 
SWATH-MS analysis of the CHIPS WT (CRISPR control) compared to CHIP KO differentiated 
SH-SY5Y cells. Cut off criteria (≤0.5 and ≥2 or ≤0.67 and ≥1.5 fold change) are represented 
by the dotted lines and shaded areas. Proteins (dots) that do not meet this fold change criteria 
are colour-coded in grey and does that do are in red. Over-represented proteins in the CHIP 
KO sample compared to WT have negative log (fold change), while under-represented 
proteins have positive values. The top 10 most under- and over-represented proteins that were 
significantly changed (P < 0.05) are numbered.  
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c. Comparing the SWATH-MS analyses of different CHIP KO models 
with the cortical neuron model 
All SWATH-MS experiments (iPSC WT vs KO, differentiated SH-SY5Y WT vs KO and 
both WT vs KO and P vs KO of cortical neurons) were compared to each other (Figure 
4.14). When assessing all proteins identified, 1240 proteins overlapped across all 
comparative proteomic screens. This reduces to 5 proteins (Table 4.3) when applying 































(P vs KO) 
Cortical neurons 
(WT vs KO) 
Figure 4.14: Overlap of comparative proteomics of different CHIP models 
SWATH-MS analyses comparing CHIP WT with CHIP KO across different cell lines in both 
undifferentiated state (iPSC and cycling SH-SY5Y) and differentiated state (cortical neurons 
and neuronal-like SH-SY5Y cells). SWATH-MS experiments of cortical neurons include two 
control cells lines (derived from the CRISPR control, WT, and the parental line, P, iPSC lines). 
All proteins identified were included.     
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Table 4.3: Potential proteins of interest shared between cortical neurons, 
differentiated SH-SY5Y and iPSC 
 
 
Focusing on significantly changing proteins, some are shared between the proteomics 
of cortical neurons and iPSC (Table 4.4). Therefore, these proteins could be 
influenced by the presence of CHIP and might be independent of the differentiation 
statues of cells. Furthermore, a few proteins were shared in common between the 
both SWATH-MS analyses of the cortical neurons and differentiated SH-SY5Y (Table 
4.5). These could be influenced by CHIP expression and be dependent on a neuronal-
like phenotype. Alternatively, proteins shared in common are related it the 
differentiated state of the cell lines.  
 
Table 4.4: Potential proteins of interest shared between cortical neurons and iPSC 
 
 
Chapter 4: Effect of CHIP on the proteome  171 




SWATH-MS analysis of undifferentiated SH-SY5Y was previously conducted by Erisa 
Nita in collaboration with Dr Jakub Faktor and Dr Bořivoj Vojtesek‡95. When 
comparing the proteomes of undifferentiated and differentiated SH-SY5Y (WT vs KO) 
cells (Figure 4.15A), the majority of the proteins identified in common are unchanged 
in both comparative proteomics. Some proteins are over- and under-represented in 
both SWATH-MS experiments, such as the neurofilament light polypeptide. However, 
most of the proteins of interest derived from the analysis of cortical neurons (the 
Annexin proteins, S100-A11 and superoxide dismutase) are unchanged in these cell 
lines.   
 
Figure 4.15B-D assess how comparable the proteomes of the undifferentiated and 
differentiated SH-SY5Y and iPSC models with isogenic STUB1 deletions are to the 
cortical neurons, respectively. In these two-dimensional comparative proteomics plots 
(comparing two CHIP WT/KO conditions), the majority of the proteins detected in 
common show no change (i.e. fold changes close to 1) in both conditions. These 
accumulate at the xy intersection (as Log2 fold changes are plotted). Moreover, 
proteins have a stochastic distribution and do not fit into a linear regression (evident 
from the Pearson coefficient close to 0), as fold changes tend to have varying 
magnitudes and directions in the paired conditions analysed. However, when focusing 
on the potential proteins of interest, these are more similar in the comparisons of 
either undifferentiated SH-SY5Y cells or iPSC with cortical neurons. In these plots, 
some proteins of interest are found in quadrants II and III, being under-represented in 
the SH-SY5Y or iPSC and under-/over-represented in cortical neurons. In contrast to 
the differentiated SH-SY5Y cells compared to cortical neurons, where proteins of 
interest tend to be close to the x-axis (i.e. changing in the cortical neurons only).  
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Figure 4.15: Comparing the proteomic differences between CHIP WT and KO across 
different cell lines and differentiation statuses 
Log2 fold changes of proteins identified in both SWATH-MS experiments are plotted. Proteins 
of particular interest are colour-coded. 
A) Undifferentiated and differentiated SH-SY5Y cells. Pearson correlation: r = 0.1339, r2 = 
0.0180 and P value (two-tailed) < 0.0005 (***).       
B) Undifferentiated SH-SY5Y cells and cortical neurons. The average of the WT/KO and P/KO 
comparative proteomics of cortical neurons was plotted. Pearson correlation: r = 0.017, r2 = 
0.0003 and P value (two-tailed) = 0.6275 (ns). 
C) Differentiated SH-SY5Y cells and cortical neurons. The average of the WT/KO and P/KO 
comparative proteomics of cortical neurons was plotted. Pearson correlation: r = -0.0397, r2 = 
0.0016 and P value (two-tailed) = 0.1958 (ns).  
D) iPSC and cortical neurons. The average of the WT/KO and P/KO comparative proteomics 
of cortical neurons was plotted. Pearson correlation: r = 0.0321, r2 = 0.0010 and P value (two-
tailed) = 0.2958 (ns).   
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4.2.4 Validation of proteomic analysis  
The variability of proteins of interest across the comparative proteomics of cortical 
neurons (with same and different CHIP genotypes) was plotted in Figure 4.16 (taking 
into account fold changes and statistical significance). For the majority of the proteins, 
WT vs KO and P vs KO data converges in one quadrant, separate from the P vs WT 
data. Annexins, S100-A11, HLA-B and IFITM are over-represented in CHIP KO, while 

























Figure 4.16: Proteins of interest identified across the comparative proteomic analyses 
of cortical neurons of different CHIP genotypes  
Data from the SWATH-MS comparing CHIP-expressing (P and WT) neurons to KO are 
represented as triangles and squares, respectively, while the proteins from the comparative 
proteomics of CHIP-expressing neurons (P/WT) are displayed as circles. Proteins of interest 
are colour-coded and meet the cut-off criteria for at least one comparative proteomics analysis 
of cells with different CHIP genotypes.   
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It is important to take into account that the intensities of the peptides detected by MS 
are affected by a combination of factors including the post-translational modifications 
and inter-molecular interactions (including the degree of aggregation, which is 
particularly relevant for α-Syn), which can affect how proteins are cleaved by trypsin 
during sample preparation for MS. Additionally, peptides have different compatibilities 
with MS detection, in terms of ionization and fragmentation potential137. For all these 
reasons, whether a protein seems to be over- or under-represented in the CHIP KO 
relative to the control samples needs to be taken with caution and validation is 
required. 
 
Thus, preliminary validation of the MS data was performed by analysing a selection 
of both under and over-represented proteins with different cellular functions, 
particularly those that have not been previously linked to CHIP. Furthermore, 
preliminary experiments investigating the same proteins of interest in different CHIP 
models, suggest whether these can be used for supporting experiments in parallel to 
cortical neurons.   
 
 
a. Human leukocyte antigen B 
Human leukocyte antigen B (HLA-B) was over-represented in the MS analysis in CHIP 
KO neurons. This protein was selected for further validation given the previously 
reported CHIP-dependent regulation of IRF1, supporting its role in immunity77, and 
the emerging link between cellular proteostasis and innate immunity138. 
 
The expression of HLA-B in the cortical neurons was evaluated using both WB (Figure 
4.17A) and IF (Figure 4.17B). Although the former showed an increase in HLA-B 
expression in CHIP KO neurons that was above the level of detection of this assay 
for this line only, the most striking phenotype was observed by IF. HLA-B was highly 
expressed the nucleus, cytoplasm and axons of the CHIP KO neurons and had only 
faint puncta in the nucleus in WT cells. The difference in homeostasis of HLA-B 
between CHIP KO and WT cells was not seen in iPSC (Figure 4.18), thus it may be 
cell-type specific or the overexpression observed in CHIP KO cortical neurons is not 
due to the presence of CHIP.  
 
 






































Figure 4.17: Expression of HLA-B in CHIP KO and WT cortical neurons 
A) Mature iPSC-derived cortical neurons (harvested at day 80 of differentiation) were lysed 
with urea-based lysis buffer (the same as that used for SWATH-MS). CHIP homozygous (-/-) 
and heterozygous (+/-) KO neurons, as well as two CHIP-expressing lines (the parental line 
(+/+) and the CRISPR control (+/+)) were analysed. For each sample, 18 μg of lysate was 
loaded per 12% gel for SDS-PAGE/WB and two gels were ran together (in the same 
apparatus). Lysate from IFNγ-treated SiHa cells was also included as positive control. One 
immunoblot was probed with a mix of anti-HLA-A pAb, anti-HLA-B pAb and HLA-C mAb (each 
1:500) and the other with anti-b-actin mAb (1:5000). 
B) Mature iPSC-derived cortical neurons of different CHIP genotypes were fixed with 4% PFA 
(harvested at day 80 of differentiation). Neurons were stained with anti-HLA-B pAb (1:100) 
and DAPI (nuclear stain). Images are z-projections (maximal projection) from stacks. Axio 
Imager, Zeiss. Scale bar, 10 µm. 
 





































Figure 4.18: Expression of HLA-B in CHIP KO and WT iPSC lines 
iPSC were lysed with urea-based lysis buffer (the same as that used for SWATH-MS). CHIP 
homozygous (-/-) and heterozygous (+/-) KO neurons, as well as two CHIP-expressing lines 
(the parental line (+/+) and the CRISPR control (+/+)) were analysed. For each sample, 20 μg 
of lysate was loaded per 12% gel for SDS-PAGE/WB and two gels were ran together (in the 
same apparatus). Lysate from IFNγ-treated SiHa cells was also included as positive control. 
One immunoblot was probed with a mix of anti-HLA-A pAb, anti-HLA-B pAb and HLA-C mAb 
(each 1:500) and the other with anti-b-actin mAb (1:5000). 
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HLA-B was identified by SWATH-MS by 3 unique peptides. One of these peptides 
(FIAVGYVDDTQFVR) has 100% sequence homology to HLA-A and HLA-C, while 
another peptide (THVTHHPVSDHEATLR) has 88% and 100%, respectively. 
Therefore, although the software assigned HLA-B to this peptide fingerprint, HLA-A 
and HLA-C should not be excluded. Only HLA-C was identified in the proteomics of 
iPSC and differentiated SH-SY5Y cells, although it was unchanged between CHIP 





Neurosecretory VGF, on the other hand, lies within the list of protein under-
represented in the CHIP KO cortical neurons. The protein showed no significant 
change in cortical neurons by WB (Figure 4.19), but a significant decrease by IF in 
CHIP KO compared to CHIP-expressing neurons (Figure 4.20). Therefore, the 
























































Figure 4.19: Expression of VGF in CHIP KO and WT cortical neurons by WB 
Mature iPSC-derived cortical neurons (harvested at day 80 of differentiation) were lysed with 
urea-based lysis buffer (the same as that used for SWATH-MS). CHIP homozygous (-/-) and 
heterozygous (+/-) KO neurons, as well as two CHIP-expressing lines (the parental line (+/+) 
and the CRISPR control (+/+)) were analysed. For each sample, 20 μg of lysate was loaded 
per 12% gel for SDS-PAGE/WB and two gels were ran together (in the same apparatus). An 
immunoblot was probed with anti-VGF Ms mAb (1:500) and the other immunoblot with anti-
VGF pAb (1:5000). The former immunoblot was then incubated with anti-CHIP mAb (1:10000). 
Finally, both immunoblots were probed with anti-β-actin mAb (1:5000).  
 




































Figure 4.20: Expression of VGF in CHIP KO and WT cortical neurons by IF 
Mature iPSC-derived cortical neurons of different CHIP genotypes were fixed with 4% PFA 
(harvested at day 80 of differentiation). Neurons were stained with anti-VGF mAb (1:1000) and 
DAPI (nuclear stain). Images are z-projections (maximal projection) from stacks. Axio Imager, 
Zeiss. Scale bar, 10 µm. 
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Previously, VGF was the single protein significantly changing across SWATH-MS 
experiments of multiple SH-SY5Y CHIP KO clones (work by Erisa Nita95). It is 
overexpressed in CHIP KO undifferentiated SH-SY5Y and showed increased 
processing into smaller fragments (Figure 4.21). This over-expression is also seen in 
CHIP KO differentiated SH-SY5Y. However, these cells display a decrease in lower 
MW isoforms and an increase in higher MW ones (Figure 4.21). Given the complex 
homeostasis of VGF in SH-SY5Y cells, it is unclear how it compares to cortical 

























Figure 4.21: Expression of VGF in CHIP KO and WT undifferentiated and differentiated 
SH-SY5Y cells 
Undifferentiated and differentiated CHIP KO and WT SH-SY5Y cells were lysed with urea-
based lysis buffer (the same as that used for SWATH-MS). For each sample, 20 μg of lysate 
was loaded per 12% gel for SDS-PAGE/WB and two gels were ran together (in the same 
apparatus). An immunoblot was probed with anti-VGF Ms mAb (1:500) and the other 
immunoblot with anti-VGF pAb (1:5000). The former immunoblot was then incubated with anti-
CHIP mAb (1:10000). Finally, both immunoblots were probed with anti-β-actin mAb (1:5000).  
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c. Membrane proteins 
Interestingly, multiple Annexin proteins and other proteins with known roles in 
maintenance of membrane integrity and repair reported in the literature, were 
detected in the MS analysis. These tend to be over-represented in the CHIP KO 
neurons and are largely unchanged when comparing the CHIP-expressing lines with 
each other, as seen in Figure 4.22. As evidence that of their detection and relative 
abundance in CHIP WT and KO cells, the mass spectra of a subset of these proteins, 
namely Annexin A2 (ANXA2) (Figure 4.23) and S100-A11 (Figure 4.24), was 
analysed closely. The b and y ions from unique peptides that identify ANXA2 and 
S100-A11 were greatly increased in the CHIP KO cortical neurons compared to WT. 
The steady state levels of ANXA2 and S100-A11 were also evaluated by IF (Figure 
4.25) and WB (Figure 4.26A), respectively. By this validation method, the over-
representation of ANXA2 by SWATH-MS was not observed. Thus, different pools of 
ANXA2 are being detected by the different methods. The WB to assess S100-A11 
protein levels, on the other hand, following the trend observed by SWATH-MS, being 
enriched in the CHIP KO cortical neurons. Chapter 5 focuses on membrane proteins 


















Figure 4.22: Identified proteins with known roles in maintenance of membrane integrity 
Proteins include: Annexin A1, A2, A4, A5, A6 and A7, protein S100-A11, Caldesmon, 
Syntaxin-1B, Synaptosomal-associated protein 29, Neuroblast differentiation-associated 
protein AHNAK and Ras-related proteins Rab-3C, 3B and 5C. Proteins from the Annexin family 
are represented as triangles. Data from the SWATH-MS comparing CHIP-expressing (P and 
WT) neurons to KO are represented in grey and red, respectively, while the proteins from the 
comparative proteomics of CHIP-expressing neurons (P/WT) are displayed in blue. 
 
 




































Figure 4.23: Mass spectra of product ions detected that identified and quantified 
Annexin A2 in WT (top) and CHIP KO (bottom) cortical neurons by SWATH-MS 
The product ions of the unique peptide of Annexin A2, TPAQYDASELK, were detected in the 
m/z swath of 603-616 (normalised to 611.80) and RT = 60.43 min. Product ions detected: y9 
(indigo), y7 (magenta), y8 (red), y6 (yellow), b9 (green) and y10 (cyan). One biological and 
technical replicate for each cell line is represented, but other biological and technical replicates 
(each n=3) are similar.  
 




































Figure 4.24: Mass spectra of product ions detected that identified and quantified S100-A11 
in WT (top) and CHIP KO (bottom) cortical neurons by SWATH-MS 
The product ions of the unique peptide of S100-A11, CIESLIAVFQK, were detected in the m/z 
swath 651-664. Product ions detected: y9 (indigo), y8 (magenta), y6 (red), y7 (yellow), y5 (green) 
and y3 (cyan). One biological and technical replicate for each cell line is represented, but other 
biological and technical replicates (each n=3) are similar.  
 




































Figure 4.25: Expression of ANXA2 in CHIP WT and KO cortical neurons 
Mature iPSC-derived cortical neurons of different CHIP genotypes were fixed with 4% PFA 
(harvested at day 80 of differentiation). Neurons were stained with anti-Annexin A2 pAb 
(1:500), anti-CHIP mAb (1:1000) and DAPI (nuclear stain). Images are z-projections (maximal 
projection) from stacks. Axio Imager, Zeiss, 63x objective. Scale bar, 100 µm. Images are 
representative of at least three biological replicates. 
 

























Some of the membrane-related proteins identified in cortical neurons (in Figure 4.22) 
were also found in SH-SY5Y and iPSC. Their relative WT/KO fold changes were 
plotted together in Figure 4.27 for comparative purposes. S100-A11, for example, was 
also found to be expressed in these cell lines but its steady state level was not 
dependent on CHIP expression, as supported by the SWATH-MS data (Figure 4.27) 
and WB (Figure 4.26B&C). Once again, this validates the reliability of the SWATH-
MS approach. Furthermore, this difference in S100-A11 proteostasis compared to 
cortical neurons suggests the existence of proteomic differences between cycling and 






Figure 4.26: Expression of S100-A11 in different CHIP cell models 
Mature iPSC-derived cortical neurons (harvested at day 80 of differentiation) (A), iPSC (B) 
and undifferentiated SH-SY5Y cells (C) of different CHIP genotypes were lysed with urea-
based lysis buffer (the same as that used for SWATH-MS). For each sample, 20 μg of lysate 
was analysed by 12% gel for SDS-PAGE/WB. The immunoblot was cut and probed with anti-
S100-A11 pAb (1:1000) and anti-β-actin mAb (1:5000). Immunoblots are representative of at 
least two independent experiments. 
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However, there are also some similarities in the SWATH-MS data between cortical 
neurons and cycling cells. As in cortical neurons, ANXA2 is over-represented in CHIP 
KO undifferentiated SH-SY5Y cells (having a fold change of 0.460 compared to 
0.104). Likewise, ANXA1, caldesmon-1 and AHNAK are over-represented in iPSC 
(0.229, 0.503 and 0.420, respectively, compared to the average fold changes of 
cortical neurons: 0.222, 0.142 and 0.339) (Figure 4.27). Therefore, in the context of 
membrane proteins of interest, it seems that the proteomes of undifferentiated SH-
SY5Y cells and iPSC are similar to that of cortical neurons. Surprisingly, the 
proteostasis of these proteins of interest in differentiated SH-SY5Y cells seem to be 














Figure 4.27: Identified proteins with known roles in maintenance of membrane integrity 
across CHIP cell models 
Proteins known to have roles in membrane homeostasis identified across the comparative 
proteomics of different CHIP cell models were compared with regards to WT/KO fold changes.  
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4.3 Discussion 
4.3.1 Proteomics to identify targets of chaperones and E3 
ligases 
Previous proteomic studies have investigated the effect of particular chaperones and 
E3 ligases on the proteome of cells. This includes deciphering their role in the 
maintenance of protein homeostasis and the size of its interactome (whether they 
regulate multiple or specific aspects of the proteome). By critically evaluating methods 
used we have decided to conduct an unbiased proteome-wide study to decipher the 
effects of this dual function, chaperone and E3 ligase, CHIP.  
 
The identification of substrates of E3 ligases is particularly challenging. This is due to 
the low abundance of ubiquitinated species139 (it is estimated that only 0.1-3% of 
substrates appear to be ubiquitinated140 at any given time141) and the often transient 
interaction between a particular E3 ligase and its substrate. Consequently, studies 
have relied on the use of tagged proteins, overexpression systems or proteasomal 
inhibitors.    
 
Traditional approaches to identify E3 substrates are based on the identification of 
interacting proteins132. For example, Galligan and his group142 transfected cells with 
tagged fragments of the E3 ligase HERC for immunoprecipitation, followed by 
analysis by LC-MS/MS. This led to the identification of nearly 300 potential 
interactions. Although this approach has had some success for monomeric E3s, it is 
limited by the ability to successfully purify interacting proteins132. Furthermore, is not 
ideal for multimeric E3s due to the weak affinity that each subunit may have 
independently for the substrate132. We hypothesise that CHIP functions both as a 
monomer and multimer, having different substrate specificities (discussed in Chapter 
6), thus may not be suitable for this assay. Furthermore, the use of tags and the 
overexpression per se may influence the biochemical properties of proteins, including 
their structure, function, regulation and interactome. 
 
Another method in attempt to maximise the chances of identifying ubiquitinated 
proteins, has been the use of proteasome inhibitors to stabilise ubiquitinated proteins. 
Simplistically, the proteasome can be inhibited by various drugs leading to the 
accumulation of ubiquitinated proteins that have been destined to the UPS for 
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degradation141,143,144. The majority of the proteins that accumulate are regulatory 
proteins with short half-life and a signal-dependent turnover141. This introduces bias 
to the proteomics data derived. Furthermore, proteasomal inhibition results in 
proteome-wide effects beyond blocking substrate degradation, due to the complex 
feedback loop. Proteasome inhibition-induced unfolded protein response (UPR) 
blocks translation and stimulates other degradation pathways, such as autophagy144. 
Therefore, methods based on proteasomal inhibition are bias for the detection of 
certain ubiquitinated species and cause proteome-wide effects.  
 
Despite the availability of multiple targeted approaches to detect ubiquitination 
substrates, their potential is hampered by inherent limitations. The use of tagged and 
overexpressed proteins and inhibitors alter the finely tuned dynamics of 
ubiquitination145, thus are not representative of the in vivo scenario140. An unbiased 
proteome-wide investigation of E3 ligases may circumvent some of the challenges of 
identifying substrates. Here, the endogenous cellular environment is maintained, 
hence promoting the identification of targets with physiological significance. For these 
reasons, we decided to investigate the protein targets of CHIP using an unbiased 
proteome-wide mass spectrometry technique, SWATH-MS.  
 
Although ubiquitinated proteins destined for degradation tend to have rapid 
destruction rates when these are not stabilised (e.g. with degradation inhibitors), the 
high sensitivity of proteomics (in particular DIA methods, such as SWATH-MS), in 
some cases, is enough to detect candidate substrates. Similarly, proteins 
ubiquitinated with non-canonical moieties (e.g. K63-linked Ub chain) can also be 
detected by SWATH-MS. In fact, protein-wide MS-based studies at basal conditions 
prevent bias towards the identification of canonical ubiquitination substrates. 
Substrates of non-canonical ubiquitination that are not destined for degradation are 
less known, as they tend to be missed in assays using proteasomal inhibitors, for 
example. Therefore, although proteome-wide SWATH-MS is an indirect approach to 
identify ubiquitinated proteins, it is likely to be informative.   
 
To study the effect of CHIP on the proteome using an unbiased proteome-wide 
approach, we performed comparative proteomics on CHIP cell models in the 
presence and absence of CHIP. Such indirect manner to identify ubiquitinated species 
has been used in the past. The underlying rational is that in E3 ligase loss-of-function 
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assays the relative abundance of proteins ubiquitinated by the particular enzyme and 
destined for degradation may increase. For example, by analysing the proteome of 
cells expressing WT or an E3 ligase-defective mutant of a member of the cullin-RING 
ligase family (ASB2), filamin A and B were identified as substrates132. In the case of 
CHIP, we believed that such loss-of-function approach is less invasive to the cellular 
proteostasis compared to its overexpression. Overexpression of the TPR domain of 
CHIP, responsible for its chaperone activity, per se is likely to influence the 
interactome of chaperones and TPR-containing proteins, interfering with multiple 




4.3.2 CHIP is a docking-dependent, chaperone-independent E3 
ligase with tight specificity  
a. General effects of CHIP deletion on the proteome 
The MS analysis of our iPSC-derived cortical neurons displayed similarities in 
neuronal-specific markers (e.g. synaptic vesicle proteins) across different samples, 
which can be regarded as an internal control, suggesting that samples have similar 
neuronal identities. Interestingly, the comparative proteomic analysis of patient-
derived cortical neurons with and without CHIP expression demonstrated that only a 
few proteins (35 or 110 depending on the selection criteria, representing about 1.7% 
and 5.4% of the proteome analysed, respectively) could be directly or indirectly 
regulated by CHIP (Figure 4.10). Likewise, when comparing the proteomics data of 
the different CHIP cell models (cortical neurons, undifferentiated and differentiated 
SH-SY5Y and iPSC), out of the 1240 proteins identified in common (Figure 4.14), only 
5 proteins (0.4%) were significantly changed (under- or over-represented) in all cell 
lines (Table 4.3). Visually, this is clear from the volcano plots of these SWATH-MS 
experiments, where the vast majority of proteins are unchanged (in grey) and the 
proteins of interest are outliers (in red) (including Figure 4.7 & Figure 4.8). Therefore, 
across different CHIP WT and KO cell lines, the deletion of this protein did not result 
in bulk changes to the proteome.   
 
The predominant idea within the field describes CHIP as being like other chaperone-
dependent E3 ligases with a broad range of substrates, thus capable of global 
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changes in the proteome. In agreement, Bhuripanyo and colleagues146 identified 226 
candidate E3 ligase substrates of CHIP. This includes previously reported CHIP 
substrates (including p53, BAG proteins and Hsp70), in addition to new substrates 
(kinase MAPK3, methyltransferase PRMT1, phosphatase PPP3CA, β-catenin and 
CDK4). Interestingly, this was achieved from an affinity-purified based MS assay with 
a functional component: using an orthogonal Ub transfer (OUT) assay in combination 
with the isolation of Ub-conjugates and MS analysis. For such, OUT ubiquitination 
enzymes and a modified His-Ub (used exclusively by the OUT enzymes and not 
native ubiquitination enzymes) were transfected into cells. Here, substrate 
identification is based on the transfer of Ub from a particular E3 to its ubiquitination 
targets, rather than on E3:substrate interactions, which tend to be transient. To our 
knowledge, this was the first proteomic analysis of CHIP to identify its E3 substrates. 
However, the system relies on the overexpression of Ub and ubiquitination enzymes, 
which compromises the reliability of the substrates identified with regards to its 
physiological significance.  
 
The chaperone functions of CHIP have also contributed to the hypothesis of CHIP 
having a wide interactome. Chaperones are highly promiscuous, interacting 
transiently with thousands of substrate proteins and promoting their folding, trafficking 
and degradation147. The broad nature of its interactome was evident from a study 
conducted by Taipale et al.147. Here, 54 chaperones, cochaperone or quality-control 
factors were tagged with 3xFLAG and following affinity purification-MS, 486 high-
confidence interactions were identified. This was organised into two tiers, the first 
containing Hsp70 and Hsp90 chaperone complexes and bridged by cochaperones 
including CHIP, and the second tier is its cochaperone-client interactions. The broad 
network of protein-protein interactions includes proteins involved in unrelated cellular 
processes (e.g. spindle assembly, DNA replication and mRNA decapping)147. Since 
CHIP was identified as a co-chaperone, some of its substrates might overlap with 
substrates of chaperones, such as Hsp70. However, it is unclear if, under basal 
conditions, CHIP shares the same broad interactome as chaperones and co-
chaperones.  
 
In fact, there is growing evidence suggesting that CHIP may have tight specificity and 
the ability to mediate direct recognition of its targets (in a chaperone-independent 
manner), under specific conditions. For example, under healthy conditions, CHIP 
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ubiquitinates the INSR and not the closely related insulin-like growth factor 1 receptor 
(IGF1R). However, upon accumulation of damaged proteins the dynamic equilibrium 
of quality-control networks is challenged and CHIP switches to protein degradation 
pathways, to counteract proteotoxicity. As a result, the INSR accumulates, which 
significantly shortens lifespan62. In line with this, the Ball group have reported that in 
unstressed cells CHIP acts as a positive regulator of IRF-1 levels, while stress leads 
to CHIP-dependent down-regulation of IRF-1. This highlights the importance of the 
cellular environment in regulation of proteostasis77. As a docking-dependent, 
chaperone-independent E3 ligase it would be expected that only a few proteins would 
be influenced by the deletion of CHIP. The data presented in this chapter supports 
this mode of action.   
 
 
b. Identification of candidate proteins  
The MS analysis of cortical neurons revealed proteins of interest that could be 
regulated directly or indirectly by CHIP in the disease context under investigation. 
These meet the standard cut off criteria, are found in both comparative proteomics of 
CHIP-expressing versus KO neurons and are excluded/unchanged between the 
control lines (P vs WT) (Figure 4.16). The P vs WT SWATH-MS analysis helps to 
accounts for differences in differentiation status or proteins that could be changed due 
to off-targets of the CRISPR/Cas9 system used. Furthermore, by comparing these 
candidate proteins to those also under- or over-represented in the other CHIP cell 
models analysed (iPSC, undifferentiated and differentiated SH-SY5Y) proteins that 
are more likely to be directly influenced by CHIP can be identified. This 
comprehensive approach also provides some insight as to whether these proteins are 
disease-specific or neuronal-specific, and how conserved this CHIP-mediated 
proteomic change is across different cell lines. Although candidate protein 
identification is primarily based on our disease-relevant CHIP model (patient-derived 
cortical neurons), the use of other cell lines can aid the search for mechanistic insight 
into the role of CHIP in the regulation of proteins. 
 
From the proteins that were consistently under- or over-represented in the SWATH-
MS analysis of cortical neurons, we focused on a subset of proteins. Given the 
identification of numerous proteins from the Annexin family, Annexins A2, A4, A5, A6 
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and A7 were all given some degree of attention. ANXA2 was of particular interest as 
it was consistently detected in the top over-represented proteins in CHIP KO cortical 
neurons and unchanged in the CHIP-expressing neurons. Also, given its functions in 
the same membrane homeostasis pathways, the ANXA2-interacting protein148, S100-
A11 was also included in this list. Finally, HLA-B was also found to be overexpressed 
across the comparative CHIP KO vs WT proteomics.   
 
VGF, SOD and the neurofilament light polypeptide were some of the under-
represented proteins in both WT vs KO and P vs KO. Firstly, VGF had been previously 
detected in proteomic analyses of the undifferentiated SH-SY5Y cells in our group95, 
hence was validated in the cortical neuron model. Secondly, CHIP has been 
associated with prevention of oxidative stress149, thus alteration of enzymes such as 
SOD, would be expected. Finally, neurofilament light polypeptide was significantly 
changed in most SWATH-MS analyses (cortical neurons, undifferentiated and 
differentiated SH-SY5Y). Neurofilament light polypeptide increases with ageing and 
is believed to be linked with different neurodegenerative diseases, including AD and 
PD150. Therefore, the change in homeostasis of neurofilament light polypeptide could 
reflect a change in overall cell health.  
 
 
4.3.3 Possible targets of CHIP 
We have previously described the vast interactome and cellular effects of CHIP in 
age-related diseases87, based on the literature. In line with this, the identification of a 
greatly distinct subset of proteins potentially regulated by CHIP, presented in this 
chapter, may suggest that CHIP functions in a wide range of cellular processes.   
 
 
a. CHIP and innate immunity 
There is compelling preliminary evidence to support an upregulation of HLA-B in the 
CHIP KO neurons. This was very striking by IF (having high expression throughout 
the neurons) (Figure 4.17B) and by MS (HLA-B was consistently detected in the top 
most over-represented proteins) (Figure 4.11). On the other hand, iPSC show no 
difference in the steady state level of HLA-B (Figure 4.18). HLAs are major 
histocompatibility complexes (MHC) class I proteins and have been reported to be 
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expressed by neurons (Figure 4.28)151. However, to our knowledge, there is no 
















Although the field of immunity in terms of neurodegeneration gained popularity over 
the years, the role of neuronal innate immunity in neurodegenerative disease is still 
understudied. MHC-I proteins function to present antigens at their surface for the 
ability to distinguish self from non-self152. Other than its role in the initiation of antigen 
receptor signalling, HLA proteins play roles in synaptic plasticity during development 
and may regulate the ability of neurons to maintain synapses152. A GWAS study by 
Hamza and colleagues112 reported HLA-DRA (MHC class II protein expressed by 
antigen-presenting cells including microglia) as a strong predictor in sporadic and late-
onset PD (Figure 4.29). This supported the involvement of immunity in PD. The group 
suggested that chronic immune activation (possibly due to α-Syn accumulation) could 
result in neuroinflammation, leading to neuronal death112. Although supporting data is 
required, it is possible that, in a synucleinopathy background, the absence of CHIP 
directly or indirectly contributes to the over-activation of the immune system, 
manifested as HLA-B upregulation. Thus, one can hypothesize that, along with MHC-
II proteins, MHC-I proteins may also contribute to the chronic immune activation seen 
in neurodegeneration. In fact, HLA-A2 and HLA-B7 have been linked to AD153,154.  
 
 
Figure 4.28: Neurons express MHC-I 
Expression of a combination of MHC-I proteins in neurons treated with IFNγ. Expression 
is not detected when untreated. Scale bar, 10µm. 
(Neumann et al.151) 
 















Furthermore, since alterations in cellular redox state are communicated to the 
immune system through antigen presentation, HLA proteins may also be affected by 
oxidative stress. Supporting evidence includes the increase in neuronal MHC-I 
proteins observed under stress152 and the presentation of oxidised proteins in the 
immunopeptidome, which can hinder interactions between T-cells and MHC-I155. 
Therefore, changes in proteotoxic and/or redox state of cells as a consequence of 
CHIP deletion could underlie this change in HLA, although these conditions of stress 
would probably have wide effects on the proteome, which were not seen.  
 
CHIP, as an integral component of proteostasis, has been suggested to play a role in 
regulating antigen presentation (of endogenous and foreign material) on MHCI-I 
proteins for immune recognition. Here, defective proteins become ubiquitinated and 
accumulate transiently to form aggregates (aggregsome-like induced structures). 
These are then cleared by the proteasome or chaperone-assisted selective 
autophagy to promote antigen presentation. CHIP is believed to aid this process156. 
Our preliminary findings relating HLA-B to CHIP function, together with previous 
evidence of CHIP-dependent regulation of IRF-177, contributes to a possible role for 
CHIP in innate immunity. 
 
 
Figure 4.29: HLA-DRA was identified as a risk gene for sporadic and late-onset PD 
Manhattan plot showing the P values for the association of 811,594 SNPs with PD. SNPs that 
surpassed genome-wide significance (P < 5 x 10-8) were SNCA and HLA-DRA.   
(Hamza et al.112) 
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b. CHIP in synaptic function and energy metabolism 
The neurosecretory protein VGF was also analysed further due to its detection in 
independent MS experiments investigating the effect of CHIP in the proteome of 
different cell lines. These included the cortical neurons and differentiated SH-SY5Y 
cells investigated during the course of this project, and undifferentiated SH-SY5Y 
previously studied by Erisa Nita95. VGF is a 68kD polypeptide that is expressed by a 
neurotrophin-induced gene responsive to BDNF157. It is synthesized by neurons 
(including cortical150) and endocrine cells157. Its processing post-translationally by 
prohormone convertases into numerous smaller peptides that have been studied in a 
mouse model (Figure 4.30), although translational studies to humans have not been 
reported. These peptides and full-length VGF are found in dense core vesicles, which 


















Patient-derived CHIP KO cortical neurons show a pronounced decrease in VGF by 
MS and IF (Figure 4.20), but no/little change by WB (Figure 4.19). The discrepancy 
of VGF phenotype could be due to extractability differences, hence detecting different 
pools of VGF. Cortical neurons show a slight decrease in the abundance of a doublet 
at around 58 and 62 kDa in CHIP KO cells (by WB using a monoclonal Ab). This 
Figure 4.30: Post-translational processing of VGF in a mouse model 
Several proteolytic cleavages process the full-length VGF protein (at the top) into several 
smaller peptides.   
(Lewis et al.157) 
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doublet is also decreased in CHIP KO differentiated SH-SY5Y cells but increased in 
undifferentiated cells of this genotype compared to WT (Figure 4.21). Therefore, this 
difference could be related to the neuronal-like phenotype of SH-SY5Y and cortical 
neurons.  
 
The deletion in differentiated SH-SY5Y also caused a decrease in lower MW forms of 
VGF (<35 kDa), but an increase in higher MW species (>100 kDa). Although this 
question was not address further, it is possible that CHIP is involved in the processing 
of full-length VGF and its preforms (the high MW species) to its smaller peptides, 
possibly through proteolytic cleavage (that has been described for other E3 
ligases158). Such processing may also be neuron specific. What undifferentiated and 
differentiated KO cells have in common is an increase in 100 kDa VGF, which is not 
seen in cortical neurons. This would also argue for a role of CHIP as an E3 ligase of 
VGF to mediate its degradation. Clearly, the homeostasis of VGF in these cell lines is 
very different, thus underlying mechanisms are likely to differ.  
 
VGF and its neuropeptides have multiple roles in the brain. TLQP-62 and AQEE-30 
increase synaptic activity, potentiation, plasticity and neurogenesis150,157, while TLQP-
21 prevents neuronal apoptosis157 and regulates pain mechanisms159 and NERP-1 
and NERP-2 peptides regulate water balance160. VGF and its neuropeptides are 
upregulated in pain models159 and in neurodegeneration. A post-mortem study 
revealed that the parietal cortex of PD patients showed a reduction in TPGH and 
NERP-1 peptides specifically, while all VGF peptides were reduced in AD. This 
suggests the involvement of VGF in physiological or pathological mechanisms during 
neuronal health and disease157,160.  
 
Interestingly, a 62 kDa peptide was reduced in CHIP KO differentiated SH-SY5Y. This 
could represent the TLQP-62 peptide, although validation is required. Reduced 
expression of this peptide (seen in AD) has been related to impaired memory 
acquisition and consolidation through a BDNF-dependent pathway that modulates 
synaptic structure and function150. In fact, it has been hypothesised that the decrease 
in VGF may correlate with loss of BDNF160. Interestingly, BDNF was also under-
represented in the CHIP KO cortical neurons by MS.  
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VGF deficits are not only related to cognitive impairment defects but also severe 
metabolic abnormalities. VGF KO mice consume twice as much oxygen at rest, along 
with impaired learning and memory157. Accordingly, patients harbouring STUB1 
mutations and CHIP KO mice have cognitive and metabolic defects13,14,88, thus it is 
possible that VGF partially mediates the neuroprotective properties of CHIP.  
 
 
c. CHIP and membrane integrity 
When analysing the proteins identified using MS, the amount of calcium and 
membrane-binding proteins detected is striking. The majority of the Annexin family 
proteins were detected in our SWATH-MS analyses and a few were significantly and 
consistently over-represented in the proteomics comparing CHIP-expressing to CHIP 
KO cortical neurons (Figure 4.22). ANXA2 (Figure 4.23) is of particular interest. 
Annexin are involved in maintenance of membrane homeostasis through multiple 
strategies. They regulate the formation of a repair cap161 and mediate repair 
mechanisms such as membrane excision162. Interesting, S100 proteins are also 
heavily involved in these pathways162 and S100-A11 was consistently detected in the 
top over-represented proteins in the CHIP KO cortical neurons in our proteomics 
(Figure 4.24), which is consistent with upregulation of its steady state levels in these 
neurons (Figure 4.26A).   
 
Accordingly, other proteins involved in membrane repair were also found to be under- 
or over-represented in the CHIP KO neurons (Figure 4.22). This includes caldesmon-
1, which plays a role in the modulation of the actin cytoskeleton, an essential step 
during repair148,163. As well as proteins involved in exocytosis-mediated plasma 
membrane repair, such as the large membrane protein AHNAK164, tSNARE proteins 
(including SNAP and syntaxin) and Rab proteins162. Interestingly, ANXA2 has been 
reported to regulate exocytosis-mediated plasma membrane repair by promoting the 
fusion of enlargeosomes (characterised by the presence of the large membrane 
protein AHNAK)164 and lysosomes (a mechanism that relies on the action of tSNARE 
proteins such as SNAP-23 and syntaxin 4)162. Some of these proteins were also found 
to be changing in the other CHIP cell models analysed (Figure 4.27). Therefore, we 
question whether the membrane repair pathway is enhanced in CHIP KO cells.  
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Given how the homeostasis of multiple proteins involved in the regulation of 
membrane integrity are being affected by CHIP deletion, we hypothesise that CHIP 
might play a role in the maintenance of membrane integrity. This biological 
significance of membrane homeostasis in the context of neurodegeneration is largely 
unknown and understudied. For this reason and given the robust ANXA2 phenotype 
observed, we decided to focus on this protein as a potential target of CHIP, important 
for its neuroprotective role. CHIP dependent regulation of ANXA2, its interaction 
dynamics with S100-A11 and its cellular consequences are discussed in Chapter 5.  
 
 
d. CHIP-regulated cellular pathways 
Whether the effect of CHIP on the candidate proteins discussed (including HLA-B, 
VGF, ANXA2 and S100-A11) is direct or indirect is still unclear. Factors such as 
oxidative stress could contribute to the phenotypes seen. Therefore, future work 
would investigate the effect of the cellular environment (including oxidative stress and 
proteotoxicity, which have been reported in CHIP KO mice) on CHIP-dependent 
regulation of its protein targets. It seems that CHIP-mediated differences in the 
proteostasis of some proteins of interest could be exacerbated in the disease context 
under study.  
 
Our CHIP KO cortical neurons of a synucleinopathy model show changes in specific 
proteins involved in a broad spectrum of functions, including immunity, metabolism 
and membrane integrity. Interestingly, although multiple pathways could be influenced 
by CHIP, gross changes in the proteome were not detected. This supports the 
hypothesis that CHIP affects the proteostasis of specific proteins and these, either 
individually or cumulatively, could play a role in the molecular mechanisms underlying 
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5.1.1 Annexin A2 at a protein level 
Annexins are a conserved family of calcium-regulated phospholipid-binding proteins 
that are required for membrane repair and the regulation of membrane proteins and 
fusion events165. They are widely expressed in plants and animals166, and humans 
have more than 23 different Annexin family members with a common core domain. 
This consists of a conversed 70-amino acid sequence that is repeated four times (and 
eight for Annexin A6, ANXA6)167, each repeat features five α-helices, which together 
form a slightly curved disc162,165,168,169. At its convex side is the membrane attachment 
sites and the type II calcium-binding sites162. The N-terminal region is unique to each 
of the Annexin members and is susceptible to post-translational modifications165,170. 
This region is also responsible for self-association properties162. Annexins are 
localised in the plasma membrane, early and late endosomes, multivesicular bodies, 
phagosomes, Golgi, mitochondria and nucleus170. Despite the inherent lipid-binding 
properties, Annexin members display different spatio-temporal and calcium-sensitive 
kinetics, thus influencing their functions within the cell167. This is further regulated by 
protein interactions, pH and lipid interactions (including ceramide, PI(4,5)P2, and 
cholesterol)167. 
 
Annexin A2 (ANXA2) is a 36kDa protein168 that is widely distributed and abundantly 
expressed in endothelial cells, monocytes, macrophages and tumour cells167. It has 
low calcium requirements for phospholipid binding170. ANXA2 tends to favour binding 
to negatively charged phospholipids, including phosphatidylinositol (PI(4,5)P2), 
phosphatidic acid (PA) and phosphatidylserine (PS)167. Interaction with different 
proteins is mediated by binding sites located throughout the ANXA2 protein. The N-
terminal region binds to tissue plasminogen activator and S100 proteins, the core 
domain to phospholipids and calcium (having two or four annexin-type calcium-
binding sites) and the C-terminal region to F-actin, herapin and plasminogen171. The 
flexible and disordered N-terminal domain is buried within repeat III of the core region 
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in the absence of calcium172. However, upon binding to calcium, the conformational 
change induced exposes its hydrophobic amino acids within the N-terminal domain, 
allowing interaction with S100 proteins171 and other lipids169. 
 
Annexins, such as ANXA2, regulate lipid segregation (including PI(4,5)P2 domain 
formation mediated by the PI(4,5)P2-binding sites, lysine residues 279 and 281, on 
ANXA2). This allows the formation of membrane indentations to promote membrane 
deformations and remodelling – a mechanism possibly underlying annexin-mediated 
membrane trafficking169. As monomers, ANXA2 can adopt two conformations, anti-
parallel and parallel, bringing together two membrane structures or inducing 
membrane indentation, respectively (Figure 5.1A&B), mechanisms that rely on its 
core domain. The N-terminus has been proposed to be required for ANXA2-mediated 
membrane aggregation by conveying a second membrane binding site169.  
 
The N-terminal domain of ANXA2 also mediates binding to S100 proteins. This occurs 
in the presence of calcium or as a result of post-translational modifications on the 
S100-binding site of annexins166,169,172. The S100 family consists of small dimeric, EF-
hand-type calcium-binding proteins. S100-A10 has lost its ability to bind to calcium, 
thus is constitutively in its active conformation and ready to interact with Annexins172. 
S100 proteins exert both intracellular and extracellular functions and can form 
symmetrical noncovalent homodimers163. 
 
ANXA2:S100 heterotetramer complex formation, with a 1:1 stoichiometry171, induces 
a shift in subcellular localisation of ANXA2 which, as a monomer, is mainly 
cytoplasmic and on early endosomes166,169,172. The complex can adopt different 
conformations, having secretory, membrane-bound, cytoplasmic and nuclear 
forms168. Underlying this change is the increased affinity of the heterotetramer for 
lipids168,169. Consequently, phospholipid binding and vesicle aggregation also occur at 
significantly lower calcium concentrations171. Other than the S100-induced 
conformational change in ANXA2 (favouring lipid-binding), S100 may enhance the 
lipid segregating properties of ANXA2 by physically linking two membrane binding 
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5.1.2 Annexin A2 at a cellular level 
Annexins have been described as membrane fusogens, calcium sensors, 
cytoskeletal- and membrane-associated proteins and signal transducers166,168,170,173. 
At a cellular level, these functions allow annexins to mediate membrane remodelling 
events (including intracellular vesicular trafficking, endocytosis and exocytosis) 
(Figure 5.1), lipid raft formation and/or stabilisation, segregation of lipid domains, 
turnover of ion channels/receptors, regulation of membrane-actin interface, 
intracellular calcium homeostasis and membrane repair (discussed in Section 5.1.4 
The role of Annexins, S100 proteins and other membrane proteins in membrane 




Figure 5.1: Dimeric forms of Annexin A2 on membranes 
A) In the zipper-like mechanism (N-terminal-independent), ANXA2 monomers adopt an anti-
parallel conformation. Here, each ANXA2 core domain binds to the PI(4,5)P2 head group on 
the membrane and adjacent ANXA2 monomers face opposite membranes. This results in a 
rigid scaffold that binds together two membrane surfaces, promoting membrane aggregation. 
B) ANXA2 monomers can also adopt a parallel (side-by-side) conformation, where the 
Ca2+/lipid-binding sites are exposed on the convex side, which attaches a membrane surface. 
This induces membrane bending, resulting in indentation and budding (right), due to the 
intrinsic curvature of the core domain. This is also a N-terminal-independent mechanism. 
C) Lateral aggregation of the ANXA2:S100 heterotetramer can adopt two conformations: each 
core domain of ANXA2 can face opposite membrane surfaces, inducing membrane 
interconnections (top), or in can orientate in a parallel manner (bottom), promoting 
microdomain formation/raft clustering and eventually membrane indentation.  
(Adapted from Drucker et al.169) 
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proliferation, mRNA transport, DNA replication and repair, and redox regulation165,168–
173. Its activities dependent on the cell type and metabolic state of cells170.  
 
In general, ANXA2 is regarded as an important component of the protein network that 
is involved in the maintenance of cell health. Despite the functional redundancy within 
the Annexin family, deletion of ANXA2 leads to endosomes with an abnormal 
morphology and turnover165,174. Regulation of endosomes is dependent on the activity 
of ANXA2:S100-A10174, since the recruitment of ANXA2 to membranes is promoted 
by S100 proteins171. Not only can the heterotetramer link two membrane surfaces 
(Figure 5.1B), allowing aggregation of lipid vesicles169, it can modulate actin 
dynamics, thus regulating trafficking and intracellular vesicle fusion events163,166.  
 
ANXA2 also regulates cell signalling and has added protective roles in response to 
stress. It associates with cholesterol- and PI(4,5)P2-rich domains, called ‘lipid rafts’, 
where ANXA2 serves as a scaffolding protein, mediating the recruitment of signalling 
components to these platforms167. This allows extracellular cues (including stressors) 
to communicate with the inside of the cell, activating intracellular signalling pathways 
accordingly. Nuclear ANXA2 is believed to be cell-cycle dependent168 or induced by 
reactive oxygen species signalling, where ANXA2 nuclear aggregation prevents 
genomic damage. This ANXA2-mediated defence mechanism has been observed 
following injury or stress175. ANXA2 also regulates stimuli-induced apoptosis176 and 
can rapidly translocate to the plasma membrane for maintenance of membrane 
integrity and response to injury163.  
 
 
5.1.3 Regulation of Annexin A2 
a. Selective degradation of Annexin A2 
Some members of the Annexin family, including ANXA2 and ANXA6, can be 
selectively degraded by CMA. Chaperones partially unfold these substrates to expose 
the buried the KFERQ-like motif that favours protein clearance by CMA via the 
lysosome170. This selective degradation contributes to the control of the homeostasis 
of specific Annexin proteins, thus it is likely to have physiological relevance170. For 
example, ANXA2 degradation correlates with cellular apoptosis induced by p53-
mediated pathways168.  
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b. Regulation by phosphorylation 
Both in vitro and in vivo experiments suggest that ANXA2 is a substrate of various 
classic calcium-activated protein kinase C (PKC) isozymes. These are activated by 
DAG in a calcium-dependent manner and bind to negatively charged phospholipids, 
in particular PS167. PKC-mediated phosphorylation of Annexins is a two-way 
regulatory mechanism, since Annexins A1, A2, A5 and A6 provide scaffolding 
functions to modulate PKC localisation and signalling167.    
 
The major phosphorylation site on ANXA2 phosphorylated by PKC isozymes is the 
serine residue at position 25166,168,177. This triggers a change in subcellular localisation 
from the nucleus to the perinuclear region, becoming associated with membranes and 
cytoskeletal elements, which intrinsically changes its interactome and function. 
pSer25ANXA2 has been implicated in exocytosis, recycling of lipid rafts and 
recruitment of PKC to PI(4,5)P2-rich membrane domains173. Interestingly, 
phosphorylation at Ser25 prevents ANXA2-mediated aggregation of membranes168,178 
(illustrated in Figure 5.1A), but stimulates the fusion of pre-aggregated 
vesicles/granules/endosomes with the plasma membrane for exocytosis167. 
 
PKC-mediated phosphorylation of ANXA2 at serine 11 has been proposed to promote 
nuclear entry of monomeric ANXA2 and, importantly, to abolish the interaction with 
the heterotetrameric conformation with S100 proteins166. Such dissociation exposes 
S100-A10 to degradation by the UPS167 and can result in accumulation of ANXA2 
monomers, which are unable to organize membranes. On the contrary, 
phosphorylation of Annexin at tyrosine 23 induces membrane translocation167 and 
may promote ANXA2 homodimer formation (devoid of S100 proteins) given the 
reduction in affinity of ANXA2 for S100 proteins177,179. Such phenomenon was 
observed for ANXA1 in the brain, where monomers dimerised when associated with 
the membrane and may play a role in neurotransmitter release at the synaptic plasma 
membrane179.  
 
Tyrosine phosphorylation of ANXA2 might become important in mediating cellular 
response to stress. During heat stress, ANXA2 translocates from the cytoplasm to the 
plasma membrane (resulting in a 2 to 3-fold increase at the cell surface) (Figure 5.2A). 
This is dependent on the expression of S100-A10 (Figure 5.2B) and on tyrosine 
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phosphorylation of ANXA2 (Figure 5.2C). Mechanistically, ANXA2 may be directed to 
the inner face of the plasma membrane by S100-A10, where it becomes 
phosphorylated by membrane-associated pp60 Src kinase. As a result, phospho-
ANXA2 couples more avidly with the inner leaflet PS and could undertake a 
conformational change that might potentiate its insertion into the plasma 
membrane180. Pp60 Src kinase becomes rapidly activated in response to oxidative 
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Figure 5.2: Stress-induced translocation of Annexin A2 to the cell surface is dependent 
on phosphorylation and interaction with S100 proteins 
A) Translocation of ANXA2 to the cell surface was observed in cells transfected with ANXA2-
GFP (Ann-2-GFP) were exposed to heat shock (42ºC for 3h). The relative fluorescent intensity 
of surface-associated ANXA2-GFP (immunostained with anti-GFP antibody) to total ANXA2-
GFP (direct GFP fluorescence) was measured.  
B) Knockdown of S100-A10 (pSUPER/p11siRNA) prevented ANXA2 translocation that is seen 
in cells transfected with the empty vector (pSUPER).  
C) Cells stably transfected with myc-tagged WT or the phospho-mutant Y23A ANXA2. The 
latter failed to show heat shock-induced surface ANXA2 expression.  
(Deora et al.180) 
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c. Regulation by ubiquitination 
Although ANXA2 has been found to be ubiquitinated, the ubiquitination sites, the 
cellular fates of ubiquitinated species and the ubiquitination enzymes responsible for 
this are unknown. Sequence analysis revealed a single Ub-interacting motif in domain 
II of the core region of ANXA2, although this was not confirmed experimentally181. 
With regards to enzymes involved in ubiquitination of Annexins, UBE3A, an E3 Ub 
ligase involved in the UPS, has been implicated in the regulation of both ANXA1 and 
ANXA2. UBE2A gene knockdown results in a downregulation of ANXA2. It is unlikely 
that UBE2A-dependent ubiquitination regulates the degradation of ANXA2, but 
instead may regulate its activity or subcellular localisation. On the contrary, 
ubiquitination-mediated degradation of S100-A10 is commonly seen in the unbound 
state, since the N-terminus of ANXA2 masks the autonomous ubiquitination signal on 
S100-A10 when they interact173.    
 
Ubiquitination of different pools of ANXA2 has been reported. Firstly, both 
pSer25ANXA2 and pTyr23ANXA2 are differentially ubiquitinated by an unknown E3 
ligase(s) (Figure 5.3A)173. Phosphorylation at Ser25 could induce subsequent 
ubiquitination and/or sumoylation, since a phosphomimic of ANXA2 (ANXA2-
Ser25Glu) readily forms ubiquitinated species. Secondly, a cytoskeletal-associated 
pool of ANXA2 was shown to be both mono- and poly-ubiquitinated (Figure 5.3B)181. 
Again, the cellular consequence of ANXA2 ubiquitination are not likely to be 
degradation, given the extended half-life of cytoskeleton-bound ANXA2 (15 h)181. 
Instead, ubiquitination may regulate internalisation of plasma membrane proteins by 
endocytosis destined to the endosomal/lysosomal pathway (commonly seen for 
monoubiquitination)173,181. Alternatively, such ubiquitination may be associated with 
ANXA2’s function as an actin-binding protein181. Thirdly, total ANXA2 was upregulated 
and ubiquitinated (both monoubiquitinated and polyubiquitinated) in cancer tissue, 
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Figure 5.3: Ubiquitination of Annexin A2 
A) Lysate (100 µg) from the cytoplasm (C) and nuclear (N) fractions of PC12 cells and 
immunoprecipitations from nuclear fractions (IP) using anti-ANXA2 or anti-Ub antibodies were 
analysed by SDS-PAGE/immunoblot and probed with anti-pSer25ANXA2 or anti-
pTyr23ANXA2 antibodies as indicated.   
B) Lysate (30 µg) of ANXA2 preparations purified from porcine intestinal mucosa (P) and 
mouse Krebs II cells (M) were analysed by SDS-PAGE/immunoblot probed with anti-ANXA2 
antibody. Preparations were immunoprecipitated with anti-Ub and anti-ANXA2 antibodies and 
also analysed by SDS-PAGE/immunoblot using anti-ANXA2 and anti-Ub antibodies, 
respectively. Incubation with the HRP-conjugated secondary antibody in the absence of 
primary antibodies (*) detected heavy and light chain IgG subunits.  
(Adapted from A: Aukrust et al.173; B: Lauvrak et al.181) 
 
Chapter 5: The possible role of CHIP in regulating the homeostasis of Annexin A2 and 
membrane integrity  208 
5.1.4 The role of Annexins, S100 proteins and other membrane 
proteins in membrane integrity 
Annexins and S100 proteins are particularly important in regulation of membrane 
homeostasis and maintenance of membrane integrity, of both intracellular and plasma 
membranes (PM)163. Although in the past PM repair used to be regarded as a passive 
process, relying on the spontaneous re-organisation of phospholipids (i.e. self-
sealing), a highly dynamic and complex repair machinery associated with an active 
repair mechanism has now been elucidated162.  
 
Experimentally, the study of membrane repair replies on lesions induced by 
mechanical stress (including microneedle puncture, glass beads, cell scraping or 
laser irradiation) or by toxins (pore-forming bacterial toxins)162. Repair of small lesions 
caused by the latter is mediated by microparticle/ectosome shedding, blebbing or 
endocytosis. For greater lesions (e.g. laser-induced damage) repair is mediated by 
exocytosis, endocytosis or excision-based mechanisms (Figure 5.4)162,163. 
Importantly, these mechanisms are not mutually exclusive and potentially collaborate 
in the repair process162. This functional redundancy illustrates the importance of 
maintenance of membrane integrity, since repair deficiency results in membrane 
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Figure 5.4: Mechanisms of membrane repair 
A) Exocytosis-mediated PM repair following the tension reduction model. Here, vesicles fuse 
around the wound perimeter to decrease membrane tension and promote re-sealing. 
B) Exocytosis-mediated PM repair following the patch-mediated membrane fusion model. 
Homotypic fusion of intracellular vesicles form a patch on the injured membrane. 
C) Endocytosis-mediated PM repair. For such, clathrin coats the newly formed vesicles and 
dynamin can then self-associate into rings around the clathrin-coated vesicles for constriction 
and subsequent vesicle scission. Repair can be clathrin- and dynamin-dependent or 
independent. Annexins A1, A2, A6 and A8 have been implicated in this form of repair.  
D) Microparticle shedding-mediated PM repair. Annexins mediate the shedding of ectosomes 
containing the damaged membrane.  
E) Contractile actomyosin pulse string contraction. 
F) PM repair by bleb formation. Once the permeability barrier is disrupted, the influx of calcium 
triggers phosphorylation of myosin II via Ca2+/calmodulin-dependent myosin light chain kinase. 
This induced myosin-driven contraction of the cortical cytoskeleton generates hydrostatic 
pressure, causing herniation of the plasma membrane (i.e. plasmalemmal protrusion) to form 
a bleb containing the damaged membrane. If the cell is able to repair the membrane lesion, 
the elevated intra-bleb calcium is pumped out and the bleb retracts. If not, Annexins are 
recruited, eventually forming a plug. 
G) Formation of 2D arrays by self-assembly of Annexins.  
(Nylandsted & Boye162) 
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Although PM lesions can be repaired by individual Annexin proteins, the concerted 
action of annexins is instrumental for efficient repair of multiple, simultaneously 
occurring lesions184. The influx of calcium from the site of injury triggers a change in 
the conformation of Annexins, promoting their sequential recruitment from the cytosol 
to the repair site162,163. Annexins (including ANXA6, ANXA1 and ANXA2) bind strongly 
to negatively charged phospholipids, such as PS, that became exposed by the injury. 
They self-aggregates into a tight structure, the “repair cap” (i.e. forming a protein 
lattice), within 6 seconds after injury (Figure 5.5A)161,184. Such fast-wound healing 
response counteracts the influx of calcium and efflux of cytoplasmic components, and 
facilitates subsequent healing161. The inherent properties of oligomerisation and 
phospholipid-binding across Annexins contribute to the redundancy in cap formation, 
which can be composed of multiple annexins. Similarly, ANXA2, and potentially 
others, can self-aggregate to form intracellular 2D arrays around the wound perimeter 
(Figure 5.4G & Figure 5.5B)162,163. This tension prevents wound expansion and brings 
the wound edges together to encourage fusion and membrane resealing163. In fact, a 
common trait among the Annexin family of proteins is their ability to induce membrane 
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Figure 5.5: Self-oligomerisation of Annexins 
A) Model of membrane repair by forming a repair cap at the site of damage consisting of 
ANXA6, ANXA1 and ANXA6. Other proteins are form he shoulder of the repair cap, while PIP2 
and PS localise adjacent to the repair cap.    
B) Disruption of the PM results in Ca2+-triggered formation of a 2D ordered protein array 
consisting of Annexin trimers that are further ordered in dimers and trimers. This activity has 
been well documented for ANXA5, ANXA2 and ANXA1. These 2D structures restrict wound 
expansion, as they enhance the tension at the membrane wound edges, promoting re-sealing.  
(A: Demonbreun et al.161; B: Lauritzen et al.163) 
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Annexins have also been implicated in PM repair by different mechanisms. ANXA2 
regulates both endocytosis- and exocytosis-mediated PM repair. For the repair of 
small lesions, ANXA2 promotes Ca2+-dependent endocytosis of the pore-containing 
or damaged membrane region to restore membrane integrity (Figure 5.4C)162. In the 
context of exocytosis-mediated PM repair, ANXA2 promotes the fusion of lysosomes 
and enlargosomes with the PM either to reduce membrane tension around the wound 
perimeter to promote sealing (following the tension-reduction model) or by direct 
fusion to form a continuous membrane over the injury site (patch model) (Figure 
5.4A)162. The ability of Annexin proteins to aggregate vesicles is key to this 
process148,162.  
 
The majority of repair mechanisms have been found to be regulated by more than 
one member of the Annexin family of proteins. Simplistically, such evolutionary 
conserved proteins display extensive functional redundancy to ensure maintenance 
of membrane integrity (relying on compensation between members if needed). 
However, the seemingly subtle biochemical differences between annexins seem to 
have cellular significance, at a mechanistic level, arguing for Annexin-specific roles 
within the family, rather than all members contributing to the overall functional 
redundancy per se. As Potez and colleagues184 concluded, by expressing several 
annexins with different calcium sensitivities, a cell is able to mount an adequate 
response to a spatiotemporally restricted injury and to withstand a sustained lesion. 
For example, repair of a single pore occurring within a thin cellular protrusion (e.g. 
neuronal axon), which results in a pronounced influx of calcium, relies on its most 
calcium-sensitive annexins (e.g. ANXA6). Here, annexins with low calcium sensitivity 
(e.g. ANXA1) are ineffective during the early stages of injury184. Instead, these serve 
as a “strategic reserve” and are indispensable in sustained injury. By having annexin 
proteins with different, but overlapping, calcium sensitivities, cells are able to 
continuously fine tune its repair response. This contributes to the temporal specificity 
of the repair machinery (Annexin members and other proteins) and allows for different 
levels of regulation of the repair cascade. Moreover, changes to the expression 
profiles of Annexins allows for a dynamic and cell-specific calcium tolerance limit, 
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5.2 Results 
5.2.1 Increased expression of Annexin A2 in CHIP KO cortical 
neurons and other CHIP cell models 
SWATH-MS revealed a consistent and significant over-representation of ANXA2 in 
the CHIP KO cortical neurons (0.107- and 0.100-fold change of the CRISPR control 
or parental line compared to CHIP KO, respectively). Considering that over-
representation of an ionised peptide detected by MS does not directly correlate with 
protein steady state levels at a cellular level, being influenced by factors including 
protein post-translational modifications and differential ionisation potentials of 
proteins, it is necessary to validate this further.  
 
The steady state levels of ANXA2 in cortical neurons from independent differentiation 
experiments were assessed by WB (Figure 5.6). A consistent and robust increase in 
CHIP KO neurons was observed. Interestingly, this phenotype was dependent on the 
neuronal status of these cell lines, as no difference in ANXA2 levels was detected in 
CHIP KO and WT iPSC (Figure 5.7). Undifferentiated SH-SY5Y cells, on the other 
hand, showed a modest increase in ANXA2 in CHIP KO cells (Figure 5.8), while 
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Figure 5.6: Annexin A2 expression in cortical neurons of different CHIP genotypes 
Mature iPSC-derived cortical neurons (harvested at day 80 of differentiation) were lysed with 
urea-based lysis buffer (the same as that used for SWATH-MS). CHIP KO neurons (-/-) as 
well as two CHIP-expressing lines (the parental line (+/+) and the CRISPR control (+/+)) were 
analysed. For each sample, 20 µg of lysate was loaded per 12% gel for SDS-PAGE/WB and 
two gels were ran in parallel (in the same apparatus). In parallel, 25 ng of human recombinant 
ANXA2 (Abcam, ab93005) was loaded as a positive control. Each immunoblot was probed 
firstly with either anti-ANXA2 Ms mAb (1:500) or anti-ANXA2 Rb pAb (1:1000), then with anti-
β-actin mAb (1:5000) and finally the immunoblot probed with anti-ANXA2 Rb pAb previously 
was incubated with anti-CHIP mAb (1:10000). These immunoblots are representative of at 
least 5 biological replicates from independent cortical differentiation experiments.  
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Figure 5.7: Annexin A2 expression in iPSC of different CHIP genotypes 
iPSC were lysed with urea-based lysis buffer (the same as that used for SWATH-MS). CHIP 
KO cells (-/-) as well as two CHIP-expressing lines (the parental line (+/+) and the CRISPR 
control (+/+)) were analysed. For each sample, 20 µg of lysate was loaded per 12% gel for 
SDS-PAGE/WB and two gels were ran in parallel (in the same apparatus). In parallel, 25 ng 
of human recombinant ANXA2 (Abcam, ab93005) was loaded as a positive control. Each 
immunoblot was probed firstly with either anti-ANXA2 Ms mAb (1:500) or anti-ANXA2 Rb pAb 
(1:1000), then with anti-β-actin mAb (1:5000) and finally the immunoblot probed with anti-
ANXA2 Rb pAb previously was incubated with anti-CHIP mAb (1:10000). These immunoblots 
are representative of at least 5 biological replicates.  
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Figure 5.8: Annexin A2 expression in undifferentiated SH-SY5Y CHIP KO and WT cells  
Undifferentiated SH-SY5Y CHIP KO and WT cells were lysed with urea-based lysis buffer (the 
same as that used for SWATH-MS). For each sample, 20 µg of lysate was loaded per 12% 
gel for SDS-PAGE/WB and two gels were ran in parallel (in the same apparatus). In parallel, 
25 ng of human recombinant ANXA2 (Abcam, ab93005) was loaded as a positive control. 
Each immunoblot was probed firstly with either anti-ANXA2 Ms mAb (1:500) or anti-ANXA2 
Rb pAb (1:1000), then with anti-β-actin mAb (1:5000) and finally the immunoblot probed with 
anti-ANXA2 Rb pAb previously was incubated with anti-CHIP mAb (1:10000). In 
undifferentiated cells, a band detected by anti-ANXA2 pAb runs in close proximity to the band 
representing CHIP (indicated by the asterisk). These immunoblots are representative of at 
least 6 (A) biological replicates.  
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Figure 5.9: Annexin A2 expression in differentiated SH-SY5Y CHIP KO and WT cells  
Undifferentiated and differentiated SH-SY5Y CHIP KO and WT cells were lysed with urea-
based lysis buffer (the same as that used for SWATH-MS). For each sample, 20 µg of lysate 
was loaded per 12% gel for SDS-PAGE/WB. The immunoblot was probed with anti-ANXA2 
Rb pAb (1:1000) and then with anti-β-actin mAb (1:5000). This immunoblots is representative 
of at least 3 biological replicates.  
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5.2.2 Subcellular localisation of Annexin A2 in CHIP models 
According to the literature168, a small subpopulation of ANXA2 is nuclear, while some 
is membrane-bound and the majority is cytoplasmic. While we do not detect nuclear 
ANXA2 by subcellular fractionation, the cytoplasmic and, to a lesser extent, the 
membrane-bound fractions are present in undifferentiated SH-SY5Y CHIP KO and 
WT cells (Figure 5.10). IF conditions were optimised to detect these pools of ANXA2 
(Figure 5.11). While ANXA2 was largely nuclear when samples were fixed with 4% 
paraformaldehyde, membrane and cytoplasmic staining was seen when fixed with the 
other reagents. Clearly, the various fixation methods cause different protein epitopes 
to become exposed to the antibodies. Fixation with 4% PFA & methanol seems to be 
optimal – allowing detection of all subcellular populations of ANXA2 (nuclear, 























Figure 5.10: Subcellular localisation of Annexin A2 and CHIP 
Differentiated SH-SY5Y CHIP KO and WT cells were harvested and lysed using a subcellular 
protein fractionation kit. Cytoplasmic, membrane and nuclear fractions were analysed by 15% 
SDS-PAGE/immunoblot. Immunoblots were probed with anti-ANXA2 pAb (1:1000) and anti-
CHIP mAb (1:10000), as well as anti-Hsp90 (1:1000) and anti-PARP (1:1000) antibodies as 
controls. Sample loading between different fractions and cell lines was based on volume, 
rather than cell count or protein concentration (due to protocol limitations). Immunoblots 
representative of 2 biological replicates.  
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Figure 5.11: Effect of fixation method on the staining of Annexin A2 
Immunofluorescence assay of CHIP WT and KO iPSC fixed with different fixation reagents (as 
indicated) and incubated with anti-ANXA2 pAb (1:500) and anti-CHIP mAb (1:1000). Nuclei 
were stained with DAPI. Axio Imager, Zeiss, 20x and 63x objectives. Scale bars, 100 mm and 
20 mm (inlet images), respectively. Images obtained from cells fixed with 4% PFA are 
representative of at least 3 biological replicates and those fixed with 4% PFA & methanol are 
representative of at least 7 biological replicates from different independent experiments.  
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As previously observed in cortical neurons (Figure 4.25), there is no difference in the 
ANXA2 staining by IF in undifferentiated SH-SY5Y CHIP KO and WT cells, 
independent of the fixation reagent used. Findings from this assay contradict those 
obtained by SWATH-MS and WB, despite the use of the same antibody for the latter 
assay. Possible explanations could be differential epitope exposure and varying 
degrees of lysate solubilization obtained by the different methods.  Potentially the pool 
of ANXA2 readily detected by IF is unchanged between these CHIP cell models. 
However, this does not exclude the existence of CHIP-mediated regulation of ANXA2, 
possibly at a post-translational level. In favour of such emerging hypothesis, as with 
most protein binding partners, CHIP and ANXA2 are present within the same 
subcellular compartment (cytoplasm).   
 
 
5.2.3 Annexin A2 interacts with CHIP 
Being present in the same subcellular compartment, CHIP and ANXA2 could interact 
directly or within a complex conformation. Following optimisation of the IP conditions, 
endogenous ANXA2 was seen to co-immunoprecipitate with endogenous CHIP 
(Figure 5.12). Unfortunately, given the “sticky” nature of self-aggregating and 
membrane-binding proteins, residual ANXA2 bound to the beads without anti-ANXA2 
antibody (lane 3). A band for CHIP was also detected in lane 3, but it is weaker than 
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Taking into account the limitations of the IP, it was important to validate this interaction 
using a different method and, moving forward, question whether it occurs in cells. For 
such, PLA detecting CHIP:ANXA2 interaction was conducted in mature cortical 
neurons (Figure 5.13). Indeed, some PLA signal was seen in CHIP WT neurons (in 
the two control lines), but not in CHIP KO neurons. Furthermore, the PLA signal 
detected is likely to be an underestimation, since these neurons were fixed with 4% 
paraformaldehyde (where ANXA2 is likely to be mostly nuclear, while CHIP is 




Figure 5.12: Co-immunoprecipitation of endogenous Annexin A2 and CHIP  
Lysate from CHIP WT undifferentiated SH-SY5Y (1 mg total protein/reaction) was incubated 
with protein-G beads alone (lane 3) or with protein-G beads that had been cross-linked to anti-
ANXA2 Ms mAb (IP: ANXA2 mAb, lane 4). A reaction of antibody with beads and without 
lysate was also included (lane 2) showing the IgG band from the antibody (in lanes 2 and 4). 
Each reaction was analysed by WB. The immunoblot was firstly probed with HRP-conjugate 
anti-Ms pAb (secondary antibody), to identify the background noise derived from the beads 
and the antibody itself (not included). It was then probed with anti-CHIP mAb (1:10000), 
exposed and then with anti-ANXA2 mAb (1:1000). This immunoblot is representative of 2 co-
IP experiments using different anti-ANXA2 antibodies (mAb and pAb). 
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Figure 5.13: Annexin A2 & CHIP interaction by PLA in cortical neurons 
A) CHIP KO and WT mature cortical neurons were fixed with 4% PFA. A single well of the 
parental line and triplicate wells of the CRISPR control and CHIP KO line were stained with 
anti-ANXA2 pAb (1:500) and anti-CHIP mAb (1:1000) antibodies (referred to as “PLA” in C). 
PLA signal (puntae in green) were quantified using ImageJ and normalised by the number of 
nuclei (stained with DAPI) within a field of view.  
B) In parallel, two wells of CHIP WT (CRISPR control) (for CHIP only and no primary Ab 
conditions) and CHIP KO (for ANXA2 only) were used for control conditions (grouped under 
“Ctrl” in C): wells were incubated with either antibodies alone (ANXA2 only in green and CHIP 
only in blue) or with no primary antibodies (in black).  
A-B) Axio Imager, Zeiss, 63x objective. Scale bar, 20 µm.  
C) Quantifications of PLA signal per nuclei of different cell lines were represented in the dot 
plot as mean ± SD. Kruskal-Wallis test and Dunn’s multiple comparisons post-test 
(comparisons between PLA and Ctrl conditions per cell line is indicated above each Ctrl), ****P 
< 0.0001, n ≥ 12 images per biological triplicate and n ≥ 12 images per control condition per 
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To investigate whether this interaction is consistent in other CHIP cell models, the 
same PLA conditions were used in undifferentiated SH-SY5Y (Figure 5.14A-C). The 
same trend was observed. In addition to CHIP KO and WT cells, cell lines derived 
from the CHIP KO cell line stably expressing the E3 ligase dead mutant H260Q (CHIP 
KO + H260Q) or wild-type CHIP (CHIP KO + WT) were also analysed. The former 
mutation lies within the U-box prevents its interaction with the E2, thus inhibiting the 
ubiquitination cascade47,186. Both these lines rescued the CHIP:ANXA2 interaction 
that was absent from the CHIP KO line. It is important to note that, as shown in Figure 
S.5, the KO+H260Q line has increased CHIP expression compared to endogenous 
CHIP (compared to CHIP WT cell line) and that not all cells of the KO+WT line express 
CHIP, and the CHIP-positive ones have increased intensity compared to cells of the 
CHIP WT line. This disparity within the CHIP KO+WT line probably gives rise to the 
variability seen in the PLA quantification. However, considering that the KO + H260Q 
line has much higher CHIP expression compared to endogenous WT CHIP, increases 
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Figure 5.14: CHIP & Annexin A2 interaction by PLA in undifferentiated SH-SY5Y 
A&B) Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the stable 
cell lines KO+H260Q and KO+WT) were fixed with 4% PFA and then methanol.  
A) For each cell line, duplicate wells were stained with anti-ANXA2 pAb (1:500) and anti-CHIP 
mAb (1:1000) antibodies (referred to as “PLA” in C and biological duplicates are colour-coded 
with black or green dots). PLA signal (puntae in green) were quantified using ImageJ in a semi-
automated manner and normalised by the number of nuclei (stained with DAPI) within a field 
of view.  
B) In parallel, three controls were included (grouped under “Ctrl” in C): wells containing CHIP 
WT cells were incubated with either antibodies alone (ANXA2 only in green and CHIP only in 
blue) or with no primary antibodies (in black).  
Axio Imager, Zeiss, 63x objective. Scale bars, 20 µm. 
Representative data of at least 2 independent PLA experiments.  
A B 
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5.2.4 CHIP-dependent changes in Annexin A2 profile in CHIP 
models 
As a preliminary and gross approach to assess the existence of CHIP-dependent 
species of ANXA2, the global profile of the steady state levels and form(s) of ANXA2 
in different CHIP cell models was analysed by 2D-gel WB in collaboration with Jitka 
Zakova† (Figure 5.15). Under un-optimised conditions, both undifferentiated SH-
SY5Y and iPSC showed similar forms of ANXA2. The CHIP KO lysates show novel 
higher-MW forms of ANXA2, that ran at around 75 kDa in SH-SY5Y cells and 50 kDa 
in iPSC (indicated by the red arrows). Beyond this predominant feature, there are 
other differences in the ANXA2 species detected when comparing CHIP WT to KO 
cells. This supports the existence of post-translational modifications of ANXA2. 





† Department of Molecular Pathology and Biology, University Hospital Ostrava, Hradec Kralove, Czech 
Republic 
C 
Figure 5.14 (continued) 
C) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. All PLA datasets passed the D’Agostino Pearson normality test. One-way ANOVA 
with Holm-Sidak’s multiple comparisons post-test (comparisons between PLA and Ctrl 
conditions per cell line is indicated above each Ctrl), **P < 0.005, ****P < 0.0001, n ≥ 11 images 
per biological duplicate and n ≥ 10 images per control condition per cell line.  
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5.2.5 CHIP-dependent ubiquitination of Annexin A2 in vitro 
Given this CHIP:ANXA2 interaction and the E3 ligase functions of CHIP, we sought 
to investigate whether CHIP could ubiquitinate ANXA2. Once the in vitro ubiquitination 
assay was optimised (Figure 5.16 A,B&D), both ubiquitinated ANXA2 species (Figure 
5.16A&D) and auto-ubiquitination of CHIP (Figure 5.16 A&B) were readily detected. 
The higher MW ANXA2 isoforms were detected with different anti-ANXA2 and anti-















Figure 5.15: Annexin A2 protein profile in CHIP KO models 
Undifferentiated SH-SY5Y and iPSC CHIP KO and WT cells were harvested with urea-based 
lysis buffer and loaded (100 µg) onto separate 2D gels for SDS-PAGE/WB (gels ran in 
parallel). Immunoblots were probed with anti-ANXA2 pAb (1:1000).  
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Figure 5.16: Optimisation of CHIP-dependent in vitro ubiquitination of Annexin A2 
In vitro ubiquitination assays using untagged human recombinant ANXA2 (A) or His-tagged 
(B) at the concentrations and react times indicated. Each reactions was analysed by two 15% 
SDS-PAGE/WB gels ran in parallel. One immunoblot was probed with anti-ANXA2 Rb pAb 
(1:1000) and the other anti-CHIP mAb (1:10000). The in vitro ubiquitination of p53 was 
conducted as positive control and stained using anti-p53 mAb (1:500) (C).  
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Figure 5.16 (continued) 
D) Time-course of in vitro ubiquitination assay using the untagged ANXA2 from 15 min to 60 
min (immunoblots on the right). *Refers to a sample that was denatured with 1:4 DTT:loading 
dye, compared to the 1:2 ratio used for the other reactions. These immunoblots were also 
probed with anti-ANXA2 Rb pAb (1:1000).   
 
Chapter 5: The possible role of CHIP in regulating the homeostasis of Annexin A2 and 






































Figure 5.17: CHIP-dependent in vitro ubiquitination of ANXA2 
In vitro ubiquitination assays using untagged human recombinant ANXA2 in the presence and 
absence of CHIP and ATP for 1h. Reactions were made in batch and loaded onto different 
gels for SDS-PAGE/WB. Immunoblots were probed with two anti-ANXA2 antibodies (1:1000 
Rb pAb, A, and 1:500 Ms mAb, B), anti-CHIP mAb (1:10000), C, and three anti-Ub antibodies 
(FK2, D, F-11, E, P4D1, F, and the K48-linkage specific antibody, G, each used at 1:1000).   
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5.2.6 CHIP-dependent ubiquitination of Annexin A2 in situ 
In attempt to detect endogenous ANXA2 ubiquitination, PLA using anti-ANXA2 and 
anti-Ub antibodies was conducted. Prior to this, the fixation methods and antibody 
conditions were optimised (Figure S.6). The PLA revealed that ANXA2 is in close 
proximity with Ub (within 40 nM) in CHIP WT SH-SY5Y cells, but not KO cells. 
Interestingly, cells expressing the E3 ligase-dead CHIP mutant (CHIP KO + H260Q) 
had a similar PLA signal to that of KO cells and was statically different from WT cells. 
The cell line re-expressing fully functional CHIP (CHIP KO + WT), rescued this 
ANXA2-Ub interaction, having a PLA signal similar to that of WT cells and statistically 
different from the other lines (Figure 5.18). In parallel to the PLA, an IF was conducted 
using the same antibodies (Figure S.7). Together with the findings from the in vitro 
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Figure 5.18: Ubiquitin & Annexin A2 interaction by PLA in undifferentiated SH-SY5Y 
A&B) Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the stable 
cell lines KO+H260Q and KO+WT) were fixed with acetone and methanol.  
A) For each cell line, duplicate wells were stained with anti-ANXA2 pAb (1:500) and anti-
Ubiquitin mAb (P4D1) (1:100) antibodies (referred to as “PLA” in C and biological duplicates 
are colour-coded with black or green dots). PLA signal (puntae in green) were quantified using 
ImageJ in a semi-automated manner and normalised by the number of nuclei (stained with 
DAPI) within a field of view.  
B) In parallel, three controls were included (grouped under “Ctrl” in C): wells containing CHIP 
WT cells were incubated with either antibodies alone (ANXA2 only in green and Ubiquitin only  
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Since different polyubiquitination chains drive ubiquitinated proteins to different 
cellular fates, we next tried to elucidate what Ub chain linkages were in close proximity 
with ANXA2. PLA using an anti-ANXA2 antibody and either K63 or K48 Ub-linkage 
specific antibody was performed in CHIP WT, KO and rescue cell lines (Figure 5.19). 
As previously observed in the Ub-ANXA2 PLA, the interaction of ANXA2 with the 
different Ub chain types was more frequent in WT cells compared to CHIP KO cells. 
The SH-SY5Y stable cell lines expressing either the E3 ligase-mutant CHIP (KO + 
H260Q) or a chaperone-dead mutant CHIP (KO + K30A) were also included in this 
assay. While the PLA signal obtained from the KO + H260Q line was not statistically 
different from that of CHIP KO cells, the KO + K30A line was able to partly rescue the 









Figure 5.18 (continued) 
C) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. Kruskal-Wallis test and Dunn’s multiple comparisons post-test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), **P < 0.005, ****P 
< 0.0001, n ≥ 10 images per biological duplicate and n ≥ 11 images per control condition per 
cell line.  
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Figure 5.19: Annexin A2 & Ubiquitin-linkage specific interaction by PLA in 
undifferentiated SH-SY5Y 
A,C,E) Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the stable 
cell lines KO+H260Q and KO+K39A) were fixed with 4% PFA and then methanol.  
A) For each cell line, triplicate wells were stained with anti-ANXA2 pAb (1:500) and anti-K48-
linkage specific Ub chain antibody (1:100) (referred to as “PLA” in B and biological replicates 
are colour-coded with black/blue/green dots). As a positive control, the anti-Ub antibody (same 
as in Figure 5.18) was used instead of the Ub chain-specific linkage antibody was used in a 
sample. PLA signal (puntae in green) were quantified using ImageJ in a semi-automated 
manner and normalised by the number of nuclei (stained with DAPI) within a field of view.  
B) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. One-way ANOVA with Holm-Sidak’s multiple comparisons post-test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), *P < 0.05, ***P < 
0.0005, ****P < 0.0001, n ≥ 5 images per biological duplicate (except for the single positive 
control) and n ≥ 5 images per control condition per cell line (and 2 images for the positive 
control).  
Axio Imager, Zeiss, 63x objective. Scale bar, 20 µm. 
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Figure 5.19 (continued) 
C) For each cell line, triplicate wells were stained with anti-ANXA2 pAb (1:500) and anti-K63- 
linkage specific Ub chain antibody (1:100) (referred to as “PLA” in D and biological replicates 
are colour-coded with black/blue/green dots). As a positive control, the anti-Ub antibody (same 
as in Figure 5.17) was used instead of a Ub chain-specific linkage antibody. PLA signal (puntae 
in green) were quantified using ImageJ in a semi-automated manner and normalised by the 
number of nuclei (stained with DAPI) within a field of view.  
D) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. Kruskal-Wallis test and Dunn’s multiple comparisons post-test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), n ≥ 5 images per 
biological duplicate (except for the single positive control) and n ≥ 5 images per control 
condition per cell line (and 2 images for the positive control).  
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CHIP expressed in the latter line carries a mutation in the TPR of CHIP, which 
prevents its binding to Hsp90 and Hsp/Hsc70186. Interestingly, K30A CHIP also has 
an intrinsic defect in E3 ligase activity (severely restricted auto-ubiquitination and 
reduced substrate ubiquitination, both in vitro and in cells) (Figure 5.20A47). This 
functional defect can be explained by structural changes. K30A CHIP has reduced 
structural flexibility, which “mimics” binding of Hsp70/90 to the ligase (Figure 
5.20B&C47). The transition from a highly flexible to a more structured TPR domain 
allosterically modulates the E3 ligase activity of CHIP. It does so by attenuating the 
correlated motions between the two U-box domains of the dimer and the 
anticorrelated motions between these and one of the TPR domains. This impairs the 
nature of the U-box, rather than altering the accessibility of either U-boxes at any 
given time47. The E3 ligase activity across these cell lines is as follows: WT > K30A > 




Figure 5.19 (continued) 
E) In parallel, controls were included (grouped under “Ctrl” in B&D): wells containing CHIP WT 
and KO cells were incubated with antibodies alone (ANXA2 only in green and either anti-
Ubiquitin antibodies only in blue). 
Axio Imager, Zeiss, 63x objective. Scale bar, 20 µm. 
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Figure 5.20: Activity and conformation of CHIP mutants 
A) In vitro Ub discharge assay using WT, K30A and H260Q CHIP. Firstly, the E2 His-UbcH5a 
was charged with Ub by incubating with the E1 UBE1, Ub and ATP. The Ub discharge from 
the E2 to His-CHIP (WT and mutants) was monitored. Reactions were analysed by SDS-
PAGE/immunoblot using antibodies against CHIP and the E2. H260Q CHIP was not able to 
discharge E2 and the activity of K30A was also impaired compared to WT CHIP, which showed 
a clear dose-dependent effect. 
B) Molecular dynamic (MD) stimulations of unliganded dimers of CHIP K30A (green) and CHIP 
WT in the absence (blue) and presence (yellow) of a Hsp90 peptide.  
C) Positional fluctuation analysis across the structure of unliganded dimers of CHIP K30A and 
CHIP WT ± Hsp90 peptide. The root mean square fluctuations obtained from the stimulations 
were averaged over amino acids and colour-coded on the crystal structure.  
(Narayan et al.47) 
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We have identified pronounced changes in the proteostasis of ANXA2 in CHIP KO 
cortical neurons and, to a lesser extent, undifferentiated SH-SY5Y. Beyond affecting 
steady state levels, the expression of CHIP induces changes in the isoforms of 
ANXA2 across cell lines, which could reflect post-translational modifications. Namely, 
CHIP-dependent ubiquitination of ANXA2 was detected in vitro and is likely to occur 
in cells. The cellular consequence of this event and what drives it remains unknown.      
 
 
5.2.7 Expression of Annexin A2 in cortical neurons correlates 
with poor membrane permeability 
Aiming to elucidate the possible significance of the increased ANXA2 levels observed 
in CHIP KO neurons and given the role of Annexins in membrane homeostasis, 
membrane integrity was assessed. For such, a cell-impermeable dye (FITC dextran) 
was added extracellularly to cells. Internalisation of the dye is a short-term marker of 
poor membrane integrity. The correlation between membrane permeability and 
endogenous ANXA2 was evaluated (Figure 5.21). ANXA2 co-localised more with 
intracellular dye in CHIP KO neurons compared to WT, at basal conditions. However, 
interpretation of dextran uptake into cells requires caution, as the dye is also 
endocytosed within minutes, thus intracellular dextran would eventually be affected 
by both the leakiness of the membrane (i.e. passive transport) and endocytosis 
velocity. Although preliminary, this observation paved way for assays addressing 
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Figure 5.21: Annexin A2 correlates with increased membrane permeability in CHIP KO 
cortical neurons 
A) Mature cortical neurons of CHIP WT and KO genotypes were treated with the cell 
impermeable dye FITC dextran at basal conditions prior to fixation with 4% paraformaldehyde. 
IF using anti-ANXA2 pAb (1:500) was performed and images were taken (n = 8 fields of view 
per cell line). Endogenous ANXA2 was seen colocalising with the dye (yellow arrows) in some 
cells, while others displayed a negative correlation (white arrows). Axio Imager, Zeiss, 63x 
objective. Scale bar, 20 µm. 
B) The colocalization index between the ANXA2 fluorescence and the dye was quantified 
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5.2.8 CHIP KO cells are more sensitive to membrane injury 
The overall membrane integrity of CHIP cell models and their resilience to damage 
was investigated by subjecting cells to different membrane injury assays. These 
included using glass beads (both rolled and vortexed), digitonin and UV laser. The 
majority of this work was carried out by me in the laboratory with Dr Jesper 
Nylandsted§.   
 
 
a. Bead rolling-induced injury 
Undifferentiated SH-SY5Y were incubated with glass beads and a cell-impermeable 
dye (FITC dextran). Beads were rolled over the cells manually and then fixed 
immediately for imaging. The percentage of cells that have internalised the dye (i.e. 
damaged cells) was quantified (Figure 5.22). Although no difference was observed in 
the percentage of damaged cells at basal conditions between CHIP genotypes, CHIP 
KO cells were significantly more sensitive to membrane injury. Given the nature of 
this assay, the majority of the injured cells lift off the plate before imaging and the 
reproducibility across fields of view is quite low. Therefore, this difference is likely to 















§ Danish Cancer Society Research Centre, Copenhagen, Denmark  
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Figure 5.22: SH-SY5Y CHIP KO cells are more sensitive to membrane injury induced by 
glass bead-rolling  
A) Undifferentiated SH-SY5Y cells were incubated with the cell-impermeable FITC dextran 
dye and injured by rolling glass beads. Cells were then fixed and fluorescence was imaged. 
Axio Imager, Zeiss, 63x objective. Scale bar, 20 µm. 
B) Fluorescence within the nucleus of cells was quantified and an arbitrary cut-off score was 
applied to determine whether a particular cell incorporated or not the cell. The percentage of 
cells with dye was per image per cell line was plotted (represented as mean ± SD). Kruskal-
Wallis test and Dunn’s multiple comparisons post-test. **P < 0.005, ****P < 0.0001, n ≥ 11 
images per biological duplicate (n = 3 per cell line for the “injury” condition and n = 1 for “no 
injury”) and n ≥ 21 images per control condition per cell line. Representative data of at least 3 
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b. Bead-induced injury by vortex  
To overcome the limitations of membrane damage induced by rolling glass beads, 
SH-SY5Y cells were detached from the plates and incubated with glass beads and 
mixed by vortex. Subsequently, cells were incubated with PI (impermeant to live cells) 
and Hoechst (permeant to live cells) to obtain a count of live and dead cells and obtain 
the cell death percentage (Figure 5.23). Although there were some small differences 
between CHIP KO and WT cells, the trends were not consistent. This method might 
have been too invasive for cells and/or was not favourable in elucidating differences 
























Figure 5.23: Membrane damage induced by mixing glass beads (by vortex) injures CHIP 
KO and WT SH-SY5Y cells to a similar extent  
Undifferentiated SH-SY5Y CHIP WT and KO cells were passaged and incubated with glass 
beads and mixed by vortex for the indicated times. Damaged and controls cells were incubated 
with Propidium iodide (impermeant to live cells) and Hoechst (permeant to live cells), allowing 
quantification of cell death, which is presented as mean ± SD. Three measurements were 
taken from cells incubated in each condition. Student’s t-test, *P < 0.05.  
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c. Digitonin-induced injury 
Digitonin, a mild non-ionic detergent, is routinely used to permeabilize cellular and 
nuclear membranes. It specifically interacts with cholesterol, creating holes and 
rendering cells permeable187. By optimising the concentration of digitonin used, the 
window showing differences between CHIP WT and KO can be widened, overcoming 
the problem associated with inducing injury by mixing glass bead with cells by vortex. 
As before, cells were incubated with PI and Hoechst following damage and then 
imaged using a cytometer. Both CHIP KO SH-SY5Y cells and iPSC showed a 
consistently higher cell death than WT cells (Figure 5.24). As expected, at higher 
digitonin concentrations or following longer incubation times, the percentage of cell 
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To provide insight into whether the activity of CHIP could be important for the 
sensitivity/resilience of cells to digitonin-induced injury, the stable cell lines re-
expressing mutant CHIP we also included in this assay (Figure 5.25). Both WT and 
CHIP KO + K30A cells behaved in a similar way and were more resistant to digitonin 






Figure 5.24: CHIP KO cells are more sensitive to membrane damage induced by 
digitonin 
A&B) Undifferentiated SH-SY5Y CHIP WT and KO cells incubated with increasing 
concentrations of digitonin for 10 min (A) and 20 min (B). Damaged and controls cells were 
incubated with Propidium iodide (impermeant to live cells) and Hoechst (permeant to live 
cells), allowing quantification of cell death, which is presented as mean ± SD. Three biological 
replicates were included per condition and cell line. t-test, *P < 0.05. The same trends were 
seen when cells are incubated for 15 min with digitonin.  
C) iPSC with different CHIP genotypes were incubated with increasing doses of digitonin for 
10 min. Three biological replicates were included per condition and cell line. Data from two 
independent experiments was combined and represented as Mean ± SD. Two-way ANOVA, 
P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001.  
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d. UV laser-induced injury 
Undifferentiated SH-SY5Y cells incubated with an impermeable dye (FM1-43 dye) 
and were imaged before and after being subjected to injury induced by UV laser 
(Figure 5.26). The cell bodies were outlined and the fluorescence intensity within the 
cell bodies were quantified as a function of time. As shown by the representative 
images (Figure 5.26A), on average, CHIP KO cells incorporate more FM1-43 dye 
intracellularly compared to WT cells (Figure 5.26B). Interestingly, the positioning of 
the CHIP WT cell bodies is similar in both pre- and post-injury scenarios, whilst CHIP 
KO cells show pronounced changes in positioning (Figure 5.26A). It seems that CHIP 
A 
B 
Figure 5.25: Membrane damage induced by digitonin is more severe in CHIP KO and 
CHIP KO + H260Q cell line 
Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the mutant stable 
cells lines) were incubated with increasing concentrations of digitonin for 10 min (A) and 20 
min (B), as in Figure 5.23. Damaged and controls cells were incubated with Propidium iodide 
(impermeant to live cells) and Hoechst (permeant to live cells), allowing quantification of cell 
death, which is presented as mean ± SD. Three biological replicates were included per 
condition and cell line. Two-way ANOVA, **P < 0.005, ***P < 0.0005, ****P < 0.0001. The 
same trends were observed in two repeated experiments with increased digitonin 
concentrations (data not included).  
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KO show increased migratory patterns in response to laser-induced injury (Figure 
5.26D). Moreover, during repair, three phenomena were observed: cell projections 
were either not, partly or fully retracted into the cell bodies (Figure 5.26C). The 
predominant repair strategy adopted by both CHIP KO and WT cells was partial 
retraction of their damaged projections. These preliminary results indicate that CHIP 
KO cells show a pronounced increase in the extent of cell body movement during 
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Figure 5.26: CHIP KO SH-SY5Y cells are more sensitive to laser-induced membrane 
damage and retract to a greater extent 
A&C) Undifferentiated SH-SY5Y cells were incubated with the cell impermeable dye FM1-43 
(Life technologies, 1mg/ml) and injured using UV laser (at sites indicated by the white crosses). 
Live cell imaging was performed before and after the injury (cells were imaged every 4-10 
s). Representative images of CHIP WT and KO cells at pre-injury, injury and 180s-post injury 
are shown. A) The cell bodies before (red) and after (yellow) injury are outlined (the outlines 
were obtained from brightfield images taken in parallel – not shown). The fluorescence 
intensity over time within the cell bodies were quantified (refer to B). The overlap of the outlines 
of the cell bodies before and after injury show whether cells have moved in the aftermath of 
the injury (the red arrows indicate cells that have moved significantly). The distances migrated 
by the cell bodies are quantified in D.  
Nikon confocal microscope equipped with a PerkinElmer spinning disk (Rapp OptoElectronic 
pulsed UV-laser) with a 63x objective. Scale bar, 9 µm.  
B) The fluorescence intensity (F) within cell bodies was quantified over time and normalised 
by the pre-injury fluorescence (F∆/F0). Averages were plotted. Data shows that CHIP KO cells 
incorporate more dye following injury, reflecting compromised repair kinetics. Student’s t-test, 
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Figure 5.26 (continued) 
C) The same representative images as those in A have the cell bodies and tip of the cellular 
projections outlined in red (before injury) or yellow (after injury) (the outlines were obtained 
from brightfield images taken in parallel – not shown). The distance between both structures 
is marked with a white line (representing the length of the cellular projection). These are then 
marked on the repeated 180-post injury images and colour-coded as pre-injury (red) or post-
injury (yellow).   
Projections showing no change in length are labelled 1 (despite potential changes in 
positioning). Those showing partial reductions in length in post-injury (i.e. representing partial 
retractions) are labelled 2. Finally, projections that have been completely retracted post-injury 
are labelled 3.  
D) Distance migrated by cells upon laser-induced injury was quantified by measuring the 
length from the end of a single projection at pre-injury to the cell body both before and after 
injury, in projections that are close to the site of injury. The mean difference (in μm) was plotted. 
Error bars represent SEM.  Projections analysed were classified according to their phenotype 
upon injury: not retracted (i.e. projection remained), partially retracted (i.e. projection reduced 
in length upon injury or part of the projection remained upon cell repair forming a tail-like 
structure) or retracted (i.e. the projection was internalised by the cell body). Examples of these 
phenotypes are shown in C. The occurrence of each phenomena per cell line is represented 
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5.2.9 CHIP KO cells do not show significant repair defects 
The increased membrane damage observed could reflect enhanced membrane 
sensitivity to injury and/or inability to repair damage. To investigate whether damaged 
cells are capable of repairing, cells were incubated with glass beads in the presence 
of a green impermeable dye (FITC dextran), then washed and incubated with a red 
impermeable dye (Texas dextran) during repair. Cells were fixed and imaged (Figure 
5.27). Cells damaged by the beads become permeable to the green dye. Those that 
repair do not internalise the red dye (remaining green), while cells that fail to repair 
become red (having both dyes co-localise). Both CHIP KO and WT SH-SY5Y cells 

























Figure 5.27: CHIP KO and WT cells are able to repair after membrane damage 
Undifferentiated SH-SY5Y and cortical neurons were incubated with the FITC dextran (green) 
dye followed by glass bead-induced injury. Cells were then washed and the Texas dextran 
(red) dye was added. Cells were allowed to recover for 5 min, followed by fixation with 4% 
paraformaldehyde. IF images show cells that were injured but have repair (green only, 
indicated by the white arrows) and those that have not repaired (incorporated both green and 
red dyes, yellow arrows). Axio Imager, Zeiss, 63x objective. Scale bar, 20 µm (exclusively for 
images in the third row: scale bar, 50 µm). Images of SH-SY5Y cells are representative of at 
least 3 independent experiments and images of cortical neurons are representative of 
biological duplicates. 
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In an attempt to quantify the ability of CHIP KO and WT cells to repair, iPSC (Figure 
5.28A) and undifferentiated SH-SY5Y (Figure 5.28B) were treated with digitonin in the 
absence of calcium, which is necessary for repair. Although all cell lines tested were 
sensitive to calcium withdrawal, there was more cell death recorded for CHIP KO 
iPSC compared to WT in the absence of digitonin. This could mean that CHIP KO 
cells are more dependent on efficient repair at basal conditions, although this would 
have to be validated further. Addition of digitonin increased the cell death in both CHIP 
KO and WT iPSC, thus the difference between the cell lines was maintained. 
However, such difference between CHIP genotypes is subtle (particularly when the 
data is normalised by the cell death observed in the absence of digitonin treatment 
for each cell line) and is unlikely to explain the pronounced differences observed when 
both sensitivity and repair are assayed (Figure 5.24 & Figure 5.25). SH-SY5Y were 
extremely intolerant to the calcium withdrawal in conjunction with digitonin treatment, 























Chapter 5: The possible role of CHIP in regulating the homeostasis of Annexin A2 and 




























Figure 5.28: CHIP KO cells are more sensitive to membrane damage induced by 
digitonin when repair is inhibited (in the absence of calcium) 
As in Figure 5.23, iPSC (A) and undifferentiated SH-SY5Y (WT, KO and the mutant stable cell 
lines) (B) were subjected to digitonin-induced injury (with increasing concentrations). 
However, instead of diluting digitonin in DMEM (Ca2+-containing medium), here digitonin was 
diluted in HBSS without calcium. Damaged and controls cells were incubated with Propidium 
iodide (impermeant to live cells) and Hoechst (permeant to live cells) immediately after the 
injury to prevent cell death associated with calcium withdrawal. Cell death was quantified and 
is presented as mean ± SD. Biological triplicates were represented as mean ± SD. Student’s 
t-test, ***P < 0.0005, ****P < 0.0001. The experiment was repeated a second time and the 
same trends were observed. Note that due to the scanning order, cells treated with 3 µg/ml 
digitonin were scanned after the 5 µg/ml conditions.   
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5.2.10 Injury-induced changes in Annexin A2 dynamics and 
interactome 
With the aim to understand the underlying molecular mechanisms contributing to the 
poor membrane integrity of CHIP KO cells, the dynamics and interactions of the key 
protein in membrane homeostasis, ANXA2, were investigated. We believed that 
changes in ANXA2 proteostasis (including levels, subcellular localisation and 
protein:protein interactions) could influence membrane integrity either directly or 
indirectly – helping to explain, at least partly, the cellular phenotype observed. At 
present, we cannot exclude the possibility that these changes in ANXA2 proteostasis 
could be unrelated to membrane homeostasis and, instead, a separate CHIP-
dependent molecular event.  
 
 
a. Annexin A2 dynamics 
As previously seen in Figure 5.21, the FITC dextran dye penetrates into cortical 
neurons at basal condition and its intracellular presence correlated with expression of 
ANXA2 more closely in CHIP KO than WT neurons. Upon injury by bead rolling, a 
positive correlation between damaged cells and ANXA2 expression was observed for 
both CHIP KO and WT neurons (Figure 5.29). ANXA2 is known to respond to 
increases in permeability by upregulating and becoming recruited to the site of 
injury163. The increase in correlation index in CHIP WT upon damage compared to 
basal condition supports such responsive nature. Phenotypically, ANXA2 also seems 
to accumulate around the nuclear staining, forming ring-like structures, in these cells. 
In contrast, in CHIP KO neurons appear to lack this dynamic response and the ANXA2 
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The damaged-induced response of endogenous ANXA2 was monitored in 
undifferentiated SH-SY5Y. A dose-time-response assay of digitonin was performed 
where the read-out was the fluorescence intensity of ANXA2 per cell (Figure 5.30). 
Importantly, the increase in ANXA2 following injury is not CHIP-dependent. However, 
the kinetics of this phenomenon could be influence by the presence of CHIP. In CHIP 
KO cells, ANXA2 intensity took slightly longer to increase following injury (refer to the 
15 minutes time-point using the 15 µg/ml dose), recorded higher fluorescence 
intensities and reached its maximum intensity later than control cells (Figure 5.30B). 
Qualitatively, with increasing digitonin treatment, ANXA2 staining in CHIP KO cells is 
predominantly within the PM initially, and then becomes nuclear. In contrast, control 
Figure 5.29: Upon damage, ANXA2 colocalises with the impermeable dye 
A) Mature cortical neurons of CHIP WT and KO genotypes were treated with the cell 
impermeable dye FITC dextran and injured by rolling glass beads. Immediately following 
injury, cells were fixed with 4% paraformaldehyde. The expression of endogenous ANXA2 was 
analysed by IF using anti-ANXA2 Rb pAb (1:500). Images were taken (n ≥ 6 fields of view per 
cell line). Axio Imager, Zeiss, 63x objective. Scale bar, 20 µm.  
B) The colocalization index between the ANXA2 fluorescence and the dye was quantified 
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cells have a diffuse cytoplasmic staining, with some cells showing membrane-bound 

































Figure 5.30: Upon damage, ANXA2 levels increase in both CHIP KO and WT 
undifferentiated SH-SY5Y cells 
A) Undifferentiated SH-SY5Y CHIP WT and KO cells were treated with different 
concentrations of digitonin (0, 10, 15, 25 and 30 µg/ml. Cells were fixed with acetone & 
methanol. The endogenous expression of ANXA2 was analysed using anti-ANXA2 pAb 
(1:500). Representative images are shown of untreated cells and treated with 10 µg/ml (for 15 
min), 25 µg/ml (for 30 min) and 30 µg/ml (for 30 min). Differences in ANXA2 subcellular 
localisation and expression are evident between CHIP KO and WT treated cells. Axio Imager, 
Zeiss, 63x objective. Scale bar, 20 µm.  
B) The mean fluorescence intensity per cell line per condition was quantified using ImageJ 
software and plotted. Dotted line represents the average ANXA2 expression at basal 
conditions. Quantification of CHIP KO cells treated with 30 µg/ml was only possible until the 
15 min time-point due to substantial cell death.  
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b. Annexin A2:S100-A11 interactome 
Given the difference in ANXA2 dynamics detected and the known injury-induced 
ANXA2:S100-A11 interaction that promotes its membrane-related functions, the 
dynamics of such interaction were evaluated. PLA revealed that such interaction is 
more frequent in CHIP-expressing cells compared to KO undifferentiated SH-SY5Y 
cells at basal conditions (Figure 5.31 and Figure S.8, where data from independent 
experiments was quantified either in a semi-automated or manual manner, and the 
control IF is represented in Figure S.9), despite the increased ANXA2 levels in CHIP 
KO cells. S100-A11 levels, on the other hand, are unchanged in this CHIP SH-SY5Y 
model (Figure 4.26). Since the complex has been implicated in the maintenance of 
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Figure 5.31: Annexin A2 & S100-A11 interaction by PLA in undifferentiated SH-SY5Y 
A&B) Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the stable 
cell lines KO+H260Q and KO+K30A) were fixed with acetone & methanol.  
A) For each cell line, duplicate wells were stained with anti-ANXA2 mAb (3:500) and anti-s100-
A11 pAb (1:500) antibodies (referred to as “PLA” in C and biological duplicates). PLA signal 
(puntae in green) were quantified using ImageJ in a semi-automated manner and normalised 
by the number of nuclei (stained with DAPI) within a field of view.  
B) In parallel, two controls were included (grouped under “Ctrl” in C): wells containing CHIP 
WT cells were incubated with either antibodies alone or with no primary antibodies. 
Axio Imager, Zeiss, 63x objective. Scale bars, 20 µm. Representative data of at least 4 
independent experiments. Representative data of at least two independent PLA experiments. 
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Furthermore, the ANXA2:S100-A11 interaction seems to be influenced by the E3 
ligase activity of CHIP. While the line expressing a E3 ligase-dead mutant CHIP (KO 
+ H260Q) was similar to KO cells, the chaperone-dead mutant CHIP (KO + K30A) 
partially rescued the ANXA2:S100-A11 interaction. Importantly, the steady state 
levels of ANXA2 and S100-A11 are similar in both stable cell lines (Figure S.10).  
 
Although the ANXA2:S100-A11 interaction is compromised in CHIP KO cells 
compared to WT at basal conditions, upon injury the difference between WT and KO 
cells ceases to be statistically different (Figure 5.32). However, the PLA signal for the 
KO damaged cells remains much lower than the control cells, illustrating that even 
upon injury the interactome of ANXA2 remains defective. Interestingly, WT cells had 
a similar PLA signal when subjected to digitonin treatment (compared to untreated 
cells), while KO cells showed a slight increase (not significant) of this interaction when 
damaged. Of note, CHIP was also found to interact with S100-A11 by PLA (Figure 
S.11). CHIP- and S100-A11-containing complexes were detected in WT cells but not 
in CHIP KO cells, in situ, pointing to a direct or indirect interaction between these 
proteins.  
C 
Figure 5.31 (continued) 
C) Automated quantifications of PLA signal per nuclei of different cell lines represented in the 
dot plot as mean ± SD. Two CHIP KO+K30A clones were pooled into the quantification. 
Kruskal-Wallis test and Dunn’s multiple comparisons post-test (statistical significance 
indicated above each Ctrl). *P < 0.05, ***P < 0.0005, ****P < 0.0001, n ≥ 12 images per 
biological duplicate and n ≥ 11 images per control condition per cell line. 
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Figure 5.32: Annexin A2 & S100-A11 interaction by PLA in untreated and digitonin-
treated undifferentiated SH-SY5Y 
A) Undifferentiated SH-SY5Y CHIP KO and WT cells were fixed with acetone & methanol. For 
each cell line, duplicate wells were stained with anti-S100-A11 pAb (1:500) and anti-ANXA2 
mAb (3:500) (referred to as “PLA” in B and biological replicates are colour-coded with 
black/green dots). PLA signal (puntae in green) were quantified using ImageJ in a semi-
automated manner and normalised by the number of nuclei (stained with DAPI) within a field 
of view. In parallel, two controls were included (images not shown, grouped under “Ctrl” in B): 
wells containing cells of both genotypes were incubated with either antibodies alone (S100-
A11 only in green and ANXA2 only in blue). Axio Imager, Zeiss, 63x objective. Scale bar, 20 
µm. 
B) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. One-way ANOVA with Holm-Sidak’s multiple comparisons post-test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), *P < 0.05, **P < 
0.005, ****P < 0.0001, n = 7 images per biological duplicate and n = 3 images per control 
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c. Annexin A2:CHIP interactome 
The dynamics of the interaction of CHIP with ANXA2 under basal conditions and upon 
membrane damage were also investigated (Figure 5.33). The PLA signal reflecting 
ANXA2:CHIP complexes showed a slight increase in interaction in CHIP WT cells 
following injury compared to basal conditions, although this was not significant. No 
change was seen in CHIP KO cells treated with digitonin compared to untreated.  
 
The observed differences in ANXA2 dynamics and interactome in our CHIP models 
at both basal conditions and in response to membrane damage opens several 
questions. It would be interesting to investigate further how the ANXA2:CHIP 
interaction changes under these conditions. For example, by immunoprecipitating 
CHIP and analysing its interacting proteins by MS other interacting proteins, possibly 
within the same complex as ANXA2 and CHIP, could be identified. Beyond this, the 
effect of the ANXA2-binding on CHIP’s structure and function (both directly, due to 
the protein:protein interaction, or indirectly, caused by the lipid-rich environment of 
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Figure 5.33: Annexin A2 & CHIP interaction by PLA in untreated and digitonin-treated 
undifferentiated SH-SY5Y 
A) Undifferentiated SH-SY5Y CHIP KO and WT cells were fixed with 4% PFA and then 
methanol. For each cell line, duplicate wells were stained with anti-CHIP mAb (1:1000) and 
anti-ANXA2 pAb (1:500) (referred to as “PLA” in B and biological replicates are colour-coded 
with black/green dots). PLA signal (puntae in green) were quantified using ImageJ in a semi-
automated manner and normalised by the number of nuclei (stained with DAPI) within a field 
of view. In parallel, two controls were included (images not shown, grouped under “Ctrl” in B): 
wells containing cells of both genotypes were incubated with either antibodies alone (CHIP 
only in green and ANXA2 only in blue). Axio Imager, Zeiss, 63x objective. Scale bar, 20 µm. 
B) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. One-way ANOVA with Holm-Sidak’s multiple comparisons post-test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), ****P < 0.0001, n 
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5.2.11 Lipids inhibit CHIP-dependent ubiquitination of Annexin 
A2 in vitro 
In parallel to studying the proteostasis of ANXA2 in our CHIP models, lipid 
composition and CHIP-lipid interactions were investigated as other possible 
underlying mechanisms contributing to the poor membrane homeostasis observed in 
CHIP KO cells. The effect of CHIP-lipid interactions (occurring either as a by-product 
of ANXA2:CHIP or unrelated to ANXA2) on CHIP’s function was assessed.    
 
The ANXA2-binding lipid, PA, was titrated into the in vitro ubiquitination assay 
containing ANXA2 and CHIP (Figure 5.34A). With increasing PA (from 1mM to 5mM) 
the ubiquitination of ANXA2 was inhibited and the auto-ubiquitination of CHIP was 
slightly impaired. Above 7mM, the concentration of PA buffer itself interfered with the 
ubiquitination reaction (both of ANXA2 and the auto-ubiquitination of CHIP). To rule 
out the possibility of the buffer used to reconstitute the lipid driving the suppression of 
ubiquitination, different buffers (HEPES- and Ethanol-based) were tested (Figure 
5.34B). The inhibitory effect of PA was observed when diluted in both buffers. Such 
inhibition did not correlate with the extent of CHIP’s auto-ubiquitination detected. Next, 
the effect of the CHIP-binding lipid, phosphatidylinositol 4-phosphate (PI4P) was also 
analysed (Figure 5.34C). With increasing PI4P, both the ubiquitination of ANXA2 and 
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Figure 5.34: Effect of lipids on CHIP-dependent ubiquitination of ANXA2, in vitro 
In vitro ubiquitination assays using untagged recombinant human ANXA2 and CHIP were 
performed in the absence and presence of lipids. PA diluted in ethanol (A) or in HEPES-based 
buffer (B) was added to the ubiquitination reactions at different concentrations. PI4P was also 
tested (C). Reactions were analysed by 12% SDS-PAGE/WB. Immunoblots were probed with 
anti-CHIP mAb (1:10000) and anti-ANXA2 antibodies (mAb, 1:500, and/or pAb, 1:1000).  
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Figure 5.34 (continued) 
In vitro ubiquitination assays using untagged recombinant human ANXA2 and CHIP were 
performed in the absence and presence of lipids. PA diluted in ethanol (A) or in HEPES-based 
buffer (B) was added to the ubiquitination reactions at different concentrations. PI4P was also 
tested (C). Reactions were analysed by 12% SDS-PAGE/WB. Immunoblots were probed with 
anti-CHIP mAb (1:10000) and anti-ANXA2 antibodies (mAb, 1:500, and/or pAb, 1:1000).  
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5.2.11 Lipids inhibit CHIP-dependent ubiquitination of Annexin 
A2 in vitro 
Given the effect of lipids on the activity of CHIP, we sought to investigate possible 
changes in lipidomic profile of the CHIP SH-SY5Y model. The relative abundance of 
some classes of phospholipids were plotted (Figure 5.35). Although the majority of 
phospholipid groups assayed did not seem to differ significantly between CHIP WT 
and KO (e.g. phosphatidylethanolamine, PE, lysophosphatidylcholine, LPC, and 
sphingomyelin, SM), some showed 1.5 to 2.5-fold change in WT compared to KO 
cells (including PA, lysoPA, LPA, and PS). This work was done in collaboration with 















‖ Institute for Physiological Chemistry, University Medical Center Mainz, Germany 
Figure 5.35: Lipidomics of CHIP KO and WT undifferentiated SH-SY5Y cells 
Undifferentiated CHIP KO and WT SH-SY5Y cells were harvested for lipidomics analysis of 
phospholipids. Phosphatidic acid (PA), lysophosphatidic acid (LPA), phosphatidylserine (PS), 
phosphatidylinositol (PI), lysophosphatidylinositol (LPI), phosphatidylethanolamine (PE), 
lysophosphatidylcholine (LPC), sphingosine (SPH), sphingomyelin (SM), ceramide (CER), 
ceramide-1-phosphate (C1P). 
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5.3 Discussion 
5.3.1 Annexinopathy in CHIP KO models 
Using an unbiased approach to identify protein changes in the CHIP KO cortical 
neurons (i.e. possible substrates of CHIP), ANXA2 was the most striking. The over-
representation detected by SWATH-MS reflected an upregulation of the protein levels 
of ANXA2 in CHIP KO cortical neurons (Figure 5.6). This was consistently seen in 
independent cortical differentiation experiments, thus accounting for the variability of 
the neuronal differentiation. The increase in ANXA2 levels is either a direct CHIP-
related phenomenon or a conserved compensatory mechanism, which could be 
relevant in the maintenance of cellular health.  
 
Interestingly, this phenotype seems to be dependent on the differentiation status and 
cell type. Undifferentiated CHIP KO iPSC do not share this increase in ANXA2 steady 
state levels, evident from both the WB (Figure 5.7) and SWATH-MS data (having a 
WT/KO fold change of 0.764). In contrast, cycling SH-SY5Y show an increase in 
ANXA2 levels by WB (Figure 5.8) and SWATH-MS (fold change of 0.764), although 
the difference between CHIP KO and WT tends to be less pronounced compared to 
that of cortical neurons. Commonly, metastatic cancer cells upregulate ANXA2163,168 
and this neuroblastoma cell line was derived from a metastatic bone tumour biopsy118. 
However, this increase seems to be dependent on CHIP genotype, which could be 
explained by the relationship between CHIP and the neuronal-like background of 
these cells or their cancerogenic nature (CHIP has been implicated in cancer87). Their 
differentiated counterparts, on the other hand, do not show a CHIP-dependent change 
in ANXA2 steady state levels by WB (Figure 5.9) nor SWATH-MS (having a fold 
change of 0.948). However, these differentiated SH-SY5Y cells and iPSC-derived 
cortical neurons are intrinsically different. As previously mentioned, the neuronal 
identity of differentiated SH-SY5Y is unclear and likely to be mixed (i.e. not cortical) 
and these cells lack the neurodegeneration-prone genetic background of our iPSC 
CHIP model and derived cortical neurons.  
 
Taken together, the effect of CHIP on the steady state levels of ANXA2 is clearly 
observed in our CHIP cortical neuron model from a disease-relevant background. 
More broadly, CHIP may affect the expression of ANXA2 in other cell lines, although 
this seems to be dependent on the cellular status and type (e.g. potentially promoted 
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by the synucleinopathy background). Whether this CHIP-dependent regulation of 
ANXA2 is direct or not remains unclear although supporting data favours CHIP-
dependent post-translational modifications of ANXA2.    
 
“Annexinopathy” was first used in 1999 and describes the involvement of Annexins in 
human diseases165. High expression of ANXA2 has been associated with more 
aggressive gliomas and increased severity of muscular dystrophy. In the latter, 
ANXA2 promotes sarcolemma wound healing by aggregating intracellular vesicles 
that fuse to form patches at sites of plasma membrane defect165. 
 
Whilst mechanistic roles of annexins in cancer progression and muscle diseases have 
been investigated, their involvement in neuron homeostasis and neurodegeneration 
is largely unknown and understudied. The first study investigating the expression of 
Annexins reported that ANXA2 and ANXA4 were present in glia but absent from 
neurons, whilst ANXA1 and ANXA6 were neuronal188. ANXA1 and ANXA2 were found 
in the PM of neuronal synapses (purified from pig cerebral cortices)179 and reactive 
astrocytes188, respectively. More recently, ANXA2 was detected in the cell body and 
processes of neurons, showing enrichment in the distal tips (Figure 5.36)189. The 
association of Annexins with the PM of neurons drove its proposed role in 
















Figure 5.36: Annexins in neuronal health and disease 
Neuronally differentiated PC12 cells stably expressing PAGFP WT tau were subjected to a 
combined detergent extraction-fixation protocol to reveal the cytoskeletal fraction. The 
expression of endogenous ANXA2 and transfected tau was analysed by immunofluorescence 
using anti-GFP and anti-ANXA2 antibodies. ANXA2 is enriched in the distal tips (in growth 
cones). Scale bar, 50 µm.  
(Gauthier-Kemper et al.189) 
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There is some degree of appreciation that the patterns of expression of annexins 
throughout the brain change during development and in pathological states. This led 
to the hypothesis that annexins may be involved in neuronal and glial responses to 
acute and chronic injury188. In 1994, Eberhard and colleagues188, reported alternations 
in the distribution of ANXA6 in affected neurons and the upregulation of ANXA1, 
ANXA2 and ANXA4 in reactive astrocytes in post-mortem brains of patients with acute 
CNS damage or chronic degeneration. Later, ANXA2 was found to be overexpressed 
in patients with Frontotemporal dementia with Ub and TDP-43 positive inclusions by 
11.3-fold and with motor neuron disease (lacking a significant number of frontal cortex 
inclusions) by 2.3-fold compared to controls. Thus, increase of ANXA2 appeared to 
correlate with the presence of inclusions (i.e. proteinopathy)190. Likewise, when a key 
component involved in the regulation of the proteome (CHIP) is removed, ANXA2 
steady state levels increase, especially in a neurodegeneration-prone genetic 
background.  
 
Although annexins have been reported to be overexpressed in frontotemporal 
dementia, AD and PD, this has not translated into comprehensive studies 
investigating regulation of the proteostasis of Annexins and its molecular mechanisms 
and cellular significance within neurons - despite the availability of tools and 
techniques largely established using models of cancer and muscle injury. Data 
presented in this chapter contributes to this gap in our understanding.  
 
 
5.3.2 CHIP-mediated regulation of Annexin A2 homeostasis 
ANXA2 is a highly dynamic protein that regulates membrane remodelling events at 
basal conditions and repairs membrane injuries. Upon injury, ANXA2 is rapidly 
recruited to the site of injury and becomes upregulated148. Such prompt response is 
only possible with tight control of the steady state levels of ANXA2 and an 
orchestrated regulation of ANXA2 in the aftermath of membrane repair. We propose 
ANXA2 as a novel target of the E3 ligase CHIP. Such regulatory event could be 
important both at basal conditions and upon membrane-induced damage.   
 
Work on the cortical neurons pioneered the hypothesis of CHIP-induced changes in 
the homeostasis of ANXA2. Going beyond assessing bulk protein levels, which are 
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likely to be tightly controlled and the final read-out of a regulatory cascade(s), we 
sought to investigate the ANXA2 isoform profile. This could elucidate potential PTMs 
across CHIP cell lines, which could influence protein stability, turnover, subcellular 
localisation and interactome. Indeed, an unbiased analysis using 2D-gel SDS-
PAGE/WB shed light into differences in ANXA2 isoforms in the presence and absence 
of CHIP (some consistent across cell lines) (Figure 5.15). Therefore, CHIP-induced 
changes in ANXA2 might occur at a post-translational level. 
 
When lacking CHIP, cells form a higher-order ANXA2 isoform. This novel ANXA2 
species is conserved across iPSC and undifferentiated SH-SY5Y lines and could be 
an aggregated form of ANXA2, which is important in membrane repair162,163,169. It is 
unclear if the CHIP KO-specific higher MW isoform arises due to a lack of CHIP-
dependent regulation directly (i.e. CHIP is a negative regulator of such isoform), or as 
a consequence of how the absence of CHIP shapes the cellular status.   
 
CHIP may influence the homeostasis of ANXA2 by acting in close proximity in a direct 
(via CHIP:ANXA2 interaction) or indirect manner (interacting with ANXA2 within a 
complex containing other protein(s) or through a third party). In these scenarios, when 
CHIP is ablated, the interaction is abolished and ANXA2 would become dysregulated. 
Alternatively, the effect of CHIP on ANXA2 dynamics may be secondary to an altered 
intracellular environment (e.g. absence of CHIP could lead to proteotoxic stress, 
which could affect ANXA2). Our investigation then pursued into studying the 
underlying mechanism of CHIP-dependent changes in ANXA2.  
 
Different methods suggest that CHIP and ANXA2 could interact in cells. Firstly, IF 
(Figure 5.11) and a subcellular fractionation assay (Figure 5.10) revealed that CHIP 
and ANXA2 have similar subcellular localisations (cytoplasmic), a requirement for 
direct protein:protein interaction. Moreover, the ANXA2 distribution observed in cells 
of different CHIP genotypes was comparable, being found in the cytoplasm, 
membrane and nucleus of cells – in line with the literature168,170. Secondly, PLA 
revealed that endogenous CHIP and ANXA2 are within <40 nm of each other in situ, 
thus direct protein:protein interaction is a possible mechanism of action in different 
CHIP cell models (Figure 5.13 & Figure 5.14). Finally, endogenous CHIP co-
immunoprecipitated with endogenous ANXA2 (Figure 5.12). At present we cannot 
conclude whether CHIP:ANXA2 interaction occurs directly and independently or 
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within a complex. Commonly, the CHIP interactome has been assessed in a 
chaperone-dependent manner, where chaperones mediate the direct interaction with 
the substrate. At least in vitro, I have found that CHIP:ANXA2 interaction does not 
require chaperones (Figure 5.16 & Figure 5.17). This is the first account of this 
interaction. In fact, to our knowledge, there is no published evidence of the interaction 
of ANXA2 with an E3 ligase enzyme.  
 
Given the E3 ligase functions of CHIP, the possibility of ANXA2 being an ubiqitination 
substrate of the enzyme was explored. CHIP-dependent ubiquitination of ANXA2 was 
readily detected in vitro using untagged ANXA2, forming both mono- and multimono- 
or poly-ubiquitinated species (Figure 5.17). In attempt to detect endogenous 
ubiquitinated ANXA2 in situ, PLA using anti-ANXA2 and anti-Ub antibodies was 
performed. Punctae (PLA signal) would implicate that ANXA2 is in close proximity 
with Ub, thus ANXA2 could be covalently bound to Ub (either one Ub, forming mono-
ubiquitinated ANXA2, or multiple, yielding multimono- or poly-ubiquitinated species). 
The PLA with both Ub and Ub-linkage specific antibodies suggested that WT cells 
might have more ubiquitinated ANXA2 species than CHIP KO cells (Figure 5.18 & 
Figure 5.19).  
 
In attempt to further validate CHIP as an E3 ligase responsible for the ubiquitination 
of ANXA2 in cells, stable cell lines expressing an E3 ligase- or chaperone-dead 
mutant CHIP (KO + H260Q and KO + K30A, respectively) were also included in this 
assay. Only the latter was capable of partly restoring the PLA signal, while CHIP KO 
+ H260Q cells was not statistically different from CHIP KO cells. Importantly, the levels 
of ANXA2 remained unchanged between the KO + H260Q and KO + K30A cell lines, 
increasing the confidence of the results presented. In parallel, the PLA addressing the 
CHIP:ANXA2 interaction showed a pronounced increase in signal in CHIP KO + 
H260Q cells compared to WT cells (Figure 5.14), thus the mutation does not abolish 
ANXA2-binding.  
 
Enzymatic kinetics together with the decreased ANXA2:Ub PLA in the KO + H260Q 
cell line might explain the observed increase in ANXA2:CHIP interaction in these cells. 
The interaction between an E3 and its substrate is weak and/or transient145 and 
substrates are tuned to dissociate with a few seconds (koff tends to be about 0.4 s-
1)191. Ubiquitin ligase trapping techniques counteract this145 and the dissociation rate, 
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rather than the Ub transfer, becomes the rate-limiting step191. Expression of mutant 
E3 ligase variants ‘trap’ putative ligase substrates, thus changing the kinetics of the 
ligase-substrate interaction by decreasing the off-rate145. Therefore, it seems that 
ANXA2 binds to H260Q mutant CHIP and, because the enzyme is catalytically dead, 
Ub is not added to the substrate. As a result, instead of substrate detachment from 
the complex, ligand-induced intermediates become stabilised – direct evidence for an 
induced-fit mechanism¶192. Taken together, this data reveals ANXA2 as a novel 
substrate for the E3 ligase CHIP.  
 
The fate of ubiquitinated ANXA2 is dictated by characteristics of the PTM, including 
the length of the Ub chain and the lysine residues of Ub used for chain formation. 
Attachment of a polyubiquitin chain consisting of at least 4 Ubs linked together through 
their K48 residue destines the substrate for proteasomal degradation. A chain using 
K63 drives endocytosis, DNA repair and initiates signalling cascades9. CHIP-
dependent ubiquitination of ANXA2 might use different Ub chains (K48 and K63), 
since the PLA signal detected as similar in all experiments in CHIP WT cells. 
Therefore, we can conclude that ANXA2 regulation via ubiquitination is complex. 
 
 
5.3.3 Membrane integrity in CHIP KO models 
There is robust evidence implying that the main function of ANXA2 is in maintenance 
of membrane integrity162,163. Accompanying the increase in ANXA2 detected in CHIP 
KO cortical neurons, is an increase in intracellular co-localisation of endogenous 
ANXA2 with the incorporation of a dye into cells, a marker of increased cell 
permeability (Figure 5.21). Therefore, despite the increase in ANXA2 in CHIP KO 
cells, like WT cells, they are permeable to this dye. This discards the linear correlation 
between increased ANXA2 and better membrane integrity, at least in terms of 
permeability, in our model. Such hypothesis could be deduced from the pathogenic 
mechanism of cancer cells to upregulate Annexins and, in turn, enhance membrane 
resilience during formation of metastasis163.  
 
 
¶ Induced-fit mechanism: Ligand binding induces a conformational change in the ligand and enzyme, 
resulting in a precise complex orientation for the enzymatic reaction. This differs from the “lock-and-
key” and selected-fit models, where either the conformational of unbound and bound proteins are 
similar or conformational change precedes ligand binding, respectively192. 
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However, two main questions remain unanswered by this assay: is ANXA2 actively 
recruited to areas rich in the intracellular dye and/or upregulated in attempt to restore 
membrane homeostasis (i.e. a protective response of ANXA2 to restore membrane 
integrity)? Or is the increase in co-localisation simply the result of increase membrane 
permeability in a background with increased ANXA2 (i.e. an epiphenomenon)? A 
compensatory mechanism of increased ANXA2 expression has been reported for 
neurons in the context of neurodegeneration188–190.  
 
It has been suggested that the overexpression of ANXA2 in acute/chronic injury of in 
neurodegeneration is a protective response to limit damage. Several deleterious 
conditions (including hypoxia ischemia, excitotoxin exposure, seizures and chronic 
neurodegeneration) result in phospholipase-mediated membrane degradation, which 
can be inhibited, at least in vitro, by Annexins. In fact, under these conditions, ANXA6 
is consistently increased in hippocampal neurons, which are more resistant to injury 
than others in this region. These findings support a neuroprotective role for annexins 
in promoting neuronal survival or recovering from injury188.  
 
Our preliminary experiment showing increased colocalization of endogenous ANXA2 
with the intracellular dye can be regarded as proof-of-concept that even if the ANXA2 
increases in CHIP KO cortical neurons a secondary, protective response, it seems to 
fail to restore membrane integrity to the extent seen in control cells.   
 
Given the differences in membrane integrity observed in cells with different CHIP 
genotypes at basal levels, we hypothesised that CHIP could also influence membrane 
resilience to injury. Underlying mechanisms that could be somewhat compromised at 
basal conditions could be exacerbated when the membrane dyshomeostasis 
phenotype is enhanced by membrane-induced damage. Although injury assays are 
not physiological per se, the signalling cascades activated are likely to be relevant in 
the context of maintenance of cell health, given the extensive redundancy in the 
proteins recruited across repair mechanisms162 (independent of the type of 
stressor)148,180.    
 
Most methods employed supported CHIP KO cells having a weaker membrane. In 
particular, digitonin-induced damage revealed robust and reproducible differences 
across cell models of different CHIP genotypes (Figure 5.24 & Figure 5.25). When the 
 
Chapter 5: The possible role of CHIP in regulating the homeostasis of Annexin A2 and 
membrane integrity  271 
stable cell lines expressing CHIP mutants were subjected to digitonin-induced injury, 
CHIP KO+H260Q cells resulted in similar cell death percentages as CHIP KO cells, 
while CHIP KO+K30A cells were similar to WT (Figure 5.25).  
 
Beyond supporting this difference in membrane resilience, UV laser-induced injury 
monitored by live-imaging revealed differences in the repair dynamics (Figure 5.26). 
Upon injury, CHIP KO cells tend to migrate more when their damaged projections are 
retained or partially retracted (showing increased cell body movement and 
“elasticity”). This could translate to a different repair mechanism being employed.   
 
Cell health is likely to be influenced by both the sensitivity to damage and ability to 
repair. To decipher which of these factors is mainly affected in CHIP KO cells, we first 
analysed whether these cells can repair following injury. Our CHIP cell models 
indicate that both WT and KO cells are able to repair following membrane injury 
(Figure 5.27) with similar kinetics (Figure 5.28). Therefore, it is likely that the increased 
membrane damage observed in KO cells reflect a sensitivity, rather than repair, 
phenotype.  
 
The exact molecular mechanisms underlying the poor membrane integrity in CHIP 
KO cells specifically are unknown. However, we have explored several potential 
CHIP-mediated mechanisms that could contribute to the phenotype observed in a 
mutually non-exclusive manner. Namely, changes in membrane proteomics and 
lipidomics (including phospholipid composition) in the presence and absence of CHIP 
were studied.  
 
 
5.3.4 Could CHIP-dependent effect(s) on membrane 
proteomics contribute to differences in membrane integrity? 
a. Dynamics of Annexin A2 
The canonical function of ANXA2 is in regulation of membrane-related events and in 
response to membrane damage162, thus having roles in normal physiological 
conditions and upon stress. As discussed, dysregulation of ANXA2 proteostasis under 
basal conditions in CHIP KO cells (either directly or indirectly by CHIP) could influence 
its physiological function and result in detrimental cellular effects (i.e. membrane 
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dyshomeostasis) or the CHIP KO background may stimulate the stress-induced 
behaviour of ANXA2. Different studied have reported that stress (mechanical and 
chemical) triggers an upregulation of ANXA2 protein levels176,180. Therefore, one 
possibility is that deletion of CHIP expression mimics such conditions of stress.   
 
We sought to investigate whether ANXA2 in CHIP KO cells retain the ability to 
respond to injury, considering its altered proteostasis at basal conditions. Our 
preliminary data not only supports the known stress-induced behaviour of ANXA2 but 
identifies some differences between CHIP KO and WT cells. Whilst at basal conditions 
ANXA2 correlated poorly with dye incorporation in CHIP-expressing neurons (Figure 
5.21), such correlation increased substantially with injury (Figure 5.29). This could be 
due to an overall upregulation of ANXA2 levels or its recruitment to damage – 
mechanisms that have been reported for ANXA2148,163,176,180. This change between 
uninjured and injured conditions was not seen in CHIP KO neurons.  
 
In agreement is a preliminary experiment analysing the effect of digitonin on the levels 
and localisation of endogenous ANXA2 in a dose- and time-dependent manner by IF 
(Figure 5.30). An increase in ANXA2 fluorescence intensity could reflect recruitment, 
upregulation of the protein or change in epitope exposure at the site of injury. The fact 
that the increase in ANXA2 was detected later in CHIP KO cells following injury could 
imply a delay in the response to damage. Also, the maximum intensity of ANXA2 
reached through the injury assay was higher in KO cells (despite showing no change 
in basal ANXA2 fluorescence between CHIP KO and WT cells). This difference in 
ANXA2 dynamics could reflect a compromised ability to mount an adequate response 
to injury and/or be the consequence of exacerbated damage due to the enhanced 
sensitivity of these cells to injury.  
 
Beyond quantitative changes in ANXA2 levels in injury, the subcellular distribution of 
ANXA2 might differ between CHIP-expressing and KO cells. With digitonin treatment, 
ANXA2 staining becomes gradually more prominent and associated with the plasma 
membrane, rather than diffuse in the cytoplasm. When extensive damage occurs, 
translocates to the nucleus. This dynamic behaviour seems to be enhanced in CHIP 
KO cells (Figure 5.30A). The cytoplasm-to-membrane translocation during injury has 
been reported163, while nuclear ANXA2 in the context of stress has only been 
observed in stimuli-induced apoptosis176 and during oxidative stress to protect from 
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genomic damage175. Likewise, in conditions of extensive PM damage, ANXA2 might 
migrate to the nucleus to protect from genomic damage and/or induce apoptosis. This 
dynamic distribution of ANXA2 in injury could reflect a protective mechanism that is 
triggered more extensively in CHIP KO cells, due to their increased sensitivity to 
damage compared to controls. At present, we cannot exclude the existence of other 
underlying mechanisms for nuclear translocations, such as PTMs, which have been 
shown to mediate nuclear entry of ANXA2166. These findings support the enhanced 
sensitivity of CHIP KO cells to membrane-induced damage.  
 
 
b. Dynamics of Annexin A2:S100-A11 interactome 
Multiple membrane-related functions of ANXA2 are S100-dependent. The dynamics 
of ANXA2:S100 interaction under basal conditions and following injury were analysed 
in attempt to elucidate the molecular mechanism underlying the increased 
permeability of CHIP KO cells and their enhanced sensitivity to injury. 
 
CHIP KO cortical neurons and SH-SY5Y cells show poor membrane integrity. The 
ANXA2:S100-A11 heterotetramer forms in response to calcium influx (a consequence 
of increased membrane permeability) to restore membrane integrity148,163. PLA 
revealed that this interaction is less frequent in CHIP KO cells at basal conditions, 
despite the increase in ANXA2 levels. Moreover, CHIP KO + H260Q cells were not 
significantly different from the CHIP KO line, while CHIP KO + K30A partially rescued 
this molecular phenotype (Figure 5.31). Since CHIP interacts with ANXA2 (Figure 
5.13 & Figure 5.14), as well as S100-A11 (Figure S.11), CHIP could act as a mediator 
of the ANXA2:S100-A11 interaction, which is not CHIP-dependent but seem greatly 
promoted by the presence of CHIP. Alternatively, CHIP-induced changes to ANXA2 
or S100-A11 homeostasis (e.g. PTMs) could promote such interaction.  
 
Although further experiments would be necessary to reach a robust conclusion, it is 
interesting to entertain the hypothesis that the ANXA2:S100-A11 interaction seems to 
be dependent on the E3 ligase functions of CHIP. These protein:protein events 
correlate with the ubiquitination activity of CHIP (H260Q < K30A < WT CHIP47). 
Alternatively, changes in the interactome of ANXA2 could be a secondary effect of 
the overexpression system per se. Overexpression of a TPR-containing protein such 
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as CHIP can affect the pool and interactome of TPR-containing proteins. This is 
particularly applicable to the KO+H260Q, which expresses very high levels of CHIP 
harbouring a functional TPR domain. Additionally, it has been reported that the H260Q 
mutant associates more strongly with Hsp90186 and Hsp70193 compared to WT CHIP.   
 
Given the well-documented formation of ANXA2:S100-A11 complexes upon injury148, 
the effect of injury on this interaction in our CHIP model was also analysed (Figure 
5.32). Upon injury, ANXA2:S100-A11 PLA was unchanged in WT cells. CHIP KO 
cells, on the other hand, recorded a subtle increase in this interaction, but the 
difference between untreated and treated cells was not significant. This increase 
could be an attempt to counteract the damage, which is expected to occur when 
incubating CHIP KO cells with this treatment (while CHIP WT cells should be relatively 
unaffected, given their increased resistance). Despite such increase, treated CHIP 
KO cells remain with less ANXA2:S100-A11 puncta than untreated control cells. 
Therefore, as in basal conditions, formation of the ANXA2:S100-A11 complex is 
compromised in CHIP KO even in the presence of external stressors. Alternatively, 
the extent of injury was too mild to induce this interaction, or this mechanism is not 
required for repair in the SH-SY5Y cells, or the interactions come into play at a later 
stage (during repair or its resolution). Future work would entail a time-course analysis 
(using PLA and live-imaging) of the interaction dynamics following digitonin-induced 
injury. 
 
The interaction of ANXA2 with CHIP shares the same positive trend as ANXA2:S100 
in response to injury (Figure 5.33). Although statistical significance was not reached, 
when the PLA signal was for each cell line and conditions was subtracted by their 
background noise (the mean of each “Ctrl” group), the difference between untreated 
and treated CHIP WT cells is significant (P < 0.05) (data not shown). This suggests 
that injury may induce the interaction of ANXA2 with the active E3 ligase CHIP, which 
is not seen in KO cells. The functional significance of this interaction under cellular 
stress is unknown. Further studies should investigate whether the consistent 
correlation between ANXA2:S100 and CHIP:ANXA2 in uninjured and injured cells is 
biologically related and causative in nature. The interaction of CHIP with ANXA2 (i.e. 
the binding per se or PTMs derived) could be important for the heterotetramer 
formation with S100-A11.  
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S100-A11 is known to enhance the capacity of cells to complete the Annexin-
mediated repair process. As a complex they promote repair and membrane-
remodelling events in multiple ways. S100-A11 mediates the recruitment of ANXA2 
to the membrane, hence accumulation of these proteins at the membrane mutually 
dependent and occurs within 15-45 seconds post-injury148. The heterotetramer 
promote different PM repair mechanisms162, including by endocytosis (Figure 
5.4A)162,174 and membrane excision (Figure 5.37)163. For the latter, ANXA2:S100-A11 
is recruited to the restoration zone of the lesion, rather than the injury site (that is 
delineated by ANXA1 in a S100-independent manner). This allows actin 
polymerisation to occur in the area where cells choose to cut off the damaged part of 
the membrane (Figure 5.37A)148,162. Annexins and S100 proteins contribute to 
cytoskeletal remodelling. ANXA2:S100-A11 not only helps to nucleate actin 
polymerisation, but it also binds to F-actin to decrease its depolarization rate, 
preserving and allowing new build-up of F-actin locally163. The F-actin build-up pulls 
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Figure 5.37: Annexins and S100 proteins in membrane repair 
A) Proposed model: 1) In the uninjured cell, membrane tension is maintained by the cortical 
cytoskeleton and repair proteins are diffuse in the cytosol. 2) Injury. 3) The increase in cytosolic 
Ca2+ results in depolymerisation of F-actin and accumulation and the accumulation of ANXA1 
at the site of injury and ANXA2:S100-A11 adjacent to it. 4) The wounded membrane 
surrounding the site of injury detaches. ANXA2:S100-A11 initiates F-actin polymerisation at 
the site of injury, which aids membrane re-sealing and the restoration of membrane tension.  
B) The kinetics and localisation of ANXA2-GFP and S100-A11-RFP following laser-induced 
damage.  
(Jaiswal et al.148) 
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5.3.5 Could CHIP-dependent effect(s) on lipidomics contribute 
to differences in membrane integrity? 
a. Effect of lipids on CHIP activity 
Membrane recruitment of ANXA2 and formation of the heterotetramer with S100 
proteins is promoted by the influx of calcium. Therefore, at basal conditions, the 
majority of ANXA2 is expected to be cytoplasmic (in agreement with our subcellular 
fractionation, Figure 5.10, and IF data, Figure 5.11). In this scenario, it is easy to 
imagine that the interaction between ANXA2 and CHIP is likely to occur within the 
cytoplasm. However, once ANXA2 is recruited to the site of membrane injury and 
becomes membrane-bound, interaction with CHIP could be ablated. However, our 
PLA data contradicts the possibility of ANXA2 and CHIP becoming separate (by > 
40nm). Digitonin treatment rather than abolishing this interaction even promoted it 
(Figure 5.33). Can ANXA2 and CHIP interact at the membrane in our model? The 
hypothesis that CHIP can translocate to the membrane was recently pioneered by 
Kopp and colleagues50. They reported membrane-bound CHIP under conditions of 
stress50. Moreover, CHIP was shown to ubiquitinate the INSR, which like ANXA2 is 
also a membrane-binding protein62. Although we could not capture CHIP at the 
membrane by IF with different fixation methods (possibly due to specific epitope 
exposure or due to the transient nature of the interaction) nor live-imaging (data not 
shown), its direct contact or close proximity with such lipid-rich environment could 
influence its activity. CHIP could also migrate to the membrane independent of 
Annexin A2, although membrane-related functions for CHIP have not been previously 
identified.  
 
It was reported that CHIP binds specifically to PA and PI monophosphates, in 
particular PI4P50. PIs constitute 10-20% (mol%) of total phospholipids, are 
synthesised in the ER and recruited to the cytoplasmic leaflet of cell membranes. They 
are converted to PI3P in early endosomes or PI4P in the Golgi, PM, and early and 
late endosomes. PI4P make up 2-5% of total PI and a substantial fraction is likely to 
be present in the PM. PA is also a component of cellular membranes, although its 
abundance is low194,195. It is generated from the phospholipiase D (PLD)-regulated 
hydrolysis of the most abundant membrane glycerophospholipid, phosphatidylcholine 
(PC). Interestingly, various PLD enzymes have been implicated in Alzheimer’s 
disease196. PA can be hydrolysed by phospholipase A to generate LPA196. Within the 
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cell, PA can regulate phospholipid biosynthesis, as it is a common precursor of 
glycerophospholipid (such as PS, PI and PE)195. Functionally, PA also regulates 
membrane vesicle trafficking (i.e. promotes membrane vesicle formation and fusion), 
by inducing membrane curvature driven by its negatively charged headgroup195,196.  
 
Through binding to PA or PI4P, potentially CHIP could become membrane-bound and 
interact with ANXA2 at this compartment. Although supporting data for this is still 
required, we sought to investigate the effect of these lipids on the E3 ligase activity of 
CHIP. Our in vitro ubiquitination data suggests that both PA and PI4P inhibits CHIP-
dependent ubiquitination of ANXA2, while the latter also prevents CHIP’s auto-
ubiquitination (Figure 5.34), thus the underlying mechanism for compromised 
ubiquitination of ANXA2 may be different. This contradicts the reported enhancement 
of auto-ubiquitination of CHIP and slight impairment of CHIP-dependent formation of 
free polyubiquitin chains in the presence of PA-containing liposomes50. The 
importance of PA and PI4P in the homeostasis of CHIP (both localisation and activity) 
is still unknown.   
 
Kopp and colleagues50 reported that CHIP mutant K30A resides in the PM (detected 
by live-imaging). The explanation proposed suggests that, given the competitive 
nature of both lipid and chaperones for the TPR domain, by abolishing chaperone 
interaction, CHIP becomes membrane-bound50. However, it has been shown that the 
inherent biophysical properties of K30A CHIP are highly similar to the chaperone-
bound WT protein (Figure 5.20B). Therefore, lipid-binding, like chaperone-binding, 
may induce structural rigidity (Figure 5.20C), which has been shown to allosterically 
inhibit U-box activity47. This could explain the reduced auto-ubiquitination of CHIP in 
the presence of specific lipids.  
 
There has been growing evidence supporting lipid-dependent regulation of proteins 
by different functional principles (Figure 5.38)197. Given the reported specificity of 
CHIP for PA and PI4P, the distribution of these lipids can regulate the recruitment of 
CHIP to specific membrane locations (illustrated by mechanisms i-iii in the figure), 
acting as lipid-anchors196,197. Furthermore, lipid-protein binding can initiate/modulate 
the functional activity of the protein by altering its conformation and electrostatic 
interactions (e.g. through allosteric regulation, mechanism iv). This lipid-induced 
regulation can be direct (e.g. PA-mediated activation of phosphatidylinositol kinases) 
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or indirect (e.g. activated as a downstream consequence of signalling cascades 
initiated by PA as a lipid secondary messenger194). Therefore, the spatial and 
















b. Lipidomics of a CHIP KO model 
The differences in lipidomic profile across cells expressing and lacking CHIP (Figure 
5.35) could be informative when studied from different angles: in the context of lipid-
dependent modulation of protein activity and with regards to membrane composition 
(affecting membrane integrity). These will be reviewed. 
 
 
i. Lipid-dependent modulation of proteostasis 
Given the in vitro observations of lipid-induced changes in CHIP activity and growing 
field of how lipid composition influences protein and membrane homeostasis, we 
sought to evaluate how the lipidomic profile of the CHIP SH-SY5Y model could 
influence protein activity at a cellular level.  Our preliminary results revealed that, 
although the concentration of the majority of phospholipid groups assayed did not 
change, PA, LPA and PS showed an increase of 1.5 to 2.5-fold change (WT/KO).   
 
Figure 5.38: Functional principles of lipid-regulated protein function 
i) Direct recruitment of a protein to the membrane by high affinity binding 
ii) Phospholipids cooperate with other local molecular interactions for protein recruitment (e.g. 
small G-protein provides the avidity necessary for membrane binding) 
iii) The anionic lipid environment drives protein binding by electrostatic interaction 
iv) Lipid binding induces allosteric activation of the protein through a conformational change 
(Adapted from Hammond et al.197) 
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ANXA2 binds preferentially to PS, as well as other negatively charged phospholipids, 
including PA167. PS is also an important component of the cellular membrane, residing 
mainly in the inner leaflet198. PS can be synthesised from pre-existing PC or PE199. 
Accumulation of PS has been shown to improve hippocampal synaptic efficiency, 
possibly by enhancing the activity of membrane-bound enzymes involved in 
neurotransmitter release and promoting long-term potentiation. Phenotypically, this 
prevented age-related decline in cognitive ability and memory200,201. Increased PS 
also promotes neuronal survival via PI3K/Akt signalling pathway199,202. 
 
Following identification of ANXA2 as a disease-relevant potential protein target of 
CHIP, we investigated the dynamics of ANXA2 proteostasis (alone and as a complex 
with S100-A11), the lipidomic profile and membrane integrity of our CHIP model(s). 
However, the relationship between these is unknown and different questions have 
been opened. One hypothesis is that ablation of CHIP expression could lead to the 
dysregulation of lipids important for the homeostasis of ANXA2 (e.g. PS or PA). This 
would be suggestive of a role for CHIP in the regulation of membrane composition, 
which has not been previously reported. The increased WT/KO fold changes favour 
CHIP as a positive regulator of specific phospholipid classes. If CHIP proves to be a 
regulator of phospholipid composition, this could have significance in research and 
clinical settings, since PS levels in mammalian cells have been difficult to modulate202.  
 
Alternatively, CHIP could function as a direct negative regulator of ANXA2 
homeostasis, thus deletion of CHIP would lead to ANXA2 accumulation (the same 
phenotype as that observed in CHIP KO cortical neurons). Lipid changes could rise 
secondary to this: dysregulation of the lipid-binding protein ANXA2 could in turn 
compromise the membrane homeostasis, in particular the levels of the lipids to which 
it binds to (PA, PS and PI – the latter two were found to be decreased in CHIP KO). 
A third hypothesis positions changes in lipid composition as an early event, as these 
would interfere with CHIP activity (as seen from the in vitro ubiquitination assay), 
eventually leading to changes in ANXA2 indirectly. Future work would investigate the 
strength of these correlations and possible underlying mechanisms to understand 
whether this correlation implies causation.       
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ii. Implications for membrane integrity 
A change in lipid composition could also help to explain the membrane-related 
phenotype observed across our CHIP models. Saturation and length of the acyl 
chains of phospholipids are important features to dictate membrane properties. 
Typically, fatty acids are attached to the sn1 position of glycerol backbone (within the 
head of the phospholipid) are predominantly saturated (SFA), while those esterified 
to sn2 tend to be mono- (MUFA) or polyunsaturated (PUFA), together referred to as 
unsaturated fatty acids (UFAs)195. The relative distribution of these in membranes is 
around 40:60 (SFAs:UFAs)203. Within the core of the lipid bilayer, acyl chains are 
tightly packed but remain highly mobile. Short lipid tails and unsaturated chains 
contributes to a more fluid membrane with high structural stability198.  
 
Fluidity influences membrane tension and bending rigidity and, in turn, membrane 
plasticity198. Seeing that repair mechanisms require extensive membrane remodelling, 
this flexibility is likely to be important in promoting membrane repair195. The nature of 
lipids reflects the flexibility and resistance of membranes, which is essential for the 
constant remodelling conducted without interfering with its barrier function and overall 
structural stability198. 
 
As proof-of-concept that particular changes in membrane composition can affect 
membrane integrity, lipidomic changes observed in Duchenne muscle dystrophy were 
compared to our CHIP model. In this progressive condition, breakdown of plasma 
membrane is the earliest detectable abnormality preceding muscle fibre loss204. Lipid 
composition is believed to be responsible for the abnormal membrane properties 
(Table 5.1)205,206. Overall, there is an increase in MUFAs (18:1) across phospholipid 
classes and a decrease in PUFAs (22:6) in PE and, possibly, in PC classes of 
phospholipids. Muscle membranes, like Duchenne muscle fibres, with increased 
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Table 5.1: Lipidomics of Duchenne muscle fibres 
Saturated phospholipids are indicated in black, mono-unsaturated in red and poly-
unsaturated in blue. Meta-analysis based on Pearce & Kakulas205 and Kunze et al.206.   



























LPC 18:0 Increase54,55 
 
 
Likewise, our CHIP KO model showed an overall increase in SFAs analysed in this 
preliminary study (Table 5.2). However, MUFAs, which make up a greater fraction of 
fatty acids analysed, were decreased in the CHIP KO cells. Of significance, PS 34:1 
was particularly decreased in KO cells compared to controls (Figure 5.35). This does 
not follow the observed increase in MUFAs seen across phospholipid classes in 
Duchenne muscle. However, the reported decrease in PUFAs is consistent with our 
observations in CHIP KO cells. The WT/KO fold change recorded for PA 38:4 and PS 
36:4 was of >2 and for PA 36:4 and LPA 20:4 was 0.5 (Figure 5.35). The changes in 
PUFAs were restricted to a few phospholipids, thus the overall concentration was 
similar between CHIP KO and control cells (Table 5.2). The decrease in phospholipid 
unsaturation (and possibly the increase in saturation, although to a less extent) could 
to increased membrane rigidity. This is associated with increased permeability and 
susceptibility to membrane injury207, thus could contribute to the poor membrane 
integrity observed in our CHIP KO cell models. Nonetheless, it is important to take 
into account that this was a preliminary lipidomic analysis of this CHIP model and that 
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Table 5.2: Concentration of phospholipid saturation classes identified by 
lipidomics of CHIP KO and WT undifferentiated SH-SY5Y cells 
Data presented are averages (nmol/g,ml).  
CHIP genotype or fold change More saturation Less saturation 
SFAs MUFAs PUFAs 
WT 0.157 22.010 25.969 
KO 0.207 17.548 23.660 
WT/KO 0.756 1.254 1.098 
 
 
Data in this chapter supported the role for CHIP in the regulation of the membrane 
proteins, ANXA2 and S100-A11, as well as their complex formation. Such regulation 
could occur post-translationally and possibly via ubiquitination, as ANXA2 was 
identified as an E3 ligase substrate of CHIP. In parallel, CHIP seems to influence lipid 
composition, which has not been previously reported. Whether the CHIP-mediated 
changes in membrane proteins and lipids are independent, yet related molecular 
events, or not, is unclear. However, these could be two mechanisms driving the same 
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6.1.1 Structure and function of CHIP 
a. Folding of the CHIP dimer 
WT CHIP has been described as predominantly dimeric38,49, but monomeric38 and 
other high multimeric forms38,49 have been reported. The elongated protomer of the 
asymmetrical dimer is the most stable, having its HH extended and its C-terminal 
residues wedged between the TPR domain and the U-box. In the compact protomer 
the TPR domain packs directly on the U-box (residues 256-265), having the E2-
binding site buried39,208. The CHIP dimer assembly pathway has been defined as 
consisting of symmetrical dimerization followed by an activation step that causes the 
dimer to break the symmetry208 (Figure 6.1A). This gives rise to an asymmetrical dimer 
(Figure 6.1B) with intra-protomer packing of the TPR domain against the U-box of one 
of the protomers. As a result, one E2-binding site on the U-box is exposed, changing 
the stoichiometry of its binding with E2 enzymes39,48,208.   
 
The folding of the asymmetric dimer has been modelled. The HH-domain dimerization 
triggers rapidly partial symmetric U-box dimerization by positioning the U-boxes of the 
protomers within interaction range (Figure 6.1Aa). More specifically, HH dimerization 
brings together five consecutive basic amino acids within the linker region 
(221KRKKR227) between the HH and U-box of each protomer (Figure 6.1B). At this 
stage, repulsive interactions grow between the positively charged linker and the 
extended helix (153RRIH158 in H7). This electrostatic repulsion is eventually revealed 
by breaking H7 of one protomer, causing its bending and breaking dimer symmetry 
(Figure 6.1Ab). This snapping of the helix in one protomer forces the opposite 
protomer to insert its C-terminal through its own TPR and U-box domain interface 
(Figure 6.1Ac). Finally, the partial U-box dimer assumes a native-like conformation, 
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Figure 6.1: Folding of dimeric CHIP 
A) Folding of the asymmetric dimer. The progressive molecular dynamics of the U-boxes (a), 
the bent/compact protomer (b) and the extended protomer (c) are represented. Folding starts 
with U-box dimerization (I in a), followed by the breaking of the helix H7 (II) to yield the bent 
protomer (b). The final events (III) are the TPR-U-box separation and the insertion of the C-
terminus (involving the interaction between the C-terminal a-helix of the TPR domain in blue 
with the C-terminus in yellow, and the latter with the U-box in red) in the extended protomer 
(c).  
B) Crystal structures of the dimeric asymmetric CHIP (mouse) and symmetric fCHIP 
(Zebrafish). The latter lacks the TPR domains. The 221KRKKR227 residues link the TPR and 
the U-box domains.  
(Ye et al.208) 
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Although the formation of an asymmetrical dimer is usually associated with energy 
frustration and structural instability, snapping of the helix is transduced into 
mechanical force that kinetically activates the CHIP dimer by disrupting a stable 
domain-domain interaction. Thus, kinetic forces generated by opposing interactions 





The inherent and dynamic property of CHIP to form homodimers allows an elegant 
interplay between a dimeric chaperone and a single ubiquitination system39,48. The 
advantages of an asymmetric structure are clear: tight regulation of CHIP activity and 
prompt switching from chaperone-mediated protein folding to proteasome-mediated 
degradation39. Additionally, asymmetry may also contribute to the regulation of the 
steady-state levels of CHIP. The asymmetry of the monomers limits the availability of 
E2-binding sites, thus it may also function to prevent premature CHIP degradation 
until assembly of the fully formed dimer208. 
 
 
c. Symmetric versus asymmetric  
Both symmetric209 and asymmetric208 dimer conformations have been described for 
human CHIP in solution and crystallized from zebrafish and mouse, respectively208,209 
(Figure 6.1B). In principle, symmetric dimers formed by two bent protomers would be 
inactive with regards to E3 ligase function. Here, there is no extended H7 helix to 
disrupt the TPR-U-box domain interface, thus the E2-binding site would remain 
buried. However, the elongated-dimer model could yield, theoretically, an active dimer 
that could bind two E2 enzymes. In this scenario, snapping of the extended helix does 
not occur and the TPR-U-box domains never interact. Here, the U-boxes do not 
dimerise208.  
 
The bent-dimer conformation can be achieved solely by deleting six C-terminal 
residues of CHIP, responsible for TPR-U-box separation. The elongated-dimer is 
formed when CHIP lacks the TPR domain (as in Zebrafish)208. Only the asymmetric 
crystal structure of mouse CHIP has been published. However, based on HDX-MS 
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data, Graf and colleagues209 reported that CHIP is a highly flexible symmetric dimer 
in solution with dynamic regions, capable of E2 binding. Structural flexibility has been 
directly linked to CHIP activity47. 
 
 
6.1.2 Single chain variable fragment (scFv) 
a. Structure and function 
The use of antibodies in molecular biology takes advantage of the nature of the 
immune system: to detect and defend our body against non-self-agents210. They have 
proven to be efficient as high-affinity, protein-based binding reagents211. The IgG 
antibody contains a unique variable region (Fv) within the antigen-binding fragment 
(Fab) (Figure 6.2A). The antigen-binding sites, the paratopes, are located at the Fab 
tips210. Antibodies have been manipulated to improve their binding affinity, 
pharmacokinetics, stability and expression levels212. They have been engineered into 
monovalent (including Fab and single chain Fv fragments, scFv) and bivalent 
fragments (e.g. F(Ab’)2)211 (Figure 6.2B)96.  
 
ScFv (Figure 6.2Bc) are heterodimeric recombinant antibodies consist of one Fv 
region (the smallest functional unit) of the classic IgG antibody, having a variable light-
chain (VL) and a variable heavy-chain (VH) connected by a flexible linker210,211,213. They 
have the same specificity and affinity for antigens as a full IgG antibody containing 
such Fv region, in a monovalent manner213. The variable regions contain both 
hypervariable and framework sequences. In total, scFv contain six hypervariable 
sequences that make up the antigen-binding site and referred to as the 
complementarity determining regions (CDRs). The framework sequences, on the 
other hand, ensure correct β-sheet folding of the VL and VH domains, allowing 
interdomain interactions. The flexible linker also contributes to proper folding213. It 
contains hydrophilic residues (preventing intercalation of the linker between the 
variable domains during protein folding) together with stretches of residues that 
enhance flexibility (Gly and Ser) and solubility (Glu and Lys)210,212. Linker length is 
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b. ScFv antibodies engineered by phage display technology 
Early methods for the generation of small recombinant antibodies were based on 
proteolysis212,214, for example Fab was digested to obtain the Fv region only (in 1971). 
Later, the first scFv antibodies were cloned by Bird et al.213, Huston et al.215 and Skerra 
et al.216 in 1988 by expressing scFv genes in E. coli and purifying them using acid-
based or affinity-based purification. Common problems faced included loss of affinity 
for antigens compared to the parent antibody, poor solubility and stability and 
aggregation.  
 
Phages are viruses that accommodate segments of “foreign” DNA. The most common 
phage-displayed vectors used in scFv production are filamentous phage strains. 
Phage infect E. coli by attaching its coat protein pIII to the bacterial host, which causes 
the coat protein to dissolve and allows the phage-displayed vector (ssDNA) to enter 
the cytoplasm. Next, the vector (containing the foreign insert) replicates in the host by 




Figure 6.2: Antibodies 
A) IgG antibody is a Y-shaped four polypeptide unit containing two heavy (H) and two light (L) 
chains held together by disulphide bonds. It has conserved constant regions (in blue) are 
located in both the fragment crystallizable, Fc, at the stem, and the antigen-binding fragment, 
Fab region, at the arms. The unique variable region, making up the Fv within the Fab region, 
is illustrated with stripes, representing the complementarity determining regions. This structure 
allows its bivalent activity, which increases the functional affinity (avidity) of the antibody for its 
antigen.  
B) Recombinant Ab fragments: F(Ab’)2 (a), Fab (b) and scFv (c).  
   (Information based on Ahmad et al.210 and Holliger & Hudson211. 
Schematic adapted from Dos Santos96) 
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stranded replicative form (RF) that makes progeny RF. Beyond the normal delivery of 
the vector, phage-display vectors cause the foreign DNA to be expressed as a protein 
in the host. For such, the host machinery is recruited to synthesize a foreign peptide 
(encoded by the DNA insert). Because the foreign gene sequence is spliced into the 
gene encoding one of the coat proteins, the foreign peptide synthesised is fused to 
the coat protein. The hybrid coat protein is then incorporated into phage particles 
(“virions”) as they are released from the host cell. The extensive secretion of progeny 
virions (several hundred per cell per division cycle) does not kill the host. Phage 
harbouring the surface peptide infect fresh bacterial host to repeat this process and 
multiply. Variation in the peptides displayed by the phages arises from possible 
mutations in the peptide encoding DNA, which can result in a different amino acid 
sequence and/or structure and would pass on to phage progeny. This highlights two 
key characteristics of phage that make phage display technology attractive in the 
generation of scFV: replicability and mutability217.  
 
 
i. Phage libraries 
Phage-display libraries are heterogenous mixtures of phage clone harbouring 
different foreign DNA insert, hence displaying different peptides on its surface. 
Libraries can be ‘genomic’ (having fragments potentially representing the entire 
genome) or derived from mRNA (cDNA libraries)217. Furthermore, phage display 
libraries can be immune, naïve or synthetic210, depending on the nature of the antigen 
of interest. While immune libraries utilise B cells from immunized animals, naïve 
libraries do not. Thus, the latter carry a broad pool of genes encoding the variable 
domains of antibodies, are not bias towards any antigen and are more successful for 
the selection of phage against a large repertoire of different antigens. Synthetic 
libraries are prepared through recombination of CDRs responsible for antigen 
binding210. Libraries promote the generation of high-affinity and high-specificity 
scFv211.      
 
 
ii. Phage display biopanning  
The method for generation of phage recombinants displaying antibodies at their 
surface was paired with affinity selection methodologies, referred to as biopanning 
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step (Figure 6.3). This enabled in vitro selection of scFv from large phage libraries, 
circumventing the need for expression systems210. For such, immobilized antigen-
bearing peptide/protein is used to capture phage displaying different peptides that 
have affinity for the antigen. Unbound non-specific phages are washed off, while the 
fraction of bound phages is eluted. This artificial selection yields a subpopulation that 
is enriched in phages harbouring scFv that may be of interest (having increased 



















This is followed by an amplification step, where the eluted phages infect fresh 
bacterial host cells. The yielded amplified stock contains millions of copies of progeny 
derived from each potential phage of interest. This can be used as input for another 
round of affinity selection and the final eluate is typically achieved following 2-3 
rounds. Given the mutability feature of phage, the phage-display peptides are 
subjected to subtle changes that culminate in an ever-fitter subset of the starting 
peptides. By periodically introducing mutations and a tight selection pressure on the 
phage population, the pool of epitopes displayed widens (surpassing that present in 
the initial phage-display library) and at the same time becomes bias towards the 
epitope of interest217. 
Figure 6.3: Phage display biopanning 
Summary of the phage display rounds of selection to obtain several antibodies with high 
specificity for a particular protein. For such, there were multiple rounds of probing against the 
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Ultimately, the aim is to generate phage that bind to the antigen of interest with high 
affinity from a large number of non-specific phage210. For such, biopanning 
incorporates two pivotal parameters: stringency and affinity. Some degree of 
stringency is necessary in order to discard the vast majority of nonspecific phages 
present in libraries, thus ensuring successful biopanning. However, stringency 
favours high fitness peptides at the cost of a decrease in yield. This parameter cannot 
be set too high at selection to make sure higher fitness phages are represented in 
subsequent rounds. This criterion is especially important in the first round of selection, 
when potential phage of interest have not been amplified. With subsequent rounds, 
yield can be compromised in favour of higher stringency217. Phage binding affinity is 
another common selection pressure applied to ensure functional scFv are later 
retrieved. This is possible because scFv displayed on phage surfaces retain active 
antigen-binding capability210.  
 
Phage recovered from the final round of biopanning are characterised 
individually210,217. Cloning techniques can be used to sequence the viral DNA and 
hence obtain the amino acid sequence of the phage-displayed peptide. Additionally, 
the DNA encoding the peptide can be cloned into expression systems for subsequent 
scFv purification and different expression formats218.     
 
 
iii. Advantages and limitations  
The use of phage display also bypasses the problems associated with hybridoma 
technology and immunization210,217. Furthermore, it is a highly scalable method. Rich 
and diverse antibody libraries with hundreds of unique antibodies per target can be 
generated using this technology, favouring the concept of genome-wide antibody 
generation218.  
 
ScFv are stable, easily manipulated and produced in a rapid and inexpensive manner. 
As a research tool, the small size of scFv is favourable when targeting epitopes that 
may be poorly accessible by other antibodies, such as cryptic epitopes, enzyme active 
sites and other protein domains211. Once generated, scFv can be delivered in multiple, 
non-mutually exclusive ways: 
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1. Using viruses, such as the adeno-associated virus, 
2. As chimeric antibodies fused to proteins that aid delivery, e.g. the blood brain 
barrier receptor for transport into the brain212, 
3. As intrabodies, where scFv are designed to be expressed in-frame and 
intracellularly to modulate specific molecular interactions in situ, leading to 
changes in the activity of the target proteins219.  
 
However, there are some limitations in the use of scFV antibodies that have been 
challenged by some groups. Firstly, monovalent scFv (antibodies with a single 
antigen-binding domain), may have limited avidity and low dissociation rates, which 
can compromise its functions. The generation of multivalent scFv antibodies largely 
circumvented this problem211,212. Secondly, given the requirement for both high levels 
of scFv and adequate epitope binding (i.e. affinity) intracellularly for cellular outcomes 
to be elicited, can limit the use of scFv as nanobodies220. 
 
 
iv. ScFv applications 
ScFv antibodies have wide applications in both the fields of research and 
therapeutics. In fact, in 2013, scFv accounted for 35% of antibody fragments in clinical 
trials212.  They are invaluable tools for the study of proteins and to modulate their 
activity and interactome (e.g. by targeting specific domains). A loss-of-function 
experiment used neutralizing scFv antibodies against Pax6 to decipher its functions 
during development212.  
 
As intrabodies, scFv have also been used to target disease proteins. For example, a 
scFv targeting an epitope on APP adjacent to its β-secretase cleavage site, prevented 
generation of the disease protein, Aβ. This supported the rational that targeting 
substrates rather than enzymes could modulate detrimental molecular mechanisms 
with greater specificity221. Another scFv nanobody against the NAC (aggregation-
prone) region of α-syn222 and effectively reduced aggregation and prevented 
toxicity220. Both studies showed that high steady-state expression levels and correct 
conformation epitope binding (i.e. stability and affinity in the cellular environment) 
were critical properties for intrabody efficiency, being more important than their in vitro 
affinity220,222. Importantly, given its success, anti-NAC can be regarded as deliverable 
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therapies to mimic gene deletions, which could disfavour disease progression and be 
useful in a disease-modelling context.  
 
The use of scFv nanobodies has translated into animal models of disease, being 
useful as biomarkers and/or aggregation-modifiers223–225. For example, scFv 
antibodies engineered against Aβ resulted in a reduction in the number of amyloid 
plaques (by 25-50% compared to controls)224, the levels of insoluble Aβ and 
hyperphosphorylated tau and improved cognitive function225 in AD mouse models. 
The exact mechanisms of action are unknown, although hypotheses include: 
1. Antibody-mediated disaggregation of pre-formed fibrils, preventing toxicity, 
2. Antibody-induced immune responses, such as activation of microglia, 
3. ScFv-mediated clearance of extracellular Aβ in an Fc-indepedent mechanism, 
4. The “sink hypothesis”, where antibodies sequester soluble Aβ and thus 
prevent oligomerisation224,225.  
 
6.1.3 Hydrogen-deuterium exchange (HDX) 
a. HDX development and applications 
HDX is a quantitative method for measuring the structural and biophysical properties 
of single protein or interacting complex226. Insulin was the first protein analysed by 
HDX in the mid-1950s and led to the understanding that amides engaged in hydrogen 
bonding for maintenance of secondary structures have slower HDX rates. In 1991, 
HDX was coupled with mass spectrometry (HDX-MS) and later paired with enzymatic 
digestion227,228. Previously, MS could only inform on primary protein structure, rather 
than protein conformation227. Therefore, the ‘gentle’ structure-dependent labelling 
approach of the HDX together with the detection sensitivity of MS resulted in a method 
with considerable analytical power229.     
 
Since then, HDX has contributed to our understanding of how biophysical properties 
relate to protein structure-function, interactions, dynamics and energetics226–228. Thus, 
HDX is commonly used in the study of protein conformation and conformational 
dynamics in the context of modifications, mutations, unfolding/refolding, protein-ligand 
or protein-protein interactions and protein aggregation227,228. This includes the 
assessment of antigen-antibody interactions (including the effect on protein folding, 
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stability and function) and identification of binding sites227–229. When a protein complex 
forms, the interface between the binding partners is protected from HDX, due to the 
steric exclusion of the deuterium-containing solvent (concept is explained below). To 
aid data interpretation, HDX experiments on the free antigen are performed in parallel. 
This reference experiment is then compared with the HDX behaviour of the antigen-
antibody complex to identify regions that display different exchange kinetics (i.e. 
potential epitopes)227. Nevertheless, the use of HDX for epitope mapping needs to be 
undertaken with caution since binding can induce changes in protein dynamics and 
conformation in regions distant from the actual binding site/interface due to allosteric 
effects227,228. Furthermore, binding can enhance the thermodynamic stability of a 
protein, causing the overall protein complex to be more strongly protected from 
HDX227,230. Commonly, HDX-MS is combined with computational analysis and/or site-
directed mutagenesis for validation of epitopes and to further our understanding of 
the mechanism of action and the structure-function relationship in question227. 
 
 
b. HDX technique 
HDX-MS allows for biophysical properties to be monitored in proteins in solution227,230. 
HDX takes advantage of the natural phenomena of hydrogen exchange228 (hydrogen 
atoms in O-H, N-H and S-H groups are labile and exchange with surrounding 
water230). By exposing a protein to deuterium-containing environment, HDX occurs 
and deuterium replaces hydrogen, particularly at sites that are more exposed230. This 
can be detected by MS because each exchange event increases the mass of the 
protein (because deuterium has a greater mass than hydrogen)227,229,230.         
 
HDX occurs at protein amide, hydroxyl, or thiol hydrogens229, thus takes place at side 
chains and the protein backbone. However, for multiple reasons, only the protein 
backbone is typically used for analysis to obtain information regarding protein 
conformation and dynamics227. Firstly, side-chains and N-terminal hydrogens undergo 
rapid back-exchange (i.e. loss of previously incorporated deuterium) during the 
quenching step229. Secondly, since the majority of residues (except prolines and the 
first amino acid of the chain) possess an amide group, HDX behaviour can be 
observed throughout virtually the entire protein. Thirdly, since the dynamics of HDX 
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of backbone amides correlate with protein structure, data can inform on regional 
conformational dynamics230.  
 
Isotope exchange of backbone amides (N-H to N-D) is influence by several factors 
and can range from seconds to hours229. Exchange is fastest in solvent-exposed 
amides (i.e. located at the surface of the protein), which are not or weakly involved in 
hydrogen bonding (e.g. for maintenance of secondary structure)227,228,230. In contrast, 
amides involved in hydrogen bonding or sequestered from the solvent (i.e. buried in 
the interior of the protein) take longer to exchange227–229. Additionally, the flanking side 
chains also affect the exchange230. All these factors influence the chemical exchange 
rate constant (kch) of each amide, which is dictated by the primary sequence in the 
absence of structure or sequestration229,230. Together, this data distinguishes regions 
of the protein that are more ordered (have increased intramolecular hydrogen bonds 
and shielded by larger side chains) and are protected from HDX, from unfolded or 
intrinsically disordered elements that lack stable hydrogen bonding, incorporating 
more deuterium226,228,230. Therefore, the level of deuteration tends to correlate with 
structural flexibility47.  
 
Eventually, even protected amides undergo HDX. This is driven by conformational 
fluctuations of the protein, where amides transition transiently to an “open” 
conformation, which is susceptible to isotope labelling230. A series of opening/closing 
events (kop and kcl) may occur prior to isotope exchange228,230, thus every amide group 
has a unique combination of criteria (kch, kop, kcl) dictating its rate of HDX230. The 
exchange mechanism is as follows229,230: 
 
 
Increasing opening/closing events occur as the protein unfolds to expose backbone 
amides within isolated regions (localised unfolding) or the entire protein (global 
unfolding)228,230. Such protein motions may result from localised or global structural 
events (e.g. induced by protein-protein interactions)228–230. This allows HDX-MS to be 
used for measuring mass shifts of individual protein segments, indicating where 
changes in behaviour occur226,230. Given enough time, addition of deuterium induces 
complete unfolding of the proteins due to protein motion and ‘protein breathing’ (the 
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alternative structures adopted naturally and transiently by proteins that differs from 
their native conformation)228,230. 
 
 
c. Continuous and pulse HDX labelling techniques 
There are two main approaches for HDX-mediated protein labelling: continuous and 
pulsed labelling227 (Figure 6.4A&B). Continuous labelling consists of taking several 
aliquots of the protein sample and incubate in deuterated buffer for certain periods of 
time followed by quenching. This strategy reveals deuterium incorporation into the 
protein structure as a function of exposure time (i.e. the increase in protein mass over 
time)227,228,230. This informs on conformational dynamics because tightly folded 
regions tend to be less dynamic, spending less time in open conformations, hence 
taking longer to exchange compared to unfolded domains227,230.  This approach is the 
most common and simple to perform228. Pulse labelling consists of inducing 
conformational changes (e.g. by the addition of a chemical denaturant or by changing 
pH or temperature) prior to a brief exposure to deuterated buffer (typically for ≤10s), 
referred to as the pulse time227,229. This method is useful in the identification of protein 
folding mechanisms and characterisation of short-lived folding intermediates, since 




d. Mass spectrometry analysis of HDX experiments  
Once the HDX experiment is completed, the protein sample is quenched to inhibit 
further HDX events. This is followed by MS-based detection, using either ‘bottom-up’ 
(Figure 6.4C)  or ‘top-down’ (Figure 6.4D) approaches228,230. The former is more 
commonly used and consists of proteolytic cleavage (typically by pepsin) after 
quenching using acidic conditions, followed by peptide fragment separation by HPLC 
and mass analysis by MS226,230. The greatest advantage of using this approach is the 
increased spatial resolution, since the level of deuterium incorporation into different 
protein fragments is coupled with peptide mapping, providing information about local 
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Figure 6.4: HDX-MS 
A) Pulse labelling method: a protein is exposed to a perturbant that induces unfolding (regions 
in grey), becoming labelled with deuterium (in red).  
B) Continuous labelling method: deuterium is gradually incorporated into a protein sample 
(red), which is quenched after subsequent labelling times.   
C) Deuterated samples from either A or B are digested by pepsin or another acid protease. 
The resulting peptides are separated by HPLC and analysed by ESI-MS or by MALDI-MS 
(different ionization methods). This yields information about the local deuterium exchange 
across the peptide backbone. This is a “bottom-up” approach.  
D) Samples from A and B can also be analysed using a “top-down” approach, which bypasses 
the proteolytic step, hence fragmentation of intact proteins only takes place in the gas phase 
of the MS. This method is useful for the evaluation of global changes in protein structure and 
stability, for thermodynamic measurements and analysis of noncovalent protein-ligand 
interactions. 
(Adapted from Wales & Engen228) 
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e. Advantages and disadvantages of HDX 
Compared to other analytical techniques, HDX is not limited by the crystallization 
properties and the size of the proteins of interest227,229,230. It only requires small 
amounts of sample (in the picomole range)226–229 and confers unparalleled 
sensitivity228–230, detecting subtle structural changes227 and higher order protein 
structures228–230. This robust and powerful technique has been used to study complex 
protein systems226,227.  
 
However, the potential of HDX is limited by some challenges. Firstly, the method 
requires the addition of deuterium into the sample, which tends to result in dilution of 
the sample and may render it incompatible with sample quantity requirements for 
MS228. Secondly, back-exchange may occur during sample preparation due to the 
introduction of protiated solvents228.  Finally, standard HDX can also be limited by 
spatial resolution, informing on region-specific HDX behaviour rather than at the 
amino-acid level. The later can be achieved by obtaining HDX data of several 
overlapping and sequential fragment ions derived from deuterated peptic peptides in 
order to cover the experimental protein with confidence226–228. Advances in HDX-MS 
are paving for direct protein structural information at single amino acid resolution226,228.   
 
6.1.4 Mapping ubiquitination sites 
Throughout the years there has been considerable efforts to study the Ub-modified 
proteome, often referred to as the ubiquitome141. Pinpointing ubiquitination sites on 
substrates is not only essential for the understanding of ubiquitination, but it the 
ultimate proof that a putative substrate is indeed ubiquitinated139. Furthermore, as 
more ubiquitination substrates are identified, the focus has shifted into investigating 
the dynamics of this phenomenon, addressing questions such as when, where, how 
and why proteins are ubiquitinated in vivo140. Understanding characteristics of specific 
ubiquitination sites (including Ub chain length and linkages and whether the 
modification occurs constitutively or is driven by a signal) informs on the diverse 
cellular fates of the PTM and how it is regulated143. Ultimately the aim is to understand 
how protein function is regulated in both physiological and pathological contexts139–
141, given that ubiquitination pathways often fail in neurodegenerative diseases140.   
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Advances in enrichment strategies (e.g. affinity-based) to isolate ubiquitinated 
substrates coupled with MS/MS have been successful in the identification of 
ubiquitination substrates and the mapping of ubiquitination sites141,143. These include 
the use of epitope-tagged Ub, tandem Ub-binding domains, Ub-specific antibodies, 
and ubiquitination remnant antibodies (represented in Figure 6.5)139.  
 
The most promising enrichment strategy is the use of an antibody against the 
ubiquitination remnant, glycine-glycine (diGly) (Figure 6.5D). The diGly signature on 
ubiquitinated peptides is yielded during proteolytic digestion of the sample – a critical 
step in sample preparation for bottom-up MS. The C-terminus of Ub (consisting of 
Arg-Gly-Gly followed by the substrate) is cleaved after the Arg residue, leaving a diGly 
remnant on the previously ubiquitinated peptide (usually attached to a lysine 
residue)143. Prior to the analysis of the diGly-containing peptides by MS, affinity 
purification using an anti-diGly antibody can be performed to enrich for these 
species139,141,143. The antibody is believed to be specific, recognising diGly sequences 
present as an adduct on the ε-amine of lysine and not internal diGly sequences. It has 
been reported that the antibody results in selective enrichment of diGly peptides by 
>50%143. Using this assay, Xu and colleagues143 have identified 236 ubiquitinated 
proteins and 374 ubiquitination sites.  
 
In the presence or absence of the enrichment strategy using the anti-diGly antitbody, 
ubiquitination (via the diGly remnant) is detected by MS by a mass shift of 114.043 
Da, where the mass of the lysine residue without and with the diGly signature is 
128.09 Da and 242.14 Da, respectively139,143. The protein sequence database is 
manipulated to yield the library of peptides following tryptic cleavage and with the 
addition of the mass of the diGly remnant on particular amino acids, typically lysine 
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Figure 6.5: Strategies to isolate ubiquitinated species 
A) Epitope-tagged Ub. The use of tagged-Ub for the purification of ubiquitinated proteins.  
B) Ubiquitin-chain specific antibodies. Ub chain-linkages can inform of the fate of different 
ubiquitination events. However, it is still unclear whether these antibodies can efficiently purify 
linkage-specific substrates to be analysed by MS.     
C) Tandem Ub-binding domains (UBD). Given the inherent low affinity of endogenous UBDs 
for Ub, which limits the purification of substrates, tandem UBDs have been engineered with 
antibody-like affinity. However, purification cannot be done under denaturing conditions, thus 
contaminant proteins are likely and might disfavour the identification low abundant substrates. 
Moreover, UBDs are bias towards the capture of polyubiquitinated versus monoubiquitinated 
substrates.  
D) Ubiquitination remnant antibody (anti-diGly antibody). When ubiquitinated proteins are 
digested by trypsin, a signature motif is achieved. Peptides harbouring diGly motifs can be 
enriched using an anti-diGly antibody.  
All these enrichment techniques can be performed prior to analysed by MS.  
(Adapted from Shi et al.139) 
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6.2 Results 
6.2.1 Bacterial expression and purification of scFv 
ScFv antibodies against CHIP (11F and 7A) previously engineered using phage 
display (Figure 6.6 & Figure 6.7) were expressed in competent bacterial cells using 
IPTG to induce expression. To ensure that induction was successful, a fraction of the 
bacterial lysate prior and subsequent to IPTG addition was analysed by SDS-PAGE 
(Figure 6.8A). IPTG resulted in protein overexpression and a strong band around 30 
kD became visible, which could possibly represent the scFv of interest. The scFv 
antibodies were then purified as described in Section 2.4.6b (for elute 5, specifically) 
and with shorter incubation times with the elution buffer (Figure 6.8B-G). The latter 
optimisation step favour protein activity (as it prevents denaturation of the scFv by the 
acidic conditions) but at the cost of a lower yield.  
 
Another optimisation step added was the buffer exchange step of scFv from Tris-
Glycine to Hepes-based buffer. For such, a fraction of the elutes were pooled and 
buffer exchanged. Unfortunately, this fraction was more diluted (Figure 6.8F&G, lanes 
labelled “Hepes”). In attempt to quantify the concentration of scFv antibodies in each 
fraction, these were analysed by SDS-PAGE along with known concentrations of BSA 
(Figure 6.8D-G). Quantification of the bands (using Image Studio Lite) was used for a 
standard concentration curve and approximate concentrations of elutes were 
calculated (Table 6.1).  
 
 
Table 6.1: Approximate concentration of the eluted single chain antibodies 
 
 
7A scFv  Concentration (µg/ml) 11F scFv Concentration (µg/ml) 
E1 19.53 E1 22.75 
E2 545.53 E2 467.42 
E3 483.74 E3 294.33 
E4 46.57 E4 32.91 
Buffer exchanged 53.63 Buffer exchanged 32.91 
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Figure 6.6: Production and validation of scFv antibodies 7A and 11F 
Binding activities were quantified by polyclonal phage ELISA using an anti-M13 phage 
polyclonal antibody (A) or anti-Protein A polyclonal antibody (B and C), both conjugated with 
horseradish peroxidase (HRP). Binding is expressed in relative light units (RLU), mean ± SD 
of duplicates. 
A) Enrichment of CHIP and CHIP-K30A binding phages by rounds of biopanning: the binding 
of CHIP and CHIP-K30A phages against CHIP, CHIP-K30A and uncoated wells.  
B) Binding activity of 7A and 11F against 0.1 mg/ml wt CHIP, CHIP-K30A and, the negative 
control, α-Syn.  
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11F MAEVQLVESGGDLVKPGGSLRLSCVASGFTFS SYYMY WVRQAPGKGLQWVA RISSDGTDTFYADAVKG 
7A  MAEVQLVESGGDLVKPGGSLRLSCVASGFTFS SYYMY WVRQAPGKGLQWVA RISSDGTDTFYADAVKG 
        __    FR1                 CD1       FR2              CD2       
7A  RFTISRDNAKNTLYLQMNSLRAEDTAVYYCA TAI-------GSD WGQGTLVTVSS EGKSSGASGESKVDD 
11F RFTISRDNAKNTLYLQMNSLRAEDTAVYYCA SRVV------GAD WGQGTLVTVSS EGKSSGASGESKVDD 
              FR3                    CD3          FR4         LINKER     
7A  ASYELTQPTSVSGSLGQRVTISC SGRTNDIGIVGAS WYQQFPGKAPKLLVY SNGNRPS 
11F AQSMLTQPASVSGSLGQKVTISC TGGNSNIGGNGVG WYQQLPGMGPRTVIY GDHYRPS 
          FR1                CD1            FR2         CD2   
7A  GVPDRFSGSYSGDSATLTITGLQAEDEADYYC QPFYTTFDSHV FGGGTHLTVL GAAAEQKLISEED 
11F GVPDRFSGSKSGSSATLTISGLQAEDEAEYYC SSWDGSLGRHV FGGGTHLTVL GAAAEQKLISEED 
               FR3                   CD3        FR4    
Figure 6.7: Alignment of the predicted amino acid sequences of the 7A and 11F scFv 
clones 
Sequences follow the following directionality: heavy chain (VH) – linker (L) – light chain (VL). 
Framework regions (FR, in black), complementary determining regions (CDR, in red or green) 
and linker (Linker, in blue). Within the CDR regions, different sequences are represented with 
different colours and changes.     
(Adapted from Dos Santos96) 
A 
Figure 6.8: Expression and purification of 7A and 11F scFv antibodies 
A) Bacterial lysates with protein expression uninduced (Unind.) and induced (Ind.) by IPTG 
were analysed. A fraction of each sample was sonicated and centrifuged and the supernatant 
(i.e. soluble proteins) was loaded on the gel.  
Gel used for SDS-PAGE was 12% acrylamide and was stained with Coomassie blue. 
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Figure 6.8 (continued) 
B&C) Samples from all the purification steps until elution of 11F (B) and 7A (C) scFv antibodies 
were analysed by SDS-PAGE. The lysate (Lys), flow through (FT) and washes show that the 
Protein A beads had greater affinity for the scFv (band at about 30 kDa) than the other proteins 
present in the lysate, although a small fraction was lost during the washes.  
D-G) 11F (D&F) and 7A (E&G) antibody elutes (including the fraction that was buffer 
exchanged) were resolved on gels alongside with known BSA concentrations to assess the 
purity and concentration of the elutes (constant volumes were loaded, 5 µl). For the 11F scFv, 
elutes 2 and 3 had the highest antibody concentration, while for the 7A antibody, fractions 2-
4 were more concentrated. Note that elute 5, which was kept in acidic conditions for longer 
during the elution step, had more proteins eluted from the column, decreasing its purity, and 
later displayed increased protein precipitation (D&F, lanes 5).  
All gels used for SDS-PAGE were 12% acrylamide and were stained with Coomassie blue.  
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6.2.2 Effect of scFv on CHIP-dependent in vitro ubiquitination 
assays using different substrates 
a. Optimisation of in vitro ubiquitination assay conditions 
Previous observations in our group have suggested that the ubiquitination of α-Syn is 
challenging to detect compared to other substrates, due to the weak binding of 
ubiquitinated α-Syn species to the nitrocellulose membrane. Therefore, the conditions 
of the in vitro ubiquitination assay were optimised using this substrate. Optimal 
denaturing conditions were investigated by changing denaturing temperature and 
incubation time (Figure 6.9A) and the reducing reagents used (Figure 6.9B). No 
ubiquitinated α-Syn (higher molecular weight above the monomeric form at 14 kDa) 
species were seen when samples were heated at 85ºC compared to 95ºC, where 
ubiquitinated species were detected after 3-10 min. Furthermore, 1:2 DTT to loading 
buffer ratio with samples incubated at 95 ºC for 3-4 min were clearly the best 
denaturing conditions to detect ubiquitinated α-Syn by WB, compared to others 
tested. Finally, the effect of using different crosslinking conditions on the membrane 
(subsequent to blotting and prior to the blocking step) was also evaluated (Figure 
6.9C). Compared to using 0.4% PFA, which was previously used in our group, 4% 
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Ubiquitin    
Figure 6.9: Optimisation of in vitro ubiquitination assays with CHIP 
In vitro ubiquitination assays using CHIP as the E3 ligase and α-Syn as the substrate were 
analysed by SDS-PAGE/WB using 12% gels. Immunoblots were probed with anti- α-Syn mAb 
(1:1000) or anti-Ubiquitin mAb (P4D1, 1:1000), as indicated. Sample preparation and the 
immunoblotting technique was optimised as follows: 
A&B) Samples were diluted in DTT and sample loading buffer (in a 1:4 ratio) and were denatured 
at 85 ºC (A) or 95 ºC (B) for the time indicated. 
C) Samples were diluted in sample loading buffer alone or supplemented with DTT (in a 1:4 or 1:2 
dilution) or with 10% β-mercaptoethanol (BME). Once mixed, samples were heated to 95ºC for 3-
4 min.  
D) Samples were denatured in optimal conditions (diluted in sample loading buffer with DTT in a 
2:1 dilution and heated to 95ºC for 3-4 min) and analysed by SDS-PAGE/WB. The same sample 
from the in vitro ubiquitination assay in the presence of ATP was loaded twice on the same gel. 
The immunoblot was cut (dashed line) and incubated with 4% or 0.4% PFA for 30 min immediately 
after the transfer. Immunoblots in A-C were treated with 4% PFA.  
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b. ScFv antibodies do not affect the auto-ubiquitination of CHIP 
It is known that CHIP activity is regulated by auto-ubiquitination54. Thus, the effect of 
scFv on the auto-ubiquitination of CHIP was assessed by immunoblot (Figure 6.10). 
No apparent differences were observed and strong bands representing auto-
ubiquitination were readily detected. This suggests that any effects of scFv antibodies 
on the ubiquitination of CHIP substrates are not likely due to differences in its intrinsic 


























Figure 6.10: Controls of in vitro ubiquitination reactions with and without scFv 
antibodies 
In vitro ubiquitination reactions missing single components or in the presence of all reagents 
were performed. These were analysed by 12% SDS-PAGE/WB and immunoblots were probed 
with anti-CHIP mAb (1:10000). Full auto-ubiquitination was only detected when all components 
of the ubiquitination cascade were added (ATP, Ub, E1, E2 and CHIP). The effect of the 
presence of 7A (A) and 11F (B) scFv antibodies (10 nM per reaction) on the auto-ubiquitination 
of CHIP was also assessed.  
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c. Effect of scFv on CHIP-dependent ubiquitination of α-synuclein 
i. In vitro ubiquitination of α-synuclein 
Prior to assessing the effect of the scFv antibodies on the in vitro ubiquitination of α-
Syn, experiments to determine whether such modification is CHIP-dependent were 
conducted, given the reported phenomenon of E2-mediated ubiquitination231. For this, 
the effect of each component in the in vitro assay on the ubiquitination of α-Syn was 
assessed (Figure 6.11). The same samples were loaded onto different SDS-PAGE 
gels to obtain immunoblots probed for α-Syn, CHIP and Ub. Importantly, there is a 
dominant α-Syn-positive band (possibly a doublet) at around 22 kDa, which is also 
Ub-positive (lane 7 in Figure 6.11 and lane 2 in Figure 6.12A&B). In fact, in the 
immunoblot probed with anti-Ub (Figure 6.11D), there are more bands lower than the 
MW of unmodified CHIP in lane 7 compared to lane 3, which are likely to represent 
ubiquitinated forms of α-Syn. Together, these blots show that α-Syn can be 
ubiquitinated, but only when all the components of the ubiquitination reaction are 
present. Moreover, E2-dependent and E3-independent ubiquitination was not seen in 
the conditions tested, thus ubiquitinated α-Syn is CHIP-dependent. Both mono- and 
poly-ubiquitination were observed (the latter is more clearly observed in lane 2 of the 
immunoblot in Figure 6.12A). Ub-positive bands were seen when the substrate, α-
Syn, was not present due to the auto-ubiquitination of CHIP and, potentially, free 
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Figure 6.11: Controls of in vitro ubiquitination assay 
In vitro ubiquitination assays using CHIP and α-Syn. The same samples were loaded in a 
15% gel and three 12% gels for SDS-PAGE/WB. All samples were denatured in 1:2 DTT to 
loading buffer ratio and at 95 ºC for 3-4 min. Membranes were fixed with 4% PFA. 
Immunoblots were probed with either: 
A) Anti-α-Syn mAb (1:1000), 
B) Anti-CHIP mAb (1:10000) (specifically the 12% immunoblot), 
C) Anti-Ub mAb FK2 that recognises mono- and poly-Ub but not free Ub (1:1000), or 
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ii. Effect of scFv on the in vitro ubiquitination of α-synuclein 
There is a range of scFv concentrations where 11F potently inhibits ubiquitination of 
α-Syn while 7A has no/little inhibitory effect (Figure 6.12A). This effect was evident 
from the lack of higher MW bands (greater than 14 kDa) in the immunoblot probed for 
α-Syn in in vitro ubiquitination reactions conducted in the presence of 11F scFv. The 
half maximal inhibitory concentration (IC50) of the 11F antibody is estimated to be 
12.41 nM to reduce by 50% the detection of monoubiquitinated α-Syn by immunoblot 
(calculated from Figure 6.12C). The higher MW ubiquitinated α-Syn species are below 
the detection limit of the immunoblot when only 0.28 ng/µl of 11F scFv is added. As 
observed in Figure 6.12C, the 7A scFv is also capable of partially inhibiting 
ubiquitinated α-Syn when present at a higher dose (lanes 5&6). The estimated IC50 
of monoubiquitinated α-Syn (~22kDa) is 116.18 nM (calculated from Figure 6.12C). 
Of note, at lower concentrations (15.07 nM or less), 7A scFv promoted ubiquitination 
of α-Syn (lanes 3&4 of Figure 6.12C). This positive effect on ubiquitination is gradually 
abolished with increasing dose and ubiquitination of α-Syn becomes inhibited by the 
scFv, supporting a biphasic response (evident when comparing lanes 3 and 6 in 
Figure 6.12C). It seems that higher MW ubiquitinated α-Syn species are more readily 
inhibited by administration of the scFv antibodies (this is more clearly observed with 
the less potent 7A scFv antibody). More extensive dose-response experiments would 
be required for more accurate IC50 values and would be informative of the kinetics of 
the scFv antibodies. The higher MW Ub-positive bands observed (Figure 6.12B) are 
likely to represent auto-ubiquitination of CHIP, which does not seem to be affected by 
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Figure 6.12: Effect of scFv antibodies on the in vitro ubiquitination of α-Syn 
In vitro ubiquitination assays using CHIP and α-Syn were performed in the presence of 
HEPES-based buffer alone, 7A or 11F scFv antibodies, as indicated. A dilution series of each 
scFv was tested and the final volume of scFv/buffer added to the reaction remained constant 
(A&B: 2 µl, C: 1 µl). Samples were denatured in loading dye (with DTT in a 2:1 dilution) and 
at 95 ºC for 3-4 min. Samples were loaded onto both 15% (A&C) and 12% (B) SDS-PAGE 
and immunoblots were fixed with 4% PFA prior to blocking. Immunoblots were probed with 
either anti-α-Syn mAb (1:1000) (A&C) or the anti-Ub mAb PD41 (1:1000) (B). The effect of 
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d. Effect of scFv on CHIP-dependent ubiquitination of ANXA2 
As seen in Chapter 5, CHIP ubiquitinates ANXA2 both in vitro and in situ. Given the 
ladder of ANXA2- and Ub-positive bands detected by WB, it seems that ANXA2 is 
monoubiquitinated and multi-monoubiquitinated or polyubiquitinated by CHIP. The 
effect of scFv antibodies on its in vitro ubiquitination was also investigated (Figure 


















Figure 6.13: Effect of scFv antibody on the in vitro ubiquitination of ANXA2 
In vitro ubiquitination assay using untagged human recombinant ANXA2 and CHIP and, when 
indicated, 11F scFv antibody (referred to as “scFv”) or its HEPES-based buffer (referred to as 
“buffer”). Two concentrations of scFv were tested (95.49 nM and 161.28 nM) and the volumes 
of scFv solution added to these reactions (2 µl and 4 µl, respectively) were matched by control 
reactions where only the buffer was added to the In vitro ubiquitination assay. Reactions were 
analysed by 12% SDS-PAGE/WB using two different anti-ANXA2 antibodies: mAb (1:1000, 
A) and pAb (1:500, B). The effect of the scFv antibody on the ubiquitination of ANXA2 is 
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6.2.3 Mapping of ubiquitination sites on α-Synuclein, Annexin 
A2 and CHIP 
Samples from in vitro ubiquitination assays were sent for MS analysis for validation 
and mapping of the ubiquitination sites on both substrates and the E3 ligase CHIP. 
This aids our understanding of the nature of the ubiquitination modifications and 
possible implications to the structure/function of the substrate. Mapping was achieved 
by detecting diGly remnant peptides following digestion with trypsin (no affinity-
purification step was included) using MS. The ubiquitination of α-Syn was mapped to 
lysine 60, which lies at the interface between the N-terminal domain and the NAC 
region34 (Figure 6.14A). This was done in collaboration with Dr Jakub Faktor and Dr 
Bořivoj Vojtesek‡. ANXA2, on the other hand, becomes ubiquitinated by CHIP on two 
lysine residues, 115 and 157 (Figure 6.14B), according to our preliminary data 
produced in collaboration with Dr Jimi Wills & Dr Alex von Kriegsheim¶. These sites 
lie on domain II of the core structure of ANXA2232.  
 
CHIP auto-ubiquitination on lysine residues (Figure 6.15) was readily detected in the 
presence, but not the absence, of ATP. Interestingly, multiple residues are 
ubiquitinated throughout the protein when no substrates were present in the in vitro 
ubiquitination assay mixture. However, in the presence of α-Syn, the majority of these 
residues were no longer ubiquitination sites and only K221 and K234 remained. When 
this is compared to the auto-ubiquitination signature of CHIP detected in the presence 
of ANXA2, it is clear that the ubiquitination signature is more complex, having 6 lysine 
residues involved in such modification. Nevertheless, it is important to note that the 
ubiquitination mapping obtained with ANXA2 as the substrate is only preliminary and 
was achieved independently from the other mapping experiments (with α-Syn and 
without substrates), which were conducted in parallel. The auto-ubiquitination sites 
mapped on CHIP in the presence of ANXA2 was a collaborative work with Dr Jimi 
Wills & Dr Alex von Kriegsheim¶, while the other experiments were performed with Dr 
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Jakub Faktor and Dr Bořivoj Vojtesek‡. Of note, although different MS services were 
































‡ Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech 
Republic 
Figure 6.14: Mapping of CHIP-dependent ubiquitination sites on α-synuclein and 
ANXA2 
In vitro ubiquitination reactions were digested with trypsin, yielding diGly signature motifs on 
ubiquitinated species. These were detected by MS/MS. 
A) The mapped K60 ubiquitination site was added to the primary structure of α-Syn presented 
by Gallegos et al.34.  
B) Preliminary data suggesting K115 and K157 sites on ANXA2 are ubiquitinated by CHIP. 
These sites were illustrated on the schematic of the primary structure of ANXA2 from 
Bharadwaj et al.232.  
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Figure 6.15: Mapping of auto-ubiquitination sites on CHIP alone and in the presence of 
different substrates 
Schematic representation of CHIP domains with the auto-ubiquitination sites at lysine residues 
detected by MS/MS based on the presence of the diGly motif. Results were obtained from in 
vitro ubiquitination assays in the presence of ATP and with or without substrates (α-Syn or 
ANXA2).  
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6.2.4 Modulating CHIP with the scFv antibody 
The structural flexibility of CHIP has been intimately linked to its function47. Thus, we 
sought to conduct biophysical analysis of the structure of CHIP when alone and in the 
presence of the purified 11F scFv antibody. HDX-MS analyses the solvent 
accessibility for residues within CHIP as a measure of dynamic conformational 
changes. Twenty unique peptides were identified (83.5% coverage of the protein) and 
characterised across a time course. The degree of deuteration at the amino acid level 
after 300s incubation was mapped onto the crystal structure of the murine CHIP 
(2C2L)39,40, as there is over 97% identity between mouse and human CHIP41.  
 
HDX-MS of CHIP alone showed that the N-terminal tail and distal segments of the U-
box displayed much greater incorporation of deuterium compared to the rest of the 
protein (Figure 6.16A&B). Increased exchange is indicative of a less rigid structure 
with more flexibility. We47 (Figure 6.16C) and others209 (Figure 6.16D) have previously 
analysed the structure of CHIP by HDX-MS. Although Graf and colleagues209 have 
also observed most deuteration occurring at the N-terminal tail of CHIP, both studies 
agree that most exchange occurred at the flexible TPR domains, which is not so 
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Figure 6.16: HDX of unliganded CHIP 
A) Schematic representation of the functional domains of CHIP. TPR1 (26-59 aa), TPR2 (60-
93 aa) TPR3 (95-127 aa), coiled-coil region (128-228 aa) and U-box (229-300 aa) (according 
to Nikolay et al.40 and Zhang et al.39 2005).   
B) HDX-MS data of unliganded human recombinant untagged CHIP after 300s incubation in 
deuterated buffer mapped onto the crystal structure of murine CHIP (PDB 2C2L). The 
deuteration level across the peptic peptides is represented as exchanged deuterons, D. 
C) Published HDX-MS data of the percentage of deuteration of the analysed CHIP peptides 
after 60s incubation in deuterated buffer that was mapped onto the crystal structure of murine 
CHIP (PDB 2C2L). 
D) Published HDX-MS data of the percentage of deuteration of the analysed CHIP peptide 
after 10s or 2min incubation in deuterated buffer that was mapped onto the crystal structure 
of murine CHIP (PDB 2C2L). The dashed line represents the 24 N-terminal residues missing 
in the crystal structure.  
(C: Modified from Narayan et al.47, 2015; D: Graf et al.209) 
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By comparing the level of deuterium exchange on the structure of CHIP when alone 
and in the presence of scFv, we can understand the dynamic conformational changes 
induced by the antibody (Figure 6.17 & Figure 6.18). The scFv protects the U-box 
from deuterium exchange, indicative of its binding site on CHIP. Moreover, possibly 
due to allosteric effects, scFv binding to CHIP induced slight changes in the TPR 
region. The TPR 1 domain, for example, became more exposed and liable to 
deuterium incorporation. Therefore, beyond showing that scFv can bind to CHIP, the 
dynamic conformational changes observed can help to explain how scFv-binding 
modulates the E3 ligase activity of CHIP differentially, in a substrate-dependent 
manner. These HDX-MS experiments were performed in collaboration with Dr Lenka 
Hernychova and Dr Bořivoj Vojtesek‡. The binding of the scFv antibody to 
endogenous CHIP was also confirmed by immunoprecipitation (Figure 6.19).  
 
To capitalise on the effect of scFv on the structure and function of CHIP observed in 
vitro, I have engineered nanobodies for cell delivery and the manipulation of the 
activity of endogenous CHIP (refer to Appendix II). Plasmids encoding tagged 
isoforms of the 11F scFv antibody were made for mammalian expression (Figure S.12 
& Figure S.14) using conventional cloning (Figure S.13). SH-SY5Y cells were 
transfected and the expression of the intrabodies was confirmed (Figure S.15).  
 
Although the effect of these intrabodies on CHIP homeostasis and the cellular 
proteome is left to be investigated, the potential applications of these intrabodies are 
extensive. For example, the intrabody can be used in the context of chemical 
genetics233 as a tool to enhance our ability to manipulate the activity of CHIP and the 
pathways in which it is implicated. Recently, Shi and colleagues234 have elucidated 
the importance of manipulating CHIP activity rather than studying its function from a 
null background. Modulation of the E3 ligase activity of CHIP specifically may be of 
interest, since mice expressing the SCAR16-related CHIP mutant T246M (lacking E3 
ligase functions only) were phenotypically different from the CHIP KO mice234.  
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Republic 
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TPR 2 Charged domain U-box TPR 1 TPR 3 
Figure 6.17: HDX-MS of CHIP in the absence and presence of 11F scFv antibody 
Graphs showing the average deuteration (%) of peptic peptides as a function of primary amino 
acid sequence of scFv-bound and free CHIP after 30s (A), 300s (B) and 900s (C) incubation 
deuterated buffer. The functional domains of CHIP are indicated at the bottom. 
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Level of deuteration: 
       - No change 
       - Increased 
       - Decreased (cca 5%) 
       - Decreased (cca 15%) 





Figure 6.18: HDX differences between CHIP alone and in the presence of scFv 
Difference in the level of deuteration between the human recombinant untagged CHIP in the 
presence and absence of the 11F scFv antibody after 300s incubation in deuterated buffer. This is 
represented schematically (mapped onto the crystal structure of murine CHIP (PDB 2C2L); A) and 
graphically (the deuteration level across the peptic peptides is represented as exchanged deuterons, 
D; B).  
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Figure 6.19: 11F scFv antibody immunoprecipitates with endogenous CHIP 
The 11F scFv antibody was conjugated to Protein A beads and incubated with cell lysate from 
WT and CHIP KO SH-SY5Y cells. As negative control, lysate was added to unconjugated 
beads. For optimal results, cell lysates were subjected to pre-clearing with unconjugated 
protein A beads prior to incubation with 11F-conjugated beads. Cell lysates and the IP 
fractions were analysed by SDS-PAGE/WB. Secondary antibody (anti-mouse pAb) controls 
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6.3 Discussion 
6.3.1 Identification of ubiquitination sites 
a. The challenge 
Studying the ubiquitome has proven to be very challenging. Despite advances in 
methodologies, large-scale analysis of ubiquitination sites have been largely 
unsuccessful139 and the number of ubiquitination events identified is small when 
compared to that of other PTMs, such as acetylation and phosphorylation141. In fact, 
only around 255 mammalian proteins reported to be ubiquitinated according to 
experimental evidence143. The field is especially scarce in the quantitative aspects 
and pathway-mapping of ubiquitination events, including linkage quantification and 
linking substrates to individual Ub pathway enzymes (e.g. E3 ligase)139,141. Matching 
substrates to specific ubiquitination enzymes is difficult given the vast array of 
machinery (around 600 ligases are encoded by the eukaryotic genome)139,141.  
 
The low relative abundance of ubiquitinated species and the low signal derived from 
the ubiquitination moiety in a particular substrate, considering that only a few lysine 
residues are typically modified in an ubiquitinated protein143, makes the detection of 
endogenous substrates challenging. Therefore, for the identification of substrates and 
mapping of ubiquitination sites, studies often use overexpression of either Ub or 
substrate141, or include an enrichment step to allow identification by MS methods139. 
Finally, studying the dynamics of ubiquitinated proteins is also challenging, since it is 
hard to decipher the fate of ubiquitinated proteins, and how individual ubiquitination 
sites on a particular protein are independently regulated and influence the overall 
homeostasis of the protein139–141. 
 
 
b. Method used to map ubiquitination sites 
All affinity-based purification techniques are limited by the presence of contaminant 
proteins in purification assays, which arise from non-specific binders to the solid 
matrix of the affinity reagent, precipitated proteins, and specific binders to Ub and Ub 
chains139. An increase in background noise can mask the detection of proteins of 
interest by MS-based techniques. Alternatively, the diGly motif can be detected by 
MS without the need for an enrichment step. The mapping of the ubiquitination sites 
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of α-Syn and ANXA2 in this project was achieved without the enrichment strategy. 
Here, the high sensitivity of DIA proteomics (SWATH-MS) was capable of identifying 
the ubiquitinated species.  
 
 
6.3.2 CHIP-dependent ubiquitination  
From our unbiased proteome-wide MS screen in CHIP WT and KO cortical neurons, 
ANXA2 was identified as a possible protein target of CHIP. Subsequent experiments 
identified ANXA2 as a candidate substrate of this E3 ligase. To confirm ANXA2 as a 
ubiquitination substrate and better understand the biochemical characteristics of this 
PTM, its ubiquitination sites were mapped in vitro. For comparative purposes, another 
E3 ligase substrate of CHIP, the disease protein, α-Syn, was also analysed, as it is 
structurally distinct from ANXA2 (α-Syn is intrinsically disordered, while ANXA2 is 
folded). Future work would assess whether these findings translate to a cellular 
model, although mapping of endogenous proteins has proven to be very challenging.   
 
 
a. CHIP-dependent ubiquitination of substrates 
In vitro ubiquitination assays in the presence of CHIP and α-Syn or ANXA2 were 
analysed both by WB and MS. Using MS we have revealed that in vitro ubiquitination 
of α-Syn is detected at a single residue, K60 (Figure 6.14A). It is likely that this site is 
involved in the mono- and poly-ubiquitination of α-Syn, which is evident from the 
ladder of α-Syn- and Ub-positive bands detected by immunoblot (Figure 6.11). 
However, it is unclear whether this is the only site involved in CHIP-dependent 
ubiquitination of α-Syn, or whether other diGly-containing remnant peptides exist but 
were below the detection limit of the mass spectrometer or have poor ionization 
potential140. The Ball group have previously reported both CHIP-dependent mono- 
and poly-ubiquitination of another intrinsically disordered protein, IRF-1, also in the 
presence of the E2 enzyme, UbcH5α77.  
 
ANXA2, in contrast, is ubiquitinated at K115 and K157 (Figure 6.14B) and has two 
clear bands above the MW of unmodified ANXA2 that are readily detected (Figure 
5.17). These could represent monoubiquitinated (at either lysine residues), which 
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seems to be the especially prominent band on the immunoblot, and multi-
monoubiquitinated (with both lysine residues modified) ANXA2. However, we cannot 
exclude the possibility of polyubiquitinated ANXA2 without further experiments.  
 
Although it is generally accepted that ubiquitination specificity arises from the pair of 
E2-E3 employed9,231 and the docking of E3 on the substrate9,47,65,80, some groups have 
tried to decipher sequences of preference on substrates for ubiquitination. It has been 
reported that ubiquitination has a slight tendency to occur at regions enriched in small 
hydrophobic residues, including Ala, Leu, Ile, Gly, Pro and Val. In fact, K*XL was 
suggested as a potential motif for ubiquitination, as it is found 1.8-fold more often in 
ubiquitinated compared to unmodified lysines139. Some small hydrophobic residues 
were indeed seen close to the ubiquitination sites on ANXA2 (highlighted in red) and 
K157, specifically, lied within a K*XL motif (underlined):   
111 ASELKASMK 119 
153 TDLEKDIIS 161. 
However, these trends were not seen in the region harbouring the ubiquitinated K60 
on α-Syn, having small hydrophobic residues more distant from K60:  
56 AEKTKEQVT 64.  
 
Additionally, lysine residues that undergo ubiquitination tend to be more exposed (on 
the surface of the protein), hence more liable to modifications (by 6.5% compared to 
unmodified lysines)139. The ubiquitination sites identified on ANXA2 lie close to the 
beginning and end of the ANX core domain II. The domain is made up of 5 α-helices 
and these lysines are within the 1st and 4th helices34,235–237 (Figure 6.20A). Within its 
globular structure, these lysine residues seem to be exposed at its surface, rather 
than buried in highly hydrophobic regions (Figure 6.20B). Furthermore, when 
analysing this highly conserved core region also present in ANXA1 Figure 6.20C235, it 
seems that the ubiquitination sites lie close to the convex side of the protein in its 
calcium-bound state, which is important for its attachment to membranes. It would 
therefore be interesting to consider whether ubiquitination affects its lipid-binding 
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Figure 6.20: Structure of Annexin A2 
A) Mapped CHIP-dependent ubiquitination sites on ANXA2 were indicated in the published 
crystal structure. 
B) The extent of disorder (red: potentially disordered region, blue: probably ordered region) 
and hydropathy (red: hydrophobic, blue: hydrophilic) predicted from the amino acid sequence 
of ANXA2. The two ubiquitination sites mapped are indicated.  
C) Globular structure of ANXA1 in the presence (left) and absence (right) of calcium. Annexins 
share high homology within their conserved 4 core domains, each with 5 helices. In the 
calcium-bound conformation, Annexins can attach to membranes through its convex (upper) 
side.  
(A: Adapted from Uniprot236, B: Adapted from Protein Data Bank237, C: Rescher & Gerke235) 
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α-Syn is considered to be an intrinsically disordered protein when in solution, lacking 
significant secondary structure (having 2% α-helical and nearly 70% random coil 
content when characterised by circular dichroism)238. Within such structure, K60 is 
likely to be exposed (Figure 6.21A)239. It is now largely accepted that lipid-binding 
induces a structural transition to α-helical (from 2 to 71%) and the interaction is 
believed to be mediated by 5-helices that lie within the N-terminal region238. The 
region found to adopt this helical conformation spans K60 (Figure 6.21B). Its α-helical 
structure is believed to be related to its physiological functions, thus it would be 
interesting to analyse the effect of ubiquitination of α-Syn:lipid interactions. 
Furthermore, K60 lies at the interface of the N-terminus with the aggregation-prone 
NAC region, thus how ubiquitination influences the conformational dynamics of α-Syn 




























Figure 6.21: Structure of α-synuclein 
A) The mapped K60 Ub site was added to the crystal structure of α-Syn. 
B) Amino acid structure of α-Syn consisting of 7 imperfect 11-residue repeats (I-VII). Region 
underlined in dark blue adopts a helical conformation in the presence of micelles.  
(A: Uniprot239, B: Alderson et al. 238) 
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CHIP-dependent ubiquitination of these substrates occurred at restricted sites, rather 
than at multiple lysines, as observed in CHIP auto-ubiquitination. In agreement, 
another group has also reported a single ubiquitination site (K1047R) for CHIP-
dependent monoubiquitination of the INSR62. This supports CHIP-dependent 
ubiquitination as highly specific and argues against the proposed promiscuous nature 
of protein ubiquitination240. The underlying mechanism is likely to be the previously 
reported docking-dependent E3 ligase activity of CHIP in the absence of Hsp7077,80. 
The ubiquitination of IRF-1 is a good example of such. One would predict 
ubiquitination to occur either within its Arg-Lys-Ser rich motif in the intrinsically 
disordered Mf2 domain of IRF-1 (a stable CHIP-binding site) or the more 
conformationally flexible C-terminal half of the protein. However, IRF-1 is actively 
ubiquitinated by CHIP in its DNA-binding domain, where CHIP binds to a lesser 
extent77,80. Potentially, E3 enzymes (including CHIP) position the charged E2 in close 
proximity of the target lysine residue, promoting Ub-acceptor site specificity241.  
 
Other studies have argued that ubiquitination is of a non-specific nature. In support, 
ubiquitination of α-Syn and CHIP was reported to be maintained when commonly 
ubiquitinated lysine residues were mutated53,240. Bringing into the equation cellular 
context, Lyumkis and colleagues242 hypothesised that quality control substrates, such 
as nascent polypeptides, are highly heterogeneous with regards to the position of 
target lysines, whilst non-quality control (i.e. regulatory) substrates have 
predetermined ubiquitination sites that have been optimized through evolution. This 
would argue that the substrates in question (ANXA2 and α-Syn) are regulated by 
CHIP for non-degradative purposes.  
 
In fact, CHIP-dependent monoubiquitination62 and polyubiquitination via the non-
canonical K63 ubiquitination-chain linkages77 has been reported, thus it is likely that 
CHIP can regulate receptor turnover and cell signalling pathways, impacting on the 
structure, function and activity of its substrates. Its functions in ubiquitination-
mediated degradative processes may be favoured in conditions of proteotoxic stress. 
This rational has been proposed by us47 and others62. Alternatively, the limited number 
of conjugation sites may be a common feature across most ubiquitination events. Xu 
et al.143 found that most peptides analysed by MS (using the diGly enrichment step) 
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from cell lysate contain a single diGly-modified lysine (157 proteins versus the 80 
proteins identified with two or more ubiquitination sites).  
 
 
b. Known ubiquitination of identified CHIP substrates  
Of the identified ubiquitination sites on ANXA2, only modification at K115 has been 
previously reported. This site and K80 have been found to be ubiquitinated in lung 
tissue collected from mice exposed to hypoxia-induced pulmonary hypertension. 
These results were obtained using an anti-diGly antibody capture and MS243. Although 
a few other reports have found ANXA2 to be ubiquitinated, the sites and enzymes 
involved are often unknown181,182. By sequence analysis Lauvrak and colleagues181 
have searched for Ub-binding domains with α-helical conformations that could 
potentially bind to the α-helical structure of ANXA2. A Ub-interacting motif (UIM) was 
identified (176 GRRAEDGSVID) spanning the 5th helix of domain II181, which is in 
close proximity to the K157 residue that we have identified as a potential CHIP-
mediated ubiquitination site on ANXA2. It was hypothesised that this could bind to 
polyubiquitin chains and promote ubiquitination in a manner that would not lead to 
degradation of the modified protein. Thus, given the involvement of ANXA2 in 
endocytosis, ubiquitination could promote internalisation of membrane proteins 
destined to the endolysosomal pathway, which is a reported cellular fate of 
monoubiquitinated species. Alternatively, ubiquitination of ANXA2 could mediate its 
actin-binding dynamics, since ubiquitinated ANXA2 species have been detected in 
the cytoskeletal fraction181.   
 
With regards to α-Syn, we found that CHIP-dependent ubiquitination occurs at lysine 
60. This site has been previously been associated with lipid peroxidation, becoming 
covalently bound to by-product 4-hydroxy-2-nonenal (HNE). It was suggested that this 
PTM promotes α-Syn oligomerisation and cell-to-cell transmission in neuronal cell 
models244. Furthermore, although there is no published evidence to directly support 
K60 as a ubiquitination site, introduction of a K60R mutation in α-Syn resulted in a 
~40% reduction in in vitro ubiquitination compared to WT (when using a Ub ligase 
fraction derived from rat brains)245. Thus, K60 may be of significance. This reduction 
was also observed for a K58R α-Syn mutant. Moreover, other residues have been 
implicated in the ubiquitination of α-Syn. Rott et al.240 have suggested that SIAH-2 
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monoubiquitinates α-Syn in vitro and in vivo (on lysines 10, 12, 21, 23, 34, 45 and 
96). While Nonaka et al.245 reported that monomeric and filamentous α-Syn are 
ubiquitinated both in vitro and in situ, at lysines 21, 23, 32, and lysines 6, 10 and 12, 
respectively, although the E3 ligase(s) responsible are unknown.  
 
The cellular consequence of α-Syn ubiquitination is also controversial and largely 
unknown. It was suggested that ubiquitination enhances the aggregation potential of 
α-Syn, possibly due to an increase in hydrophobicity, ultimately forming toxic 
inclusions within cells. Supporting this is the observation that ubiquitinated α-Syn is 
present within LBs (ubiquitinated at lysines 12, 21 and 23)240. Different forms of 
ubiquitinated α-Syn species have been found, having one, two and three Ub 
molecules246 (monoubiquitinated α-Syn makes up around 10% of α-Syn purified from 
LBs240). Tofaris et al. suggested that rather than representing ubiquitination-
dependent degradation of α-Syn, this PTM most likely reflects a disease-specific 
pathway. Either it represents an unsuccessful attempt at targeting α-Syn for 
proteasomal or lysosomal degradation, or a cytoprotective response to prevent 
aberrant α-Syn interactions246.  
 
 
c. CHIP auto-ubiquitination  
We have mapped the auto-ubiquitination sites of CHIP in the absence and presence 
of the substrates investigated (α-Syn and ANXA2). This could shed light into sites that 
are important for its E3 ligase activity and those that could be influenced by its 
substrate.  
 
In the presence of α-Syn, K221 and K234 were detected as ubiquitination sites on 
CHIP (Figure 6.15). From the significant and distinctive laddering of CHIP- and Ub-
positive bands on the immunoblot (Figure 6.10 & Figure 6.11), it is probable that CHIP 
incorporates polyubiquitin chains at these sites, yielding multiple ubiquitinated species 
of different molecular weights. Interestingly, the complexity and robustness of the 
auto-ubiquitination pattern of CHIP when in the absence of α-Syn was greater than in 
the presence of this substrate. The number of lysine residues involved in the auto-
ubiquitination of CHIP is decreased in the presence of α-Syn (2 versus 9 sites 
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detected, Figure 6.15). Although this requires further validation, it seems that the 
bands on immunoblots representing ubiquitinated forms of CHIP are also slightly 
reduced in the presence of α-Syn (lane 3 compared to lane 7 in Figure 6.11D and 
lanes 5 versus 13 and 6 versus 14 in Figure 6.10A). 
 
We question whether α-Syn prevents the auto-ubiquitination of CHIP, which could be 
of interest at both biochemical and cellular levels. In contrast, the presence of ANXA2 
does not seem to impair CHIP’s auto-ubiquitination. Therefore, α-Syn, specifically, 
could prevent the auto-ubiquitination of CHIP by sterically inhibiting its ubiquitination 
sites, competing with Ub or binding to an unknown non-catalytic inhibitory site on 
CHIP. However, this needs to be interpreted with caution, since the mapping of 
ubiquitination sites in the presence of ANXA2 and absence of substrates were derived 
from two independent experiments. Future work would investigate if this is a 
phenomenon of substrate inhibition# by introducing titration experiments, and whether 
it is dependent on the conformation of the substrate (i.e. folded vs. unfolded).  
 
With regards to CHIP-dependent auto-ubiquitination in the presence of ANXA2, 
preliminary data identified six different potential sites of auto-ubiquitination. These 
included K22, K125, K221 and K255, which were also detected in the independent 
experiment analysing the auto-ubiquitination of CHIP in the absence of substrates. 
The diGly motif at K221 could be of particular interest as it was consistently detected 
in the absence of substrates and presence of either α-Syn or ANXA2. Future work 
would question the biochemical significance of these modifications.  
 
Only two auto-ubiquitination sites on CHIP have been reported: K253 and K2254. Of 
these, only K22 was detected in some of the conditions that we tested. This site has 
been associated with K48- and K63-specific Ub chain linkages, suggesting that auto-
ubiquitination of CHIP is mediated by K48- and K63-polyubiquitination and/or by 
mixed chains54. On the other hand, the K2 auto-ubiquitination has only been 
implicated in monoubiquitination of CHIP by Ube2w53.  
 
 
# Substrate inhibition: enzyme inhibition by its substrate in excess. This causes deviations from 
Michaelis-Menten kinetics, where the velocity curve of a reaction rises to its maximum as the substrate 
concentration increases and then decreases278.   
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It has been proposed that auto-ubiquitination tends to occur at more highly exposed 
residues139, such as K2 and K22 on the extended N-terminal region of CHIP53,208. Both 
our HDX-MS results of CHIP alone (Figure 6.16B) and those reported by Graf and 
colleagues209 (Figure 6.16D) show that the N-terminal segments of the TPR domain 
(in particular residues 1-28 from our study and residues 2-48 from Graf et al.209) are 
the most exposed regions. This region contains helix-turn-helix repeats that seem 
largely unfolded209. Therefore, to some extent, our data agrees with the proposed 
hypothesis that auto-ubiquitination tends to occur at more exposed regions, although 
this is not the case for the other auto-ubiquitination sites identified.  
 
On the contrary to some papers53,54, we found auto-ubiquitination of CHIP to be 
mediated primarily by polyubiquitinated chains, rather than monoubiquitination, and 
highly efficient. Some discrepancies could be explained by differences in the 
biochemical properties of recombinant CHIP and other enzymes used, as well as the 
conditions used for the in vitro ubiquitination assay.  
 
Different hypotheses have been proposed for the molecular significance of auto-
ubiquitination. This modification has been regarded as an effective reporter of the 
interaction between E2 and E3, thus a read-out of the activity of the E3 ligase247. 
Others have suggested that the addition of Ub per se could be a driver of the 
ubiquitination cascade: since E3s are themselves ubiquitinated, this could represent 
a mechanism by which U-box E3s directly participate in the transfer of Ub from the 
E2 to the substrate54. A more generically and widely-accepted view, is that auto-
ubiquitination regulates the E3 ligase activity, either by changing its intrinsic 
ubiquitination functions (via conformational changes) or modifying its interactome. For 
example, monoubiquitination of CHIP (on K2) has been suggested to enhance its 
activity by stabilising its interaction with the deubiquitinase ataxin-3. This allows a 
dynamic regulation of substrate ubiquitination by removing the Ub on CHIP once the 
substrate is fully modified, thus restricting the length of Ub chains added and 
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d. Limitations of the ubiquitination mapping strategy  
Accurate mapping of the ubiquitination and auto-ubiquitination sites can be 
compromised by limitations of the proteomics technique and diGly strategy used. 
Firstly, false-positive assignments (identification of mis-localized ubiquitination sites) 
can occur. Typically, these span peptides that contain internal lysine residues 
adjacent to amino acids of a similar mass to glycine (such as Leu, Asn or Asp), where 
the 114.043 Da is observed as a part of the peptide sequence rather than derived 
from the ubiquitination of lysine. Inadequate mass accuracy (>10 ppm) and peptide 
coverage (<3%) contribute to this problem. Mis-cleavage events also complicate the 
assignment of ubiquitination. For example, Lys-Asn at the C-terminus of a peptide can 
be regarded as diGly-containing lysine. To prevent the assignment of false-positives, 
a high-mass accuracy spectrometer was used and parent ions were identified with 
high resolution139. Secondly, given the limited depth of the MS, under-sampling for 
low abundance or low occupancy sites is a common problem141. To ensure adequate 
levels of ubiquitinated species, mapping of ubiquitination sites on candidate 
substrates was performed on in vitro ubiquitination reactions conducted under optimal 
conditions.  
 
Finally, although the use of the diGly signature allows the identification of ubiquitinated 
species in a direct manner, data derived must be interpreted with caution. The diGly 
signature is a result of ubiquitination and Ub-like modifications, such as ISG15 and 
NEDD8139. However, a study into the diGly-modified proteome by Kim and 
colleagues141 concluded that >94% of the identified sites represented ubiquitination, 
rather than the other modifications. Another limitation of diGly-based methods is that 
the motif does not reveal whether a target site is mono- or polyubiquitinated141. For all 
the reasons discussed, further validation of candidate proteins and ubiquitination sites 
is crucial. Future work would include mutating these candidate sites and evaluating 
whether ubiquitination is abolished/affected.  
 
 
6.3.3 Effect of scFv on CHIP’s E3 ligase activity    
A major aim of this chapter was to create tools that would manipulate CHIP activity 
(initially in vitro and later in situ) in order to better understand its functions. Given 
CHIP’s intrinsic E3 ligase function, we sought to investigate the effect of scFv 
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antibodies on the ubiquitination activity of CHIP of ANXA2 and α-Syn. ScFv antibodies 
(7A and 11F) were successfully purified from bacteria (Figure 6.8) and their activity 
was tested using the in vitro ubiquitination assays.  
 
The scFv antibody with high affinity for CHIP, 11F, inhibited α-Syn ubiquitination 
(Figure 6.12) and enhanced ANXA2 ubiquitination (Figure 6.13). The underlying 
mechanism explaining such opposing effects is unknown. Although we see scFv-
induced changes in CHIP structure by HDX (Figure 6.17 & Figure 6.18), at present 
we cannot exclude whether these effects are a result of scFv-induced changes in the 
exposure of ubiquitination sites on the substrates directly, rather than CHIP-
dependent effects. Moreover, the antibody with lower affinity for CHIP, 7A, only had 
a negative effect on the ubiquitination of α-Syn when used at a concentration that was 
9.35-times higher than that of 11F (115.9 nM compared to 12.4 nM per reaction). It is 
unclear if the differences in binding sites or affinities for the same site explain the 
discrepancies in the concentration needed to have an inhibitory effect on α-Syn 
ubiquitination.  
 
In attempt to investigate how the 11F scFv might modulates CHIP activity, I have 
analysed their interaction by HDX-MS (Figure 6.17 & Figure 6.18) and IP (Figure 
6.19). The purified antibody is capable of direct-binding and capturing of endogenous 
CHIP from human cells. The HDX-MS data provided insights into the conformational 
dynamics induced by scFv on the structural and functional domains of CHIP.  
 
ScFv binding to CHIP induced protection (HDX difference (∆D) < 0.5) of units: TPR 2 
and 3 (residues 62-105) and U-box (residues 215-233). However, more robust 
protection was observed in the rest of the U-box domain, where scFv induced 
protection of residues 238-252, 260-284 and, to a less extent, 253-259. Therefore, it 
is highly likely that this scFv antibody binds to residues around this region (~240-280). 
One would expect the high degree of flexibility in the U-box to be significantly reduced 
in the presence of scFv, which is likely to affect its E3 ligase activity. Changes in other 
regions of CHIP could be secondary to scFv binding - for example due to allosteric 
regulations (previously reported for CHIP47), compensatory structural dynamics or 
dimerization. The binding of scFv to CHIP induces some structural changes that are 
similar to the binding of E2 enzymes (UbcH5a and Ubc13) to CHIP. This includes 
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increased protection of the U-box residues 239-259 from HDX and the modulation of 
segments of the TPR domain209.  
 
At this point, mechanistic insight into the effect of scFv on CHIP activity is still scarce 
and would require further investigation. Possible mechanisms of action include scFv-
induced conformational change of CHIP, modulation of CHIP’s E3 ligase activity 
and/or interactome. These mutually non-exclusive hypotheses are entertained in the 
following sections and could help to explain the opposing effect of the 11F scFv 
antibody on CHIP-dependent ubiquitination of its substrates, α-Syn and ANXA2.  
 
 
a. Potential scFv-induced conformational change in CHIP  
Binding of scFv to the U-box domain of CHIP could interfere with CHIP dimerization 
or higher order oligomerisation. By size exclusion chromatography (SEC) and native 
gel (data not shown), we have detected a scFv-dependent collapse in higher-order 
CHIP species. Characterisation of these species is ongoing. We hypothesise that the 
11F scFv antibody promotes the transition of either dimeric to monomeric or 
tetrameric to dimeric isoforms of CHIP.  
 
The binding of scFv to the U-box could affect CHIP dimerization, as it spans the E3-
protomer dimer interface (residues 239-259)47. ScFv may sterically prevent U-box 
dimerization, which is key for the electrostatic repulsion between the linker and the 
HH, driving the bending of the extended protomer208. Therefore, formation of the 
asymmetric dimer may not form. It is unclear if a symmetric dimer would form, since 
it does not require U-box dimerization (the elongated-dimer model)208. However, if the 
presence of scFv induces a shift from dimeric to monomeric CHIP, major charged 
domain changes would be expected, becoming more exposed to deuterium as a 
monomer. The coiled-coil domain located within the charged region is involved in 
stabilisation of the dimer40.      
 
 
b. Potential scFv-induced changes in CHIP’s intrinsic activity   
Protein structure is inherently associated with function47. Therefore, by changing the 
conformation of CHIP, scFv might influence its activity, including intrinsic E3 ligase 
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function and substrate specificity. It has been suggested that the dimer conformation 
of CHIP is necessary for its functioning as an E3 ligase40,146,208. As a monomer CHIP 
may be inactive. However, dimerization of the inactive monomers may activate the U-
box, assembling rapidly into an active dimer40,208. The members of the closely related 
RING Ub ligase family (MDM2 and MDMX) are an example of such. By forming 
heterodimers, the E2-binding RING domain becomes stabilised, overcoming the lack 
of intrinsic E3 ligase activity of MDMX248,249.  
 
Although 11F scFv could induce collapse of the dimer into monomeric CHIP, both 
auto-ubiquitination and some substrate ubiquitination (of ANXA2, but not α-Syn) are 
retained. This argues against CHIP being an inactive monomer and scFv-induced 
modulation of auto-ubiquitination. The prevailing hypothesis that dimers are required 
for ubiquitination activity is also challenged by the monomeric U-box E3 ligase, E4B, 
which is capable of auto-ubiquitination and substrate ubiquitination70. Likewise, CHIP 
could function as both a monomer and dimer, although supporting evidence is limited. 
It would therefore be interesting to map the auto-ubiquitination sites on CHIP by MS 
in the presence and absence of 11F scFv.  
 
Furthermore, as a monomer, the activity of CHIP may depend on its conformation. 
The CHIP bent promoter would be inactive due to the tight packing of the TPR-U-box 
interface, having the E2 binding site buried. However, in principle, the extended 
protomer should be active, with a single U-box exposed (according to the different 
dimer conformations proposed by Ye et al.208).  
 
Alternatively, rather than inactive, CHIP may have limited activity as a monomer. Such 
activity may be sufficient for auto-ubiquitination, for example, but not for specific 
substrate ubiquitination events, which might require the fully active, dimeric form. In 
line with this, 11F scFv inhibits α-Syn in vitro ubiquitination without affecting CHIP’s 
auto-ubiquitination. Thus, dimeric CHIP could be required for ubiquitination of this 
substrate. Likewise, it was hypothesised that dimeric CHIP may be required for the 
binding and subsequent ubiquitination of IRF-177.  
 
Such dynamics have been observed by E3 ligases that follow a 1:1 stoichiometry of 
E2 binding to its catalytic domain where, as monomers, ubiquitination efficiency is 
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low70. The symmetric homodimer of RING finger protein 4 is an example of such249. 
Regarding CHIP, it is unlikely that stoichiometry changes between the monomer and 
dimer, due to its half-of-sites active asymmetric dimer conformation. Alternatively, 
enhanced activity may correlate with the increased binding strength of the dimer. For 
example, disruption of the dimeric conformation of a RING E3 ligase (by mutating C-
terminal residues) completely abolished its activity, while mutating residues at the E2 
interface has a weaker effect250. Therefore, scFv-induced collapse of the dimer may 
result in insufficient binding strength of the E3 ligase for the ubiquitination of α-Syn.    
 
 
c. Potential scFv-induced changes in CHIP’s substrate specificity    
ScFv-induced changes in CHIP’s substrate specificity can be mediated inter- and 
intra-molecularly. This could explain the seemingly controversial effect of the scFv 
antibody on the ubiquitination of α-Syn and ANXA2. Dimer formation may alter the 
interactions and cellular functions of the E3 ligase complex. Such conformational and, 
in turn, functional variability has been reported for the RING family of E3 ligases, for 
example, which function as monomers, dimers (homodimers and heterodimers) or 
multi-subunit complexes251. More subtle intramolecular changes in the conformational 
dynamics of CHIP induced by scFv binding may drive a change in substrate 
specificity. It has been shown that changes to the TPR-domain of CHIP (e.g. via 
Hsp70 binding) were sufficient to modulate the docking-dependent E3 ligase activity. 
Hsp70 binding reduces flexibility of the TPR domain, which allosterically alters the 
conformation of the U-box and hence its catalytic activity47. Therefore, direct changes 
to the flexibility of the U-box (including scFv binding) are likely to have important 
implications in the ubiquitination cascade. Changes to the flexibility of the U-box have 
been predicted to influence the transfer of Ub from the CHIP-E2-Ub complex to the 
substrate47.  
 
The reduction in flexibility induced by Hsp70 binding inhibited CHIP-dependent 
ubiquitination of intrinsically unfolded proteins (such as IRF1 and p53), but stimulated 
ubiquitination of folded substrates like BAG-1s. This structural plasticity of CHIP 
allows it to switch its E3 ligase functions “on” and “off”. Underlying this is the influence 
of protein motion and flexibility on substrate selection242 and E3 ligase-mediated 
ubiquitination via E2:E3 interactions47. Like HSP binding and HSP-binding mimetic 
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mutations in CHIP47, the binding of scFv to CHIP could induce structural changes that 
cause CHIP to favour the ubiquitination of a folded protein, like ANXA2, but not the 
intrinsically disordered protein, α-Syn. We believe that scFv alters the dynamics of 
the U-box rather than altering its accessibility to either of the U-boxes at any given 
time (as seen in the Hsp70-CHIP complex)47. A potentially significant difference 
between Hsp70- and scFv-binding scenarios is that under certain conditions (e.g. in 
the presence of IRF-1) Hsp70-bound CHIP does not undergo auto-ubiquitination47, 
whilst we detect auto-ubiquitination of CHIP when scFv is present in all conditions 
tested. Therefore, the biochemical status of CHIP is different.  
 
Importantly, understanding the effects of the scFv antibody on CHIP can enrich our 
knowledge of CHIP’s conformational variability – a property that widens the scope of 
its substrates and, consequently, the cellular functions of CHIP242. The obvious next 
steps would be to map the ubiquitination sites on substrates and CHIP in the presence 
and absence of both 11F scFv and either substrate (α-Syn or ANXA2), and conduct 
more biophysical and biochemical analyses into scFv-induced changes of CHIP 
structure and function.  
 
The main outputs from this chapter include the generation of scFv antibodies and their 
characterisation, including interphase mapping of the scFv:CHIP interaction and 
scFv-mediated regulation of CHIP activity. This foundation work and the intrabodies 
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Chapter 7: Final discussion & Future work 
 
7.1 Final discussion: Summary 
7.1.1 Development of CHIP models and proteomic analysis 
Despite strong evidence supporting the neuroprotective effects of CHIP, the details of 
its intrinsic role in neuronal health and disease is largely undefined. This thesis aimed 
to identify the protein targets of this dual function chaperone and E3 ligase in a 
disease context. Given the association of CHIP with α-Synucleinopathies, our model 
for target identification was derived from a patient with Lewy body Parkinsonism. 
However, considering that the majority of neurodegenerative diseases are 
proteinopathies and CHIP plays an integral role in proteostasis, understanding its 
effects could be relevant across different diseases. Furthermore, many E3 ligases are 
associated with neuronal dysfunction (about 13% of E3-encoding genes are mutated 
in neurological diseases – 83 genes and 70 different diseases252).   
 
The project design was centred around two main criteria. Firstly, target identification 
was conducted prior to the manifestation of hallmarks of cell pathology (e.g. inclusion 
body formation and neurite degeneration) and using an unbiased approach. The 
underlying rational was our aim to elucidate possible early proteomic changes that 
could be relevant in disease initiation/progression and, in turn, for disease-
modification. This contrasts with the majority of studies aimed to understand the role 
of CHIP in neurodegeneration, which tend to use models with proteotoxic stress.  
 
Secondly, given the highly dynamic and tightly regulated ubiquitination processes, 
this project focused on studying the effect of CHIP on the proteome at endogenous 
levels of expression. Again, this contrasts with the norm, where overexpression 
systems tend to be used when studying CHIP. Here, not only are ubiquitination 
cascades likely to be affected, but its TPR domain may also alter the interactome of 
TPR-containing proteins and the dynamic nature of the chaperone network. In fact, 
many substrates identified using such an approach have proven difficult to validate 
as physiologically relevant. Our loss-of-function CHIP cell models are likely to be less 
disruptive to protein homeostasis. 
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I have engineered patient-derived iPSC so that they lack the expression of CHIP using 
CRISPR/Cas9 based gene-editing technology. Those cells were differentiated into 
mature cortical neurons (Chapter 3) and this isogenic system was used to investigate 
the effect of CHIP on the proteome using label-free DIA by SWATH-MS (Chapter 4). 
Protein targets identified were validated in these cortical neurons and iPSC, as well 
as another neuronal-like cell model that we have previously used to manipulate the 
expression of CHIP (provided by Erisa Nita95; Chapter 4 and 5). The use of multiple 
models counteracts the effects of clonal variability, differentiation variability and cell 
line-specific differences (that could be associated with cell cycling and/or neuronal 
identity).  
 
Interestingly, a restricted number of proteins (around 35 proteins) were identified by 
SWATH-MS as significantly changing in the absence of CHIP function (Chapter 4). 
This supports its functions as a chaperone-independent, docking-dependent E3 
ligase, which has been previously proposed by us47,77 and others62. Moreover, it 
suggests that our model is likely to reflect an early state of disease, with no/low stress 
levels, since proteotoxic stress is associated with considerable changes in the 
proteome due to the activation of the molecular chaperone network.  
 
These 35 proteins could be regarded as both an under- or over-estimation of the 
protein targets of CHIP. They may not all be direct targets of CHIP (i.e. ubiquitination 
substrates or chaperone clients). Instead, CHIP could regulate some upstream 
components of the pathway, which indirectly affect components downstream that 
could be more readily detected by SWATH-MS. Conversely, since these 35 proteins 
seem to belong to multiple, unrelated pathways, CHIP could regulate numerous 
proteins and signalling cascades. This number could also be an underestimation 
because only modifications that modify the trypsinisation pattern of proteins and/or 
protein levels can influence the candidate proteins detected. Therefore, like the 
majority of MS-based proteomic techniques and experimental designs, SWATH-MS 
analysis of a loss-of-function model can be bias towards the identification of 
ubiquitination substrates destined for degradation, compared to proteins that undergo 
K63-mediated ubiquitination, for example.  
 
We have identified potential targets of CHIP that are involved in a vast array of cellular 
processes, including innate immunity (HLA-B and, previously, IRF177), regulation of 
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metabolism (VGF) and membrane homeostasis (calcium- and phospholipid-binding 
proteins, such as ANXA2 and S100-A11; Chapter 4) (Figure 7.1). These may 
contribute to the neuroprotective effects of CHIP, independently or in a cumulative 
manner. 
 
Chapter 5 focused on the effect of CHIP on ANXA2 homeostasis. ANXA2 was found 
to be upregulated in CHIP KO neurons and in close proximity with CHIP (interacting 
directly or indirectly, e.g. within 40 nm). Our SH-SY5Y CHIP model, with lower fold 
change in ANXA2 protein level, provided insights into CHIP-mediated changes in 
ANXA2 isoforms and interactome (with its binding protein S100-A11 and CHIP). I 
detected CHIP-dependent ubiquitination of ANXA2 in vitro and, possibly, in situ, thus 
CHIP could function to maintain correct homeostasis of ANXA2 (Chapter 5). The 
ubiquitination sites in ANXA2 were mapped to lysine residues 115 and 157, although 
these preliminary results need to be further validated (Chapter 6). Accordingly, 
























































Figure 7.1: Activity of CHIP in normal conditions and under proteotoxic stress 
In normal conditions (left) CHIP regulates the proteostasis of a restricted number of substrates 
that belong to a vast array of cellular processes, including membrane homeostasis and innate 
immunity. Regulation is likely to occur in a chaperone-independent, docking-dependent 
manner. Under proteotoxic stress (right) CHIP may be diverted to quality control mechanisms 
to counteract accumulating misfolded/unfolded proteins. Unfolded/misfolded α-Syn is 
illustrated in this schematic (red rectangle) as a substrate entering the protein triage, where it 
can become refolded into an α-helical state or targeted for proteasomal or lysosomal 
degradation. This may or not involve the actions of chaperone (in purple) (we have shown that 
CHIP is capable of ubiquitinating intrinsically unfolded α-Syn in a chaperone-independent 
manner, in vitro). Generally, quality control mechanisms recruit the molecular chaperone 
network. Oligomeric (depicted by the multiple red rectangles) and amyloid fibrils (multiple red 
arrows) of α-Syn induce proteotoxic stress.  
(Crystal structure of CHIP derived from: Zhang et al.,39) 
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7.1.2 Changes in lipid homeostasis and membrane integrity 
Given the crucial role of ANXA2 in maintenance of membrane integrity and as a 
modulator of membrane-related cellular events (e.g. endocytosis), its dysregulation is 
likely to be detrimental for cells. I have presented evidence suggesting that CHIP KO 
cells have a compromised membrane integrity, having increased permeability and 
sensitivity to injury (Chapter 5). This could be a direct effect of the upregulation of 
ANXA2 and/or its impaired interaction dynamics with S100-A11 (the complex is 
important for membrane repair). Alternatively, ANXA2 upregulation could be a 
compensatory mechanism in attempt to restore membrane integrity (e.g. by promoting 
interaction with S100-A11), which could be impaired due to other CHIP-dependent or 
independent factors. Nonetheless, as proof-of-concept, a preliminary experiment 
showed that, even if the increase in ANXA2 in CHIP KO cortical neurons is a 
secondary protective response, it fails to restore membrane homeostasis (with 
regards to membrane resilience to damage and permeability at basal conditions), 
when compared to control cells. Finally, defects in ANXA2 homeostasis can also be 
an epiphenomenon that is unrelated to membrane integrity.  
 
 
a. CHIP-dependent lipid regulation in an Annexin-independent 
manner 
A plausible underlying mechanism for the change in membrane properties observed 
is CHIP-mediated regulation of lipid homeostasis, in a manner that is independent of 
ANXA2. CHIP plays an integral role in proteostasis, preventing activation of the 
UPR65. Recently, lipid homeostasis has been also directly associated with the UPR in 
the ER, at various levels253,254. Alterations in membrane lipid composition and fluidity 
(including an increase in membrane saturation and cholesterol accumulation) have 
been shown to induce the UPR. Such induction is independent of proteostasis, 
although the proteins activated (including UPR proteins, IRE-1 and PERK) are in 
common with those recruited during proteotoxic stress253,254. Such pathway 
convergence despite varying stimuli makes us question whether enzymes related to 
the UPR also have lipid-related functions. In fact, a branch of the UPR (IRE-1/XBP1) 
is a well-characterised positive regulator of membrane lipid synthesis9. Furthermore, 
membrane homeostasis has been correlated with the efficiency of the ER in resolving 
proteotoxic stress9. There is also evidence to suggest that abnormal lipid synthesis 
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itself drives ER dysfunction26. The relationship between the UPR and lipid metabolism 
has been seen in the context of neurological conditions. Dystonia is characterised by 
defects in membrane biology and ER homeostasis (Figure 7.2) and the underlying 
mechanism is the dysregulation of lipid homeostasis255.    
 
Therefore, we propose that CHIP-mediated changes in lipid composition could 
position CHIP at the interface between maintenance of lipid and protein homeostasis. 
Such a non-canonical, novel function of CHIP, could be important as there is 
increasing evidence linking proteinopathies (including neurodegenerative diseases) 

























Figure 7.2: Membrane and ER dysfunctions in neurological condition 
The neurological condition, dystonia, is caused by torsinA dysfunction. This impacts lipid 
composition, membrane structure and/or function, impacting organelle homeostasis. 
Schematics represented are based on findings from a fly model of disease.  
A) Lipid composition of membranes in control (left) and dystonia pathogenesis (right). 
Diseased membrane has reduced levels of bulk membrane lipids and multiple defects, which 
compromises membrane properties (including fluidity, plasticity, fission and fusion).  
B) Dystonia has reduced neuronal ER volume, which can result in defects in protein secretion 
and ER homeostasis.  
(Adapted from Cascalho et al.255) 
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b. CHIP-dependent lipid regulation in an Annexin-dependent manner 
CHIP-mediated lipidomic changes could be achieved through the regulation of 
Annexin proteins. Annexins segregate membrane lipids and are at the centre of major 
pathways regulating cellular cholesterol homeostasis (Figure 7.3). The later includes 
the incorporation of cholesterol into late endosomes and its transport along the 
endocytic route. Overexpression of ANXA6 has been shown to increase its 
association with late endosomes, promoting the redistribution of cholesterol from PM 
and other membranes towards endosomal membranes. Ultimately, dysregulation of 
Annexins impact on the intricate network of feedback mechanisms associated with 
cellular lipid homeostasis, including cholesterol258. The maintenance of adequate 
levels of both lipids and Annexins is critical for endosomal function and the turnover 
of proteins (e.g. integrins)258,259. 
 
Interestingly, Annexins have been shown to be upregulated in neurological 
conditions188,189, which could account for the accumulation of cholesterol in late 
endosomes observed in neurogenerative diseases and ageing257,258. In parallel, cell 
models of AD show reduced membrane fluidity due to cholesterol depletion at the 
PM260. Our CHIP KO models show a robust increase in sensitivity to membrane 
damage induced by the cholesterol-sequestering agent, digitonin. Thus, varying 
cholesterol content, which could be directly or indirectly related to CHIP expression, 
could result in membrane fragility in CHIP KO cells. Although Annexins could be 
responsible for the lipidomic changes, we cannot exclude the possibility of CHIP 
interfering with lipid composition, such as cholesterol, in an Annexin-independent 














































Figure 7.3: Annexin-mediated cholesterol metabolism and trafficking within the cell 
Annexins function at multiple stages of the endocytic pathway. Routes highlighted in orange 
are modulated by cholesterol. Those in green are recycling pathways and indicates points of 
interaction with other cytosolic proteins.  
Annexins are involved in the maturation of early endosomes (EE) into late endosomes (LE) 
(1). This is achieved through the recruitment of Annexins to the surface of LE through binding 
to acidic phospholipids and cholesterol. Also, Annexins function as ”tethers” for the formation 
of membrane contact sites (MCS) between the ER and late endosomes/lysosomes, which are 
functional platforms for the exchanges of lipids (including cholesterol) and ions. Finally, 
Annexins can also be involved in the secretion of exosomes from multivesicular bodies (MVBs) 
(Adapted from Rentero et al.258) 
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7.1.3 Modulating CHIP 
We have engineered tools to manipulate the activity of CHIP in an endogenous state 
(Chapter 6). This contributes to our aim of comprehensively evaluating the role played 
by CHIP in human neuronal cell health and, specifically, its proteostasis. ScFv 
antibodies generated using phage display technology were purified and introduced 
into mammalian expression vectors for delivery as intrabodies. At present, our data 
indicates that the 11F scFv antibody binds to the U-box domain of CHIP and induces 
a shift from higher order structures to lower MW species. It is likely that the scFv 
interferes with the dimerization or tetramerization of CHIP. We expect its intrinsic 
activity and substrate specificity to be influenced by the scFv-induced conformational 
changes. To test this, we investigated the effect of the scFv on CHIP-dependent 
ubiquitination of two substrates of interest: ANXA2 and α-Syn (Chapter 6). Unlike 
ANXA2, the ubiquitination of α-Syn by CHIP has been previously reported37,68 
although, to our knowledge, we are the first to map the ubiquitination site involved 
(K60). Moreover, both the identification of ANXA2 as a ubiquitination substrate of 
CHIP and the ubiquitination sites involved were novel.  
 
Accordingly, in vitro, we have observed a decrease and increase in CHIP-dependent 
ubiquitination of α-Syn and ANXA2, respectively, in the presence of scFv. Here, 
substrate specificity could be governed by the secondary structure of the substrate, 
since the lower MW isoform of CHIP (induced by the scFv and potentially monomeric) 
is capable of ubiquitinating the folded substrate ANXA2 but not the intrinsically 
unfolded α-Syn. Therefore, the scFv antibody can function as a “molecular switch” to 
modulate the intrinsic and dynamic E3 ligase functions of CHIP.  
 
A couple of studies have modulated the levels of CHIP in cell models using 
trehalose261 and lanosterol262. Both treatments protected from proteotoxic stress, 
oxidative stress and cell death by enhancing protein clearance mechanisms (including 
the UPS and autophagy)261,262. The authors concluded that, at the molecular level, 
trehalose increased the expression of Hsp70, which in turn alleviated CHIP 
dysfunction in patient fibroblasts with a hereditary CHIP-mutant related ataxia. The 
underlying hypothesis is that, since the mutation occurs at the dimer interface of CHIP, 
monomeric CHIP is non-functional261. In this thesis, we show that binding of the scFv 
antibody to CHIP may alter its conformation (Chapter 6), and potentially its function. 
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Given these observations, we believe this structure-function relationship deserved 
more investigation, thus we are currently working with the Hoppe Laboratory 
(University of Cologne, Germany) to determine the effect of monomeric CHIP on 
human substrates.  
 
Lanosterol treatment induced expression of CHIP through increased stabilisation 
conferred by the binding of lanosterol to the TPR domain of CHIP. At a cellular level, 
this treatment enhanced both CHIP-mediated proteasomal and lysosomal clearance 
mechanisms262. It is unclear how binding of lanosterol influences the chaperone and 
E3 ligase activity of CHIP (given the reported allosteric interactions between the TPR 
and U-box domains47). Interestingly, lanosterol is an intermediate of cholesterol 
synthesis and induces ubiquitination and degradation of rate-limiting enzymes of 
cholesterol synthesis262. This endorses the emerging question of whether there is a 
relationship between cholesterol and CHIP, seeing that our CHIP models display 
different phenotypes towards treatment with the cholesterol-sequestering agent, 
digitonin (Chapter 5).  
 
Targeting E3 ligases is known to be challenging given their involvement in multiple 
pathways simultaneously. CHIP, with its chaperone and E3 ligase functions, is central 
in various processes. Hence, merely overexpressing it is likely to result in pronounced 
changes to the cellular proteostasis and have detrimental side-effects65. The 
development of tools to manipulate the E3 ligase functions of CHIP in a more targeted 
manner, e.g. the use of scFv antibodies, is likely to minimise the problems associated 
with manipulating CHIP activity. Modulation of CHIP activity is likely to be beneficial 
when studying the homeostasis and functions of CHIP and could, potentially, 
contribute to the identification and development of therapeutic targets and tools. Joshi 
et al. stressed the need to investigate properties of CHIP and strategies that could 
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7.2 Final discussion: In the context of 
neurodegeneration 
The exercise of positioning findings in a wider context can add depth to the possible 
conclusions drawn. With this objective, I attempt to evaluate the underlying rational 
and main findings of my PhD project from the context of neurodegeneration, 
elucidating its potential significance within the field. The hypotheses developed within 
the following sections are for discussion purposes and have not necessarily been 
addressed in this thesis.  
 
 
7.2.1 Relevance of CHIP loss-of-function in disease 
We have focused on loss-of-function CHIP cell models. Loss-of-function of CHIP 
could be of relevance in a disease context, where CHIP may be recruited to the 
protein quality control machinery in order to counteract proteotoxic stress – a 
characteristic of progressive neurodegeneration (Figure 7.1). This dynamic, context-
specific activity of CHIP has been previously proposed. Kanack et al.49 observed that 
heat-stressing CHIP enhanced its chaperone activity and suppressed its E3 ligase 
functions. This translated to CHIP-mediated refolding of denatured/misfolded proteins 
rather than degradation, under conditions of cellular stress. Moreover, Tawo et al.62 
not only observed a shift in CHIP activity towards quality control mechanisms under 
proteotoxic stress, but this was accompanied by the accumulation of one of its E3 
ligase target, the INSR. Likewise, ANXA2 accumulation could be due to the absence 
of CHIP-mediated turnover mechanisms (Figure 7.4). The same end-effect could also 
be achieved if CHIP becomes trapped within cytoplasmic inclusions, such as LBs 
(where CHIP has been detected25), which “diverts” it from its primary functions and 
reduces the effective chaperone-free concentration of CHIP in the cytoplasm. This 

































7.2.2 Lipid-dependent α-Synuclein toxicity 
a. α-Synuclein monomers 
In the context of synucleinopathy, there is growing evidence supporting lipid-
dependent α-Syn toxicity. These could be influenced by changes in cellular lipid 
composition and membrane integrity. The “3K” α-Syn mouse and cell models shed 
some light on the lipid-mediated α-Syn activity and resultant toxicity263,264. This model 
amplified the effect of the PD-related E46K α-Syn mutant, by introducing two 
additional E-to-K mutations (E35K + E61K) on neighbouring KTKEGV motifs involved 
in lipid-binding263,264. Introduction of these mutations resulted in a stepwise increase 
in neurotoxicity264. These mutations inhibit fibril formation264 and decrease the ratio 
Figure 7.4: Inhibition of the neuroprotective functions of CHIP in neurodegeneration 
CHIP may be neuroprotective by regulating the homeostasis of specific protein targets. Tawo 
et al.5 have suggested that CHIP may regulate the turnover of the insulin receptor (INSR), 
preventing ageing. Possibly, CHIP-mediated regulation of ANXA2 is also part of CHIP’s 
neuroprotective actions, and could influence membrane integrity.  
In neurodegeneration, CHIP may be recruited towards quality control mechanisms and/or 
become trapped in Lewy bodies (represented schematically here), resulting in the 
accumulation of ANXA2, it was reported for the INSR5. This could have deleterious cellular 
consequences. 
 (LB image derived from: Spillantini et al.24; crystal structure of CHIP derived from: 
Zhang et al.39)     
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between aggregation-resistant α-Syn tetramers and aggregation-prone monomers263. 
Therefore, the pathomechanism of this model may be predominantly driven by the 
intrinsic activity of monomeric α-Syn. This supports the rational that a shift in α-Syn 
equilibrium from tetramer/multimer to monomer has detrimental effects. Likewise, the 
SNCA triplication line (our iPSC model) manifests this shift towards increased 
monomeric α-Syn, thus may result in similar defects as the E46K and 3K models264.  
 
Biochemically, the mutations increase the membrane avidity of α-Syn263. 
Acute/subacute consequences of expression of 3K α-Syn include defects in vesicle 
trafficking, vesicle clustering and, eventually, membrane rearrangements. This is due 
to the increased vesicle binding of the mutants (in a lipid-induced α-helical structure), 
and its loss of membrane curvature selectivity. The mutations trigger a change from 
“curvature sensor” (important for its intrinsic functions in synaptic vesicles) to a robust 
“curvature inducer”. This leads to the formation of multiple, round cytoplasmic 
inclusions comprised of clusters of vesicles and tubules from diverse subcellular 
membranes (such as endocytic, lysosomal and Golgi), which are intimately 
associated with the focal accumulation of α-Syn. Here, α-Syn is diverted from its 
physiological functions at the synapse, which is like to have consequences for 
neuronal functioning. These abnormal vesicle clusters are an early pathogenic step 
towards Lewy-type α-Syn aggregates. Not only is such clustering likely to be 
detrimental for cells, the excess monomeric α-Syn eventually forms β-sheet-rich α-
Syn aggregates that also contribute to the growing toxicity (Figure 7.5)263,264. 
 
α-Syn-induced membrane curvature, as well as expansion, can compromise 
membrane integrity (Figure 7.6)265–267. Binding of α-Syn monomers can result in 
uncontrolled membrane curvature, membrane remodelling (such as blebbing; Figure 
7.6A)266 and expansion via thinning and phospholipid rearrangement (Figure 7.6B). 
The end-effect is loss of membrane integrity, membrane remodelling and 
fragmentation267,268. Interestingly, the expansion per α-Syn is highly dependent on 










































Figure 7.5: α-Synuclein homeostasis and toxicity 
A) Unfolded α-Syn binds to curved membranes, adopting an a-helical conformation. 
B) α-Syn monomers bind to vesicles (B1). α-Syn multimerization (B2) might weaken α-
Syn:lipid interaction, yielding monomers (B3). The process repeats (B1’-B3’). 
C) KTKEGV mutant monomers (such as the 3K model) bind to vesicles (C1) and their inability 
to multimerize prolong this lipid interaction (C2). This can result in defects in vesicle trafficking 
and membrane rearrangements, such as tubulation (C3). A longer-term consequence is the 
formation of β-sheet-rich α-Syn aggregates (C4).  
D) Excess monomeric α-Syn caused by SNCA triplication, for example, (D1) results in similar 
lipid-mediated toxicity (D2-D4) due to the shift towards free monomers. 
(Adapted from Dettmer et al.264) 
 



































Figure 7.6: α-Synuclein-induced defects in membrane properties 
A) In a concentration-dependent manner, α-helical α-Syn can bind to vesicles, causing 
curvature strain that induces remodelling, which initiates as membrane budding. The size and 
shape of the remodelling event depends on the concentration and orientation of α-Syn 
monomers. 
B) α-Syn incorporation into the lipid bilayer results in lateral expansion of the lipids. This can 
result in:  
- Thinning of the membrane due expansion of lipid molecules out of the membrane plane and 
interdigitation (a) or lipid conformational changes (b), 
- Curvature (c).  
Changes in bilayer thickness and curvature stress can result in loss of membrane integrity, 
increasing its permeability.  
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Membrane remodelling events (including blebbing) and permeability can trigger 
ANXA2 recruitment and upregulation, as a response mechanism162. Thus, it remains 
an open question whether CHIP KO neurons have enhanced lipid-mediated α-Syn 
pathology, and ANXA2 proteomic changes arise secondary to this. Alternatively, 
ANXA2-mediated lipidomic changes could potentially influence α-Syn toxicity. ANXA2 
mediates lipid raft formation (cholesterol-rich) and lipid segregation of acidic 
phospholipids (including PI and PS) – to which α-Syn has preferential binding265. 
Furthermore, both ANXA2 and α-Syn bind to cholesterol and PA. Therefore, there 
could be some degree of cross-talk between their homeostasis and lipid-mediated 
interactions, which is unknown and could be relevant in our CHIP model.  
 
 
b. α-Synuclein aggregates 
Another mechanism of α-Syn-induced pathology mediated by lipids relies on the 
action of α-Syn pathogenic aggregates. Different membrane properties (e.g. 
increased membrane fluidity, short hydrocarbon chains, anionic phospholipids such 
as PI, PUFA, rafts, and cholesterol) favour the aggregation kinetics of α-Syn260,268,269. 
Considering the changes in phospholipid composition observed in our CHIP model, 
membrane fluidity may be affected, which can influence α-Syn aggregation. Likewise, 
although not directly addressed, changes in cholesterol could also influence the 
interaction between α-Syn oligomers and membranes.   
 
Monomeric α-Syn can become stabilised at membranes promoting its 
multimerization264. Different mechanisms have been proposed for lipid-induced 
aggregation. Firstly, lipids confer α-Syn to a small and/or two-dimensional surface 
(e.g. vesicle), increasing the effective concentration and driving aggregation through 
mass action. Mechanistically, this brings the more C-terminal unstructured regions 
into close proximity, which facilitates nucleation of inter-molecular β-sheet structure, 
forming oligomers. Secondly, lipid-induced conformational changes (i.e. an α-helical 
state) can favour intermolecular interactions leading to aggregation. These 
mechanisms are mutually non-exclusive and could have a cumulative effect26.  
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As oligomers, α-Syn can disrupt membranes by forming pores in the PM (Figure 
7.7)264,269,270. Pores result in increased permeability, allowing a detrimental calcium 
influx that drives cell death269. Pore formation is a characteristic of other amyloid 
proteins, such as Aβ, thus could be a pathomechanism in common across 
neurodegenerative diseases. Moreover, aggregate-induced permeabilization of 
endolysosomal membranes has been proposed as a mechanism for cell-to-cell 




























Figure 7.7: Pore formation in the membrane by oligomeric α-synuclein 
α-Syn oligomers can induce pore formation by two mechanisms: 
A) Toroidal model: involves the sequential binding of α-Syn monomers to the membrane, 
resulting in the formation of pores/channels with a α-helical conformation. 
B) Barrel model: α-Syn oligomers with a β-sheet-rich structure form ring structures with a 
central pore.  
These mechanisms are dose-dependent and the end-effect is increase membrane 
permeabilization.  
(Pacheco et al.270) 
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c. CHIP, lipid homeostasis and α-Synuclein pathology 
Taken together, lipids play a critical role in α-Syn homeostasis and pathology269. 
Therefore, dysregulation of lipid composition and alternations to the protein:lipid 
interactome are likely to influence pathology. We have shown preliminary evidence 
that CHIP, possibly through its E3 ligase functions, could influence membrane 
integrity and resilience to injury. Thus, CHIP could function in the regulation of 
membrane homeostasis by influencing lipid composition (our CHIP model shows 
differential lipidomics), or by regulating proteins involved in the maintenance of 
membrane integrity (such as the Annexin family). The exact mechanism explaining 
how these changes influence membrane properties, α-Syn pathology and cell 
functioning is unclear.  
 
Lipidomic changes in the context of increased α-Syn expression (SNCA triplication), 
in particular, are likely to be of biological significance. Recently, it has been shown 
that modulation of lipid metabolism pharmacologically influenced α-Syn aggregation 
and pathology, possibly by preventing α-Syn:lipid interactions272,273. Moreover, age-
related changes in lipid composition captures disease proteins (including α-Syn) in a 
membrane-bound state that precedes protein deposition, highlighting the important of 
lipid changes in disease progression274. The effect of lipid dysregulation in the α-Syn 
pathological cascade has been proposed: 
1. Normal conditions: monomeric and tetrameric α-Syn are in equilibrium.  
2. Mild α-Syn accumulation: α-Syn itself triggers changes in lipid homeostasis. 
These are counteracted by cellular compensatory mechanisms.  
3. Great α-Syn accumulation accompanied by pronounced lipid dysregulation: 
the effects of prolonged α-Syn accumulation exceed compensatory 
mechanism, causing lipid accumulation, which activates the UPR and inhibits 
membrane trafficking. The threshold is influenced by the cell’s lipid 
homeostasis (e.g. risk factors affecting lipid metabolism tend to promote α-
Syn accumulation)272. 
 
Our CHIP model is in an α-Syn overexpression background. CHIP deletion may 
induce the unfavourable lipidomic changes that promote α-Syn toxicity, either directly 
or indirectly. Given the absence of LB-like aggregates, mechanisms driven by the 
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monomeric rather than aggregates of α-Syn may take place. Therefore, our model 
could mimic the lipid-mediated α-Syn toxicity seen in the 3K model. If this proves to 
be true (future studies are necessary), CHIP KO neurons may have poor membrane 
integrity due to enhanced lipid- and α-Syn-dependent deleterious effects. Thus, 
through lipid changes, CHIP may regulate α-Syn homeostasis and be neuroprotective 
against α-Syn-induced toxicity.   
 
Other than through modulation of the lipid composition, this thesis suggests that α-
Syn homeostasis could be regulated by CHIP-dependent ubiquitination (Chapter 6) 
(Figure 7.8). The occurrence of CHIP-dependent ubiquitination of α-Syn in cells at 
endogenous conditions still needs to be confirmed, and its physiological relevance 
addressed. α-Syn binding to lipids is achieved through electrostatic interactions 
between the positively charged lysine residues and negatively charged phospholipid 
headgroups (such as PS and PA)275. Therefore, ubiquitination could abolish the 
contact of the K60 side chain with phospholipid(s), potentially influencing its 
interaction with membranes and, in turn, its lipid-mediated functions in health and/or 
disease. Moreover, K60 lies at the interface between the lipid-binding N-terminal 
region and the aggregation-prone NAC region, thus ubiquitination could also 
modulate (and possibly inhibit) aggregation of α-Syn. If this proves to be correct, CHIP 
could be neuroprotective by preventing lipid-mediated toxicity and/or shifting α-Syn 
















































Figure 7.8: α-Synuclein aggregation process and possible ways in which CHIP could 
regulate α-synuclein homeostasis 
α-Syn is prone to aggregate and this is enhanced by SNCA multiplications (through a shift in 
the equilibrium of α-Syn) and mutations. Through its chaperone and/or E3 ligase functions, 
CHIP could prevent the aggregation of α-Syn. Eventually Lewy bodies form, containing 
ubiquitinated α-Syn species. The dynamic conformations of α-Syn are represented: unfolded 
(red rectangle), β-sheet and α-helical.  
 (LB image derived from: Spillantini et al.24; crystal structure of CHIP derived from: 
Zhang et al.39)     
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7.2.3 Potential neuroprotective effects of CHIP 
Beyond its reported roles in α-synucleinopathies, over the years CHIP became an 
established neuroprotective protein15,49,78,149, largely through its anti-ageing properties 
(the biggest risk factor of neurodegenerative diseases). We now question whether 
CHIP-mediated changes in the homeostasis of proteins and lipids could contribute to 
its neuroprotective functions.  
 
In line with the established beneficial role of CHIP in cellular health, we would expect 
that CHIP-mediated regulation of its protein targets ensures their adequate 
homeostasis, preventing proteotoxicity. As a protector of ER stress, CHIP may 
regulate longevity by influencing the UPR65. Supporting evidence of the relationship 
between the UPR and life-span is the mdt-15 loss-of-function worm model, which has 
a constitutively activated UPR and reduced lifespan253. Interestingly, the long-lived 
INSR-mutant worms have altered UPR threshold253 and CHIP has been proposed as 
a regulator of the INSR62. Furthermore, the relationship between lipid metabolism, 
stress response and longevity has also been proposed253. Mdt-15 is essential for the 
expression of genes involved in fatty acid metabolism and stress responses. Beyond 
having a reduced lifespan, Mdt-15 worms are more sensitive to stress253. Interestingly, 
both of these phenotypes were also observed in CHIP KO mice14,15,104.  
 
Unexpectedly, we found that the lipidomic signature of CHIP KO SH-SY5Y cells 
shares some similarities with the lipidomic changes observed in neurodegeneration. 
This opens the question whether CHIP-mediated regulation of lipid composition 
contributes to its neuroprotective functions. As in AD mouse models and the cortex of 
AD patients256, CHIP KO cells show a decrease in PA (including 38:4) and PS. Lipid 
dysregulation during the course of neurodegeneration results in altered membrane 
properties256, causing for example endolysosomal membrane damage and organellar 
dysfunction – seen in various neurodegenerative diseases, including AD and 
LBD257,271. Genes involved in lipid metabolism and cellular membrane damage have 
been associated with AD256 and PD269. Additionally, although we have not directly 
quantified cholesterol content in our CHIP model, CHIP KO cells displayed enhanced 
sensitivity to a cholesterol-specific injury. Cholesterol levels were reported to be 
increased in the cortex of AD patients256 and in exosomes of carriers of ε4 allele of 
apolipoprotein E256,257.   
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Changes in lipid composition can contribute to neuronal vulnerability and increased 
risk of neurodegeneration257. This is not surprising, as lipid membrane integrity is 
crucial for the maintenance of membrane potential269, hence neuronal function. In fact, 
it has been suggested that lipid dysregulation is an early pathological event in 
neurodegeneration271, thus identification of early protein-lipid interactions could be of 
interest274. The modulation of lipid metabolism has been shown to have 
neuroprotective effects273 and may be particularly relevant for cortical neurons, which 
have been shown to correlate with longevity276. Long-lived cortical neurons 
accumulate damage that progressively impairs their function276 and is likely to 
compromise membrane integrity. Therefore, if lipid changes prove to be CHIP-
dependent and of biological significance, they may contribute to the neuroprotective 




7.3 Future work 
7.3.1 CHIP-dependent ubiquitination of substrates identified 
a. Investigate whether the CHIP:substrate interaction is direct or 
indirect  
We have identified a novel interaction between CHIP and ANXA2 (and, to a more 
preliminary degree, between CHIP and S100-A11). This was shown by co-IP and PLA 
assays. Given the limitations of the co-IP experiment, an additional method to confirm 
that CHIP and ANXA2 are in close proximity in cells should be performed. For 
example, proteins can be cross-linked prior to cell lysis and analysed by SEC and 
WB, to elucidate whether CHIP and ANXA2 are within the same fraction. If within a 
complex, the SEC fractions containing ANXA2 and CHIP could be analysed by MS 
and WB to identify binding partners. 
 
However, none of these methods inform us whether these proteins are interacting 
directly or indirectly (being, for example, within the same complex). Binding site 
mapping, using a peptide library analysed by affinity chromatograph or ELISA and 
HDX-MS, would provide evidence of the kinetics of their interaction in vitro77. Regions 
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responsible for the interaction could be subsequently mutated to abolish CHIP:ANXA2 
in vitro and in situ, for validation purposes. 
 
 
b. Validation of ubiquitination sites 
Subsequent work would validate the ubiquitination sites mapped on CHIP and its 
substrates, α-Syn and ANXA2, using mutational experiments both in vitro and in situ 
– a common mechanism to confirm candidate ubiquitination sites141,143. This is 
particularly relevant seeing that these sites have not been previously reported. 
Accordingly, mapping of ubiquitination by MS is regarded as an effective technique 
for the identification of novel targets and sites (having reported 72% of substrates and 
92% of sites identified as novel143). Importantly, previous studies have reported 
similarities between ubiquitination sites mapped in vitro and those found in human 
cells (e.g. CHIP-dependent ubiquitination of the INSR at K1047 was mapped in vitro 
and once mutated in human cells the turnover of the receptor was compromised)62.  
 
Furthermore, future experiments would assess whether these ubiquitination events 
happen endogenously in cells, under what conditions and with that cellular 
consequences. The relationship between ANXA2 ubiquitination and the 
ANXA2:S100-A11 interactome, lipid homeostasis and membrane integrity can also 
be assessed.  
 
 
c. Preliminary data to decipher the fate of ubiquitination species 
Since ubiquitinated ANXA2 species were detected in vitro and potentially in situ, and 
may be CHIP-dependent, we performed preliminary experiments to unravel the fate 
of ubiquitinated ANXA2, hence elucidating its cellular significance. Cells were treated 
with a panel of inhibitors of ubiquitination-mediated and/or -dependent pathways to 
see if any definite effects on ubiquitinated ANXA2 species (evaluated by PLA; Figure 
7.9). Endosomal/lysosomal inhibitors (BafA1 and chloroquine), the autophagy 
inhibitors (BafA1 and 3-MA), endocytosis inhibitor (V34-2) and proteasomal inhibitors 
(MG-132 and Lactacystin) were used. Blocking the pathway to which ubiquitinated 
ANXA2 is destined to would interfere with the homeostasis of ANXA2. The autophagy 
inhibitors (BafA1 and 3-MA) significantly decreased Ub:ANXA2 PLA signal, while the 
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proteasomal inhibitors (Lactacystin and MG-132) increased it. Ubiquitinated ANXA2 
is likely accumulate when its degradation mechanism is impaired. This rational would 
suggest that ANXA2 turnover is mediated by proteasomal degradation.  
 
It is important to note that, for practical reasons, the panel of inhibitors were tested in 
two groups (independent experiments), each with control conditions included (DMSO 
treatment). The big relative difference in the levels of Ub:ANXA2 between DMSO 
treated cells can be due to multiple factors, including batch-to-batch variability of the 
PLA kit. Since changes in the abundance of ubiquitinated ANXA2 species were 
detected in this preliminary experiment, this could be addressed further to better 
understand the mechanism underlying CHIP-dependent regulation of ANXA2 
homeostasis. Future work would repeat this experiment (increasing the n number might 
overcome such batch-to-batch variability observed), inhibit these pathways with other 
pharmacological agents and include CHIP KO cells (potentially as negative controls, if 
ubiquitination of ANXA2 is CHIP-dependent). The protein levels of ANXA2 should also be 
measured. However, pharmacological-inhibition of such tightly regulated process, 
such as ubiquitination, is complicated to interpret due to the limitations of the inhibitors 
(including off-targets) and regulatory feedback loops. Alternatively (or in parallel), the 
ubiquitinated sites of ANXA2 could be mutated in cells and its homeostasis 
investigated.  
 
As a preliminary approach to understand the effect of ANXA2 ubiquitination on the 
membrane-related functions of ANXA2, as a heterotetramer with S100-A11, the PLA 
assessing ANXA2:S100-A11 was also conducted following drug treatments (Figure 
7.10). Only BafA1 treatment increased the ANXA2:S100-A11 PLA signal, thus it is 
possible that altered ANXA2 homeostasis influences its functional interactome. 
However, this experiment needs to be repeated to increase the n number, before 













































Figure 7.9: Effect of inhibiting ubiquitin-dependent pathways on the interaction of 
Annexin A2 and ubiquitin, using PLA (preliminary results) 
Undifferentiated SH-SY5Y WT cells were treated with different inhibitors of ubiquitination-
mediated pathways.  
A&B) Bafilomycin A1 (BafA1): autophagy and endosomal/lysosomal inhibitor. 3-
Methyladenine (3-MA): autophagy inhibitor. Chloroquine: endosomal/lysosomal inhibitor. V34-
2: endosomal inhibitor.  
A) Cells were fixed in 4% PFA and then methanol. One well per condition was stained with 
anti-ANXA2 pAb and anti-Ubiquitin mAb (P4D1) antibodies (referred to as “PLA” in B). PLA 
signal (puntae in green) were quantified using ImageJ in a semiautomated manner and 
normalised by the number of nuclei (stained with DAPI) within a field of view. In parallel, two 
controls were included per treatment (grouped under “Ctrl” in B). Wells were incubated with 
either antibodies alone (ANXA2 only in green and Ubiquitin only in blue). Axio Imager, Zeiss, 
63x objective. Scale bars, 20 μm 
B) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. One-way ANOVA with Holm-Sidak’s multiple comparisons test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), *P < 0.05, **P < 
0.005, ***P < 0.0005, ****P < 0.0001, n ≥ 4 images per biological duplicate and n = 5 images 








































Figure 7.9 (continued) 
Undifferentiated SH-SY5Y WT cells were treated with different inhibitors of ubiquitination-
mediated pathways.  
C&D) Lactacystin and MG-132 are proteasomal inhibitors.  
C) Cells were fixed in 4% PFA and then methanol. One well per condition was stained with 
anti-ANXA2 pAb and anti-Ubiquitin mAb (P4D1) antibodies (referred to as “PLA” in D). PLA 
signal (puntae in green) were quantified using ImageJ in a semiautomated manner and 
normalised by the number of nuclei (stained with DAPI) within a field of view. In parallel, two 
controls were included per treatment (grouped under “Ctrl” in D). Wells were incubated with 
either antibodies alone (ANXA2 only in green and Ubiquitin only in blue). Axio Imager, Zeiss, 
63x objective. Scale bars, 20 μm.  
D) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. One-way ANOVA with Holm-Sidak’s multiple comparisons test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), *P < 0.05, **P < 
0.005, ***P < 0.0005, ****P < 0.0001, n ≥ 4 images per biological duplicate and n = 5 images 








































Figure 7.10: Effect of inhibiting ubiquitin-dependent pathways on the interaction of 
Annexin A2 and S100-A11, using PLA (preliminary results) 
Undifferentiated SH-SY5Y WT cells were treated with different inhibitors of ubiquitination-
mediated pathways. Bafilomycin A1 (BafA1): autophagy and endosomal/lysosomal inhibitor. 
3-Methyladenine (3-MA): autophagy inhibitor. Choloquine: endosomal/lysosomal inhibitor. 
V34-2: endosomal inhibitor.  
A) Cells were fixed in acetone & methanol. One well per condition was stained with anti-
ANXA2 mAb and anti-S100-A11 pAb antibodies (referred to as “PLA” in B). PLA signal (puntae 
in green) were quantified using ImageJ in a semiautomated manner and normalised by the 
number of nuclei (stained with DAPI) within a field of view. In parallel, two controls were 
included per treatment (grouped under “Ctrl” in B). Wells were incubated with either antibodies 
alone (S100-A11 only in green and ANXA2 only in blue). Axio Imager, Zeiss, 63x objective. 
Scale bar, 20 μm.  
B) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. One-way ANOVA with Holm-Sidak’s multiple comparisons test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), *P < 0.05, **P < 
0.005, ***P < 0.0005, ****P < 0.0001, n = 5 images per biological duplicate and n = 5 images 
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7.3.2 Modulating CHIP 
a. ScFv-induced conformational changes 
Despite the exciting potential of scFv in research, extra validation of the scFv 
antibodies both in vitro and in situ is necessary. It is important to confirm the binding 
site of scFv antibodies on CHIP (e.g. epitope mapping using a CHIP peptide library) 
and their effect on its structure by other methods (e.g. SEC in parallel to native WB), 
and this work is ongoing. Also, in vitro ubiquitination assays with scFv led us to the 
hypothesis that different multimerization forms of CHIP have varying substrate 
specificities, which could be dictated by its conformational state. Future studies will 
focus on testing this hypothesis with different folded and unfolded substrates and 
translate this to cell models. Furthermore, given the allosteric regulation between the 
TPR and U-box domains of CHIP, it is important to investigate the effect of scFv 
antibodies on the chaperone functions of CHIP (e.g. using a luciferase-based protein 




Preliminary experiments evaluated the expression and subcellular localisation of 
tagged scFv intrabodies by IF (Figure 7.11). It seems that in WT cells, scFv localises 
to the cytoplasm and nucleus. In contrast, the staining seems stronger and more 
restricted to the nucleus in CHIP KO cells. Therefore, it is possible that, in the 
presence of its target, CHIP, scFv localises to the cytoplasm potentially to interact 
with CHIP, whilst in its absence scFv mislocalises. Future experiments would assess 
this further and test whether transfected scFv and endogenous CHIP interact (e.g. by 
PLA and IP/pull-down assays).  
 
Given the finding that scFv induces ANXA2 ubiquitination in vitro, I sought to test if 
Ub:ANXA2 PLA signal is enhanced in scFv-expressing cells (Figure 7.12). A 
preliminary data supports this hypothesis, but further experiments are needed for 
conclusions to be drawn. Although single-cell analysis is possible with scFv 
intrabodies, the transfection efficiency requires optimisation prior to whole-cell 
analysis. Once achieved, whole proteomic analysis by SWATH-MS of WT cells with 
and without scFv intrabodies could inform on substrates that are differentially 
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modulated by CHIP, when its activity is influenced by the scFv, compared to when 































Figure 7.11: ScFv expression in cells 
Undifferentiated CHIP KO and WT SH-SY5Y cells were transiently transfected with V5-tagged 
11F scFv. Cells were fixed with 4% PFA and stained with anti-V5 mAb. Axio Imager, Zeiss, 
20x objective. Scale bars, 100 μm and 25 μm (inlet).  
Figure 7.12: ScFv expression enhances interaction between ubiquitin and Annexin A2 
by PLA (preliminary results) 
Undifferentiated CHIP WT SH-SY5Y cells were transiently transfected with V5-tagged 11F 
scFv. Cells were fixed with 4% PFA and then methanol and stained with anti-V5 pAb (1:500, 
goat), anti-ANXA2 pAb (1:500, rabbit) and anti-Ubiquitin mAb (P4D1, mouse) (1:100) 
antibodies. PLA with anti-Rabbit and anti-Mouse secondary antibodies was performed to 
identify Ub in close proximity with ANXA2 (indicated by the green puncta). Cells were also 
incubated with a 630-conjugated anti-Goat secondary antibody to identify cells expressing the 
scFv antibody (shown in red). Axio Imager, Zeiss, 63x objective. Scale bar, 10 μm. 
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7.3.3 CHIP and lipid homeostasis 
a. Cholesterol 
As discussed, there is evidence of ANX-dependent regulation of cholesterol 
metabolism258,259, proof-of-concept that CHIP may be affected by cholesterol 
regulation (via lanosterol administration262) and reports of cholesterol dysregulation in 
ageing and neurodegenerative diseases257,258,260. Together, this makes it quite 
interesting that our CHIP KO models are significantly more sensitive to digitonin-
induced membrane damage (cholesterol-specific insult). Ongoing studies are 
evaluating the levels of cholesterol in our CHIP KO models and future lipidomic 
analysis will quantify cholesterol content. 
 
 
b. Polyunsaturated fatty acids 
We performed preliminary analysis of the polyunsaturated fatty acids (PUFAs) content 
in our undifferentiated SH-SY5Y CHIP model in collaboration with Dr Irena Dapic and 
Dr Laura Bindila‖ (Figure 7.13). Our lipidomic analysis revealed a subtle increase in 
docosahexaenoic acid (DHA) in CHIP KO cells, as well as pronounced decreases in 
eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA). These omega-3 
PUFA may have significant neuroprotective effects in acute neurological injury201 and 
are decreased in neurodegenerative diseases, including AD and PD199,277. CHIP 
expression correlated with the neuroprotective EPA, which could be part of the 
molecular mechanisms underlying the neuroprotective functions of CHIP. 
Interestingly, EPA supplement showed significantly increased PE, PS and PI levels 
in the brain199. Likewise, CHIP KO cells have decreased EPA levels that correlate with 
PS, PI and PE total levels. Future work would repeat this experiment, assay more 
PUFAs, and include the SH-SY5Y lines stably expressing mutant forms of CHIP, for 







‖ Institute for Physiological Chemistry, University Medical Center Mainz, Germany 
 


















7.3.4 CHIP and calcium homeostasis 
Most membrane-related proteins significantly changed in the SWATH-MS analysis of 
patient-derived cortical neurons with and without CHIP expression are also regulated 
by calcium, including ANXA2. When conducting PM damage assays in the absence 
of calcium, in attempt to isolate sensitivity to injury from ability to repair, CHIP KO 
iPSC seemed to be less tolerant to calcium withdrawal. Given these two observations, 
it would be interesting to investigate calcium homeostasis in our CHIP models. At 
present, we cannot exclude the possibility that changes in phospholipid- and calcium-
binding proteins and membrane sensitivity could be driven by differences in calcium 
handling. It has been reported that reduced calcium can result in protein misfolding 
and activation of the UPR, which in turn alters lipid synthesis26.  
 
 
7.3.5 Are the observed membrane defects and changes in 
Annexin homeostasis related? 
Although there is supporting evidence in the literature relating Annexin dysregulation 
with poor membrane integrity, it is unclear whether the differences in membrane and 
Figure 7.13: Composition of polyunsaturated fatty acids of CHIP KO and WT 
undifferentiated SH-SY5Y cells (preliminary results) 
Fatty acid composition is represented as fold changes (WT/KO). For EPA and DPA both free 
(medium) and esterified (pellet) forms are represented. Linoleic acid (LA, omega-6), α-linoleic 
acid (ALA, omega-3), docosahexaenoic acid (DHA, omega-3), eicosapentaenoic acid (EPA, 
omega-3) and docosapentaenoic acid (DPA, omega-3).  
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Annexin homeostasis observed in our models have a causal relationship and are 
CHIP-dependent. Supporting experiments are required to assess the following 
questions: is the CHIP KO + H260Q cell line (expressing the E3 ligase-dead mutant) 
more sensitive to injury due to diminished Ub-ANXA2 species and/or reduced 
ANXA2:S100-A11 interaction? Is ANXA2 ubiquitination important for the ANXA2 
interactome? Are CHIP-dependent and Annexin-independent changes in lipid profile 
underlying the differences in integrity, which in turn influence the homeostasis of 
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Appendix I 
The following figures are supplementary to Chapter 3: Engineering iPSCs to generate 





































Figure S.1: Overview of morphological changes during the course of cortical 
differentiation from iPSC 
Phase contrast images of the differentiating cultures over time.  
A) Images from cultures of the second differentiation experiment. Day 62 and 80 images show 
maturation of neurons within the same well across the different cell lines. These wells were 
within the pool of cultures harvested for MS analysis at day 80. Neural rosettes are indicated 
by the arrows or the center of the rosette is labeled with an asterisk (*).  



























































Figure S.1 (continued) 
Phase contrast images of the differentiating cultures over time.  
B) Images from cultures of the first differentiation experiment.  
Scale bar, 200 µm.  
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The following figures and tables are supplementary to Chapter 4: Effect of CHIP on 













































Figure S.2: Morphology of undifferentiated CHIP SH-SY5Y model 
Phase contrast images showing the morphology of CHIP WT and KO cells. Scale bar, 200 
µm. 
 
















































Figure S.3: Pathway analysis derived from the proteomics of our CHIP cortical neuron 
model 
SWATH-MS data comparing CHIP KO with CHIP expressing lines was analysed using the 
Ingenuity Pathway Analysis software. Only significantly changing proteins were used for the 
analysis. Both Alzheimer’s disease- and Parkinson’s disease-related pathways were related 
to the proteins identified. When the relationship could be predicted between the diseases and 
specific proteins (represented by gene names), the dashed line is coloured (blue represents 
an inhibitory relationship) rather than grey.  
 
















































Figure S.4: Markers of differentiated SH-SY5Y cells 
Immunofluorescence images of α-Syn and β(III)-tubulin expression in CHIP KO and WT SH-
SY5Y cells. Both proteins are implicated in neurons and the latter is neuron-specific. The cell 
lines form complex networks of processes that resemble axons and dendrites. Cells were fixed 
with 4% paraformaldehyde and stained with anti-α-synuclein mAb (1:500) and anti-b(III)-
tubulin mAb (1:1000). Scale bar, 100 µm. 
 
















































Table S.1: Most over-represented proteins in CHIP KO cortical neurons compared to 
neurons derived from the parental iPSC line.  
The top 10 most over-represented proteins that were significantly changed (P < 0.05) are 
numbered and labelled in Figure 4.7.  
 
















































Table S.2: Most under-represented proteins in CHIP KO cortical neurons compared 
to neurons derived from the parental iPSC line 
The top 10 most under-represented proteins that were significantly changed (P < 0.05) are 




















































Table S.3: Most over-represented proteins in CHIP KO cortical neurons compared to 
neurons derived from the WT (CRISPR control) iPSC line 
The top 11 most over-represented proteins that were significantly changed (P < 0.05) are 




















































Table S.4: Most under-represented proteins in CHIP KO cortical neurons compared 
to neurons derived from the WT (CRISPR control) iPSC line 
The top 10 most under-represented proteins that were significantly changed (P < 0.05) are 




















































Table S.5: Most over-represented proteins in CHIP WT (CRISPR control line) cortical 
neurons compared to neurons derived from the parental iPSC line 
The top 10 most over-represented proteins that were significantly changed (P < 0.05) are 




















































Table S.6: Most under-represented proteins in CHIP WT (CRISPR control line) 
cortical neurons compared to neurons derived from the parental iPSC line 
The top 10 most under-represented proteins that were significantly changed (P < 0.05) are 
numbered and labelled in Figure 4.9.  
 
 
















































Table S.7: Most over-represented proteins in CHIP KO iPSC compared to WT iPSC 
The top 10 most over-represented proteins that were significantly changed (P < 0.05) are 
numbered and labelled in Figure 4.12.   
 
 
















































Table S.7 (continued) 
 
















































Table S.7 (continued) 
 
















































Table S.8: Most under-represented proteins in CHIP KO iPSC compared to WT iPSC 
The top 10 most under-represented proteins that were significantly changed (P < 0.05) are 
numbered and labelled in Figure 4.12.   
 
 
















































Table S.8 (continued) 
 
















































Table S.9: Most over-represented proteins in CHIP KO compared to WT differentiated 
SH-SY5Y 
The top 10 most over-represented proteins that were significantly changed (P < 0.05) are 




















































Table S.9 (continued) 
 
















































Table S.10: Most under-represented proteins in CHIP KO compared to WT 
differentiated SH-SY5Y  
The top 10 most under-represented proteins that were significantly changed (P < 0.05) are 
numbered and labelled in Figure 4.13.   
 
 





















































Table S.10 (continued) 
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The following figures are supplementary to Chapter 5: The possible role of CHIP in 














































Figure S.5: CHIP & Annexin A2 expression in undifferentiated SH-SY5Y 
Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the stable cell lines 
KO+H260Q and KO+WT) were fixed with 4% PFA and then methanol. Parallel wells to those 
used for PLA (Figure 5.13) were incubated with anti-ANXA2 pAb (1:500) and anti-CHIP mAb 
(1:1000) antibodies. 
Axio Imager, Zeiss, 20x objective. Scale bar, 100 µm. 
 
















































Figure S.6: Optimisation of the detection of endogenous ubiquitin by IF  
Undifferentiated SH-SY5Y CHIP WT cells were fixed with different methods and stained using 
anti-ANXA2 Rb pAb (1:1000) and either anti-Ub mAbs (F-11 or P4D1) (1:100). The antibody 
concentration had been previously optimised (data not shown). Scale bar, 20 mm  
 
















































Figure S.7: Ubiquitin and Annexin A2 expression in undifferentiated SH-SY5Y 
Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the stable cell lines 
KO+H260Q and KO+WT) were fixed with acetone and methanol. Parallel wells to those used 
for PLA (Figure 5.17) were stained with anti-ANXA2 pAb (1:500) and anti-Ubiquitin mAb 
(P4D1) (1:100) antibodies. Axio Imager, Zeiss, 20x objective. Scale bars, 100 µm. 
Figure S.8: Annexin A2 & S100-A11 interaction by an independent PLA experiment in 
undifferentiated SH-SY5Y quantified manually  
Manual quantifications of an independent experiment to that of Figure 5.31 (performed with 
the same conditions). PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. Kruskal-Wallis test and Dunn’s multiple comparisons post-test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), **P < 0.005, ***P 
< 0.0005, ****P < 0.0001, n ≥ 12 images per biological duplicate and n ≥ 11 images per control 
condition per cell line. 
 
















































Figure S.9: S100-A11 and Annexin A2 expression in undifferentiated SH-SY5Y 
Undifferentiated SH-SY5Y cells of different CHIP genotypes (WT, KO and the stable cell lines 
KO+H260Q and KO+K30A) were fixed with acetone & methanol. Parallel wells to those used 
for PLA (Figure 5.30) were stained with anti-ANXA2 mAb (3:500) and anti-s100-A11 pAb 
(1:500) antibodies. Axio Imager, Zeiss, 20x objective. Scale bar, 100 µm. 
 
















































Figure S.10: Annexin A2 expression in undifferentiated SH-SY5Y cells expressing either 
a U-box mutant CHIP (H260Q) or TPR-mutant CHIP (K30A) 
Undifferentiated SH-SY5Y cells stably expressing different CHIP mutants were lysed with 
urea-based lysis buffer (the same as that used for SWATH-MS). For each sample, 20 µg of 
lysate was loaded per 12% gel for SDS-PAGE/WB and two gels were ran in parallel (in the 
same apparatus). In parallel, 25 ng of human recombinant ANXA2 (Abcam, ab93005) was 
loaded as a positive control. Each immunoblot was probed firstly with either anti-ANXA2 Ms 
mAb (1:500) or anti-ANXA2 Rb pAb (1:1000), anti-S100-A11 pAb (1:1000) and anti-β-actin 
mAb (1:5000).  
 
















































Figure S.11: S100-A11 & CHIP interaction by PLA in undifferentiated SH-SY5Y 
A, B, D) Undifferentiated SH-SY5Y CHIP WT and KO cells were fixed with 4% PFA.  
A) For each cell line, duplicate wells were stained with anti-S100-A11 pAb (1:500) and anti-
CHIP mAb antibodies (1:1000) (referred to as “PLA” in C and biological duplicates are colour-
coded with black or green dots). PLA signal (puntae in green) were quantified using ImageJ in 
a semi-automated manner and normalised by the number of nuclei (stained with DAPI) within 
a field of view.  
B) In parallel, three controls were included (grouped under “Ctrl” in C): wells containing CHIP 
WT cells were incubated with either antibodies alone (CHIP only in green and S100-A11 only 
in blue) or with no primary antibodies (in black). 
C) Quantifications of PLA signal per nuclei of different cell lines represented in the dot plot as 
mean ± SD. Kruskal-Wallis test and Dunn’s multiple comparisons post-test (comparisons 
between PLA and Ctrl conditions per cell line is indicated above each Ctrl), ****P < 0.0001, n 
≥ 11 images per biological duplicate and n ≥ 11 images per control condition per cell line.  






















































Figure S.11 (continued) 
A, B, D) Undifferentiated SH-SY5Y CHIP WT and KO cells were fixed with 4% PFA.  
D) Parallel to wells were treated in the same way and used for IF rather than PLA, using the 
same antibodies.  
Axio Imager, Zeiss, 20x objective. Scale bar, 100 µm.  
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Appendix II 
This appendix supports Chapter 6: Modulating the activity of CHIP using single-
chain antibodies.   
Generation of ScFv intrabodies to modulate endogenous CHIP 
activity in cell models 
a. Cloning of tagged scFv into nanobodies for delivery 
Based on the sequence of 11F scFv, I designed two DNA inserts where the scFv was 
C-terminally tagged with either V5 or 3xFLAG tags (Figure S.14). Host plasmids 
carrying the inserts were cleaved (Figure S.13A) and the inserts were introduced to a 
mammalian expression cassette, pSF-CMV (Figure S.13B & Figure S.14). For 
validation purposes, the DNA from competent cells transformed with the ligation 
products was digested again with the restriction enzymes to confirm the size of the 
insert (Figure S.13C). The sequence of the insert was confirmed by sequencing the 









































































Figure S.12: DNA encoding 3xFLAG- and V5-tagged 11F scFv antibodies 
A SGSG linker between the protein and tag was added to enhance flexibility and 
aid detection of the tag. An extra alanine was added as well to prevent methylation. 
Two restriction enzyme (RE) sequences were added at either end of the DNA (5’ 
BamHI and 3’ XbaI) although the REs that will be used are NcoI and XbaI, because 
the sequence for the former RE is created by the sequence for BamHI together 
with the start of the coding region of 11F, thus preventing frameshift mutations. 
 














































Figure S.14: Mammalian expression vector used for the expression of nanobodies in 
cells 
pSF-CMV includes kozak consensus sequence to promote expression.  
A 
B C 
Figure S.13: Generation of the tagged scFv 11F plasmid for mammalian expression 
A) The products of the double digestion of the holding plasmids (encoding 3xFLAG-tagged 
and V5-tagged 11F) and pSF-CMV plasmid with restriction enzymes (XbaI and NcoI) were 
resolved on a 1% agarose gel.  
B&C) Ligation products were used to transform competent cells and their DNA was extracted. 
A fraction of the DNA was resolved on a 1% agarose gel undigested (B) and digested (C).  
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b. Optimisation of scFv transfection into cells 
Once generated, the scFv encoding plasmids (11F_V5 and 11F_FLAG) were used to 
transfect a neuroblastoma cell line, SH-SY5Y (Figure S.15). Control cells were 
transfected with the an empty pSF-CMV plasmid. The expression of the scFv 
antibodies obtained when using different transfection methods (electroporation and 
attractene) was evaluated by WB. Both 11F_V5 and 11F_FLAG yielded a band at 
around 35 kDa when transfected into cells using attractene. This suggests that the 
scFv antibodies are expressed intracellularly, although whether they are correctly 
folded and functional remains to be investigated.   
 
 
c. Effect of scFv transfection in the homeostasis of CHIP 
In order to capitalise on the scFv as tools to manipulate CHIP structure and function 
in situ, cell deliverable nanobodies have been generated and expressed in 
mammalian cells. These induce the intracellular expression of tagged scFv (Figure 
S.15A), having several applications.  
 
Since the aim of generating scFv antibodies was to manipulate the activity and 
interactome of CHIP in cells, rather than causing bulk changes in CHIP homeostasis 
(e.g. impair its turnover), the expression levels of CHIP in cells transfected with the 
scFv antibodies was evaluated (Figure S.15B). The immunoblot suggests that CHIP 
steady state levels are not affected by scFv transfection, although these are only 
preliminary result. If confirmed, any proteomics changes subsequently observed 
when scFv is expressed are likely to be due to scFv-mediated regulation of CHIP 
































Figure S.15: ScFv intrabodies 
Cells lysates of WT and CHIP KO SH-SY5Y cells previously transfected with 3xFLAG- and 
V5-tagged 11F scFv and trasnfected after 24 h were analysed using precast gradient gels (4-
12 % Bis-Tris Gels, Invitrogen) SDS-PAGE/WB (40 µg per sample was loaded). As a positive 
control, purified CHIP dimer (3.7 ng) was loaded alongside the samples. E, electroporation 
used for transfection, A, attractene used for transfection. 
A) Immunoblots was probed with either anti-FLAG mAb (1:1000) or anti-V5 mAb (1:1000). 
B) Subsequently, immunoblots were probed with anti-CHIP mAb (1:10000) and anti-GAPDH 
mAb (1:5000).  
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